---
document_datetime: 2024-08-29 13:35:52
document_pages: 167
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/balversa-epar-public-assessment-report_en.pdf
document_name: balversa-epar-public-assessment-report_en.pdf
version: success
processing_time: 199.5741535
conversion_datetime: 2025-12-20 15:44:10.335504
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

27 June 2024 EMA/336561/2024 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Balversa

International non-proprietary name: erdafitinib

Procedure No. EMEA/H/C/006050/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                   | ..............................................6                                                             |
|------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier......................................................................................6        |                                                                                                             |
| 1.2. Legal basis                                                                                                             | ..........................................................................................................6 |
| 1.3. Information on Paediatric requirements...................................................................6              |                                                                                                             |
| 1.3.1. Similarity..........................................................................................................6 |                                                                                                             |
| 1.3.2. New active Substance status...............................................................................6           |                                                                                                             |
| 1.4. Scientific advice                                                                                                       | ...................................................................................................7        |
| 1.5. Steps taken for the assessment of the product.........................................................7                 |                                                                                                             |
| 2. Scientific discussion                                                                                                     | ................................................................................9                           |
| 2.1. Problem statement                                                                                                       | ...............................................................................................9            |
| 2.1.1. Disease or condition...........................................................................................9      |                                                                                                             |
| 2.1.2. Epidemiology and risk factors, screening tools/prevention                                                             | ......................................9                                                                     |
| 2.1.3. Biologic features................................................................................................9    |                                                                                                             |
| 2.1.4. Clinical presentation, diagnosis and stage/prognosis                                                                  | ............................................10                                                              |
| 2.1.5. Management...................................................................................................10       |                                                                                                             |
| 2.2. About the product                                                                                                       | ..............................................................................................13            |
| 2.3. Type of Application and aspects on development....................................................14                    |                                                                                                             |
| 2.4. Quality aspects                                                                                                         | ..................................................................................................15        |
| 2.4.1. Introduction....................................................................................................15    |                                                                                                             |
| 2.4.2. Active substance                                                                                                      | .............................................................................................16             |
| 2.4.3. Finished medicinal product................................................................................19          |                                                                                                             |
| 2.4.4. Discussion on chemical, and pharmaceutical aspects............................................23                      |                                                                                                             |
| 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                    | ......................23                                                                                    |
| 2.4.6. Recommendations for future quality development................................................23                      |                                                                                                             |
| 2.5. Non-clinical aspects                                                                                                    | ............................................................................................24              |
| 2.5.1. Introduction....................................................................................................24    |                                                                                                             |
| 2.5.2. Pharmacology                                                                                                          | .................................................................................................24         |
| 2.5.3. Pharmacokinetics.............................................................................................27       |                                                                                                             |
| 2.6. Methods of analysis                                                                                                     | ............................................................................................27              |
| 2.7. Pharmacokinetic drug interactions                                                                                       | ........................................................................29                                  |
| Potential interactions with metabolic enzymes                                                                                | ..............................................................29                                            |
| 2.7.1. Toxicology                                                                                                            | ......................................................................................................30    |
| 2.7.2. Ecotoxicity/environmental risk assessment                                                                             | .........................................................38                                                 |
| 2.7.3. Discussion on non-clinical aspects......................................................................38            |                                                                                                             |
| 2.7.4. Conclusion on the non-clinical aspects................................................................42              |                                                                                                             |
| 2.8. Clinical aspects                                                                                                        | ..................................................................................................42        |
| 2.8.1. Introduction....................................................................................................42    |                                                                                                             |
| 2.8.2. Clinical pharmacology                                                                                                 | ......................................................................................45                    |
| 2.8.3. Discussion on clinical pharmacology...................................................................92              |                                                                                                             |
| 2.8.4. Conclusions on clinical pharmacology.................................................................98               |                                                                                                             |
| 2.8.5. Clinical efficacy                                                                                                     | ...............................................................................................98           |
| 2.8.6. Discussion on clinical efficacy..........................................................................             | 129                                                                                                         |
| 2.8.7. Conclusions on the clinical efficacy...................................................................               | 134                                                                                                         |

<div style=\"page-break-after: always\"></div>

| 2.8.8. Clinical safety................................................................................................   | 134                                                                                              |
|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| 2.8.9. Discussion on clinical safety ............................................................................        | 152                                                                                              |
| 2.8.10. Conclusions on the clinical safety...................................................................            | 158                                                                                              |
| 2.9. Risk Management Plan ......................................................................................         | 158                                                                                              |
| 2.9.1. Safety concerns.............................................................................................      | 158                                                                                              |
| 2.9.2. Pharmacovigilance plan                                                                                            | .................................................................................. 159           |
| 2.9.3. Risk minimisation measures............................................................................            | 159                                                                                              |
| 2.9.4. Conclusion....................................................................................................    | 160                                                                                              |
| 2.10. Pharmacovigilance..........................................................................................        | 160                                                                                              |
| 2.10.1. Pharmacovigilance system                                                                                         | ............................................................................ 160                 |
| 2.10.2. Periodic Safety Update Reports submission requirements..................................                         | 161                                                                                              |
| 2.11. Product information ........................................................................................       | 161                                                                                              |
| 2.11.1. User consultation.........................................................................................       | 161                                                                                              |
| 2.11.2. Additional monitoring                                                                                            | ................................................................................... 161          |
| 3. Benefit-Risk Balance............................................................................161                   |                                                                                                  |
| 3.1. Therapeutic Context .........................................................................................       | 161                                                                                              |
| 3.1.1. Disease or condition.......................................................................................       | 161                                                                                              |
| 3.1.2. Available therapies and unmet medical need.....................................................                   | 161                                                                                              |
| 3.1.3. Main clinical studies .......................................................................................     | 162                                                                                              |
| 3.2. Favourable effects                                                                                                  | ............................................................................................ 162 |
| 3.3. Uncertainties and limitations about favourable effects...........................................                   | 162                                                                                              |
| 3.4. Unfavourable effects.........................................................................................       | 163                                                                                              |
| 3.5. Uncertainties and limitations about unfavourable effects                                                            | ....................................... 165                                                      |
| 3.6. Effects Table....................................................................................................   | 165                                                                                              |
| 3.7. Benefit-risk assessment and discussion...............................................................               | 166                                                                                              |
| 3.7.1. Importance of favourable and unfavourable effects............................................                     | 166                                                                                              |
| 3.7.2. Balance of benefits and risks...........................................................................          | 166                                                                                              |
| 3.7.3. Additional considerations on the benefit-risk balance                                                             | ......................................... 167                                                    |
| 3.8. Conclusions .....................................................................................................   | 167                                                                                              |
| 4. Recommendations...............................................................................167                     |                                                                                                  |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

International Conference On Harmonisation Of Technical Requirements For

ADC

Antibody-Drug Conjugate

ADME

Absorption, Distribution, Metabolism, Elimination

ADR

Adverse Drug Reactions

AE

Adverse Event

AGP

Alpha-1 Acid Glycoprotein

ALDG

Adaptive Licensing Discussion Group

ASAP

Accelerated Stability Assessment Programme

AUC

Area Under The Curve

BA

Bioavailability

BCS

Biopharmaceutics Classification System

BSC

Best-Supportive Care

CCP

Critical Control Point

CHMP

Committee For Medicinal Products For Human Use

CI

Confidence Interval

CPP

Critical Process Parameter

CPS

Combined Positive Score

CQA

Critical Quality Attribute

CR

Complete Response

CTCAE

Common Terminology Criteria For Adverse Events

CV

Coefficient Of Variation

CYP

Cytochrome

DCR

Disease Control Rate

DDI

Drug-Drug Interaction

DOR

Duration Of Response

DSC

Differential Scanning Calorimetry

DVS

Dynamic Vapor Sorption

EC

European Commission

ECG

Electrocardiogram

ECOG

Eastern Cooperative Oncology Group

EMA

European Medicines Agency

ESI

Elektrospray-Ionisation

ESMO

European Society For Medical Oncology

EU

European Union

FGFR

Fibroblast Growth Factor Receptor

GC

Gas Chromatography

GCP

Good Clinical Practice

GLP

Good Laboratory Practice

GMP

Good Manufacturing Practice

HDPE

High Density Polyethylene

HPLC

High Performance Liquid Chromatography

HR

Hazard Ratio

HRQoL

Health-Related Quality Of Life

ICH

Registration Of Pharmaceuticals For Human Use

ICP-MS

Inductively Coupled Plasma Mass Spectrometry

IDMC

Independent Data Monitoring Committee

IPC

In-Process Control

IR

Infrared

ITT

Intent-To-Treat

JP

Japanese Pharmacopoeia

LDPE

Low Density Polyethylene

MAA

Marketing Authorisation Application

MedDRA

Medical Dictionary For Regulatory Activities

MS

Mass Spectrometry

mUC

Metastatic Urothelial Carcinoma

MVAC

Methotrexate/Vinblastine/Doxorubicin/Cisplatin

NAS

New Active Substance

NGS

Next Generation Sequencing

NIR

Near Infrared Spectroscopy

NLT

Not Less Than

NMR

Nuclear Magnetic Resonance

NMT

Not More Than

NOAEL

No Adverse Effect Level

NSCLC

Non-Small Cell Lung Cancer

OOS

Out Of Specification

OR

Odds Ratio

ORR

Objective Response Rate

OS

Overall Survival

PAR

Proven Acceptable Range

PBPK

Physiologically Based Pharmacokinetic Modelling

PCR

Polymerase Chain Reaction

PCTFE

Polychlorotrifluoroethylene

PD-(L)1

Programmed Death-Ligand

PDCO

Paediatric Committee

PFS

Progression-Free Survival

Ph. Eur.

European Pharmacopoeia

PK

Pharmacokinetics

PP

Polypropylene

PPES

Palmar-Plantar Erythrodysaesthesia Syndrome

PPQ

Process Performance Qualification

PR

Partial Response

PSD

Particle Size Distribution

PT

Preferred Term

PVC

Polyvinyl Chloride

QTPP

Quality Target Product Profile

RECIST

Response Evaluation Criteria In Solid Tumors

RPE

Retinal Pigment Epithelium

RPED

Retinal Pigment Epithelial Dystrophy

RPM

Rotations Per Minute

SAE

Serious Adverse Event

SAR

Structure-Activity Relationships

SD

Stable Disease

SmPC

Summary Of Product Characteristics

SoC

Standard Of Care

SOC

System Organ Class

TEAE

Treatment-Emergent Adverse Events

TGA

Thermo-Gravimetric Analysis

TSE

Transmissible Spongiform Encephalopathy

UC

Urothelial Carcinoma

UHPLC

Ultra-High Performance Liquid Chromatography

USP

United States Pharmacopoeia

UV

Ultraviolet

WHO

World Health Organization

XRPD

X-Ray Powder Diffraction

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Janssen-Cilag International N.V. submitted on 8 September 2023 an application for marketing authorisation to the European Medicines Agency (EMA) for Balversa, through the centralised procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 16 December 2021.

The applicant applied for the following indication.

Balversa is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harboring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations with disease progression during or following at least one line of therapy containing a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor in the locally advanced unresectable or metastatic treatment setting.

## 1.2. Legal basis

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, nonclinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

## 1.3. Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0126/2017 on the granting of a product-specific waiver for all paediatric subsets.

## 1.3.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report, addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## 1.3.2. New active substance status

The applicant requested that the active substance erdafitinib contained in the above medicinal product be considered as a new active substance, as the applicant claims it is not a constituent of a medicinal product previously authorised within the European Union.

<div style=\"page-break-after: always\"></div>

## 1.4. Scientific advice

The applicant received the following scientific advice on the development relevant for the indication subject to the present application:

| Date             | Reference                 | SAWP co-ordinators                |
|------------------|---------------------------|-----------------------------------|
| 19 November 2015 | EMEA/H/SA/3195/1/2015/I   | Dieter Deforce and Helgi Helgason |
| 9 November 2017  | EMEA/H/SA/3195/2/2017/III | Martin Mengel and Olli Tenhunen   |

The scientific advice(s) pertained to the following quality, non-clinical, and clinical aspects:

- Designation of Starting Materials for the synthesis of the Drug Substance
- Adequacy of the proposed nonclinical pharmacology, ADME, and toxicity studies to support registration.
- Existence of unmet medical need in a proposed target indication.
- The potential of Study BLC2001 with supporting data from EDI1001 to support registration.
- The main elements of the proposed Phase 3 study including studied population, comparators, statistical design, endpoints and its potential to provide confirmatory data following registration.

## 1.5. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Janet Koenig Co-Rapporteur:  Alexandre Moreau

| The application was received by the EMA on                                                                                                                      | 8 September 2023   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| The procedure started on                                                                                                                                        | 28 September 2023  |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                    | 19 December 2023   |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                                    | 27 December 2023   |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                         | 25 January 2024    |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                             | 23 February 2024   |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on | 03 April 2024      |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                        | 11 April 2024      |
| The CHMP agreed on a list of outstanding issues to be sent to the applicant on                                                                                  | 25 April 2024      |
| The applicant submitted the responses to the CHMP List of Outstanding                                                                                           | 28 May 2024        |

<div style=\"page-break-after: always\"></div>

| Issues on                                                                                                                                                                                |              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                 | 12 June 2024 |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Balversa on | 27 June 2024 |
| Furthermore, the CHMP adopted a report on New Active Substance (NAS) status of the active substance contained in the medicinal product                                                   | 27 June 2024 |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

## Claimed therapeutic indication (initially)

Balversa is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harboring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations with disease progression during or following at least one line of therapy containing a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor in the locally advanced unresectable or metastatic treatment setting.

Before taking erdafitinib, the physician must have confirmation of select FGFR3 gene alterations as confirmed with an appropriate diagnostic test.

## 2.1.2. Epidemiology and risk factors, screening tools/prevention

Urothelial cancer (UC) is the tenth most common malignancy worldwide, with approximately 570,000 new cases per year and causing approximately 210,000 deaths per year worldwide (Globocan 2020). Ninety percent of all UC cases originate in the bladder, while the remaining cases originate in other parts of the urinary tract (Hepp et al, 2020; Miyazaki &amp; Nishiyama, 2017). Smoking tobacco is the strongest risk factor, accounting for approximately 50-65% of new cases each year, and exposure to occupational and environmental toxins accounts for approx. 18% of new cases each year. Schistosomiasis is a common risk factor in certain regions (Africa and Middle East) associated with squamous cell carcinoma of the bladder (EAU Guideline invasive metastatic bladder cancer, 2020).

Bladder cancer is over four times more common in men than in women, with a respective incidence of 9.5/100,000 among men and 2.4/100,000 among women worldwide. Gender differences in the incidence of urothelial bladder cancer are most likely due to different smoking habits and exposition to exogenous carcinogens (International Agency for Research on Cancer. World Health Organization. 2021).

While the majority of new cases can be attributed to preventable risk factors, metastatic urothelial carcinoma (mUC) is incurable and is associated with significant morbidity and a dismal prognosis, with 5-year survival rates less than 10% (Saginala 2020).

## 2.1.3. Biologic features

Erdafitinib is a pan-FGFR tyrosine kinase inhibitor. The fibroblast growth factor family of receptors (FGFRs) are protein tyrosine kinases and consist of 4 related members (FGFR1, FGFR2, FGFR3, FGFR4) (Parker 2014). Activating mutations and translocations in FGFR genes have been associated with neoplastic progression and tumour vascularisation in multiple cancer types including UC (Dienstmann 2014; Parker 2014). Deregulation of FGFR signalling (e.g., via FGFR mutation and gene fusion) may be involved in bladder cancer pathogenesis (Babina 2017; Dienstman 2014; Touat 2015). Recurrent FGFR mutations and gene fusions are observed in urothelial cancer (Robertson 2017). Approximately 15 to 20% of locally advanced or metastatic UCs are found to harbour FGFR mutations and gene fusions, thus, FGFR inhibition may be particularly appropriate in those patients.

<div style=\"page-break-after: always\"></div>

## 2.1.4. Clinical presentation, diagnosis and stage/prognosis

Typically, UC presents with painless haematuria. At initial diagnosis, approx. 75% of cases are nonmuscle-invasive bladder cancer (NMIBC) and 25% are muscle invasive or even more advanced (ESMO guideline for bladder cancer, 2014). Urothelial carcinoma is a progressive disease with a part of patients presenting with or progressing to locally advanced or metastatic urothelial carcinoma. Untreated metastatic UC is associated with a median survival time rarely exceeding 3 to 6 months (Bellmunt et al, 2012). Approximately 10%-15% of patients present with metastatic UC at the time of diagnosis. Despite the low frequency of de novo disease, approximately half of the patients with locally advanced UC progress to metastatic disease within two years of cystectomy. Locally advanced or metastatic UC is an incurable disease with poor long-term survival and represents a high unmet medical need. Among patients treated with a cisplatin-containing regimen as the first-line treatment, the median OS is approximately 12 to 14 months and the 5-year mortality rate exceeds 85% (von der Maase et al, 2005).

## 2.1.5. Management

In urothelial cancer, locally advanced disease may be resectable or unresectable. If the disease is deemed resectable, a multidisciplinary approach ensues, which could involve neoadjuvant systemic therapy + surgery + adjuvant systemic therapy +/- radiation (systemic therapy may include chemotherapy and/or immunotherapy). If the disease is deemed unresectable, it is treated as if metastatic. Metastatic urothelial cancer is incurable and systemic therapy is given with the intent of palliation of cancer-related symptoms, delay in disease progression and prolongation of survival while maintaining quality of life.

Available systemic therapies in the EU can be broadly categorised as platinum-based chemotherapy regimens, other chemotherapy regimens, antibodies targeting programmed death receptor-1 or programmed death-ligand 1 (anti-PD-(L)1), and antibody-drug conjugates (ADCs). Due to the significant toxicities and morbidities, in particular kidney dysfunction and peripheral neuropathy, a relevant proportion of patients do not receive any systemic chemotherapy and the number of patients who are eligible for subsequent therapies decreases with every line of treatment (ESMO; Powles 2022).

Importantly, no therapies for a biomarker-selected population are approved so far.

Recommended treatments according to the European Society for Medical Oncology (ESMO; Powles 2022) at the time of the current submission are shown below.

First-line therapy for advanced or metastatic UC in patients who are fit enough to tolerate cisplatin is cisplatin-containing combination chemotherapy, such as gemcitabine-cisplatin or dose-dense MVAC (methotrexate/vinblastine/ doxorubicin/cisplatin) (Sternberg 2006). For cisplatin-containing treatment combinations overall survival between 12.5 and 15.8 months are reported (Bellmunt 2012, Loehrer 1992). For patients that are ineligible for cisplatin, combination therapy with carboplatin-gemcitabine is an option that is associated with generally inferior outcomes.

Anti-PD-(L)1 agents represent an important therapeutic advantage for patients with mUC:

- in platinum-eligible patients,
- o for the first-line maintenance treatment in patients with locally advanced or metastatic UC who are progression-free following platinum-based chemotherapy avelumab is approved as monotherapy (Powles 2020).

<div style=\"page-break-after: always\"></div>

- o for use in patients with progressive disease after prior platinum-based chemotherapy pembrolizumab (Bellmunt 2017), atezolizumab (Balar 2017) and nivolumab (Galsky 2020) are approved.
- in cisplatin-ineligible patients,
- o as first-line treatments pembrolizumab and atezolizumab monotherapy are currently approved for PD-L1 positive tumours

(https://www.ema.europa.eu/en/medicines/human/EPAR/Keytruda;

https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq).

- Furthermore, nivolumab was approved as adjuvant therapy for patients with muscle-invasive UC with PD-L1 expression with high risk of recurrence after radical cystectomy. Thus, future patients may have received nivolumab prior to the first line treatment in the metastatic setting.
- For patients who have previously received both, platinum-based chemotherapy and an anti-PD(L)1 agent, the antibody-drug conjugate enfortumab vedotin is approved in the EU since 2022. Enfortumab vedotin was investigated in a Phase 3 randomised controlled trial (n=608) comparing enfortumab vedotin with single-agent chemotherapy after prior platinum chemotherapy and checkpoint inhibitor immunotherapy, which demonstrated significant OS benefit of approx. 4 months (12.91 months vs 8.94 months; HR 0.704, 95% CI: 0.581, 0.852). Patients with preexisting comorbidities such as neuropathy and diabetes may not be candidates for enfortumab vedotin due to the toxicity profile, including neuropathy, and hyperglycaemia and severe cutaneous skin reactions, (McGregor 2021; Petrylack 2019; Rosenberg 2022).

Single-agent chemotherapy agents, e.g., docetaxel, paclitaxel and vinflunine are typically reserved for patients who have progressed after one or more lines of anti-cancer therapies. These treatments provide limited clinical benefit with ORR ranging from 10% to 20%, median PFS of approximately 2 months, and 30% to 40% 1-year survival rates (Bellmunt 2009; Culine 2006; Lorusso 1998; McCaffrey 1997; Witte 1997).

Vinflunine is approved in the EU based on a RCT in comparison to best supportive care, a significant difference in median PFS (3.0 vs 1.5 months) and a trend in median OS (6.9 vs 4.6 months) was shown (Bellmunt 2009).

Table 1: Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for Advanced or Metastatic Urothelial Carcinoma

| Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for Advanced or Metastatic Urothelial Carcinoma a   | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for Advanced or Metastatic Urothelial Carcinoma a   | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for Advanced or Metastatic Urothelial Carcinoma a   | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for Advanced or Metastatic Urothelial Carcinoma a   | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for Advanced or Metastatic Urothelial Carcinoma a   | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for Advanced or Metastatic Urothelial Carcinoma a   | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for Advanced or Metastatic Urothelial Carcinoma a   | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for Advanced or Metastatic Urothelial Carcinoma a   | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for Advanced or Metastatic Urothelial Carcinoma a   |
|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| ESMO Recommend                                                                                                                         |                                                                                                                                        |                                                                                                                                        | Endpoints                                                                                                                              | Endpoints                                                                                                                              | Endpoints                                                                                                                              | Endpoints                                                                                                                              | Endpoints                                                                                                                              | EU Marketing Authorisatio n Status                                                                                                     |
| ation                                                                                                                                  | Product                                                                                                                                | Sample Size                                                                                                                            | OS (mo)                                                                                                                                | PFS (mo)                                                                                                                               | ORR                                                                                                                                    | CR                                                                                                                                     | DOR (mo)                                                                                                                               |                                                                                                                                        |
| Patients fit enough to tolerate cisplatin-based combination chemotherapy                                                               | Patients fit enough to tolerate cisplatin-based combination chemotherapy                                                               | Patients fit enough to tolerate cisplatin-based combination chemotherapy                                                               | Patients fit enough to tolerate cisplatin-based combination chemotherapy                                                               | Patients fit enough to tolerate cisplatin-based combination chemotherapy                                                               | Patients fit enough to tolerate cisplatin-based combination chemotherapy                                                               | Patients fit enough to tolerate cisplatin-based combination chemotherapy                                                               | Patients fit enough to tolerate cisplatin-based combination chemotherapy                                                               | Patients fit enough to tolerate cisplatin-based combination chemotherapy                                                               |
| First-line SoC                                                                                                                         | Gemcitabine- cisplatin a,b                                                                                                             | Gemcitabine +cisplatin N=203                                                                                                           | 13.8                                                                                                                                   | 7.4                                                                                                                                    | 49.4 %                                                                                                                                 | 12.2 %                                                                                                                                 | 9.6                                                                                                                                    | Generics approved in EU member states via MRP                                                                                          |
| First-line alternative                                                                                                                 | Dose-dense MVAC c                                                                                                                      | ddMVAC N=126                                                                                                                           | 12.5                                                                                                                                   | 10                                                                                                                                     | 39%                                                                                                                                    | 13%                                                                                                                                    | Not report ed                                                                                                                          | Generics approved in EU member states via MRP                                                                                          |
| First-line alternative                                                                                                                 | MVAC with granulocyte colony- stimulating factor d                                                                                     | MVAC +GCSF N=134                                                                                                                       | 15.1                                                                                                                                   | 9.5                                                                                                                                    | 72%                                                                                                                                    | 25%                                                                                                                                    | Not report ed                                                                                                                          | Generics approved in EU member states via MRP                                                                                          |

<div style=\"page-break-after: always\"></div>

| Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for or Metastatic Urothelial a   | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for or Metastatic Urothelial a   | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for or Metastatic Urothelial a   | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for or Metastatic Urothelial a   | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for or Metastatic Urothelial a   | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for or Metastatic Urothelial a   | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for or Metastatic Urothelial a   | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for or Metastatic Urothelial a   | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for or Metastatic Urothelial a   |
|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Advanced First-line alternative                                                                                     | gemcitabine, cisplatin and paclitaxel e                                                                             | Carcinoma G+C+P N=312                                                                                               | 15.8                                                                                                                | 8.3                                                                                                                 | 55.5 %                                                                                                              | 13.5 %                                                                                                              | Not report ed                                                                                                       | Generics approved in EU member states via MRP                                                                       |
| SoC maintenance treatment                                                                                           | BAVENCIO (avelumab) g                                                                                               | Avelumab+BSC N=350                                                                                                  | 21.4                                                                                                                | 3.7                                                                                                                 | 9.7%                                                                                                                | 6%                                                                                                                  | Not report ed                                                                                                       | Post approval variation 21 Jan 2021 h                                                                               |
| Second-line                                                                                                         | KEYTRUDA (pembrolizu mab) i                                                                                         | Pembrolizumab N=270                                                                                                 | 10.1                                                                                                                | 2.1                                                                                                                 | 21%                                                                                                                 | 9%                                                                                                                  | 29.7                                                                                                                | Post approval variation 24 Aug 2017* j                                                                              |
| Second-line                                                                                                         | TECENTRIQ (atezolizuma b) k                                                                                         | Atezolizumab N=467                                                                                                  | 11.1                                                                                                                | 2.1                                                                                                                 | 13.4 %                                                                                                              | 3%                                                                                                                  | 21.7                                                                                                                | Initial MAA approval** 20 Sep 2017 l                                                                                |
| Second line, less preferred                                                                                         | OPDIVO (nivolumab) m                                                                                                | N=270                                                                                                               | 8.6                                                                                                                 | 2.0                                                                                                                 | 20%                                                                                                                 | 3%                                                                                                                  | 10.4                                                                                                                | Post approval variation 02 June 2017 n                                                                              |
| Second line, less preferred                                                                                         | IMFINZI (durvalumab ) o                                                                                             | N=61                                                                                                                | Not report ed                                                                                                       | Not report ed                                                                                                       | 31.0 %                                                                                                              | Not report ed                                                                                                       | Not reach ed                                                                                                        | Not approved for this indication p                                                                                  |
| ESMO Recommend                                                                                                      |                                                                                                                     |                                                                                                                     | Endpoints                                                                                                           | Endpoints                                                                                                           | Endpoints                                                                                                           | Endpoints                                                                                                           | Endpoints                                                                                                           | EU Marketing Authorisatio                                                                                           |
| ation Second-line in                                                                                                | Product JAVLOR                                                                                                      | Sample Size Vinflunine + BSC                                                                                        | OS (mo)                                                                                                             | PFS (mo) 3.0                                                                                                        | ORR                                                                                                                 | CR                                                                                                                  | DOR (mo)                                                                                                            | n Status Initial MAA                                                                                                |
| patients where anti- PD-(L)1 therapy is not possible                                                                | (vinflunine) q                                                                                                      | N=253                                                                                                               | 6.9                                                                                                                 |                                                                                                                     | 8.6%                                                                                                                | 0%                                                                                                                  | 7.4                                                                                                                 | approval 21 Sep 2009 r                                                                                              |
| Second-line in patients where anti- PD-(L)1 therapy is not possible                                                 | TAXOTERE (docetaxel) s                                                                                              | N=30                                                                                                                | Not report ed                                                                                                       | Not report ed                                                                                                       | Not report ed                                                                                                       | Not report ed                                                                                                       | 4                                                                                                                   | Not approved for this indication t                                                                                  |
| Third-line after platinum and an anti PD-(L)1 agent u,v (includes chemotherapy followed by maintenance avelumab)    | PADCEV (enfortumab vedotin)                                                                                         | enfortumab vedotin N=301                                                                                            | 12.9                                                                                                                | 5.6                                                                                                                 | 40.6 %                                                                                                              | 4.9%                                                                                                                | 7.4                                                                                                                 | Initial MAA approval 13 April 2022 x                                                                                |
| Patients not eligible for cisplatin-based combination chemotherapy                                                  | Patients not eligible for cisplatin-based combination chemotherapy                                                  | Patients not eligible for cisplatin-based combination chemotherapy                                                  | Patients not eligible for cisplatin-based combination chemotherapy                                                  | Patients not eligible for cisplatin-based combination chemotherapy                                                  | Patients not eligible for cisplatin-based combination chemotherapy                                                  | Patients not eligible for cisplatin-based combination chemotherapy                                                  | Patients not eligible for cisplatin-based combination chemotherapy                                                  | Patients not eligible for cisplatin-based combination chemotherapy                                                  |
| First-line SoC                                                                                                      | carboplatin and gemcitabine f                                                                                       | gemcitabine/carb oplatin N=119 methotrexate/ carboplatin/ vinblastine N=119                                         | 9.3 8.1                                                                                                             | 5.8 4.2                                                                                                             | 41.2 % 30.3 %                                                                                                       | 3.4% 3.4%                                                                                                           | Not report ed                                                                                                       | Not applicable, used per treatment guidelines                                                                       |
| SoC maintenance treatment                                                                                           | BAVENCIO (avelumab) g                                                                                               | Avelumab+BSC N=350                                                                                                  | 21.4                                                                                                                | 3.7                                                                                                                 | 9.7%                                                                                                                | 6%                                                                                                                  | Not report ed                                                                                                       | Post approval variation 21 Jan 21 h                                                                                 |
| First line in patients whose tumors express 22C3                                                                    | KEYTRUDA (pembrolizu mab) y                                                                                         | Pembrolizumab N=370                                                                                                 | 11.3                                                                                                                | 2.2                                                                                                                 | 28.6 %                                                                                                              | 8.9%                                                                                                                | 30.1                                                                                                                | Post approval variation 24 Aug 2017* j                                                                              |
| First line in patients whose tumors express SP142                                                                   | TECENTRIQ (atezolizuma b) y                                                                                         | Atezolizumab N=119                                                                                                  | 15.9                                                                                                                | 2.7                                                                                                                 | 22.7 %                                                                                                              | 9%                                                                                                                  | Not reach ed                                                                                                        | Initial MAA approval** 20 September 2017 l                                                                          |

<div style=\"page-break-after: always\"></div>

| Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for Advanced or Metastatic Urothelial Carcinoma a   | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for Advanced or Metastatic Urothelial Carcinoma a   | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for Advanced or Metastatic Urothelial Carcinoma a   |   Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for Advanced or Metastatic Urothelial Carcinoma a |   Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for Advanced or Metastatic Urothelial Carcinoma a | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for Advanced or Metastatic Urothelial Carcinoma a   | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for Advanced or Metastatic Urothelial Carcinoma a   |   Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for Advanced or Metastatic Urothelial Carcinoma a | Treatment Regimens Recommended by the European Society for Medical Oncology (ESMO) for Advanced or Metastatic Urothelial Carcinoma a   |
|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| Second line following anti- PD-(L)1 therapy                                                                                            | PADCEV (enfortumab vedotin) w                                                                                                          | N=89                                                                                                                                   |                                                                                                                                   16.1 |                                                                                                                                    6.7 | 51%                                                                                                                                    | 22%                                                                                                                                    |                                                                                                                                   13.8 | Not approved in this indication x                                                                                                      |

Key: BSC=best supportive care; CR=complete response; ddMVAC=dose-dense methotrexate+vinblastine+doxorubicin+cisplatin; DOR=duration of response; EU=European Union; G+C+P= gemcitabine+cisplatin+paclitaxel; GCSF= granulocyte colony-stimulating factor; ITT=intent-to-treat [analysis]; MAA=marketing authorisation application; mUC=metastatic urothelial carcinoma; MVAC=methotrexate+vinblastine+doxorubicin+cisplatin; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; SoC=standard of care; UC=urothelial carcinoma; US=United States

* Approval as monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy and whose tumours express PDL1 with a combined positive score (CPS) 10 was initially granted on 24 Aug 2017; the indication was later restricted to exclude patients whose tumours express PD-L1 with a CPS &lt;10, based on review of interim analysis data from KEYNOTE-361.
- **   On 2 July 2018, the indication was restricted to include \"and whose tumours have a PDL1 expression 5%,\" based on the review of interim analysis data by the IDMC from study IMvigor211.
- ***   According to the ESMO guideline, treatment with vinflunine, docetaxel, and paclitaxel can be considered for platinum-refractory disease, although vinflunine is the only EMA-approved agent. Combinations with taxanes may be considered as an option in selected patients a

## Sources:

- a. Powles T, Bellmunt J, Comperat E, et al, for the ESMO Guidelines Committee. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(3):244-258. doi: 10.1016/j.annonc.2021.11.012.
- b. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068-3077. doi: 10.1200/JCO.2000.18.17.3068.
- c. Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992; 10:1066-1073.
- d. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and GCSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006; 42:50-54.
- e. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012; 30: 1107-1113.
- f. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012; 30: 191-199.
- g. Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. NEJM. 2020;383(13):1218-1230. doi: 10.1056/NEJMoa2002788.
- h. European Public Assessment Report: Bavencio. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio
- i. Bellmunt J, Necchi A, De Wit R, et al. Pembrolizumab (pembro) versus investigator's choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial. J Clin Oncol. 2021; 39:4532.

j.

European Public Assessment Report: Keytruda. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda

- k. Powles T, Durn I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet.  2018;391(10122):748-757. doi.org/10.1016/S0140-6736(17)33297-X.
- l. European Public Assessment Report: Tecentriq. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq

m.

Galsky MD, Saci A, Szabo P, et al. Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended follow-up from CheckMate 275. Clinical cancer research: an official journal of the American Association for Cancer Research.

2020;26(19):5120-5128. doi:10.1158/1078-0432

- n. European Public Assessment Report: Opdivo. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo
- o. Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016; 34:3119-3125.

p.

European Public Assessment Report: Imfinzi. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi

- q. Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454.
- r. European Public Assessment Report: Javlor. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/javlor
- s. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997;15(5):1853-1857. doi: 10.1200/JCO.1997.15.5.1853.
- t. European Public Assessment Report: Taxotere. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/taxotere
- u. Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021 Mar 25;384(12):1125-1135. doi: 10.1056/NEJMoa2035807.
- v. Rosenberg JE, Powles T, Sonpavde GP, et al. Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. J Clin Oncol. 2022;40(6\\_suppl):4516.
- w. McGregor BA, Bradley A, Balar A, et al. Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2. J Clin Oncol. 2021;39 (suppl 15):4524.
- x. European Public Assessment Report: Padcev. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/padcev5
- y. Vuky J, Balar AV, Castellano D, et al. Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer. J Clin Oncol. 2020; 38: 2658-2666.
- z. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017; 389:67-76.

There is an unmet need for more effective therapies for patients with advanced urothelial cancer having received one or two lines of treatment.

## 2.2. About the product

Erdafitinib is a pan-FGFR tyrosine kinase inhibitor.

Erdafitinib belongs to the pharmacotherapeutic group: antineoplastic agents, protein kinase inhibitors.

ATC code: L01EN01

The claimed indication was Balversa is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations with disease progression during or following at

<div style=\"page-break-after: always\"></div>

least one line of therapy containing a programmed death receptor-1 (PD-1) or programmed deathligand 1 (PD-L1) inhibitor in the locally advanced unresectable or metastatic treatment setting.

The finally approved indication is Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PDL1 inhibitor in the unresectable or metastatic treatment setting (see SmPC section 5.1).

The recommended starting dose of Balversa is 8 mg orally once daily. This dose should be maintained and serum phosphate level should be assessed between 14 and 21 days after initiating treatment. Uptitrate the dose to 9 mg once daily if the serum phosphate level is &lt;9.0 mg/dL, and there is no drugrelated toxicity. After day 21 the dose should not be up-titrated regardless of serum phosphate level. Treatment should continue until disease progression or unacceptable toxicity occurs.

## 2.3. Type of application and aspects on development

Several clinical pharmacology and PK studies have been performed in healthy volunteers and patients with advanced or refractory solid tumours or lymphoma. The clinical pharmacology profile and population pharmacokinetic (PK) and population pharmacokinetic/pharmacodynamic (PK-PD) analyses of erdafitinib, are summarised in this dossier based on data from the completed Phase 1 studies in healthy volunteers, Phase 1 studies in subjects with advanced or refractory solid tumours or lymphoma, the Phase 2 studies in subjects with urothelial carcinoma (BLC2001 and BLC2002), subjects with advanced solid tumours and FGFR alterations (CAN2002), Asian subjects with NSCLC or other selected solid tumours (LUC2001), and the Phase 3 study in subjects with advanced or metastatic UC (BLC3001). The clinical development programme in support of the proposed indication concerns the following clinical studies:

- one phase 3 study BLC3001 with 2 cohorts in patients with advanced urothelial carcinoma:
- -BLC3001 Cohort 1 - in patients who had received 1 or 2 prior treatment including therapy with an anti-PD-(L)1-containing therapy, erdafitinib versus chemotherapy, ie, vinflunine or docetaxel;
- -BLC3001 Cohort 2 - in patients who had received 1 prior treatment, and no prior anti-PD-(L)1containing therapy, erdafitinib versus pembrolizumab.
- Data sets from 2 phase 2 studies in patients with advanced urothelial carcinoma,
- -BLC2001 - in patients who may or may not have received prior therapy; erdafitinib monotherapy.
- -BLC2002 - cohort of erdafitinib monotherapy within multi-arm phase 1b/2 study, no prior therapy.

The study considered to be key to the proposed indication is study BLC3001 cohort 1, a phase 3 randomised, open-label study comparing erdafitinib versus chemotherapy, ie, vinflunine or docetaxel in 'FGFR positive' (for details please refer to biomarker / CDx section below) urothelial carcinoma. Data from cohort 2 are included to support the overall activity of erdafitinib in urothelial carcinoma.

Specific CHMP guidelines relevant for the current application:

- Guideline on the evaluation of anticancer medicinal products in man. EMA/CHMP/205/95 Rev.5, 22 September 2017.
- Points to consider on application with 1. Meta-analyses; 2. One pivotal study. CPMP/EWP/2330/99, 31 May 2001

<div style=\"page-break-after: always\"></div>

CHMP scientific advice in relation to this MAA on quality aspects was obtained in November 2015 (ref. EMEA/H/SA/3195/1/2015/I). CHMP scientific advice in relation to this MAA on nonclinical and clinical aspects was obtained in November 2017 (ref. EMEA/H/SA/3195/2/2017/III).

## Paediatric investigation plan

No paediatric investigation plan (PIP) was submitted. A product specific waiver P/0126/2017 was granted for ureter and bladder carcinoma. The PDCO had agreed that FGFR3 mutations have not been observed in paediatric samples of urothelial cancer.

## 2.4. Quality aspects

## 2.4.1. Introduction

The finished product is presented as immediate release film-coated tablets containing 3 mg, 4 mg or 5 mg of erdafitinib as active substance.

Other ingredients are:

## Balversa 3 mg film-coated tablets

Tablet core Croscarmellose sodium Magnesium stearate (E572) Mannitol (E421) Meglumine Microcrystalline cellulose (E460)

## Film-coating (Opadry amb II)

Glycerol monocaprylocaprate Type I Polyvinyl alcohol-partially hydrolysed Sodium lauryl sulfate Talc Titanium dioxide (E171) Iron oxide yellow (E172)

## Balversa 4 mg film-coated tablets

Tablet core Croscarmellose sodium Magnesium stearate (E572) Mannitol (E421) Meglumine

Microcrystalline cellulose (E460)

Film-coating (Opadry amb II) Glycerol monocaprylocaprate Type I Polyvinyl alcohol-partially hydrolysed Sodium lauryl sulfate Talc Titanium dioxide (E171) Iron oxide yellow (E172) Iron oxide red (E172)

## Balversa 5 mg film-coated tablets

Tablet core Croscarmellose sodium Magnesium stearate (E572) Mannitol (E421) Meglumine Microcrystalline cellulose (E460)

<div style=\"page-break-after: always\"></div>

Film-coating (Opadry amb II) Glycerol monocaprylocaprate Type I Polyvinyl alcohol-partially hydrolysed Sodium lauryl sulfate Talc Titanium dioxide (E171) Iron oxide yellow (E172) Iron oxide red (E172) Iron oxide black (E172)

The product is available in a high-density polyethylene (HDPE) bottle with a child-resistant polypropylene (PP) closure and induction seal liner, or in a polyvinyl chloridepolychlorotrifluoroethylene (PVC-PCTFE) blister with aluminium push-through foil, as described in section 6.5 of the SmPC.

## 2.4.2. Active substance

## 2.4.2.1. General information

The chemical name of erdafitinib is N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1Hpyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine corresponding to the molecular formula C25H30N6O2. It has a relative molecular mass of 446.56 g/mol and the following structure:

<!-- image -->

## Figure 1: Active substance structure

The chemical structure of erdafitinib was elucidated by a combination of elemental analysis, high resolution mass spectrometry (MS), infrared (IR) spectroscopy, ultraviolet (UV) spectroscopy and nuclear magnetic resonance (NMR) spectroscopy. The solid-state properties of the active substance were measured by X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), thermogravimetry (TGA), IR and dynamic vapor sorption (DVS) analysis. Physico-chemical characterisation included appearance, melting point, solubility, permeability, dissociation constant (pKa), partition/distribution (log P/log D) coefficients, specific optical rotation, polymorphism, hygroscopicity, and particle size distribution (PSD).

The active substance is a non-hygroscopic crystalline yellow powder, slightly soluble to practically insoluble or insoluble in aqueous media over a wide range of pH values. However, based on in-vitro permeability and solubility data in combination with human clinical data, it was concluded that erdafitinib qualifies as BCS 1 (Biopharmaceutics Classification System Class 1) compound at the highest proposed clinical dose of 9 mg per intake, despite the fact that erdafitinib is not considered as highly soluble from a chemical point of view. The molecule has a non-chiral molecular structure. Polymorphism has not been observed for erdafitinib. The particle size distribution of the active substance is controlled by the final crystallisation step, which assures consistency in the particle size of each active substance batch.

<div style=\"page-break-after: always\"></div>

The applicant requested erdafitinib to be considered as a new active substance (NAS). During the assessment, a major objection was raised concerning the applicant's justification of erdafitinib NAS claim, requesting additional information about database searches performed by the applicant for structurally related substances in relation to the therapeutic moiety of the claimed NAS. The applicant has adequately addressed this issue and, therefore, erdafitinib is to be qualified as a new active substance in itself as it was concluded that it is not a constituent of a medicinal product previously authorised within the European Union.

## 2.4.2.2. Manufacture, characterisation and process controls

Satisfactory GMP documentation has been provided for all sites involved in manufacturing and testing of the active substance. The synthesis flow scheme for erdafitinib is depicted in the dossier.

The process description for erdafitinib is adequately described, covering all synthesis steps from the firstly used starting materials to the final active substance. The proposed starting materials have been defined in accordance with ICH Q11 and the related Q&amp;A document. The proposed manufacturers are stated for each starting material and the routes of synthesis are indicated. The specifications are considered suitable and ensure the consistent and satisfactory quality of the starting materials. The analytical procedures are described, and validation data of chromatographic methods are presented. Information on structure elucidation has also been provided. Control of other raw materials includes the reagents and solvents of each process step.

During the assessment, a major objection was raised due to insufficient information presented in the dossier with regards to the quality and control of the isolated intermediates. The applicant provided in response the requested information on specifications, analytical procedures, method validations and analytical data for the isolated intermediates. This additional information was assessed as acceptable and the major objection was considered resolved.

An additional major objection was raised during the assessment due to insufficient description of reaction conditions (i.e. quantities or input materials, drying times and temperatures, vacuum and distillation conditions, pH), as well as for the insufficiently justified control strategy. In its response, the applicant provided an updated process flow chart and narrative manufacturing descriptions, based on the quantities of materials used in the process to produce a batch of the typical commercial size. The maximum commercial batch size is stated. Reaction parameters, such as reaction and stirring temperatures and times, distilled amounts, distillation conditions, drying temperatures and drying times are indicated at all reaction stages. The proposed control strategy is considered acceptable with this additional data. Batch analysis data from commercial scale batches demonstrate the consistent quality of the active substance. The major objection is considered resolved.

Process validation on three erdafitinib batches has been conducted.

The characterisation of the active substance and its impurities are in accordance with the EU 'Guideline on chemistry of active substances'. Descriptions of actual and potential impurities as well as their origin, fate and carryover to the final active substance have been provided and assigned to the respective synthesis steps. The specified and unspecified impurities comprise starting materials, intermediates, reagents, solvents, impurities observed in starting materials, reaction by-products and degradation products. These impurities are controlled in the respective starting materials or the final active substance, respectively, or justification for omission of control has been provided, also backed by spiking/purging experiments and batch analysis. Data on structure elucidation (NMR and MS) have been provided for several unspecified impurities and the single specified impurity.

Residual solvents (including potential contaminants) are controlled according to ICH Q3C guideline.

<div style=\"page-break-after: always\"></div>

A risk assessment for the potential presence of elemental impurities was conducted in accordance with the ICH Q3D guideline. Based on the risk assessment and following confirmatory testing using a validated inductively coupled plasma mass spectrometry (ICP-MS) method, it is concluded that testing for each elemental impurity in the active substance specification is not necessary.

Erdafitinib (itself not genotoxic) is indicated for the treatment of patients with unresectable or metastatic urothelial carcinoma, to which ICH S9 applies. As such, potential genotoxic impurities may be controlled according to the limits for non-mutagenic impurities in ICH Q3A. A discussion of genotoxic impurities, including residual class 1 solvents, was nonetheless provided.,. The applicant initially proposed that no additional testing in the active substance is required for these impurities. However, the control and fate of one of these impurities was not sufficiently justified by the applicant and a major objection was raised questioning the control strategy for this impurity. Upon provision of additional comprehensive process-specific data, the major objection was considered resolved. Batch results showed that none of these genotoxic impurities was observed at relevant levels. The depletion of these impurities was demonstrated by the results of spiking studies. In conclusion, routine testing at the active substance level for the impurities identified as potentially mutagenic is not required.

Information on nitrosamines has been provided. There are no nitrosating agents, recovered solvents, reagents or catalysts used in any erdafitinib manufacturing process steps. Nevertheless, a theoretical assessment for the possibility of nitrosamine formation at the level of an intermediate was presented upon request. Based on this data, the presence of nitrosamines at levels of concern in the active substance can be excluded.

The active substance synthesis route has been essentially unchanged during development and has been used to manufacture all batches used in non-clinical and clinical studies, as well as for process qualification and stability testing. Manufacturing process optimisations have been implemented from the initial Synthesis Method A to the proposed commercial Synthesis Method B, leading to a higher purity of the isolated active substance. Changes introduced have been presented in sufficient detail and have been justified. The quality of the active substance used in the various phases of development is considered to be comparable to that produced by the proposed commercial process.

Erdafitinib active substance is packaged in double low-density polyethylene (LDPE) bags with safe seal closure (crimp system), then stored in a HDPE drum. For the primary packaging material, compliance with the Commission Regulation EU/10/2011 has been confirmed, and a specification is provided along with analytical methods, an IR reference spectrum and certificates of analysis.

## 2.4.2.3. Specification

The active substance specification includes tests for: appearance, identity (IR), assay (ultra-high performance liquid chromatography - UHPLC), impurities (UHPLC), residual solvents (gas chromatography - GC) and residue on ignition (Ph. Eur.), the latter being added to the specification following a request raised during evaluation.

The proposed active substance specification includes relevant testing parameters. The specification was established taking into account applicable ICH and EU guidelines and compendial considerations, as well as manufacturing capability, batch analysis data and stability results. Sufficient justification has been provided for the acceptance criteria for the tested parameters.

During assessment, the proposed limit for total impurities has been tightened upon request to align with batch analysis and stability data.

Furthermore, acceptable justifications based on physico-chemical properties of erdafitinib, process characteristics and/or development data are provided for omission from specifications of certain tests.

<div style=\"page-break-after: always\"></div>

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis data for a sufficient number of active substance batches were provided. All batches manufactured by the commercial process meet the acceptance criteria of the active substance specification. Overall, the batch analysis results show that the manufacturing process can produce active substance with consistent quality.

## 2.4.2.4. Stability

Stability data were provided from primary stability erdafitinib batches (manufactured at commercial scale, using the commercial synthesis method, at the synthesis development site and at the commercial site for at least the final manufacturing step) and from process performance qualification (PPQ) erdafitinib batches (manufactured at commercial scale, using the commercial synthesis method, at the commercial site). All active substance batches used in stability studies were stored in the intended commercial package. Results for up to 60 months under long-term conditions (25C / 60% RH) and intermediate conditions (30C / 75% RH) and for up to 6 months under accelerated conditions (40C / 75% RH) according to the ICH guidelines were included in the dossier. Photostability testing following the ICH Q1B guideline and testing under stress conditions (thermal, hydrolytic, oxidative and photochemical conditions, and in the presence of formaldehyde) was also conducted.

The primary stability programme is completed. The PPQ stability programme is ongoing and there are currently 48-month stability data available. The applicant presented a post-approval commitment to report to the agency any confirmed out-of-specification result or significant negative trend, which is endorsed.

The parameters tested are the same as for release, with the exception of several quality attributes which are not expected to change throughout shelf-life. The analytical methods used were the same as for release and were demonstrated to be stability indicating.

Available stability data indicate that erdafitinib active substance remains stable during storage under the different storage conditions, when stored in the proposed container closure system. The test results for all batches, storage conditions and time points comply with the proposed specifications and no significant stability related changes have been observed for any tested parameter.

In conclusion, the stability results indicate that the active substance manufactured by the proposed supplier is sufficiently stable. The stability results justify the proposed retest period of 60 months in the proposed container, without any special temperature storage conditions.

## 2.4.3. Finished medicinal product

## 2.4.3.1. Description of the product and pharmaceutical development

The finished product is presented as film-coated tablets containing 3 mg, 4 mg or 5 mg of erdafitinib as active substance, described as follows:

- The 3 mg tablet is a yellow, round biconvex, film-coated tablet of 7.6 mm in diameter, debossed with '3' on one side and 'EF' on the other side. This tablet has been assigned the formulation number JNJ-42756493-AAA-G023 and may be abbreviated as G023.

<div style=\"page-break-after: always\"></div>

- The 4 mg tablet is an orange, round biconvex, film-coated tablet of 8.1 mm in diameter, debossed with '4' on one side and 'EF' on the other side. This tablet has been assigned the formulation number JNJ-42756493-AAA-G024 and may be abbreviated as G024.
- The 5 mg tablet is a brown, round biconvex, film-coated tablet of 8.6 mm in diameter, debossed with '5' on one side and 'EF' on the other side. This tablet has been assigned the formulation number JNJ-42756493-AAA-G025 and may be abbreviated as G025.

The composition for each strength of erdafitinib finished product is presented in the dossier. The qualitative composition of different strengths is the same, except for the small differences in the film coatings. The quantitative composition of different strengths is proportional. The choice of pharmaceutical form/strengths adequately addresses the proposed dosing regimen.

No novel excipients and no excipients of human or animal origin are used in the manufacture of erdafitinib tablets. The chosen excipients of the immediate release film-coated tablets are described in Ph. Eur., except the Opadry Yellow, Opadry Orange and Opadry Brown coating mixtures, which consists of pharmacopeial ingredients and for which adequate specifications are set. Representative certificates of analysis have been provided for all excipients. The function and rationale for selection of each excipient at the proposed level have been adequately discussed and justified. The compatibility between the active substance and excipients has been demonstrated based on the stability results. The list of excipients is included in section 6.1 of the SmPC and in paragraph 2.4.1 of this report.

No overages are used for the manufacture of the finished product, apart from the overage of coating material to compensate for losses during the film coating step.

The development of the finished product has been described in sufficient detail, starting from oral solution to hard capsules to film-coated tablets. The oral solution was used for Phase 1 studies. A degradation product was observed during development studies and the finished product was changed to a capsule formulation (that was also used in Phase 1 studies) with meglumine used as stabiliser. Finally, film-coated tablets were developed containing 1% meglumine and 2% erdafitinib. Three relative bioavailability studies were performed to support bridging of early formulations to the final commercial formulation. The commercial formulation is the same as the one used in the pivotal Phase 3 clinical study, as well as in clinical pharmacology (Phase 1) and selected Phase 2 studies, with the only difference being the debossing of the tablets which is not expected to impact product quality and performance. Similarity of the commercial formulation and formulation used in clinical phase 3 study has been sufficiently demonstrated by comparative dissolution profiles.

Based on the Quality Target Product Profile (QTPP) established for the finished product which describes a film-coated tablet for oral administration. The development of the manufacturing process is described in sufficient detail. An overview of the finished product critical quality attributes (CQAs) identified, together with a justification for their criticality designation, has also been included in the dossier. Optimisation of various process parameters has been discussed for each manufacturing step and comprehensive control strategy for critical process parameters (CPPs) is set in place.

The development and selection of the dissolution method has been described in sufficient detail and its discriminatory power was adequately demonstrated.

The primary packaging is either a HDPE bottle with a child-resistant PP closure and induction seal liner or a PVC-PCTFE blister with aluminium push-through foil. The materials comply with Ph. Eur. and EC requirements. The provided description and details on specifications and dimensions for the proposed container closure systems are considered sufficient. The choice of the container closure systems has been validated by stability data and both formats are adequate for the intended use of the product.

<div style=\"page-break-after: always\"></div>

## 2.4.3.2. Manufacture of the product and process controls

The erdafitinib finished product is manufactured, filled, packaged, and tested in accordance with GMP.

A flow diagram supplemented by a narrative description of the manufacturing process and selected CPPs and in-process controls (IPCs), is provided in the dossier. Agreed. The manufacturing process has been described in sufficient detail. In-process controls during the finished product manufacture have been established based on the manufacturing process development studies and are considered adequate for this type of pharmaceutical form. Critical IPCs have been defined and justified.

The batch formula is provided for the proposed batch size) and is in accordance with the declared composition of the finished product.

The manufacturing process has been validated on three consecutive commercial scale consecutive batches per strength. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner.

## 2.4.3.3. Product specification

The finished product release and shelf-life specifications include appropriate tests for this kind of dosage form: appearance (visual inspection), identification of the active substance (UHPLC, UV), identification of meglumine (near infrared, NIR - tested only at release), active substance assay (UHPLC), meglumine assay (NIR at release and UHPLC during shelf-life), related substances (HPLC), uniformity of dosage units/content uniformity (UHPLC/Ph. Eur.), dissolution (UHPLC/Ph. Eur.) and microbial purity (Ph. Eur.).

The release and shelf-life specifications presented for the finished product cover relevant parameters for solid oral dosage forms. The applicant provided a comprehensive justification for each specified parameter.

During the assessment, a major objection was raised, requesting tightening of the specification limit for dissolution in line with dissolution data for the proposed commercial formulation used in clinical trials. The applicant agreed to tighten the limit and the major objection was considered resolved.

Specified impurities have been included in the finished product specification and sufficient characterisation, mutagenicity assessment and toxicological qualification information for these impurities were provided. At the request of CHMP, the limits for one specified impurity and the limit for total impurities were tightened and a limit for meglumine was added to the shelf-life specifications. Overall, the limits for impurities at finished product level are in line with ICH Q3B guideline and considered acceptable.

The potential presence of elemental impurities in the finished product has been assessed following a risk-based approach in line with the ICH Q3D guideline. Based on the risk assessment it can be concluded that it is not necessary to include any elemental impurity controls in the finished product specification. The control strategy for residual solvents at the finished product level is justified, in line with ICH Q3C(R8) guideline

A risk assessment concerning the potential presence of nitrosamine impurities in the finished product has been performed considering all suspected and actual root causes in line with the 'Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products' (EMA/409815/2020) and the 'Assessment report- Procedure under Article 5(3) of Regulation EC (No) 726/2004- Nitrosamine impurities in human medicinal products' (EMA/369136/2020). A risk has been identified for potential formation of nitrosamine impurities of erdafitinib and meglumine (both contain

<div style=\"page-break-after: always\"></div>

secondary amines) with residual nitrite in the excipients. Erdafitinib is intended for advanced cancer therapy within the scope of ICH S9, therefore nitrosamines can be controlled to ICH Q3B levels. Nevertheless, nitrite spiking studies have been performed using a validated UHPLC-MS procedures and results demonstrated that nitrosamines are not formed in the finished product. Based on the information provided, it is accepted that there is no risk of nitrosamine impurities at relevant levels in the active substance or the related finished product. Therefore, no specific control measures are deemed necessary.

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis results provided confirm the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

## 2.4.3.4. Stability of the product

Stability data were provided from primary stability batches and PPQ batches of each strength of finished product, manufactured at commercial scale at the commercial site, stored for up to 48 months under long term conditions (25C / 60% RH) and under intermediate conditions (30C / 75% RH) for the finished product packaged in HDPE bottles, for up to 36 months under long term conditions (25C / 60% RH) and under intermediate conditions (30C / 75% RH) for the finished product packaged in PVC-PCTFE blisters and for up to 6 months under accelerated conditions (40C / 75% RH) for both packaging configurations, according to the ICH guidelines.

The primary stability programme is completed, while the PPQ stability programme is ongoing. The applicant presented a post-approval commitment to report to the agency any confirmed out-ofspecification (OOS) result or significant negative trend, which is endorsed.

A bracketing approach is applied for stability studies. Only 3 mg and 5 mg batches have been tested for the full stability programme, whereas the only test performed on stability for the 4 mg strength was the appearance of the tablet. This approach is considered acceptable. Furthermore, 2-month inuse stability studies for the finished product packaged in HDPE bottles were performed at the beginning and end of shelf-life using the 3 mg strength as it is considered worst case due to the lowest active substance concentration. This is acceptable.

In addition, finished product batches were subjected to forced degradation studies, including exposure to light in line with ICH Q1B.

Stability testing was conducted according to the proposed commercial release specifications and methods, except for the assay of meglumine as described in product specification section of this report. The analytical methods used in the stability studies were demonstrated to be stability indicating.

In general, in both primary stability and PPQ stability programs, results met the specification limits under all storage conditions for all strengths of finished product when packaged in HDPE bottles or PVC-PCTFE blisters.

A slight increase within specification limits in specified degradation products has been observed for the primary stability batches stored under intermediate conditions, when packaged in HDPE bottles or PVCPCTFE blisters. However, no stability related changes were observed for the PPQ batches. A slight decrease within specification limits in assay of meglumine was observed during storage under all tested conditions for the finished product packaged in HDPE bottles or PVC-PCTFE blisters. This decrease is

<div style=\"page-break-after: always\"></div>

expected as meglumine acts as a formaldehyde scavenger. In addition, a slight decrease within specification limits in dissolution upon storage at intermediate and accelerated conditions was observed and was sufficiently explained by the applicant. An OOS result for dissolution at the 30-month time point was observed for one 5 mg PPQ batch when stored at 30C/75% RH and packaged in HDPE bottles or PVC-PCTFE blisters. However, it is expected that finished product stored as indicated within the EU will be of adequate quality at the end of shelf-life in both packaging formats.

In conclusion, the observed physical and chemical changes were small and not likely to have a significant effect on efficacy and safety of the product when used according to the directions in the SmPC.

Based on available stability data, the proposed shelf-life of 48 months for the finished product packaged in HDPE bottles and of 36 months for the finished product packaged in PVC-PCTFE blisters, without any special storage conditions (as stated in the SmPC (section 6.3)) is acceptable.

## 2.4.3.5. Adventitious agents

No excipients derived from animal or human origin have been used.

## 2.4.4. Discussion on chemical, and pharmaceutical aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

During assessment, five major objections were raised on quality grounds concerning: (1) incomplete justification of the erdafitinib new active substance claim, (2) missing critical information from the dossier with regards to the quality and control of isolated intermediates, (3) inappropriate description of reaction conditions and insufficient justification for the process control strategy applied for the active substance synthesis, (4) incomplete justification for the proposed control strategy for one genotoxic impurity at the active substance level and (5) tightening of specification limit for dissolution of the finished product. The major objections, as well as all the other concerns raised throughout the procedure, have been satisfactorily resolved.

## 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.4.6. Recommendations for future quality development

Not applicable.

<div style=\"page-break-after: always\"></div>

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

Erdafitinib is an orally active small molecule inhibitor of all four isoforms of FGFR kinase with potent activity in vitro and anti-tumour activity in vivo in FGFR pathway-dependent xenograft tumour models bearing FGFR activating alterations.

Erdafitinib is proposed for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma, harbouring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations with disease progression during or following at least one line of therapy containing a programmed death-1 receptor (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor in the locally advanced unresectable or metastatic treatment setting.

The non-clinical programme has been designed according to ICH (International Council for Harmonisation) S9 guideline on non-clinical evaluation of anticancer pharmaceuticals in line with the proposed indication (advanced cancer).

The nonclinical primary pharmacodynamic profile of erdafitinib was characterised in several in vitro and in vivo models.

Secondary pharmacodynamic studies were performed in vitro to assess the potential of erdafitinib to inhibit off-target receptors, ion channels, or neurotransmitter transporters.

Erdafitinib was investigated in a battery of safety pharmacology studies to evaluate potential effects in the cardiovascular and respiratory systems. The disposition of erdafitinib including absorption, distribution, metabolism, and excretion was evaluated in nonclinical species (rat, dog) and was compared with pharmacokinetic information obtained in humans, where applicable. Toxicokinetic (TK) assessments were included in all safety/toxicology and investigative toxicology studies.

## 2.5.2. Pharmacology

## 2.5.2.1. Primary pharmacodynamic studies

## In vitro pharmacology

Erdafitinib activity was evaluated against a panel of 387 kinases (KinomeScan) using a site-directed ATP-independent competition binding assay. Erdafitinib binds to all four isoforms of FGFR with IC50 around 1 nM. Six other kinases had IC50 values in low nanomolar range as shown in parentheses: RET (2.05 nM), PDGFRB (3.56 nM), CSF-1R (3.94 nM), FLT4 (4 nM), VEGFR2 (5.88 nM), and KIT (6.95 nM).

To confirm the in vitro activity in a cellular context, the BaF3-engineered model system was studied. In cellular assays, erdafitinib inhibited growth of FGFR1-overexpressing BaF3 cells in the absence of IL3 with an IC50 of 19 nM. The inhibitory effect was reduced around 480-fold in the presence of IL-3. The IC50 values for FGFR3- and FGFR4-overexpressing BaF3 cells in the absence of IL-3 were 11.3 nM and 24.4 nM, respectively. In contrast, growth inhibition of VEGFR2-dependent cells required the IC50 of 1,190 nM demonstrating lower erdafitinib potency against this kinase in a cellular context as compared to the biochemical assay.

To demonstrate the ability of erdafitinib to inhibit the proliferation of non-engineered cell lines, the compound was tested against a panel of 21 human tumour cell lines with different tissue origins and driver alterations. The evaluation showed that eight of them had IC50 values of less than 10 nM.

<div style=\"page-break-after: always\"></div>

Among these 8 cell lines were representatives of lung, gastric, colorectal and bladder cancer (RT-112 and RT-4) cell lines, the latter exhibiting IC50 values of 1.13 nM and 4.8 nM, respectively. A study in another panel of 82 cell lines of 17 tumour entities and in broader panels of 271 breast and lung cancer cell lines revealed an association of nanomolar GI50 activity with FGFR overexpression.

Erdafitinib inhibited FGFR autophosphorylation in four cell lines featuring activation of each FGFR isoform, namely in SNU-16 gastric cancer (FGFR2) and MDA-MB-453 breast cancer (FGFR4) cells at the concentrations of 10 nM and higher, in the KMS-11 multiple myeloma (FGFR3) cell line from 30 nM onwards and in NCI-H1581 lung cancer (FGFR1) cells from 100 nM. In the latter cell line, the phosphorylation of FGFR substrate 2 alpha (FRS2  ), a direct downstream target of FGFR, and the endogenous phosphorylation of ERK1/2 was also inhibited. Sustained inhibition of FGFR phosphorylation for at least 8 hrs was also demonstrated following a 1-h incubation of FGFR2-amplified Kato III gastric cancer cells with erdafitinib. This extended pEGFR inhibition was associated with lysosomal accumulation of the compound.

## In vivo pharmacology

Anti-tumour activity of erdafitinib were evaluated in xenograft models implanted in CD-1 mice.

In RT-112 (cell line derived from a human urinary bladder transitional cell carcinoma) bladder cancer xenografts in CD-1 mice, erdafitinib significantly dose-dependently reduced tumour growth and significantly decreased the final tumour weight by 85% (p=0.0001) at the oral dose of 25 mg/kg QD. In BALB-c nude mice with RT-112 bladder cancer xenografts, erdafitinib led to significant tumour growth inhibition of 101.3% (p&lt;0.0001) at 12.5 mg/kg BID administered orally. A good PK/PD correlation was observed in BALB/c mice as peak plasma and tumour concentrations of erdafitinib were associated with the maximum pERK inhibition (around 40%). Cmax of erdafitinib at the efficacious dose of 12.5 mg/kg BID was 28.5 ng/ml, which is far below the average plasma concentration observed for the minimum dose in patients (4 mg QD: total Cmax 675 ng/ml). However, in the RT112VM tumour model with FGFR3-V555M mutation tumour growth inhibition did not exceed 36.9% (p = 0.0595).

Beside bladder cancer, good anti-tumour activity was demonstrated in several gastric cancer models (e.g. KatoIII and SNU-16). Tumour regression was observed from doses of 6.25 mg/kg BID (Cmax = 91.3 ng/ml) or 20 mg/kg QD. A correlation between plasma levels of erdafitinib and inhibition of FGFR phosphorylation was observed in SNU-16 xenografts.

Overall, efficacy was low in breast and lung cancer models and modest in liver cancer xenografts. In a small number of lung cancer PDX models with FGFR alterations, erdafitinib efficacy was better in models with higher FGFR fusion expression levels.

Erdafitinib exhibited tumour growth inhibition in hepatocellular carcinoma xenografts with FGF19 amplification or FGF19 overexpression but not in the case of simultaneous HGF overexpression, and not in cholangiocarcinoma PDX models with FGF19 gene amplification.

## 2.5.2.2. Secondary pharmacodynamic studies

In vitro receptor binding assays were done in a panel of 51 targets (receptors, ion channels, neurotransmitter transporters) demonstrated 55.6-85.5% inhibition of 10 targets at 10 M and 55% inhibition of 5-HT1B at 1 M.

## 2.5.2.3. Safety pharmacology programme

In vitro studies

<div style=\"page-break-after: always\"></div>

In HEK293 cells transfected with the hKvLQT1/hminK genes, erdafitinib inhibited IKs current with the IC50 value of 25.3 M. This is far above the unbound clinical plasma Cmax of 11.5 nM. . In hERGtransfected HEK293 cells, IKr current was inhibited with IC50 of 408 nM, which is 35.5-fold higher than the expected clinical plasma levels of erdafitinib. However, low recovery of locally applied drug concentrations was observed in the hERG assay. The corrected IC50 value could not be determined since the recovery was only measured at one test item concentration (10  M).

## In vivo studies

The potential electrophysiological effects of erdafitinib were assessed at concentrations from 10 nM to 10 M in isolated, arterially perfused rabbit ventricular wedge preparations. Relative to vehicle (n = 6), erdafitinib (n = 6) at 10 and 100 nM did not significantly or physiologically relevantly change the QT interval and TdP score. At 1 and 10 M, erdafitinib significantly prolonged the QT interval (+10% and +29%, respectively) and increased TdP score (+2.0 and +3.5, respectively). Erdafitinib significantly and dosedependently increased the Tpeak to Tend interval at 100 nM .

In guinea pigs, erdafitinib dose-dependently increased the duration of the QT and QTcB intervals starting from 2.5 mg/kg IV (Cmax = 1740 ng/ml corresponding to unbound Cmax = 184 ng/ml). These erdafitinib levels are 35.8 times higher than clinical unbound Cmax of 11.5 nM. The duration of the PQ interval increased at 20 mg/kg, and QRS duration significantly increased after administration of 40 mg/kg. Profound ECG changes were observed starting at 20 mg/kg. In the isolated, spontaneously beating right atrium of the guinea pig, erdafitinib slightly to moderately decreased the rate of contraction at 3 and 10 M (it should be noted that the actual organ exposure was below 66% threshold). The compound dose-dependently increased the force of contraction relative to controls.

In artificially ventilated anesthetised dogs, an increase in the duration of the QT interval and in the action potential duration (APD) at 90% of repolarisation at the endocardium of the right ventricle were seen at 0.32 mg/kg (unbound Cmax = 59.2 ng/ml). At 0.63 mg/kg (unbound Cmax = 112 ng/ml), a decrease in pulmonary artery blood pressure and left ventricular end-diastolic pressure, increases in the duration of the PQ interval and in the duration of QTcB and QTcF intervals were noted, with no morpholog ic changes of the ECG. At 1.25 mg/kg, a dose -dependent decrease was noted in left ventricular dp/dtmin. At 2.5 mg/kg, an increase in heart rate and a concomitant decrease in RR interval duration were observed. At 10 mg/kg, erdafitinib induced a tendency to increase aortic blood pressure (systolic and diastolic), the time constant of relaxation (tau) and pressure rate product. Cardiovascular effects in this study were observed at the lowest dose applied, with the exposure being only 11.5-fold the expected clinical exposure based on Cmax, u.

## In vivo GLP studies

Erdafitinib was administered orally to male beagle dogs (n = 4/dose) at escalating doses of 1, 2.5 and 5 mg/kg body weight. A vehicle solution containing 20% w/v hydroxypropyl -cyclodextrin was also administered. Toxicologically relevant changes in respiratory rate and oxygen saturation rate were absent at every dose tested. A single oral administration of erdafitinib to conscious male Beagle dogs up to 2.5 mg/kg (Cmax = 90.2 ng/ml, Cmax,u = 12.4 ng/ml) did not induce any relevant changes in cardiovascular and ECG parameters. After dosing at 5 mg/kg (Cmax = 265 ng/ml, Cmax,u = 36.3 ng/ml), a decrease in heart rate and a prolongation of the QT interval were seen in one dog. When corrected for heart rate, minimal increases in QTcB (14.2% and 12.5%) and QTcF (13.0% and 10.6%) were observed in the same dog. The Cmax in this dog was 228 ng/ml (unbound Cmax = 31.2 ng/ml based on 13.7% of unbound erdafitinib in dog plasma) and was lower than the average. The safety margin in this GLP study was only 2.4.

<div style=\"page-break-after: always\"></div>

Erdafitinib did not cause any respiratory changes in conscious dogs at oral doses up to 5 mg/kg (total plasma exposure of 265 ng/ml; unbound concentration of 36.3 ng/ml). This represents a safety margin of ca. 7 relative to the unbound Cmax for a 9 mg QD clinical dose.

No dedicated safety pharmacology study was performed to evaluate CNS effects of erdafitinib. CNS endpoints were included in the toxicology studies and the effects are described in Toxicology section.

## 2.5.2.4. Pharmacodynamic drug interactions

No studies on pharmacodynamics drug interactions were conducted. This is acceptable as erdafitinib is not intended to be used in combination therapies.

## 2.5.3. Pharmacokinetics

The disposition of erdafitinib including absorption, distribution, metabolism, and excretion was evaluated in rats and dogs and was compared with pharmacokinetic information obtained in humans, where applicable.

## 2.6. Methods of analysis

Table 2. Overview of the validated bioanalytical methods

| Study nr.   | Analyte     | Matrix                | Range           | Method   | GLP status    |
|-------------|-------------|-----------------------|-----------------|----------|---------------|
| BA10077     | erdafitinib | dog plasma            | 0.2 - 100 ng/ml | LC-MS/MS | no formal GLP |
| BA10081     | erdafitinib | dog Li-heparin plasma | 0.2 - 100 ng/ml | LC-MS/MS | no formal GLP |
| BA10981     | erdafitinib | rat plasma            | 0.4 - 400 ng/ml | LC-MS/MS | no formal GLP |
| BA10076     | erdafitinib | rat plasma            | 0.4 - 400 ng/ml | LC-MS/MS | no formal GLP |

## Absorption

Following IV administration, the volume of distribution for erdafitinib in mice, rats and dogs was moderate and exceeded total body water, indicating distribution outside plasma. Plasma clearance was high, exceeding hepatic blood flow in rats and dogs and nearing hepatic blood flow in mice. After oral dosing, the Tmax was rapid in mice and moderate in rats and dogs. The T1/2 was short in rodents and dose-dependent in dogs. Oral bioavailability was low in rodents (12% in mice; ca. 1.8% in rats) and complete in dogs (&gt;100%).

Systemic exposure (Cmax and AUC) to erdafitinib generally increased more than dose proportionally in all 3 species, with accumulation ranging from 1.2x to 4.6x for Cmax and from 1.3x to 6.9x for AUC compared to single-dose exposures.

## Distribution

Erdafitinib was found to be a moderate-to-high permeability compound.

<div style=\"page-break-after: always\"></div>

Binding of  3 H-erdafitinib to plasma proteins from Swiss CD1 mouse (pool of males and pool of females), Sprague Dawley rat (pool male and female), NMRI/Nu mouse (pool of males), nude rat RNU (pool of males), Beagle dog (pool of male and female) and human (males) was investigated by means of equilibrium dialysis.

Plasma protein binding of erdafitinib was species-specific. The free fraction ranged from 5.9 to 11.3% in mice, between 2.2 and 7.2% in rats and was 10.6% in guinea pigs and 13.7% in dogs. In human plasma, erdafitinib was highly protein-bound with a concentration-dependent free fraction of 0.55 to 0.74%. Among plasma proteins, strong association with  1-acid glycoprotein was observed.

Binding to microsomal proteins was the weakest in the rat with free fractions of 94.6 - 98.0% and stronger in the dog (fu between 76.4 and 77%). In human, binding to microsomal proteins was concentration-dependent and an unbound fraction ranged from 24.8 to 86.1%.

Blood-to-plasma partitioning was also species-specific. Blood-to-plasma ratio in human (0.6) was the lowest, followed by the nude RNU rat (0.8), mouse and Sprague Dawley rat (around 1), and Beagle dog (1.61).

In Sprague Dawley rats, highest erdafitinib concentrations were found in lungs and in the liver. No brain accumulation was observed. In pigmented rats following administration of [ 14 C]-erdafitinib, high radioactivity levels were detected in the small intestine wall, the liver and the kidney outer medulla. After 72 h post-dose, radioactivity was still present in the lens of the eye and uveal tract/ciliary body, kidney (cortex and medulla), liver, spleen, exorbital lacrimal gland, intra-orbital lacrimal gland, , nonpigmented and pigmented skin and the gastrointestinal tract walls. No apparent association of erdafitinib with melanin was noted.

## Metabolism

Intrinsic clearance, Km and Vmax of  3 H-erdafitinib were determined in rat, dog and human liver and intestinal microsomes and in human and dog hepatocytes.

Metabolic rate of erdafitinib decreased in the order rat &gt; mouse &gt; dog &gt; human. The metabolism was saturated in animal species at 3  M, but not in humans. In human and rat hepatocytes, most important in vitro metabolic pathways were O-demethylation (M6) followed by glucuronidation (M2or oxidation (M9). In rat hepatocytes, in addition to a few unidentified more hydrophilic secondary metabolites, other metabolites resulted from addition of one oxygen (M5) and a combination of addition of one oxygen and glucuronidation (M3). In dog hepatocytes, metabolites M2, M6 and M9 were detected.

3 H-erdafitinib was orally administered to male rats at 4 and 60 mg/kg and male dogs at 0.25 and 1 mg/kg. For both species, metabolic profiles in plasma were qualitatively comparable between both doses. In rat plasma, M2 was by far the major circulating entity at 4 mg/kg whereas at 60 mg/kg the parent drug and M2 were observed, which is in line with saturation kinetics. In dog plasma, parent drug and metabolites M2, M4 and M11 (addition of one oxygen) were the major circulating entities. Minor entities detected in plasma were M1 (rat only), M3, M4 (rat only), M5, M6, M7, M8 (Ndealkylation) and M9 (rat only). In rat faeces, the main components were the unchanged drug (4.56% of the dose), and metabolites M6 (O-demethylation, 9.55% of the dose), M5 (addition of one oxygen, 1.68% of the dose), M4 and M7 (loss of 2 hydrogens, 6.64% and 5.01% of the dose, respectively). The glucuronide of M6 (M2), prominent in plasma, was absent in faeces probably due to deconjugation to its aglycon M6 in the gut microflora. In dog faeces, unchanged erdafitinib (1.39% and 5.37% of the low and high dose, respectively), M4 and M7 and numerous minor metabolites were seen. M4 and M7 are likely artefacts formed from M6.

<div style=\"page-break-after: always\"></div>

In rat urine, M2 was by far the most important entity (0.97% of the dose) following 4 mg/kg. At 60 mg/kg, M2 represented 1.09% of the dose while its aglycon M6 was also important (0.9% of the dose). Minor metabolites in rat urine resulted from a combination of oxidation and glucuronidation (M3) and a combination of O-demethylation and loss of two hydrogens followed by addition of one oxygen (M9). In dog urine, only metabolite M2 (0.74% of the low dose and 1.09% of the high dose) and unchanged erdafitinib (0.24% of the low dose and 0.36% of the high dose) were detected.

In the pooled faeces extracts from the bile duct-cannulated rats administered oral  14 C-erdafitinib at 4 mg/kg, M6 and the parent drug were the main entities representing 16.3% and 21.5% of the administered dose. M20 (aglycon of M13) represented 1.94% of the dose. These entities could be attributed to intestinal secretion. The main metabolites in rat bile were M2 (formed by O-demethylation of erdafitinib (M6) and subsequent glucuronidation, 14.2 % of the dose), M15 (addition of one oxygen to M6 on the phenyl (M26) and subsequent glucuronidation, 9.24 % of the dose) and M13 (further Odemethylation of M6 (M20) and subsequent glucuronidation, 4.08% of the dose).

In plasma of mice, only parent erdafitinib was found after oral dosing. After IV administration, M6 and M8 (N-depropylation) were detected beside the unchanged drug. In mouse faeces, M20 (36% of the oral dose and 25% of the IV dose), M6 and M9 (-CH2, -2H,+O) were observed. In urine, M13 (2x Odemethylation and glucuronidation, 1.4% of the oral dose and 4.5% of the IV dose), M20 (2x Odemethylation), M2 (O-demethylation and glucuronidation) and M6 (O-demethylation) were detected.

Erdafitinib metabolism in human liver microsomes was low. Therefore, human hepatocytes were considered a more suitable system to investigate the involvement of CYP enzymes. The formation of M6 was inhibited by ketoconazole by 22% and by sulphaphenazole by 90.6% indicating that CYP2C9 is mainly involved in M6 metabolic pathway with a minor contribution of CYP3A4. The formation of M8 is largely mediated by CYP3A4 as it was inhibited by ketoconazole by 73%. These results were further confirmed by metabolic profiling in CYP-specific supersomes and suggest that mainly CYP2C9 and CYP3A4 are responsible for erdafitinib biotransformation in human.

Unchanged erdafitinib was by far the major drug-related material in human plasma. Thus, no metabolites represented more than 10% of the total drug-related material. In human faeces, parent drug (14.1 - 20.8% of the dose) and M6 formed by O-demethylation (23.8 - 24.2% of the dose) were the major entities. The main component in urine was unchanged compound (11.3% of the dose) followed by M6 (2.05%). No human-specific metabolites were found.

## Excretion

Erdafitinib was predominantly excreted via faeces in animals (through biliary route) and humans. Faecal elimination represented 66.4-69.9% of the total radioactivity in human healthy volunteers, 3874% in mice, 75.2-75.8% in dogs, and 87.6-95.1% in intact rats. In bile duct-cannulated rats, 12% of the dose was excreted in faeces and 47.9% via bile. The contribution of the renal elimination was 17.8-19.2% of the total radioactivity in humans, 2-12% in mice, 5.44-6.30% in dogs, 2.32-2.73% in intact rats, and 30.6% in bile duct-cannulated rats.

## 2.7. Pharmacokinetic drug interactions

## Potential interactions with metabolic enzymes

Erdafitinib was found not to inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 and CYP2D6 at clinically relevant concentrations. The compound was demonstrated to be an irreversible inhibitor of CYP3A. Erdafitinib does not induce CYP1A2 and CYP2B6. Its effect on CYP3A4 is less clear. In one of three donors, erdafitinib induced CYP3A4 more than 2-fold at 15Cmax,u and above, albeit a clear

<div style=\"page-break-after: always\"></div>

concentration dependency was missing. The applicant investigated the impact of erdafitinib on the PK of CYP3A4 substrate midazolam (see clinical part).

The effect on UGT enzymes was not investigated.

Erdafitinib is a P-gp substrate. Due to saturation of the P-gp-mediated transport above 0.3  M, DDI at intestinal level can be excluded as 0.1dose/250ml = 8.06  M. Erdafitinib is not a substrate of BCRP, OATP1B1 and OATP1B3.

Erdafitinib is an in vitro inhibitor of P-gp, MATE1, MATE2-K, OCT1, OCT2.

## 2.7.1. Toxicology

## 2.7.1.1. Single dose toxicity

Single dose toxicity studies with erdafitinib were not performed.

## 2.7.1.2. Repeat dose toxicity

Repeat-dose oral toxicity was evaluated in albino Swiss mice dosed for up to 2 weeks, in SpragueDawley rats and Beagle dogs dosed for up to 3 months.

Rats and dogs were selected as relevant species for the pivotal 1- and 3-month repeat-dose toxicology studies since erdafitinib was shown to be pharmacologically active in both animal species.

<div style=\"page-break-after: always\"></div>

## 3-Month Oral Toxicity Study in Rats (TOX10846)

Table 3: 3-Month oral toxicity study in rats

|   Study ID | Species/ Sex/Number/ Group                                                       | Dose/Route/ (Vehicle/Form ulation)                  | NOAEL                                       | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|------------|----------------------------------------------------------------------------------|-----------------------------------------------------|---------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|      10846 | Rats (Sprague Dawley) 0, 4, 8, 16 + 32 mg/kg: 10M + 10F TK for all doses 3M + 3F | 0, 4, 8 mg/kg q.d. PO 16, 32 mg/kg 7 days on/off PO | Males: 4 mg/kg q.d. Females:  4 mg/kg q.d. | 0 mg/kg No noteworthy findings 4 mg/kg q.d. 1 F died - gavage-related M: FGF23  , D3 , , DPD  , PTH  F: FGF23  8 mg/kg q.d. M: FGF23  , D3  , DPD  , PTH , Ca  F: FGF23 , D3  , DPD  , PTH  , Ca , sternum deformation (2 females), broken nail (1 animal), reticulocytes+platelets , chondroid dysplasia (sternum, stifle), atrophic changes of harderian gland, increased number of hair follicles in skin, mineralisation of kidney M+F : diffuse cornea atrophy of the eyes Diffuse atrophy of exorbital lacrimal gland 16 mg/kg 7 days on/off M: AST  , ALT  , AST , GGT, FGF23, limping, deformed tail (2/10), F: AST  , ALT , FGF23, PTH , limping, deformed sternum (2/10) 32 mg/kg 7 days on/off 2 M died - gavage-related 1 M died - treatment-related M: FGF23, D3, PTH , cycle tail deformation (7/10), sternum deformation (5/10), limping (10/10) F: FGF23, D3, PTH , cycle tail deformation (1/10), sternum deformation (9/10), limping (7/10), necrosis of ovarian corpora lutea, acute inflammation of the cervix 16+32 mg/kg M+F: deformities + discoloration of bones and incisors, chondroid dysplasia, mineralisation of kidney, atrophy of tongue epithelium and oral mucosa |

M: males, F: females, P phosphate, FGF23: fibroblast growth factor-23, PTH: parathyroid hormone, D3: 1,25 (OH)2 vitamin D3, Ca: calcium, ALP: alkaline phosphatase, WBC: white blood cells, DPD: Deoxypyridinoline, AST: aspartate aminotransferase, ALT: alanine aminotransferase, GGT:  -glutamyltranferase

Mortalities were reported at 8 mg/kg/day (daily dosing) and 32 mg/kg/day (intermittent dosing, 7 days on/7 days off). The cause of death at 8 mg/kg/day was not determined, and the deaths at 32 mg/kg/day were attributed to soft tissue mineralisation of the heart and aorta, which were proposed to have contributed to the rats' poor condition.

The predominant microscopic findings included atrophy of gland structures, chondroid dysplasia in multiple bones and larynx+trachea, soft tissue mineralisation of multiple organs, atrophy, decreased

<div style=\"page-break-after: always\"></div>

cellularity, degeneration of ontoblasts, degeneration/inflammation and increase in hair follicles/reduced size. Test-article-related effects on female reproduction organs were reported at 32 mg/kg/day.

Table 4: Mean toxicokinetic data of erdafitinib in 3-month oral toxicity study in rats.

<!-- image -->

| Dose (mg/kg)              | Study Day   | C..x (ng/mL)   | C..x (ng/mL)   | AUCo-24h (ng-h/mL)   | AUCo-24h (ng-h/mL)   |
|---------------------------|-------------|----------------|----------------|----------------------|----------------------|
|                           |             | M              | E              | M                    | E                    |
| 4 (q.d)                   | 6           | 2.64           | 6.43           | 10.1!]               | 29.612]              |
|                           | 90          | 6.98           | 13.4           | 26.312]              | 45.2                 |
| 8 (q.d)                   | 6           | 6.40           | 31.9           | 29.6[11              | 94.32]               |
|                           | 90          | 26.212         | 59.7 257       | 99.82]               | 2312] 936            |
| 16 (7 days on/7 days off) | 6           | 28.0           |                | 105]                 |                      |
|                           | 90          | 88.5           | 462            | 32712]               | 1780                 |
| 32 (7 days on/7 days off) | 6           | 524            | 886            | 558011               | 4170                 |
| 32 (7 days on/7 days off) | 90          | 3602]          | 929            | 191012]              | 100002]              |

n=3 uuless otherwise stated l. AUC values from individual animals were excluded when calculated with more than 25%extrapolation

Day 6 and Day 90 is at the end of the first and last 7-day dosing period for the intermittently dosed groups.

F = female: M =male

## 3-Month Oral Toxicity Study in Dogs (TOX10849)

The purpose of this study was to determine and assess the potential toxicity of JNJ-42756493-AAA, when administered once daily by the oral route (via gavage) to beagle dogs, for a period of three months. Additionally, one group was included which was dosed daily every other week to investigate the effects of intermittent dosing.

The toxicokinetic parameters of JNJ-42756493-AAA were also studied.

<div style=\"page-break-after: always\"></div>

Table 5: 3-Month oral toxicity study in dogs.

|   Study ID | Species/ Sex/Number/ Group                                         | Dose/Route/ (Vehicle/Form ulation)                    | NOAEL            | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|------------|--------------------------------------------------------------------|-------------------------------------------------------|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|      10849 | Dogs (Beagle) 0, 0.5, 0.75, 1.5 + 4M + 4F TK for all doses 4M + 4F | 0, 0.5, 0.75 mg/kg q.d. PO 1.5 mg/kg 7 days on/off PO |  0.5 mg/kg q.d. | 0 mg/kg No noteworthy findings 0.5 mg/kg q.d. M: FGF23  , ocular discharge F: FGF23 , reticulocytes , , WBC  , thyroid weight , chondroid dysplasia of distal femur M+F : epithelial atrophy of tongue, parotid salivary gland + lacrimal glands, rough haircoat, piloerection, longer nails 0.75 mg/kg q.d. M: FGF23  F: FGF23 , hunched posture, stiffness of the hindlegs, reticulocytes , thyroid weight , follicle of thyroid gland M+F : rough haircoat, piloerection, longer nails, abnormal red skin, P, PTH , D3 Urine: DPD, ocular changes, irregular surface/mineralisation of heart + aorta , chondroid dysplasia of sternum + femur, epithelial atrophy of tongue, parotid salivary gland + lacrimal glands 1.5 mg/kg 7 days on/off M: haemorrhagic faeces (1) F: follicle of thyroid gland, increased hair follicles of skin ear M+F: rough haircoat, piloerection, longer nails, abnormal red skin, reticulocytes , , WBC  , ALP , FGF23 , PTH , abnormal dentin, atrophy of tongue + oral mucosa Urine: DPD  , ocular changes, irregular surface/mineralisation of heart + aorta , chondroid dysplasia of sternum + femur, epithelial atrophy of parotid salivary gland + lacrimal glands, abnormal dentin |

M: males, F: females, P phosphate, FGF23: fibroblast growth factor-23, PTH: parathyroid hormone, D3: 1,25 (OH)2 vitamin D3, Ca: calcium, ALP: alkaline phosphatase, WBC: white blood cells, DPD: Deoxypyridinoline, AST: aspartate aminotransferase, ALT: alanine aminotransferase

At the dose of 0.5 mg/kg/day, ocular changes consisted of bilateral watery or purulent ocular discharge, periocular alopecia, blepharospasm, diffuse corneal opacification and low tear production.

The predominant target organs were aorta (vascular/degeneration), heart (mineralisation/degeneration), bone femur and sternum (chondroid dysplasia), skin (increased hair follicles) and epithelial atrophy in the tongue, oral mucosa, parotid salivary glands, eye, teeth and lacrimal glands.

<div style=\"page-break-after: always\"></div>

Table 6: Mean toxicokinetic data of erdafitinib in 3-month oral toxicity study in dogs. (from Module 2.6.6)

| Dose (mg/kg)               | Study Day   | Cmx (ng/mL)   | Cmx (ng/mL)   | AUCo-24h (ng-h/mL)   | AUCo-24h (ng-h/mL)   |
|----------------------------|-------------|---------------|---------------|----------------------|----------------------|
|                            |             | M             | E             | M                    | F                    |
| 0.5 (q.d.)                 | 6           | 18.5          | 8.45          | 108                  | 40.2                 |
|                            | 90          | 21.6          | 15.9          | 172                  | 92                   |
| 0.75 (q.d.)                | 6           | 27.2          | 20.7          | 218                  | 146                  |
|                            | 90          | 38.9          | 26.1          | 394                  | 213                  |
| 1.5 (7 days on/7 days off) | 6           | 117           | 71.0          | 1130                 | 682                  |
|                            | 90          | 113           | 98.1          | 1300                 | 969                  |

n=4:F =female; M=male

Systemic exposure to JNJ-42756493 increased in a greater than proportional manner across the dose range on Day 6 and Day 90 in both sexes. Because of the high inter-animal variability, a sex-related difference could not be determined

## 2.7.1.3. Genotoxicity

In vitro , erdafitinib was negative for an increase in reverse mutations in Ames tests in bacteria and for chromosomal aberrations, polyploidy and endoreduplication in a micronucleus test in TK6 cells, respectively. Erdafitinib did also not increase the formation of micronuclei in PCEs of rat bone marrow in vivo at MoE of &gt; 90 x based on Cmax (unbound).

## 2.7.1.4. Carcinogenicity

Not conducted.

## 2.7.1.5. Reproductive and developmental toxicity

The reproductive and developmental toxicity of erdafitinib was investigated in a non-GLP pilot study and a GLP pivotal embryo-foetal toxicity study in Sprague-Dawley rats. In accordance with ICHS9 and ICHS5 (R3) guidelines no studies on fertility and early development and on pre- and postnatal development have been performed. Furthermore, due to the embryolethal and teratogenic effects in rats, investigation in a second species was not necessary.

Effects on epididymides and testes were observed in a non pivotal 2-week rat study at exposure levels &gt;10-fold those reached in humans.

Table 7: Pivotal embryo-foetal developmental study in Sprague-Dawley rats with erdafitinib.

| Study ID / GLP /TK           | Number Female/ group   | Route & dose (mg/kg/day)                          | Dosing period   | Endpoints                                                                                                                                                                                                                                                                           |       |
|------------------------------|------------------------|---------------------------------------------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|
| TOX12329 / GLP: yes/ TK: yes | Main: 22 TK: 6         | Oral (gavage) Ctrl: 0 (vehicle) LD: 1 MD: 4 HD: 8 | GD6 to GD17     | Maternal animals: Mortality, clinical signs, food consumption and body weight Post-mortem evaluation: macroscopic abnormalities, pregnancy status, the numbers of corpora lutea of pregnancy, implantations, early and late resorptions, and live and dead foetuses. Live foetuses: | F0 F1 |

<div style=\"page-break-after: always\"></div>

| Body weight, sex External, visceral and skeletal abnormalities   |
|------------------------------------------------------------------|

## Major findings

##  1 mg/kg q.d

## Maternal observations:

-  FC during GD 18-20
-  BWG during GD 15-20

## Litter data:

-  No Corpora lutea, no implantations, no live foetuses,

##  4 mg/kg q.d

## Foetal observations:

-  Foetal BW
-  Foetal anomalies (% F/L):

Visceral: subclavian artery, retroesophageal (0.8/4.5)

## 8 mg/kg q.d

## Maternal observations:

-  BWG during GD 12-15
-  Corrected BWG

## Litter data:

-  early, late and total resorptions
-  mean % post-implantation loss

## Foetal observations:

-  Foetal anomalies (% F/L):

Visceral:

Gross external:

ectrodactyly (7.6/25.0)

Visceral: aortic arch, retroesophageal (11.7/42,9); aortic arch, interrupted (5/21.4); subclavian artery, retroesophageal (8.3/28.6)

Skeletal: paw, multiple abnormalities associated with ectodactyly (9.9/25.0); thoracic vertebrae, multiple abnormalities (8.5/25.0); limb, multiple abnormalities: absent, bent or misshapen long bones (7.0/18.8)

## Toxicokinetics

|                                        | 1 mg/kg     | 4 mg/kg    | 8 mg/kg   |
|----------------------------------------|-------------|------------|-----------|
| AUC 0-last (ngh/mL)                   |             |            |           |
| Day 6                                  | NC          | 14.4       | 47.1      |
| Day 17                                 | NC          | 24.1       | 105       |
| Cmax (ng/mL)                           |             |            |           |
| Day 6                                  | 0.68        | 4.93       | 12.7      |
| Day 17                                 | 0.73        | 10.0       | 38.8      |
| Proof of foetal exposure (D17) (ng/mL) |             |            |           |
| Dams/foetuses +1 hour                  | 0.827/<LLOQ | 10.5/<LLOQ | 32.2/1.34 |
| Dams/foetuses +2 hours                 | 0.436/<LLOQ | 5,17/0.545 | 38.2/2.63 |

## NOAEL (mg/kg &amp;AUC)

## Relative Exposure Multiples

| Steady-state Exposure in Human Subjects and at Relevant Doses in Toxicology Studies   | Maternal AUC (ngh/mL)              | Maternal AUC (ngh/mL)              | Unbound (Free) Exposure Multiples at Relevant. Clinical Doses   | Unbound (Free) Exposure Multiples at Relevant. Clinical Doses   |
|---------------------------------------------------------------------------------------|-------------------------------------|-------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
|                                                                                       | Total                               | Unbound c                           | 4 mg q.d.                                                       | 9 mg q.d.                                                       |
| 4 mg q.d. human exposure - minimum clinical dose (Day 21))                            | 13516 a                             | 37.8 a                              | NA                                                              | NA                                                              |
| 9 mg q.d. human exposure - maximum clinical dose (Day 21)                             | 39587 b                             | 98.7 b                              | NA                                                              | NA                                                              |
| Rat Embryo-foetal Development Study                                                   | Rat Embryo-foetal Development Study | Rat Embryo-foetal Development Study | Rat Embryo-foetal Development Study                             | Rat Embryo-foetal Development Study                             |
| 1 mg/kg q.d. (GD 17)                                                                  | NC d                                | NC d                                | NC d                                                            | NC d                                                            |
| 4 mg/kg q.d. (GD 17)                                                                  | 24.1                                | 1.74                                | <0.1x                                                           | <0.1x                                                           |

F0 Females:

8 mg/kg q.d.

F1 Litters: 1mg/kg q.d.

<div style=\"page-break-after: always\"></div>

| 8 mg/kg q.d. (GD 17)   | 105   | 7.56   | 0.2x   | 0.1x   |
|------------------------|-------|--------|--------|--------|

a  Mean steady-state plasma AUC after 21 days of daily erdafitinib administration at the minimum clinical dose of 4 mg q.d. in Part 1 of Study EDI1001 in Patients (5 subjects)

b  Mean steady-state plasma AUC after 21 days of daily erdafitinib administration at the maximum recommended clinical dose of 9 mg q.d. in Part 2 of Study EDI1001 in Patients (Mod5.3.3.2/EDI1001/Tab16; 6 subjects)

c  Mean unbound fraction of erdafitinib is 7.2% in rat plasma, respectively.

d  (due to the limited plasma concentrations available, no AUC evaluation was possible)

NA=not applicable; NC= not calculated; TK=toxicokinetics; GD=gestation day; BWG=body weight gain; BW=body weight; LD=low dose; MD=mid dose; HD=high dose; FC=food consumption; Ca=calcium; F=foetus; L=litter; q.d.=once daily

## 2.7.1.6. Toxicokinetic data

Table 8: Nonclinical exposure multiples in animals and humans

| Steady-state Exposure in Human Subjects and at Relevant Doses in Toxicology Studies   | AUC (ng-h/mL)   | AUC (ng-h/mL)              | Unboumd (Free) Exposure Multiples at Relevant Clinical Doses   | Unboumd (Free) Exposure Multiples at Relevant Clinical Doses   |
|---------------------------------------------------------------------------------------|-----------------|----------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
|                                                                                       | Total           | Unboumd *4 mg q.d.9 mg q.d |                                                                |                                                                |
| 4 mg q.d. human exposure - minimum climical dose (Day 21)                             | 13,516          | 37.84                      |                                                                |                                                                |
| 9 mg q.d. human exposure - maximum clinical dose (Day 21)                             | 39,587 b        | 98.7 b                     |                                                                |                                                                |
| Rat 3-Month Repeat-Dose Toxicity Study                                                |                 |                            |                                                                |                                                                |
| 8 mg/kg q.d. (highest daily dose) - males (Day 90)                                    | 866             | 7.19                       | 0.2x                                                           | 0.1x                                                           |
| 8 mg/kg q.d. (highest daily dose) - females (Day 90)                                  | 231             | 16.6                       | 0.4x                                                           | 0.2x                                                           |
| Dog 3-Month Repeat-Dose Toxicity Study                                                |                 |                            |                                                                |                                                                |
| 0.75 mg/kg q.d. (highest daily dose) - males (Day 90)                                 | 394             | 54.0                       | 1.4x                                                           | 0.5x                                                           |
| 0.75 mg/kg q.d. (highest daily dose) - females (Day 90)                               | 213             | 29.2                       | 0.8x                                                           | 0.3x                                                           |
| Rat Embryo-fetal Development Study                                                    |                 |                            |                                                                |                                                                |
| 4 mg/kg q.d. (teratogenicity level) (Gestation Day 17)                                | 24.1            | 1.74                       | 0.1x                                                          | =0.1x                                                          |

*Mean steady-state plasma AUC after 21 days of daily erdafitinib adminishration at the minimum clinical dose of 4 mg q.d in Paut l of Study ED1100l in Patients (Mod5.3.3.2/ED1100l/Tabl6)

b Mean steady-state plasma AUC after 21 days of daily erdafitinib adminishation at the maximum recommended clinical dose of 9 mg q.d. in Part 2 of Study ED11001 in Patients (Mod5.3.3.2/ED1100l/Tab16)

* Mean umboumd fiaction of erdafitinib is 7.2% and 13.7% in rat and dog plasma, respechively.

- = not applicable

## 2.7.1.7. Local Tolerance

## Skin sensitisation - Local Lymph Node Assay in the Mouse (TOX10363)

Assessment of erdafitinib's skin sensitisation potential has been performed using the local lymph node assay (LLNA).

CBA/Ca mice (4 females/group) received control or erdafitinib at concentrations of 2.5%, 5%, or 10% (in dimethylformamide). The mice were treated by daily application of 25  L of the appropriate concentration or control to the dorsal surface of both ears for 3 consecutive days. The proliferative response of the lymph node cells from the draining auricular lymph nodes was assessed 5 days following the initial application, by measurement of the incorporation of 3H-methyl thymidine.

The stimulation indices obtained for 2.5, 5 and 10% were 2.7, 4.1 and 7.7, respectively, relative to concurrent vehicle-treated controls. As a stimulation index of 3 or more was recorded for 2 of the concentrations tested, erdafitinib was considered to have the potential to cause skin sensitisation. The concentration of erdafitinib, which would result in a stimulation index of 3 relative to concurrent vehicle-treated controls, was calculated to be 3.5%.

<div style=\"page-break-after: always\"></div>

## 2.7.1.8. Other toxicity studies

Other Toxicology Studies included phototoxicity, skin sensitivity, eye and vascular irritation tests.

## Phototoxicity

Erdafitinib absorbs light in the range of 200 - 450 nM with molar extinction coefficients substantially higher than the 1000 l mol -1  cm -1  threshold for photoreactive compounds of the ICH S10 guideline. The phototoxic potential of erdafitinib was determined in two independent in vitro non-GLP 3T3 NRU phototoxicity tests using Balb/c 3T3 mouse fibroblasts. Both experiments revealed Photo-irritation factors (PIF) &gt; 5 (152.5 and 290.07) and thus, erdafitinib was phototoxic in vitro . In a subsequent in vivo phototoxicity study in male pigmented rats the highest concentration used in the in vivo phototoxicity study was in the range of clinical unbound Cmax (8.352 ng/ml) at the MRHD of 9 mg/d while exposure ratio based on AUC were below 1 (0.4 x). The phototoxicity in the eye was not assessed. A constellation of dermatologic adverse events has been observed in clinical trials with erdafitinib. These skin disorders are class effects of FGFR tyrosine kinase inhibitors (erdafitinib, pemigatinib, infigratib, futibatinib) and target related rather than phototoxicities. Toxic events of the skin (including palmar-plantar erythrodysaesthesia syndrome, dry skin, rash, erythema, skin ulcer, xeroderma, rash maculo-papular, skin exfoliation, skin fissures, skin lesion, hyperkeratosis, skin atrophy) occurred in &gt; 50 % in the clinic with erdafitinib.

## Skin sensitivity, eye and vascular irritation tests

Erdafitinib caused skin sensitisation in the murine local lymph node assay at concentrations of 3.5%. Erdafitinib did not induce any vascular irritation in the HET-CAM assay. In an in vitro Bovine Corneal Opacity-Permeability Eye Irritation assay, erdafitinib induced a severe increase in corneal opacity that was associated with microscopic changes in the corneal epithelium and stroma. As such, erdafitinib scored positive as an eye irritant.

## Impurities

Two impurities, (process impurity and degradation product) and (degradation product) were observed at or above the reporting threshold of 0.05 % (ICH Q3A/B). JNJ-42541707 with maximal batch levels of 0.07 % (0.06 %) was toxicologically qualified in the 3-month oral repeat dose toxicity study in rats (TOX10846) up to 32 mg/kg/d whereas JNJ-55002818 was qualified in an independent qualification study of 1-month duration in the rat (TOX10565) spiked with and without 4 % of the degradation product.

For impurity the highest dose used in the study was 32 mg/kg/d corresponding to a toxicologically qualified impurity limit of 2.06% in humans at a maximal dose of 9 mg daily.

For impurity the study results exhibited no differences in relation to clinical signs, clinical chemistry and haematology measurements and histopathology findings. All changes observed were small, and/or fell within the range of the historical control data or vehicle values. Additionally, the toxicity profile was consistent with that observed in the 1 and 3-month toxicity studies at equal dose levels. The toxicologically qualified impurity dose at NOAEL in rat was 0.16 mg/kg/d corresponding to a toxicologically qualified impurity limit of 88.9 % in humans.

A risk assessment and classification of all impurities concerning the mutagenic potential was evaluated according to ICH M7 by means of analysis by database and literature searches for carcinogenicity and mutagenicity data and in silico assessment by SAR prediction methodologies (DEREK and SARAH) and LEADCCOPE. In case of a suspected structural alert, an AMES test has been conducted.

<div style=\"page-break-after: always\"></div>

## 2.7.2. Ecotoxicity/environmental risk assessment

The applicant provided a Phase I ERA including the PECSURFACEWATER calculation.

Using a default Fpen of 0.01, the PECSURFACEWATER was calculated to be 0.045 g/L. Thus, the PEC does meet the Phase I PEC Trigger. Additionally, for Fpen, a refinement based on prevalence was used in Phase I. Based on estimates from the International Agency for Research on Cancer (IARC), the prevalence of urothelial carcinoma in Europe ranges from 8.9 (Moldova) to 45.2 (Greece) in 100000.

Therefore,

FPEN-REFINED = PREGION = 0.000452

The Phase I PECSURFACEWATER is recalculated as:

PECSURFACE WATER = (9mg/day x 0.000452 x 1000 g/mg)/(200 L/day x 10)

## PEC SURFACE WATER = 0.002 g/L

The recalculated Phase I PECSURFACEWATER based on the FPEN-refined is &lt; the action limit of 0.01 g/L.

For the PBT screening the applicant cited the study from Janssen Report (study no.: DS-TEC-110422).

## Summary of main study results

| Substance (INN/Invented Name): Erdafitinib                          | Substance (INN/Invented Name): Erdafitinib   | Substance (INN/Invented Name): Erdafitinib                                                                                      | Substance (INN/Invented Name): Erdafitinib   |
|---------------------------------------------------------------------|----------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|
| CAS-number (if available): 1346242-81-6                             | CAS-number (if available): 1346242-81-6      | CAS-number (if available): 1346242-81-6                                                                                         | CAS-number (if available): 1346242-81-6      |
| PBT screening                                                       |                                              | Result                                                                                                                          | Conclusion                                   |
| Bioaccumulation potential- log K ow                                 |                                              | log Kow = 3.96 log Dow (pH 1) = -1.03 log Dow (pH 4) = -0.05 log Dow (pH 7) = 1.77 log Dow (pH 9) = 3.55 log Dow (pH 12) = 3.96 | Potential PBT, N Validity check pending      |
| Phase I                                                             | Phase I                                      | Phase I                                                                                                                         | Phase I                                      |
| Calculation                                                         | Value                                        | Unit                                                                                                                            | Conclusion                                   |
| PEC surfacewater , default or refined (e.g. prevalence, literature) | 0.002                                        |  g/L                                                                                                                           | > 0.01 threshold N                           |
| Other concerns (e.g. chemical class)                                |                                              |                                                                                                                                 | N                                            |

## 2.7.3. Discussion on non-clinical aspects

Erdafitinib has a high binding affinity in low nanomolar range (below or around the unbound Cmax of 11.5 nM at the recommended clinical dose (9 mg once daily)) for all four isoforms of FGFR and six other kinases (RET, PDGFRB, CSF-1R, FLT4, VEGFR2 and KIT). For FGFR kinases, potent binding of erdafitinib translated into inhibition of FGFR phosphorylation and of downstream signalling and into cell growth inhibition in FGFR-dependent BaF3 cells and non-engineered lung, gastric, colorectal and bladder cancer cell lines. Erdafitinib potency against VEGFR2, FLT4, PDGFRB, RET and KIT was lower in a cellular context as compared to the biochemical assay.

The antiproliferative selectivity of erdafitinib was tested on a large panel of human cancer cell lines of diverse tissue origin. Results highlighted the functional selectivity of erdafitinib for FGFR altered pathway. Erdafitinib inhibited the proliferation of a panel of selected cancer cell lines harbouring FGFR

<div style=\"page-break-after: always\"></div>

alterations, including the RT-112 cell line that was derived from a human urinary bladder transitional cell carcinoma (alterations of FGFR3) with IC50 of 1.3 nM. JNJ-42756493 has lysosomotropic properties in vitro and this lysosomal accumulation of JNJ-42756493 contributes to extended target inhibition.

Erdafitinib-induced tumour regression in RT-112 mouse bladder cancer xenograft model (featuring FGFR3 alterations) demonstrating a good PK/PD correlation as erdafitinib plasma levels corresponded to pERK inhibition. Pharmacological activity of erdafitinib in bladder cancer models was observed at clinically relevant concentrations supporting the proposed indication. However, in the RT112-VM tumour model with FGFR3-V555M mutation erdafitinib activity was acceptable.

No clinically relevant off-target activity of erdafitinib was observed in in vitro receptor binding assays.

Erdafitinib inhibited IKs current with the IC50 value of 25.3 M, which is far above the unbound clinical plasma Cmax of 11.5 nM. In hERG-transfected HEK293 cells, IKr current was inhibited with IC50 of 408 nM, which is 35.5-fold higher than the expected clinical plasma concentrations of erdafitinib. However, low recovery of drug concentrations was reported in this assay. Low drug recovery was observed in the assay but the corrected IC50 value was not determined.

In guinea pigs, intravenous erdafitinib increased the duration of the QT and QTcB intervals in a dosedependent fashion from 2.5 mg/kg onwards (unbound Cmax = 184 ng/ml, 35.8 times higher than clinical unbound Cmax). In artificially ventilated anesthetised dogs, an increase in the duration of the QT interval and in the action potential duration (APD) at 90% of repolarisation at the endocardium of the right ventricle were observed starting at 0.32 mg/kg (unbound Cmax = 59.2 ng/ml, 11.5-fold the expected clinical exposure based on Cmax,u).

In a dedicated GLP safety pharmacology study in dogs, 5 mg/kg oral erdafitinib decreased heart rate and prolonged QT interval in one animal. The NOAEL was 2.5 mg/kg with Cmax of 12.4 ng/ml representing 2.4-fold of the expected clinical exposure which is not considered acceptable as a safety margins. As this effect appears in the clinical exposure range it is included in the RMP part II module SII and the SmPC section 5.3.

Erdafitinib had no effect on respiratory parameters in dogs when administered up to 5 mg/kg corresponding to ca.7-fold clinical exposure based on Cmax.

The bioanalytical methods for determination of erdafitinib in rat and dog plasma were successfully developed and validated. Mouse studies were conducted as non-GLP and non-pivotal.

Plasma protein binding and blood-to-plasma partitioning of erdafitinib was species-specific. An unbound fraction in human was 0.55-0.74%. Among plasma proteins, erdafitinib was strongly bound to  1-acid glycoprotein. In rats, highest erdafitinib concentrations were found in lungs and in the liver. No brain accumulation was detected. No apparent association of erdafitinib with melanin was observed.

Metabolic rate of erdafitinib decreased in the order rat &gt; mouse &gt; dog &gt; human. The main metabolic pathways of erdafitinib were Phase I reactions (O-demethylation and oxidation) followed by glucuronidation. A good correlation between in vitro and in vivo metabolism was observed. No humanspecific metabolites were detected. In humans, CYP2C9 and CYP3A4 are mainly responsible for erdafitinib biotransformation. Erdafitinib was predominantly excreted through faeces in animals (via biliary route) and humans.

Erdafitinib is not an inhibitor of the most major CYP enzymes but the compound irreversibly inhibits CYP3A. Erdafitinib is a P-gp substrate and inhibits OCT2 and P-gp to a clinically relevant extent and is reported in section 4.5 of the SmPC.

Repeat-dose toxicology studies were performed in rats and dogs. In the pivotal 1-month (data not shown) and 3-month dog toxicology studies, no mortality was observed during the treatment window

<div style=\"page-break-after: always\"></div>

or in the recovery period. This is in contrast to the rat pivotal studies where mortality occurred during the 3-month study but not during the 1-month (data not shown) study. Every other day (QOD) administration was not better tolerated than daily administration (QD).

The predominant microscopic findings reported in rats included atrophy of gland structures (mammary gland), soft tissue mineralisation of multiple organs (kidneys, lung, stomach, tongue, duodenum), decreased cellularity (bone marrow femur), chondroid dysplasia (larynx, trachea), degeneration of odontoblasts (teeth) and degeneration/inflammation heart.

Neurobehavioural endpoints as safety parameters were included in the 1-month rat study using a modified Irwin's method (see PD part above). Erdafitinib showed minimal neurofunctional aberrations (impaired wire manoeuvre and flaccid body tone), which were considered a potential direct effect of treatment, from a maximum plasma concentration (Cmax) of 12.1 ng/mL (unbound concentration of 0.871 ng/mL) which is below the clinical steady-state Cmax (total or unbound) for a 9 mg once daily dose. No effects on the CNS were observed with the other FGFR inhibitors (Pemazyre, Febseltiq, Lytgobi). A possible hypothesis could be the acutely drug induced imbalance of inorganic phosphorus, of which an acute increase could lead to rapid but transient muscle weakness (lower muscle strength). Although these findings were observed in the clinical range at the recommended clinical dose, these are minimal and transient. Thus, it is concluded that the risk of a translational effect on locomotion in human is considered minimal and that no evidence exists that point out similar locomotor effects occurring in humans.

The toxicity profile determined in rats and dogs is consistent between the two species and with other FGFR inhibitors. Toxicities observed with erdafitinib are considered related to the inhibition of FGF/FGFR pathways in different tissues. FGFR inhibitors, via FGF23 pathways, are known to induce hyperphosphataemia in vivo . In animal studies, hyperphosphataemia resulted in histological findings of soft tissues mineralisation mainly in aorta, heart and/or stomach. The animal-to-human exposure ratios at the lowest dose levels where hyperphosphataemia in combination with soft tissues mineralisation occurred at below the clinical exposure range in dogs and at clinical exposure range in rats. In general, there were dose-related increases in serum phosphate levels across the dose groups, and soft tissues mineralisation was observed at higher serum phosphate levels.

In investigative studies, more pronounced histopathological changes were seen in rats which received the low phosphate and Vitamin D3 deficient diet when compared to those receiving a normal diet. The administration of a phosphorus-scavenger diet (sevelamer 3%) significantly reduced all vascular and mineralisation lesions when compared with animals that received a low phosphorus diet, although higher exposures were noted in the P-scavenger groups. This result might be an important issue in the clinical setting and clinical recommendations for hyperphosphataemia are made in the SmPC section 4.2.

FGFR signalling has been implicated in lens induction, lens cell proliferation and survival, lens fibre differentiation and lens regeneration. Therefore, the findings in the eye can be attributed to the direct effect of erdafitinib on the ocular system.

Relative exposure multiples were calculated using unbound concentrations because of the large species differences in unbound fraction. The animal-to-human exposure ratios at the highest daily dose of 8 mg/kg and 0.75 mg/kg tested in the 3-month rat and dog study, respectively, are low (&lt;1). Thus, interpretation of the observed adverse effects is difficult since the exposure multiples following repeat dose administration of erdafitinib are much lower than the AUC in humans at the intended clinical dose of 8 or 9 mg.

Findings of the repeat-dose toxicology studies are reflected under section 5.3 of the SmPC.

<div style=\"page-break-after: always\"></div>

Erdafitinib was evaluated in a standard GLP genotoxicity battery (AMES, in vitro micronucleus on TK6 cells and rat micronucleus after oral administration for 2 days). All studies performed met the criteria requested in the related recommendations and allow the conclusion that erdafitinib had no genotoxicity properties. This is reflected in section 5.3 of the SmPC.

In accordance with ICH S9 guideline, carcinogenicity studies are not warranted to support marketing for therapeutics intended to treat patients with advanced cancer. No preneoplastic lesions and/or tissue-specific proliferative effects occurred in the general toxicity studies. This is reflected in section 5.3 of the SmPC.

Erdafitinib was phototoxic in vitro and not phototoxic in vivo at or below clinical exposures. Skin toxicity events were observed in the clinic and occurred in &gt; 50% of erdafitinib subjects. These findings were similarly observed with other agents of that pharmacological class of active ingredients (FGFR tyrosine kinase inhibitors) and were target related rather than photoactivated drug induced cytotoxicity. To avoid potential phototoxicity recommendation for sun exposure protection when in treatment with erdafitinib is included in the SmPC (see SmPC section 4.4.).

A risk assessment and classification of all impurities concerning the mutagenic potential was evaluated according to ICH M7 by means of analysis by database and literature searches for carcinogenicity and mutagenicity data and in silico assessment by SAR prediction methodologies (DEREK and SARAH) and Leadscope. A following review of human expert knowledge confirmed the final conclusion on mutagenicity (review not presented). The classification of the potential genotoxic impurities according to ICH M7 was agreed.

## Reproductive and developmental toxicity

The reproductive and developmental toxicity of erdafitinib has been sufficiently investigated in embryofoetal developmental studies in rats according to the guidelines ICH S9 and ICH S5 (R3).

Dedicated animal fertility studies have not been conducted with erdafitinib. Erdafitinib showed effects on female reproductive organs in rats in 3-months study (necrosis of the corpora lutea) at exposure approximating the AUC in patients at the maximum recommended dose of 9 mg q.d. (see SmPC 5.3). Ovarian corpora lutea necrosis can potentially impact fertility. However, these studies may have a low sensitivity to detect any effect on human fertility since exposure levels attained in treated animals were not significantly higher than those measured in patients. Effects on epididymides and testes were observed in a non pivotal 2-week rat study at exposure levels &gt;10-fold those reached in humans.

Literature supports a role for FGFR signalling in multiple aspects of regulation and maintenance of the male and female reproductive systems. Given the involvement of FGF/FGFR signalling in reproductive physiology, potential for impairment of fertility in male and female patients through inhibition of FGFR signalling by a small molecule pan-FGFR tyrosine kinase inhibitor cannot be excluded. This is adequately reflected in section 4.6 of the SmPC.

Erdafitinib was clearly embryolethal and teratogenic in rats at exposures far below the human exposure at the maximum recommended dose of 9 mg q.d. Based on the mechanism of action of erdafitinib (FGFR tyrosine kinase inhibitor), the effects on embryo-foetal development seen in rats are expected. These effects should be regarded as relevant for humans and erdafitinib should be classified as a suspected human teratogen.

Adequate recommendations for use during pregnancy in line with the 'Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labelling' (EMEA/CHMP/203927/2005) are included in section 4.4 and 4.6 of the SmPC.

<div style=\"page-break-after: always\"></div>

## Environmental risk assessment

Erdafitinib PECsurfacewater value is below the action limit of 0.01 g/L and a Phase II ERA is considered not necessary. Erdafitinib is potentially not a PBT substance. However, the data presented are preliminary and a conclusion cannot be made until the study report is submitted. The applicant is requested to submit a study report on an experimentally derived logKow as post-authorisation measure by Q1 2025 (REC).

## 2.7.4. Conclusion on the non-clinical aspects

Anti-tumour activity of erdafitinib achieved through FGFR inhibition was demonstrated in vitro and in vivo . Beside FGFR, erdafitinib targets other kinases at clinically relevant concentrations in biochemical assays but the activity in the cellular context is lower. Cardiovascular and respiratory effects of erdafitinib were characterised in a series of safety pharmacology studies including toxicokinetic assessment.

The pharmacokinetics and DDI potential of erdafitinib were thoroughly investigated.

The toxicity profile of erdafitinib in rats and dogs is overlapping and most of the findings could be attributed to the pharmacological activity of erdafitinib as an irreversible inhibitor of FGFR. Effects included increased inorganic phosphorus and calcium in plasma, ectopic mineralisation in various organs and tissues as well as lesions in bone/cartilage. The findings occurred at exposures lower than the human exposure at the intended clinical dose of 8 mg. Most effects were reversible with the exception of chondroid dysplasia in rats and dogs and ectopic mineralisation. Erdafitinib exerts no genotoxic potential. However, a phototoxic risk for erdafitinib at clinical exposures cannot be ruled out. Erdafitinib is teratogenic and causes foetal harm when administered to pregnant women. Further, erdafitinib scored positive as an eye irritant.

Overall, the toxicology programme of erdafitinib is adequate.

As the ERA is concerned, the applicant will submit a study report on an experimentally derived logKow as post-authorisation measure by Q1 2025 (REC).

## 2.8. Clinical aspects

## 2.8.1. Introduction

## GCP aspects

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Table 9: Overview of Studies Contributing Information to the Summary of Clinical Pharmacology Studies

| Study ID                   | Objective(s)                                                                            | Participants                                                                                                         | Dose                                                                         | Route                     | Formulation                                                                                                                                                        | Included in Pop PK   | Pivotala   |
|----------------------------|-----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|------------|
| 42756493ED11001 (ED11001)  | Single and multiple dose PK                                                             | Participants with advanced or refractory solid tumors or lymphoma                                                    | 0.5,2,4,6,9, 12 mg once daily 10, 12 mg, intermittent (7 days on/7 days off) | Oral                      | Part 1 Once daily: oral solution or capsule Intermittent doses: capsule Part 2 Once daily: capsule Part 3: Once daily: capsule Part 4: Intermittent doses: capsule | X                    |            |
| 42756493EDI1005 (EDI11005) | Absorption, metabolism, excretion                                                       | Healthy male participants                                                                                            | 12 mg                                                                        | Oral                      | Single oral solution containing 12 mg unlabeled erdafitinib admixed with 14C-erdafitinib                                                                           | X                    |            |
| 42756493EDI1007 (EDI1007)  | Drug interaction Erdafitinib alone Erdafitinib + fluconazole Erdafitinib + itraconazole | Healthy participants                                                                                                 | 4 mg                                                                         | Oral                      | Tablet                                                                                                                                                             |                      |            |
| 42756493EDI1008 (ED11008)  | Single dose PK Hepatic Impairment                                                       | Participants who either have hepatic impairment or normal hepatic function who qualify for the healthy control group | 6mg (2x3 mg), single dose                                                    | Oral (fasting condition  | 3,4, and 5 mg tablets X                                                                                                                                            |                      |            |

<div style=\"page-break-after: always\"></div>

| Study ID                               | Objective(s)                                                                                     | Participants                                                                                                                                                                       | Dose                                                                | Route                           | Formulation                                                        | Included in Pop PK   | Pivotal*   |
|----------------------------------------|--------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------|--------------------------------------------------------------------|----------------------|------------|
| 42756493NAP1001 (NAP1001)              | Drug interaction Erdafitinib alone Erdafitinib + carbamazepine                                   | Healthy participants                                                                                                                                                               | 12 mg (3x4 mg)                                                      | Oran (standard ized breakfast ) | 4 mg tablets                                                       | X                    |            |
| 42756493BLC2001 (BLC2001) Main Study   | Efficacy and PK                                                                                  | Participants who had histologic demonstrationfor metastatic or surgically unresectable urothelial cancer, that harbor target FGFR3 gene mutations or FGFR gene fusions             | 6, 8 mg once daily 10 mg intermittent (7 days on/7 days off)        | Oral                            | Regimen 1 Intermittent: tablet Regimens 2 and 3 Once daily: tablet | X                    | X          |
| 42756493BLC2001 (BLC2001) DDI Substudy | Drug interaction Midozalam alone Erdafitinib + Midozalam Metformin alone Erdafitinib + Metformin | Participants with advanced solid tumors, including those with metastatic or surgically umresectable urothelial cancer, that harbor target FGFR gene mutations or FGFR gene fusions | 8 mg with the possibility of uptitration                            | Oral                            | Tablet                                                             | X                    |            |
| 42756493GAC1001 (GAC1001)              | Single and multiple dose PK                                                                      | Japanese participants with advanced or refractory solid malignancies or lymphoma                                                                                                   | 2,4, 6 mg once daily 10, 12 mg, intermittent (7 days on/7 days off) | [.10                            | Part 1 Once daily: capsule Part 1 Intermittent doses: capsule      | X                    |            |

<div style=\"page-break-after: always\"></div>

| StudyID                   | Objective(s)                | Participants                                                                                                                         | Dose                                                                                                                                                                          | Route   | Formulation Included in Pop PK   | Pivotala   |
|---------------------------|-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|----------------------------------|------------|
| 42756493HCC1001 (HCC1001) | Single and multiple dose PK | Asian participants with advanced HCC                                                                                                 | Intermittent dosing: 8, 10, or 12 mg; Continuous dosing: 8 mg                                                                                                                 | Oral    | 3,4, and5 mg tablets X           |            |
| 42756493LUC2001 (LUC2001) | PK and PD                   | Asian participants with NSCLC or selected solid tumors (urothelial cancer, gastric cancer, esophageal cancer, and cholangiocarcinoma | 8 mg (with option to uptitrate to 9 mg)                                                                                                                                       | Oral    | 3,4, and 5 mg tablets X          |            |
| 42756493BLC2002 (BLC2002) | PK and PD                   | Participants with metastatic or locally advancedurotheliai cancer                                                                    | 6 or 8 mg (with/without option to uptitrate to 9 mg depending on cohort)                                                                                                      | Oral    | 3,4, and 5 mg tablets X          |            |
| 42756493CAN2002 (CAN2002) | PK and PD                   | Participants with advanced solid tumors and FGFR gene alterations                                                                    | Adults and Adolescents (15 to <18 years): 8 mg (with possible uptitration to 9 mg) Adolescents (12 to <15 years): 5 mg (with possible uptitration to 6 mg or further to 8 mg) | Oral    | 3,4, and 5 mg tablets X          |            |
| 42756493BLC3001 (BLC3001) | Efficacy and PK             | Participants with advanced urothelial cancer andselected FGFR gene aberrations                                                       | 8 mg                                                                                                                                                                          | Oral    | 3,4, and5 mg tablets X           |            |

a  PK and/or PK-PD results described in proposed label.

## 2.8.2. Clinical pharmacology

Erdafitinib (referred to as JNJ-42756493 during early development) is an oral pan-FGFR tyrosine kinase inhibitor (FGFR 1, 2, 3 and 4).

Erdafitinib has been studied in healthy subjects and in subjects with cancer with oral doses ranging from 0.5 mg to 12 mg once daily [QD].

Based on the currently proposed SmPC, the recommended starting dose of erdafitinib is 8 mg orally once daily. This dose should be maintained and serum phosphate level should be assessed between 14 and 21 days after initiating treatment. The dose is then to be up-titrated to 9 mg once daily if the serum phosphate level is &lt;9.0 mg/dL, and there is no drug-related toxicity.

The basic PKs of erdafitinib have been characterised using non-compartmental analysis in the Phase I ADME study (EDI1005) in healthy subjects, and in the Phase I FTIH study (EDI1001) of single and multiple doses of erdafitinib in patients with advanced or refractory solid tumors or lymphoma.

The potential effect of intrinsic and extrinsic factors on erdafitinib PK has been quantitatively assessed in the hepatic impairment study (EDI1008), Japanese safety/PK study (GAC1001), 'Asian' safety/PK study (HCC1001), formulation/food studies (EDI1002, EDI1003, EDI1004, EDI1006),

<div style=\"page-break-after: always\"></div>

fluconazole/itraconazole DDI study (EDI1007), carbamazepine DDI study (NAP1001), midazolam/metformin DDI study (BLC2001), and using population PK analysis.

## 2.8.2.1. Pharmacokinetics

## Absorption

## Bioavailability

Healthy Subjects

## EDI1005 (ADME)

| Study title      | An Open-Label Phase 1 Study to Determine the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of ( 14 C) Radiolabeled Erdafitinib to Healthy Male Subjects                                                                                                                                                                                                                 |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study design     | This was a Phase 1, single-centre, open-label, 1-treatment study in 8 healthy adult male participants.                                                                                                                                                                                                                                                                                                  |
|                  | All participants received a single oral dose of 12 mg unlabelled erdafitinib, given as a solution (0.5 mg/mL) admixed with 14 C-erdafitinib under fasting conditions.                                                                                                                                                                                                                                   |
|                  | Plasma samples for determination of erdafitinib concentrations and measurement of total radioactivity were collected at pre-dose and over 312 hours after administration.                                                                                                                                                                                                                               |
|                  | Faeces and urine samples were collected for measurement of total radioactivity and erdafitinib (urine). Participants remained at the study site for 14 days after dose administration and possibly longer (up to 28 days), until at least 85% of the total radioactivity was recovered or no more than 1% of the radioactivity was excreted in urine and faeces every 24 hours over 2 consecutive days. |
| Study objectives | (PK) The primary objective was to investigate the absorption, metabolism, and excretion of erdafitinib in healthy male adult participants after administration of a single oral dose of 12 mg of un-labelled erdafitinib admixed with 14 C-erdafitinib.                                                                                                                                                 |
| Study period     | 24 March 2016 to 06 August 2016                                                                                                                                                                                                                                                                                                                                                                         |
| No. of subjects  | Of 8 subjects dosed, 6 (75%) subjects completed the study and 2 (25%) subjects exited the study prior to completion. However, as all 8 subjects provided the required PK assessments, they were included in the safety and PK analyses                                                                                                                                                                  |
| Treatment        | The JNJ-42756493 supplied for this study was a 0.5 mg/mL JNJ-42756493-AAA oral aqueous solution, admixed with 14 C JNJ-42756493. Study drug was provided as drink vials containing liquid formulation for oral self-administration.                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

Results

Table 10: Summary of Plasma PK Results of Erdafitinib and Total Radioactivity After Single Oral Administration of 12 mg Erdafitinib Admixed With  14 C JNJ-42756493

| PK Parameters a          | Total JNJ-42756493   | Total Radioactivity   |
|--------------------------|----------------------|-----------------------|
| N                        | 8                    | 8                     |
| C max , ng (eq.)/mL      | 525128              | 508163               |
| t max , h                | 2.50 (2.00 - 3.00)   | 2.00 (2.00 - 4.00)    |
| AUC last , ng (eq.).h/mL | 304307156           | 303887335            |
| AUC  , ng (eq.).h/mL    | 319137545           | 318067854            |
| t 1/2term , h            | 66.315.8            | 65.313.1             |
| CL/F, L/h                | 0.3950.0929         | -                     |
| V d /F, L                | 37.510.6            | -                     |
| MRT, h                   | 90.620.6            | -                     |

a meanSD, tmax: median [range]

Erdafitinib  was  highly  bound  to  plasma  proteins.  The  unbound  fraction  of  erdafitinib  was  low  and averaged 0.37 (0.09) %, with individual values ranging between 0.22% and 0.49%.

An inverse relationship was observed between the fraction unbound and 1 -acid glycoprotein.

The unbound exposure parameters Cmax and AUC corrected for the unbound fraction averaged 1.90 (0.541) ng/mL and 116 (33.2) ng.h/mL, respectively .

Table 11: Estimation of the Percentage Oral Absorption

|                                                                                   | AbsorbedErdafitinib   | ReportedDatafrom StudyED11005   |
|-----------------------------------------------------------------------------------|-----------------------|---------------------------------|
| Urine                                                                             | 18.7%                 |                                 |
| Total radioactivity excreted in urine (unchanged drug and metabolites)            |                       | 18.7%                           |
| Feces                                                                             | 65.2%                 |                                 |
| Total radioactivity recovered in feces (unchanged drug and metabolites)           |                       | 68.7%                           |
| Unchanged drug recovered in feces during the first 3 days (conservative estimate) |                       | 3.5%                            |
| Total urine and feces                                                             | 83.9%                 |                                 |
| Recovery of radioactivity in urine and feces samples                              |                       | 87.4%                           |
| Estimated % absorption                                                            | 96.0%                 |                                 |

Subjects with advanced or refractory solid tumours or lymphoma

## EDI1001 (FTIH)

Study title

A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma.

Study design

The study consisted of 4 parts:

-  Part 1 was the dose escalation phase, designed to determine the RP2D. Part 1 started with a standard 3+3 design and investigated continuous doses of 0.5, 2, 4, 6, 9, and 12 mg erdafitinib taken once daily in cycles of 21 days and intermittent

<div style=\"page-break-after: always\"></div>

doses of 10 and 12 mg (7 days on/7 days off) in cycles of 28 days. The 0.5-, 2-, and 4-mg doses were administered as an oral solution. The 6 mg cohort acted as a bridging cohort; the first 5 participants were treated with the oral solution and the next 4 participants with the capsule formulation. The 9, 10, and 12 mg doses were administered as capsules. The 9 mg continuous dose was identified as the first RP2D and the 10 mg intermittent dose (7 days on/7 days off) as the second RP2D.

-  Part 2 was a tumour biopsy cohort to evaluate the PD effect of erdafitinib in tumors and to confirm FGFR pathway inhibition at or below the first RP2D (9 mg continuous dose). Erdafitinib 6 and 9 mg once daily were administered as capsules in Part 2.
-  Part 3 was the first dose expansion phase at the first RP2D (9 mg continuous dose) and consisted of 3 disease-specific cohorts (squamous NSCLC, small cell lung cancer, and breast cancer) and 1 mixed-disease solid tumour cohort. Erdafitinib was administered as capsules in Part 3.
-  Part 4 was the second dose expansion phase at the second RP2D (10 mg intermittent dose, 7 days on/7 days off) and consisted of an NSCLC cohort and a cross-histology cohort with selected tumour types. Erdafitinib was administered as capsules in Part 4.

Blood samples for analysis of erdafitinib concentration in plasma were collected at the following times:

-  Part 1: Cycle 1 Day 1 at predose, 0.5, 1, 2, 3, 4, 6, 8, 24, 48, and 72 hours postdose. Cycle 1 Day 8 (for continuous dose cohorts) or Day 7 (for intermittent dose cohorts) and Cycle 2 Day 1 at predose, 0.5, 1, 2, 3, 4, 6, 8, and 24 hours postdose. Cycles 3 and 4 at predose.
-  Part 2: Cycle 1 Day 1 and Cycle 2 Day 1 (for continuous dose cohorts) at predose, 0.5, 1, 2, 3, 4, 6, 8, and 24 hours postdose. Cycles 3 and 4 on Day 1 (predose).
-  Parts 3 and 4: sparse samples were collected in Cycle 1 on Day 1 and Day 7 or Day 8, and in Cycles 2, 3, and 4 on Day 1 (predose).

Selected samples were used to determine erdafitinib free concentrations. Serum and plasma were collected in Part 1 to assess changes in the following markers of FGFR inhibition pre- and postdose: FGF-23, PTH, vitamin D, and calcium, in addition to monitoring serum phosphate levels.

Cardiac monitoring included 24-hour Holter monitoring and echocardiograms in Part 1 and triplicate 12-lead ECGs at multiple timepoints in all parts of the study [ see PD Part below ].

- Study objectives To determine the safe and biologically active Phase 2 doses (RP2Ds) for erdafitinib in the Part 1 dose escalation phase and to evaluate the feasibility of treating a molecularly defined subset of participants with different solid tumors at the RP2Ds (Parts 3 and 4). Secondary objectives were to evaluate the PK, PD (biomarkers in blood, in skin, and in the tumour), and predictive biomarkers for erdafitinib.

## Study period

DATE STUDY INITIATED: 19 June 2012

DATE OF CLINICAL CUT-OFF: 03 January 2017

## Treatment

In Part 1, study drug was provided as either a liquid formulation or as capsules for oral administration. In Parts 2, 3, and 4, study drug was supplied as capsules packaged in blister packs.

## Results

<div style=\"page-break-after: always\"></div>

Single-dose PK parameters of erdafitinib in patients with advanced or refractory solid tumors or lymphoma are presented in the table below:

Table 12: Summary of Single Dose Plasma PK Parameters of Erdafitinib on Cycle 1 Day 1 for the Continuous and Intermittent Dose Cohorts

| Dose (mg)          | N   | Mean (SD)         | Mean (SD)    | Mean (SD)         | Mean (SD)         |
|--------------------|-----|-------------------|--------------|-------------------|-------------------|
|                    |     | tmaxa (b)         | Cmax (ng/mL) | AUC0-24 (ng.h/mL) | AUC0-72 (ng.h/mL) |
| Continuous Doses   |     |                   |              |                   |                   |
| Part 1             |     |                   |              |                   |                   |
| 0.5                | 3   | 1.00 (0.50-6.00)  | 24.4 (8.11)  | 393 (93.4)        | 873 (203)         |
| 2                  | 4   | 2.50 (1.00-4.07)  | 108 (51.5)   | 1757 (678)        | 4394 (1964)b      |
| 4                  | 7   | 1.75 (0.95-6.17)  | 182 (77.1)   | 3226 (1508)       | 6743 (3318)c      |
| 6                  | 9   | 2.07 (0.52-24.00) | 248 (103)    | 4239 (2138)       | 8361 (3250)d      |
| 9                  | 9   | 2.07 (2.00-6.00)  | 431 (177)    | 7410 (3213)       | 17564 (9364)e     |
| 12                 | 7   | 1.22 (0.50-2.00)  | 745 (246)    | 12374 (4400)      | 30175 (13807)     |
| Part 2             |     |                   |              |                   |                   |
| 9                  | 10  | 3.44 (2.03-8.00)  | 578 (234)    | 10069 (2559)d     |                   |
| Intermittent Doses |     |                   |              |                   |                   |
| Part 1             |     |                   |              |                   |                   |
| 10                 | 14  | 2.57 (1.00-6.00)  | 566 (168)    | 10058 (3136)f     |                   |
| 12                 | 13  | 2.08 (1.00-4.00)  | 912 (473)    | 14209 (5421)      |                   |

As tabulated above, after a single dose (Cycle 1 Day 1) in the 76 participants with serial PK sampling, tmax values ranged between 1.00 and 3.44 hours post-dose across the different cohorts.

Fraction of erdafitinib unbound to plasma proteins ranged on average between 0.250% and 0.506% at corresponding AGP concentrations of 131 and 86.4 mg/dL. The unbound fraction was inversely related to AGP concentrations.

The tmax was not dose-dependent across the 0.5 to 12 mg dose range.

After Cmax, the plasma concentration-time profile declined with a long t1/2.

Cmax and AUCs increased with increasing dose without consistent or significant deviations from the dose-proportionality across the range of dose levels.

Multiple-dose plasma PK parameters obtained on Cycle 2 Day 1 for continuous doses and on Cycle 1 Day 7 for intermittent doses are summarised in the table below:

<div style=\"page-break-after: always\"></div>

Table 13: Summary of Multiple Dose Plasma PK Parameters of Erdafitinib on Cycle 2 Day 1 for the Continuous and on Cycle 1 Day 7 for the Intermittent Dose Cohorts

| Dose (mg)                          | N                                  | Mean (SD)                          | Mean (SD)                          | Mean (SD)                          | Mean (SD)                          | Mean (SD)                          | Mean (SD)                          |
|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                                    |                                    | tmara                              | Cmax (ng/mL)                       | AUC,                               | Cmin (ng/mL)                       | Accumulation Ratio                 | Accumulation Ratio                 |
|                                    |                                    | (b)                                |                                    | (ng.h/mL)                          |                                    | Cmar                               | AUC                                |
| Continuous Doses (Cycle 2 Day l)   | Continuous Doses (Cycle 2 Day l)   | Continuous Doses (Cycle 2 Day l)   | Continuous Doses (Cycle 2 Day l)   | Continuous Doses (Cycle 2 Day l)   | Continuous Doses (Cycle 2 Day l)   | Continuous Doses (Cycle 2 Day l)   | Continuous Doses (Cycle 2 Day l)   |
| Part 1                             |                                    |                                    |                                    |                                    |                                    |                                    |                                    |
| 0.5                                | 3                                  | 2.27 (1.00-4.07)                   | 65.6 (22.3)                        | 1084 (5.22)b                       | 44.9 (13.9)                        | 2.74 (0.58)                        | 3.19 (0.181)b                      |
| 2                                  | 4                                  | 2.58 (1.92-4.00)                   | 377 (247)                          | 9283(5090)                         | 263 (201)                          | 3.43 (1.30)                        | 4.96 (1.16)c                       |
| 4                                  | S                                  | 4.00 (2.25-7.00)                   | 675 (267)                          | 13516 (8619)b                      | 429 (178)                          | 3.18 (0.78)                        | 3.08 (0.50)b                       |
| 6                                  | 8                                  | 2.55 (2.00-8.02)                   | 818 (352)                          | 13789 (7060)                       | 552 (344)                          | 3.46 (1.21)                        | 4.16 (1.87)d                       |
| 9                                  | 1                                  | 3.00                               | 494                                |                                    | 290                                | 4.15                               |                                    |
| 12                                 | 3                                  | 2.00 (1.00-8.25)                   | 3057 (1622)                        | 64085 (43539)                      | 2317 (1527)                        | 3.94 (1.10)                        | 4.55 (1.22)                        |
| Part 2                             |                                    |                                    |                                    |                                    |                                    |                                    |                                    |
| 9                                  | 6                                  | 2.65 (2.00-23.75)                  | 2018 (744)                         | 39587 (17575)                      | 1247 (766)                         | 3.61 (0.843)                       | 3.74 (0.304)                       |
| Intermittent Doses (Cycle 1 Day 7) | Intermittent Doses (Cycle 1 Day 7) | Intermittent Doses (Cycle 1 Day 7) | Intermittent Doses (Cycle 1 Day 7) | Intermittent Doses (Cycle 1 Day 7) | Intermittent Doses (Cycle 1 Day 7) | Intermittent Doses (Cycle 1 Day 7) | Intermittent Doses (Cycle 1 Day 7) |
| Part 1                             |                                    |                                    |                                    |                                    |                                    |                                    |                                    |
| 10                                 | 13                                 | 3.00 (0.92-24.00)                  | 1792 (624)                         | 35880 (12798)                      | 1185 (534)                         | 3.24 (0.684)                       | 3.60 (0.792)f                      |
| 12                                 | 10                                 | 2.25 (1.00-6.00)                   | 2132 (1032)                        | 41339 (20781)                      | 1311 (784)                         | 2.66 (0.649)                       | 3.16 (0.668)                       |

A Median (range); b N=2; c N=3; d N=6; e N=5; f N=11.

Cmax and AUC increased with the dose without showing relevant or consistent deviations from dose proportionality.

In the intermittent dose cohorts (Cycle 1 Day 7), the mean systemic exposure increased between the 10 and 12 mg dose levels, as expected based on the previously observed dose-proportionality of the PK. Although steady state was not fully achieved after 7 days of administration, the accumulation ratios for AUC were 3.60 and 3.16 for the 10 and 12 mg intermittent doses, respectively (see table above). Cycle 2 Day 1 concentrations were higher than the Cycle 1 Day 1 concentrations, albeit lower than Cycle 1 Day 7, and pre- dose samples had measurable drug concentrations due to incomplete washout after 7 days off erdafitinib.

## Supplementary PK analysis

Beside other analysis, Individual dose normalised PK parameters pooled over dose levels were presented per dose regimen (daily and intermittent dosing) and for both dosing regimens combined, including descriptive statistics were provided.

<div style=\"page-break-after: always\"></div>

Table 14: Individual Dose Normalised PK Parameters, Including Descriptive Statistics (C2D1) - Pooled for All Dose Levels

Pooledresults ofstudy42756493EDl1001

Dose normalized to 8 mg

|                | Dose normalized PK parameters of erdafitinib - Daily dosing   | Dose normalized PK parameters of erdafitinib - Daily dosing   | Dose normalized PK parameters of erdafitinib - Daily dosing   | Dose normalized PK parameters of erdafitinib - Daily dosing   | Dose normalized PK parameters of erdafitinib - Daily dosing   | Dose normalized PK parameters of erdafitinib - Daily dosing   | Dose normalized PK parameters of erdafitinib - Daily dosing   | Dose normalized PK parameters of erdafitinib - Daily dosing   | Dose normalized PK parameters of erdafitinib - Daily dosing   |
|----------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Subject        | eGFR [mL/min/1. 73 m]                                        | C2D1 Cmln [ng/mL]                                             | C2D1 Cmax [ng/mL]                                             | C2D1 AUC24h [ng.h/mL]                                         | C2D1 Unbound CmIn [mg/mL]                                     | C2D1 Unbound Cmax [ng/mL]                                     | C2D1 Unbound AUC24h [ng.h/mL]                                 | C2D1 CL/F [L/h]                                               | C2D1 CLtr/F [L/h]                                             |
| n              | 50                                                            | 30                                                            | 30                                                            | 21                                                            | 30                                                            | 30                                                            | 21                                                            | 21                                                            | 21                                                            |
| Mean           | 99.3                                                          | 936                                                           | 1399                                                          | 29268                                                         | 2.69                                                          | 4.17                                                          | 81.5                                                          | 0.362                                                         | 112                                                           |
| SD             | 25.7                                                          | 607                                                           | 711                                                           | 17519                                                         | 1.16                                                          | 1.66                                                          | 28.2                                                          | 0.186                                                         | 45.6                                                          |
| Min            | 58                                                            | 215                                                           | 439                                                           | 9995                                                          | 0.687                                                         | 1.90                                                          | 34.8                                                          | 0.105                                                         | 59.1                                                          |
| Median         | 97                                                            | 755                                                           | 1240                                                          | 23068                                                         | 2.69                                                          | 3.70                                                          | 78.8                                                          | 0.347                                                         | 101                                                           |
| Max            | 150                                                           | 2680                                                          | 3260                                                          | 75889                                                         | 5.53                                                          | 8.23                                                          | 135                                                           | 0.800                                                         | 230                                                           |
| %CV            | 25.9                                                          | 64.9                                                          | 50.8                                                          | 59.9                                                          | 43.1                                                          | 39.9                                                          | 34.5                                                          | 51.4                                                          | 40.8                                                          |
| Geometric Mean | 96.1                                                          | 774                                                           | 1238                                                          | 25220                                                         | 2.43                                                          | 3.88                                                          | 76.7                                                          | 0.317                                                         | 104                                                           |

Pharmacokinetic results from the main efficacy and safety studies BLC2001 (Phase II) and BLC3001 (pivotal Phase III) are summarised below:

BLC2001 (Phase II)

Table 15: Summary of Single and Multiple Dose Plasma Concentrations of Erdafitinib on Cycle 1 Day 1 and Cycle 1 Day 21 for the Continuous and Intermittent Dose Cohorts

| Parameter (Unit)              | Mean (SD)                   | Mean (SD)                 | Mean (SD)                     |
|-------------------------------|-----------------------------|---------------------------|-------------------------------|
|                               | 6 mg Continuous (Regimen 2) | 8mgContinuous (Regimen 3) | 10 mgIntermittent (Reginen 1) |
| Cycle 1 Day 1                 |                             |                           |                               |
| N                             | 74                          | 92                        | 32                            |
| C2h                           | 311.0 (134.8)               | 373.0 (168.1)             | 529.5 (224.9)                 |
| C4h                           | 290.0 (117.9)               | 365.3 (155.6)a            | 504.0 (189.6)                 |
| Cycle 1 Day 21b               |                             |                           |                               |
| N                             | 59                          | 45                        | 25                            |
| Predose (steady-state trough) | 1039.1 (585.7)              | 1097.5 (542.0)            | 1312.6 (782.5)                |
| C2h                           | 1255.1 (640.0)              | 1371.4 (586.6)            | 1686.5 (872.3)c               |
| C4h                           | 1257.4 (663.2)d             | 1329.9 (550.1)e           | 1753.4 (917.8)f               |

a N=91; b Cycle 1 Day 21 data presented only include those participants who received the same dose on Day 21 as the starting dose (ie, participants who had no dose increases or reductions);  c N=23; d N=60; e N=46; f N=24.

BLC3001 (pivotal Phase III study)

Erdafitinib PK parameters for Cohort 1 are summarised in the table below:

<div style=\"page-break-after: always\"></div>

Table 16: Summary of Erdafitinib Observed Plasma Concentrations (ng/mL) Over Time; Cohort 1 PK Analysis Set

|                | Plasma Concentrations of Erdafitinib (ng/mL)   | Plasma Concentrations of Erdafitinib (ng/mL)   | Plasma Concentrations of Erdafitinib (ng/mL)   | Plasma Concentrations of Erdafitinib (ng/mL)   | Plasma Concentrations of Erdafitinib (ng/mL)   | Plasma Concentrations of Erdafitinib (ng/mL)   |
|----------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
|                | 8 mg without uptitration                       | 8 mg without uptitration                       | 8 mg without uptitration                       | 8 mg uptitrated to 9 mg                        | 8 mg uptitrated to 9 mg                        | 8 mg uptitrated to 9 mg                        |
|                | Cycle 1 Day 14 Postdose                        | Cycle 2 Day 1 Predose                          | Cycle 2 Day 1 2-4 Houlr Postdose               | Cycle 1 Day 14Postdose                         | Cycle 2 Day 1 Predose                          | Cycle 2 Day 1 2-4 Hour Postdose                |
| N              | 20                                             | 24                                             | 21                                             | 89                                             | 93                                             | 84                                             |
| Mean           | 1458                                           | 986                                            | 1112                                           | 1225                                           | 1414                                           | 1605                                           |
| Median         | 1120                                           | 917                                            | 1020                                           | 1180                                           | 1330                                           | 1445                                           |
| SD             | 1272                                           | 669                                            | 714                                            | 530                                            | 660                                            | 705                                            |
| Min            | 102                                            | 12.3                                           | 23.9                                           | 381                                            | 315                                            | 449                                            |
| Max            | 5290                                           | 2570                                           | 3090                                           | 2960                                           | 3590                                           | 3870                                           |
| %CV            | 87.2                                           | 67.9                                           | 64.2                                           | 43.2                                           | 46.7                                           | 43.9                                           |
| Geometric Mean | 1054                                           | 706                                            | 815                                            | 1115                                           | 1266                                           | 1460                                           |
| %Geometric CV  | 109                                            | 149                                            | 141                                            | 47.2                                           | 51.8                                           | 46.6                                           |

Concentrations below quantification limit (&lt;1 ng/mL) are considered as 0.

Erdafitinib PK parameters for Cohort 2 are summarised in the table below:

Table 17: Summary of Erdafitinib Observed Plasma Concentrations (ng/mL) Over Time; Cohort 2 PK Analysis Set

|                    | Plasma Concentrations of Erdafitinib (ng/mL)   | Plasma Concentrations of Erdafitinib (ng/mL)   | Plasma Concentrations of Erdafitinib (ng/mL)   | Plasma Concentrations of Erdafitinib (ng/mL)   | Plasma Concentrations of Erdafitinib (ng/mL)   | Plasma Concentrations of Erdafitinib (ng/mL)   |
|--------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
|                    | 8 mg without uptitration                       | 8 mg without uptitration                       | 8 mg without uptitration                       | 8 mg uptitrated to 9 mg                        | 8 mg uptitrated to 9 mg                        | 8 mg uptitrated to 9 mg                        |
|                    | Cycle 1 Day 14Postdose                         | Cycle 2 Day 1 Predose                          | Cycle 2 Day 1 2-4 Houl' Postdose               | Cycle 1 Day 14 Postdose                        | Cycle 2 Day 1 Predose                          | Cycle 2 Day 1 2-4 Hour Postdose                |
| N                  | 22                                             | 21                                             | 22                                             | 127                                            | 127                                            | 113                                            |
| Mean               | 1466                                           | 1179                                           | 1360                                           | 1190                                           | 1229                                           | 1402                                           |
| Median             | 1420                                           | 1240                                           | 1505                                           | 1000                                           | 1050                                           | 1160                                           |
| SD                 | 969                                            | 771                                            | 754                                            | 772                                            | 818                                            | 829                                            |
| Min                | 25.9                                           | 22.5                                           | 123                                            | 259                                            | 34.0                                           | 143                                            |
| Max                | 3000                                           | 2550                                           | 2700                                           | 4640                                           | 5290                                           | 5100                                           |
| %CV                | 66.1                                           | 65.4                                           | 55.4                                           | 64.8                                           | 66.6                                           | 59.1                                           |
| Geometric          | 927                                            | 761                                            | 1047                                           | 1007                                           | 991                                            | 1205                                           |
| Mean %Geometric CV | 216                                            | 205                                            | 109                                            | 62.2                                           | 83.3                                           | 60.8                                           |

Concentrations below quantification limit (&lt;1 ng/mL) are considered as 0.

## BCS-class

Erdafitinib is a BCS Class I compound with high solubility, moderate to high permeability, and gastrointestinal stability.

## Bioequivalence

A total of 4 biopharmaceutic studies (EDI1002, EDI1003, EDI1004, EDI1006), in addition to a formulation bridging cohort in the first-in-human study (EDI1001), were conducted to support biopharmaceutical properties of erdafitinib and the development of the final formulation.

<div style=\"page-break-after: always\"></div>

The mean PK parameters of erdafitinib from all relative bioavailability studies conducted in healthy participants are presented in the table below:

Table 18: PK Parameters Across Studies EDI1002, EDI1003, EDI1004, and EDI1006

|                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                            | Median(Range)                                                                                                                                                                                                                                                                                                              | Mean (SD)                                                                                                                                                                                                                                                                                                                  | Mean (SD)                                                                                                                                                                                                                                                                                                                  | Mean (SD)                                                                                                                                                                                                                                                                                                                  | Mean (SD)                                                                                                                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study ID                                                                                                                                                                                                                                                                                                                   | Dose (mg)                                                                                                                                                                                                                                                                                                                  | Formulation                                                                                                                                                                                                                                                                                                                | N                                                                                                                                                                                                                                                                                                                          | tmax (h)                                                                                                                                                                                                                                                                                                                   | Cmax (ng/mL)                                                                                                                                                                                                                                                                                                               | AUCiast (ng.h/mL)                                                                                                                                                                                                                                                                                                          | AUC(ng.h/mL)                                                                                                                                                                                                                                                                                                               | tin (h)                                                                                                                                                                                                                                                                                                                    |
| Single-dosestudiesassessingtheimpactofformulationchanges                                                                                                                                                                                                                                                                   | Single-dosestudiesassessingtheimpactofformulationchanges                                                                                                                                                                                                                                                                   | Single-dosestudiesassessingtheimpactofformulationchanges                                                                                                                                                                                                                                                                   | Single-dosestudiesassessingtheimpactofformulationchanges                                                                                                                                                                                                                                                                   | Single-dosestudiesassessingtheimpactofformulationchanges                                                                                                                                                                                                                                                                   | Single-dosestudiesassessingtheimpactofformulationchanges                                                                                                                                                                                                                                                                   | Single-dosestudiesassessingtheimpactofformulationchanges                                                                                                                                                                                                                                                                   | Single-dosestudiesassessingtheimpactofformulationchanges                                                                                                                                                                                                                                                                   | Single-dosestudiesassessingtheimpactofformulationchanges                                                                                                                                                                                                                                                                   |
| EDI1002                                                                                                                                                                                                                                                                                                                    | 10                                                                                                                                                                                                                                                                                                                         | Tablet;G018;fasted                                                                                                                                                                                                                                                                                                         | 8                                                                                                                                                                                                                                                                                                                          | 3.50 (1.00-4.01)                                                                                                                                                                                                                                                                                                           | 357 (107)                                                                                                                                                                                                                                                                                                                  | 19900 (6251)                                                                                                                                                                                                                                                                                                               | 25300 (7474)                                                                                                                                                                                                                                                                                                               | 53.8 (7.02)                                                                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                                                                            | 10                                                                                                                                                                                                                                                                                                                         | Solution; G004; fasted                                                                                                                                                                                                                                                                                                     | 8                                                                                                                                                                                                                                                                                                                          | 2.10 (1.01-2.75)                                                                                                                                                                                                                                                                                                           | 373 (141)                                                                                                                                                                                                                                                                                                                  | 20100 (6537)                                                                                                                                                                                                                                                                                                               | 24700 (7124)                                                                                                                                                                                                                                                                                                               | 52.2 (3.46)                                                                                                                                                                                                                                                                                                                |
| EDI1003                                                                                                                                                                                                                                                                                                                    | 10                                                                                                                                                                                                                                                                                                                         | Tablet;G018;fasted                                                                                                                                                                                                                                                                                                         | 12                                                                                                                                                                                                                                                                                                                         | 3.00 (2.00-8.00)                                                                                                                                                                                                                                                                                                           | 357 (113)                                                                                                                                                                                                                                                                                                                  | 21900 (7680)                                                                                                                                                                                                                                                                                                               | 25400 (8890)                                                                                                                                                                                                                                                                                                               | 49.1 (5.29)                                                                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                                                                            | 10                                                                                                                                                                                                                                                                                                                         | Capsule;G014;fasted                                                                                                                                                                                                                                                                                                        | 12                                                                                                                                                                                                                                                                                                                         | 3.00 (2.00-6.00)                                                                                                                                                                                                                                                                                                           | 372 (110)                                                                                                                                                                                                                                                                                                                  | 23000 (7620)                                                                                                                                                                                                                                                                                                               | 26400(8850)                                                                                                                                                                                                                                                                                                                | 49.7 (6.76)                                                                                                                                                                                                                                                                                                                |
| EDI1004                                                                                                                                                                                                                                                                                                                    | 10                                                                                                                                                                                                                                                                                                                         | Tablet; G018 (17 micron); fasted                                                                                                                                                                                                                                                                                           | 11                                                                                                                                                                                                                                                                                                                         | 2.00 (1.50-4.00)                                                                                                                                                                                                                                                                                                           | 433 (143)                                                                                                                                                                                                                                                                                                                  | 21845 (7780)                                                                                                                                                                                                                                                                                                               | 25206 (9717)                                                                                                                                                                                                                                                                                                               | 50.7 (8.1)                                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                                            | 10                                                                                                                                                                                                                                                                                                                         | Tablet; G025(78 micron); fasted                                                                                                                                                                                                                                                                                            | 12                                                                                                                                                                                                                                                                                                                         | 2.51 (1.50-8.00)                                                                                                                                                                                                                                                                                                           | 389 (93.7)                                                                                                                                                                                                                                                                                                                 | 20788 (6089)                                                                                                                                                                                                                                                                                                               | 23788 (7285)                                                                                                                                                                                                                                                                                                               | 46.0 (4.9)                                                                                                                                                                                                                                                                                                                 |
|                                                                                                                                                                                                                                                                                                                            | 10                                                                                                                                                                                                                                                                                                                         | Tablet;G025(119micron);fasted                                                                                                                                                                                                                                                                                              | 11                                                                                                                                                                                                                                                                                                                         | 2.99 (1.00-8.00)                                                                                                                                                                                                                                                                                                           | 411 (109)                                                                                                                                                                                                                                                                                                                  | 22227 (6707)                                                                                                                                                                                                                                                                                                               | 26171 (8460)                                                                                                                                                                                                                                                                                                               | 50.2 (3.3)                                                                                                                                                                                                                                                                                                                 |
| Single-dosestudyassessingtheeffectofconcomitantfoodintake                                                                                                                                                                                                                                                                  | Single-dosestudyassessingtheeffectofconcomitantfoodintake                                                                                                                                                                                                                                                                  | Single-dosestudyassessingtheeffectofconcomitantfoodintake                                                                                                                                                                                                                                                                  | Single-dosestudyassessingtheeffectofconcomitantfoodintake                                                                                                                                                                                                                                                                  | Single-dosestudyassessingtheeffectofconcomitantfoodintake                                                                                                                                                                                                                                                                  | Single-dosestudyassessingtheeffectofconcomitantfoodintake                                                                                                                                                                                                                                                                  | Single-dosestudyassessingtheeffectofconcomitantfoodintake                                                                                                                                                                                                                                                                  | Single-dosestudyassessingtheeffectofconcomitantfoodintake                                                                                                                                                                                                                                                                  | Single-dosestudyassessingtheeffectofconcomitantfoodintake                                                                                                                                                                                                                                                                  |
| EDI1006                                                                                                                                                                                                                                                                                                                    | 9                                                                                                                                                                                                                                                                                                                          | Tablet;G025and G024;fasted                                                                                                                                                                                                                                                                                                 | 16                                                                                                                                                                                                                                                                                                                         | 2.52 (2.00-5.98)                                                                                                                                                                                                                                                                                                           | 354 (101)                                                                                                                                                                                                                                                                                                                  | 21067 (5415)                                                                                                                                                                                                                                                                                                               | 21649 (5729)                                                                                                                                                                                                                                                                                                               | 69.5 (23.1)                                                                                                                                                                                                                                                                                                                |
|                                                                                                                                                                                                                                                                                                                            | 9                                                                                                                                                                                                                                                                                                                          | Tablet;G025andG024;fed                                                                                                                                                                                                                                                                                                     | 16                                                                                                                                                                                                                                                                                                                         | 3.98 (2.00-6.00)                                                                                                                                                                                                                                                                                                           | 304 (80.0)                                                                                                                                                                                                                                                                                                                 | 19752 (5374)                                                                                                                                                                                                                                                                                                               | 20262 (5581)                                                                                                                                                                                                                                                                                                               | 63.3 (15.5)                                                                                                                                                                                                                                                                                                                |
| AUC=areaundertheconcentration-time curve;CI=confidenceinterval;Cmax=maximum concentration;CV=coefficientofvariation;GMR=geometricmeanratio; ID=identity;N=number ofparticipants;PK=pharmacokinetics;ti/n=half-life. The10-mgdosecomprised2x5-mgtablets andthe9-mgdosecomprised1x5-mgtablet+1x4-mgtablet. Source:Appendix 6 | AUC=areaundertheconcentration-time curve;CI=confidenceinterval;Cmax=maximum concentration;CV=coefficientofvariation;GMR=geometricmeanratio; ID=identity;N=number ofparticipants;PK=pharmacokinetics;ti/n=half-life. The10-mgdosecomprised2x5-mgtablets andthe9-mgdosecomprised1x5-mgtablet+1x4-mgtablet. Source:Appendix 6 | AUC=areaundertheconcentration-time curve;CI=confidenceinterval;Cmax=maximum concentration;CV=coefficientofvariation;GMR=geometricmeanratio; ID=identity;N=number ofparticipants;PK=pharmacokinetics;ti/n=half-life. The10-mgdosecomprised2x5-mgtablets andthe9-mgdosecomprised1x5-mgtablet+1x4-mgtablet. Source:Appendix 6 | AUC=areaundertheconcentration-time curve;CI=confidenceinterval;Cmax=maximum concentration;CV=coefficientofvariation;GMR=geometricmeanratio; ID=identity;N=number ofparticipants;PK=pharmacokinetics;ti/n=half-life. The10-mgdosecomprised2x5-mgtablets andthe9-mgdosecomprised1x5-mgtablet+1x4-mgtablet. Source:Appendix 6 | AUC=areaundertheconcentration-time curve;CI=confidenceinterval;Cmax=maximum concentration;CV=coefficientofvariation;GMR=geometricmeanratio; ID=identity;N=number ofparticipants;PK=pharmacokinetics;ti/n=half-life. The10-mgdosecomprised2x5-mgtablets andthe9-mgdosecomprised1x5-mgtablet+1x4-mgtablet. Source:Appendix 6 | AUC=areaundertheconcentration-time curve;CI=confidenceinterval;Cmax=maximum concentration;CV=coefficientofvariation;GMR=geometricmeanratio; ID=identity;N=number ofparticipants;PK=pharmacokinetics;ti/n=half-life. The10-mgdosecomprised2x5-mgtablets andthe9-mgdosecomprised1x5-mgtablet+1x4-mgtablet. Source:Appendix 6 | AUC=areaundertheconcentration-time curve;CI=confidenceinterval;Cmax=maximum concentration;CV=coefficientofvariation;GMR=geometricmeanratio; ID=identity;N=number ofparticipants;PK=pharmacokinetics;ti/n=half-life. The10-mgdosecomprised2x5-mgtablets andthe9-mgdosecomprised1x5-mgtablet+1x4-mgtablet. Source:Appendix 6 | AUC=areaundertheconcentration-time curve;CI=confidenceinterval;Cmax=maximum concentration;CV=coefficientofvariation;GMR=geometricmeanratio; ID=identity;N=number ofparticipants;PK=pharmacokinetics;ti/n=half-life. The10-mgdosecomprised2x5-mgtablets andthe9-mgdosecomprised1x5-mgtablet+1x4-mgtablet. Source:Appendix 6 | AUC=areaundertheconcentration-time curve;CI=confidenceinterval;Cmax=maximum concentration;CV=coefficientofvariation;GMR=geometricmeanratio; ID=identity;N=number ofparticipants;PK=pharmacokinetics;ti/n=half-life. The10-mgdosecomprised2x5-mgtablets andthe9-mgdosecomprised1x5-mgtablet+1x4-mgtablet. Source:Appendix 6 |

AUC=area under the concentration-time curve; CI=confidence interval; Cmax=maximum concentration; CV=coefficient of variation; GMR=geometric mean ratio;

ID=identity; N=number of participants; PK=pharmacokinetics; t1/2=half-life.

The 10-mg dose comprised 25-mg tablets and the 9-mg dose comprised 15-mg tablet + 14-mg tablet.

## Influence of food

## EDI1006

Study title

Randomized, Open-Label, 2-Way Crossover Study to Determine the Effect of Food on the Pharmacokinetics of Erdafitinib in Healthy Participants

Study design

This was a Phase 1, randomised, open-label, single-centre, 2-way crossover study in 16 healthy participants.

On Day 1 of Period 1, participants were randomised to 1 of 2 treatment sequences, AB  or  BA.  The  following  treatments  were  administered  on  Day  1  of  each  period (separated by at least 28 days):

Treatment A, fasted (reference): a single dose of 9 mg erdafitinib (14-mg tablet and 15-mg tablet) under fasted conditions (  10 hours).

Treatment B, fed (test): following an overnight fast (  10 hours), a high-fat and high- calorie breakfast was provided and had to be consumed within 30 minutes. A single dose of 9 mg erdafitinib (14-mg tablet and 15-mg tablet) was administered 30 minutes after the start of the breakfast.

Serial blood samples were collected over 336 hours after each dose of erdafitinib for determination of plasma concentrations.

Blood samples to assess Plasma Protein Binding (PBB) were collected predose and 2 hours postdose for each treatment.

Study objectives

(PK)  The  primary  objective  was  to  evaluate  the  effect  of  food  on  the  relative bioavailability of a single 9-mg oral dose of erdafitinib in healthy participants.

Study period

DATE STUDY INITIATED: 14 March 2017

DATE STUDY COMPLETED: 12 May 2017

<div style=\"page-break-after: always\"></div>

| No. of subjects   | All 16 subjects received single oral dose of 9-mg (as one 4-mg tablet and one 5-mg tablet) erdafitinib, administered under fasted (Treatment A) or fed (Treatment B) conditions in a crossover manner.   |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment         | Erdafitinib (JNJ-42756493) was supplied as a 4-mg tablet [G-024] and a 5-mg tablet [G-025].                                                                                                              |

## Results

Cmax, AUClast , and AUC were comparable under fasted and fed conditions. The 90% CIs of the GMRs of Cmax, AUClast, and AUC were within the standard bioequivalence range of 80% to 125%.

Table 19: Summary of the Statistical Analysis of the Pharmacokinetic Parameters of Erdafitinib After a Single Dose of 9 mg Erdafitinib Administered as 1x 4 mg (G-024) And 1x 5 mg (G-025) Oral Tablets Under Fasted (Treatment A) and Fed Condition (Treatment B, Highfat Breakfast)

|                           | Geometric Mean                                  | Geometric Mean                                              |                           |               |                        |
|---------------------------|-------------------------------------------------|-------------------------------------------------------------|---------------------------|---------------|------------------------|
| Phaimacokinetic Parameter | Treatment A 9 mg erdafitinib fasted (reference) | TreatmentB 9 mg erdafitinib fed (high-fat breakfast) (test) | Geometric Mean Ratio, (%) | 90% CI, (%)   | Intra- subject CV, (%) |
| 11                        | 16                                              | 16                                                          |                           |               |                        |
| Cmax (ng/mL)              | 341                                             | 294                                                         | 86.15                     | 80.58 -92.11  | 10.8                   |
| AUClast (ng.h/mL)         | 20353                                           | 19071                                                       | 93.70                     | 88.76 - 98.92 | 8.7                    |
| AUC (ng.h/mL)            | 20871                                           | 19540                                                       | 93.62                     | 88.90 - 98.60 | 8.3                    |

## Distribution

Based on the results of Clinical Study EDI1001 (see study design in section 'Absorption' above), the mean (CV%) Vd/F of erdafitinib in participants with cancer was 28.8 L (51.2%).

The mean (CV%) Vd/F of erdafitinib in heathy participants (pooled analysis EDI1002-EDI1007) was 37.4 L (33.1%).

Volume of distribution is limited in both populations largely due to AGP binding. The difference of Vd/F in participants with cancer versus healthy participants is also likely due to differences in AGP levels and protein binding of erdafitinib in plasma.

## Plasma Protein Binding

The plasma protein binding of erdafitinib was studied in vitro . In vitro , mean Fraction of drug unbound (Fu) ranged between 0.55% (erdafitinib concentration range of 15 to 150 ng/mL) and 0.74% (concentration range of 750 to 1500 ng/mL) in pooled human plasma from healthy participants. Erdafitinib (15 ng/mL) was more highly bound to AGP (94.1% to 99.5% at AGP concentration from 0.02% to 0.20%) compared with human serum albumin (53.4% to 83.9% at human serum albumin concentration from 1% to 6%), and the percent of the unbound fraction was dependent on the purified protein concentration.

In clinical studies, protein binding was assessed based on predose samples spiked with erdafitinib (similar to in vitro analyses) and ex vivo using samples obtained around the time of maximum erdafitinib concentrations in both healthy participants and participants with cancer. As erdafitinib Fus

<div style=\"page-break-after: always\"></div>

were strongly related to AGP levels, this relationship was modelled and described using a nonlinear relationship in the PopPK model.

Fu was estimated based on AGP concentrations, where IIV on the dissociation constant allowed an influence of measured free concentrations. There was a nonlinear relationship between AGP concentration and Fu, which was well described by the equation Fu=Kd/(Kd+AGP), where Kd, was estimated at 30.3 ng/mL. Mean Fu of erdafitinib in plasma was 0.33% in participants with cancer, corresponding to 99.67% bound.

The relationship between PK parameters and Fu was consistent with erdafitinib being a low extraction ratio drug. Consistent with the expectation for a low extraction ratio drug, changes in total CL/F, AUC, and Cmax of erdafitinib were observed with changes in Fu, while free parameters corrected for these relationships, albeit not completely. The PopPK model was set up based on distribution of free erdafitinib to characterise changes in total and free exposure.

## Blood-to-Plasma Ratio

As investigated in vitro , blood-to-plasma ratio was 0.60, with no concentration dependency.

## Transporters

In vitro transporter studies indicated that erdafitinib is a substrate of P-gp but not of BCRP, OATP1B1, and OATP1B3.

## Elimination

Erdafitinib is cleared via multiple pathways. As outlined in the Population PharmacokineticPharmacodynamic Report (2018) not shown), based on totality of available in vitro and clinical PK data, a physiologically-based PK model estimated the clearance of erdafitinib to be composed of metabolism by cytochrome P450 (CYP) 2C9 (39%), CYP3A4 (20%), renal clearance (13%), intestinal secretion (21%), and additional hepatic clearance (8%).

Mean (CV%) total CL/F and unbound CL/F of erdafitinib across all daily doses in the first-in-human Study EDI1001 was 0.362 L/h (51.4%) and 112 L/h (40.8%), respectively, see table below:

<div style=\"page-break-after: always\"></div>

Table 20: Individual Dose Normalised PK Parameters, Including Descriptive Statistics (C2D1) - Pooled for All Dose Levels

Pooled results of study 42756493EDl1001

Dose normalized to 8 mg

|                | Dose normalized PK parameters of erdafitinib - Daily dosing   | Dose normalized PK parameters of erdafitinib - Daily dosing   | Dose normalized PK parameters of erdafitinib - Daily dosing   | Dose normalized PK parameters of erdafitinib - Daily dosing   | Dose normalized PK parameters of erdafitinib - Daily dosing   | Dose normalized PK parameters of erdafitinib - Daily dosing   | Dose normalized PK parameters of erdafitinib - Daily dosing   | Dose normalized PK parameters of erdafitinib - Daily dosing   | Dose normalized PK parameters of erdafitinib - Daily dosing   |
|----------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Subject        | eGFR [mL/min/1. 73 m]                                        | C2D1 Cmin [ng/mL]                                             | C2D1 Cmax [ng/mL]                                             | C2D1 AUC24h [ng.h/mL]                                         | C2D1 Unbound Cmin [ng/mL]                                     | C2D1 Unbound Cmax [ng/mL]                                     | C2D1 Unbound AUC24h [ng.h/mL]                                 | C2D1 CL/F [L/h]                                               | C2D1 CLfree/F [L/h]                                           |
| n              | 50                                                            | 30                                                            | 30                                                            | 21                                                            | 30                                                            | 30                                                            | 21                                                            | 21                                                            | 21                                                            |
| Mean           | 99.3                                                          | 936                                                           | 1399                                                          | 29268                                                         | 2.69                                                          | 4.17                                                          | 81.5                                                          | 0.362                                                         | 112                                                           |
| SD             | 25.7                                                          | 607                                                           | 711                                                           | 17519                                                         | 1.16                                                          | 1.66                                                          | 28.2                                                          | 0.186                                                         | 45.6                                                          |
| Min            | 58                                                            | 215                                                           | 439                                                           | 9995                                                          | 0.687                                                         | 1.90                                                          | 34.8                                                          | 0.105                                                         | 59.1                                                          |
| Median         | 97                                                            | 755                                                           | 1240                                                          | 23068                                                         | 2.69                                                          | 3.70                                                          | 78.8                                                          | 0.347                                                         | 101                                                           |
| Max            | 150                                                           | 2680                                                          | 3260                                                          | 75889                                                         | 5.53                                                          | 8.23                                                          | 135                                                           | 0.800                                                         | 230                                                           |
| %CV            | 25.9                                                          | 64.9                                                          | 50.8                                                          | 59.9                                                          | 43.1                                                          | 39.9                                                          | 34.5                                                          | 51.4                                                          | 40.8                                                          |
| Geometric Mean | 96.1                                                          | 774                                                           | 1238                                                          | 25220                                                         | 2.43                                                          | 3.88                                                          | 76.7                                                          | 0.317                                                         | 104                                                           |

? Excluded from descriptive statistics.

NAs: Not Assessable.

These results are comparable with those estimated in the pooled PopPK model (11 clinical studies, including BLC3001) of 0.321 L/h and 107 L/h, respectively.

Based on pooled data in healthy volunteers after single doses, mean (CV%) t1/2 was 59.3 hours (57.5%).

## Dose proportionality and time dependencies

Dose proportionality was assessed using PK data from the first-in-human Study EDI1001 with single and multiple continuous doses ranging between 0.5 and 12 mg once daily, and from the PK Study GAC1001 in Japanese participants receiving single doses ranging between 2 and 12 mg and multiple continuous doses ranging between 2 and 6 mg once daily.

In Study EDI1001, following daily dose administration of 0.5-, 2-, 4-, 6-, 9-, and 12 mg erdafitinib, AUC and Cmax on Cycle 1 Day 1 and Day 21 (Cycle 2 Day 1) increased with dose without showing relevant or consistent deviations from dose proportionality. The slope of the linear regression (on loglog scale) was not significantly different from unity.

Similar observations were made in Study GAC1001. Following single (2 to 12 mg) and multiple (2 to 6 mg) dose administration of erdafitinib, AUC and Cmax increased with dose without showing relevant or consistent deviations from dose proportionality.

The mean (CV%) steady-state accumulation ratio in participants with cancer across all doses (pooled results) was 4.07 (32.0%) based on AUC, corresponding to mean effective t1/2 of 58.9 hours.

The effective t1/2 estimate in participants with cancer was consistent with the t1/2 determined after a single dose of 59.3 hours in healthy participants based on dose normalised (to 8 mg) pooled data for HV after SD (N= 105) confirming that erdafitinib PK is time-independent.

<div style=\"page-break-after: always\"></div>

## Special populations

## Impaired renal function

Renal excretion of erdafitinib was low; approximately 13.3% of the total administered dose of erdafitinib was excreted renally, and mean renal CL was 0.0541 (0.0146) L/h.

In the PopPK analysis, mild (N=422, or 421 excluding paediatric participants) and moderate (N=301) renal impairment did not have a significant impact on erdafitinib oral CL relative to participants with normal renal function.

Limited data are available in participants with severe renal impairment.

A post hoc subgroup analysis was conducted in the first-in-human Study EDI1001 [ study design in section 'Absorption' above ], where 36 participants had mild renal impairment and 2 participants had moderate renal impairment compared with 39 participants with normal renal function. Due to the low number of participants with moderate renal impairment in this study, PK parameters from participants with mild and moderate renal impairment were pooled for comparison with normal renal function.

Dose-normalised PK parameters (total or free) are presented in the tables below, for single and steady-state Cmax, AUC, and Cmin (steady-state only), stratified by daily or intermittent dose.

Table 21: Comparison of Erdafitinib Exposure on Cycle 1 Day 1 in Participants With Normal Renal Function and Mild/Moderate Renal Impairment (Subgroup Analysis From Study EDI1001

## Dose-Normalised Cmax                                              Dose-

## Normalised unbound Cmax

| Regimen            | N   | Normal    |   N | Mild + Moderate   | Rat io   | N   | Nor mal      |   N | Mild + Moderate   | Rat io   |
|--------------------|-----|-----------|-----|-------------------|----------|-----|--------------|-----|-------------------|----------|
| Daily doses        | 2 8 | 405 (154) |  21 | 435 (198)         | 1.0 7    | 2 8 | 1.40 (0.481) |  20 | 1.13 (0.490)      | 0.8 1    |
| Intermittent doses | 1 0 | 535 (207) |  17 | 523 (274)         | 0.9 8    | 1 0 | 1.35 (0.541) |  17 | 1.90 (0.900)      | 1.4 1    |
| All participants   | 3 8 | 439 (177) |  38 | 475 (236)         | 1.0 8    | 3 8 | 1.38 (0.490) |  37 | 1.48 (0.799)      | 1.0 7    |

|                    | Dose-Normalised AUC 0-72 Normalised unbound AUC 0-72   | Dose-Normalised AUC 0-72 Normalised unbound AUC 0-72   | Dose-Normalised AUC 0-72 Normalised unbound AUC 0-72   | Dose-Normalised AUC 0-72 Normalised unbound AUC 0-72   | Dose-Normalised AUC 0-72 Normalised unbound AUC 0-72   | Dose-Normalised AUC 0-72 Normalised unbound AUC 0-72   | Dose-Normalised AUC 0-72 Normalised unbound AUC 0-72   | Dose-   | Dose-           | Dose-   |
|--------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|---------|-----------------|---------|
| Regimen            | N                                                      | Normal                                                 | N                                                      | Mild + Moderate                                        | Rat io                                                 | N                                                      | Nor mal                                                | N       | Mild + Moderate | Rat io  |
| Daily doses        | 2 1                                                    | 15129 (7444)                                           | 13                                                     | 15163 (7375)                                           | 1.0 0                                                  | 2 1                                                    | 49.9 (16.3)                                            | 12      | 42.5 (14.4)     | 0.8 5   |
| Intermittent doses | 0                                                      | -                                                      | 0                                                      | -                                                      | -                                                      | 0                                                      | /                                                      | 0       | -               | -       |
| All participants   | 2 1                                                    | 15129 (7444)                                           | 13                                                     | 15163 (7375)                                           | 1.0 0                                                  | 2 1                                                    | 49.9 (16.3)                                            | 12      | 42.5 (14.4)     | 0.8 5   |

Table 22: Comparison of Erdafitinib Exposure on Cycle 2 Day 1 in Participants With Normal Renal Function and Mild/Moderate Renal Impairment (Subgroup Analysis From Study EDI1001)

|                    | Dose-Normalised C max   | Dose-Normalised C max   | Dose-Normalised C max   | Dose-Normalised C max   | Dose-Normalised C max   | Dose-Normalised Unbound C max   | Dose-Normalised Unbound C max   | Dose-Normalised Unbound C max   | Dose-Normalised Unbound C max   |
|--------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Regimen            | N                       | Norma l                 | N Moderate              | Mild +                  | Rat io                  | Normal Moderate                 | N                               | Mild +                          | Rat io                          |
| Daily doses        | 17                      | 1391 (786)              | 13                      | 1410 (631)              | 1.0 1                   | 4.40 (1.76) (1.54)              | 13                              | 3.86                            | 0.8 8                           |
| Intermittent doses | 8                       | 1048 (495)              | 14                      | 646 (302)               | 0.6 2                   | 3.37 (2.66) (1.13)              | 14                              | 2.45                            | 0.7 3                           |

<div style=\"page-break-after: always\"></div>

|                    | Dose-Normalised AUC 0-24 Unbound AUC 0-24   | Dose-Normalised AUC 0-24 Unbound AUC 0-24   | Dose-Normalised AUC 0-24 Unbound AUC 0-24   | Dose-Normalised AUC 0-24 Unbound AUC 0-24   | Dose-Normalised AUC 0-24 Unbound AUC 0-24   | Dose-Normalised AUC 0-24 Unbound AUC 0-24   | Dose-Normalised AUC 0-24 Unbound AUC 0-24   | Dose-Normalised               | Dose-Normalised               | Dose-Normalised               |
|--------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|-------------------------------|-------------------------------|-------------------------------|
| Regimen            | N                                           | Normal                                      | N                                           | Mild + Moderate                             | Rat io                                      | N                                           | Nor mal                                     | N                             | Mild + Moderate               | Rat io                        |
| Daily doses        | 13                                          | 28814 (19815)                               | 8                                           | 30005 (14240)                               | 1.0 4                                       | 1 3                                         | 81.3 (27.6)                                 | 8                             | 81.9 (30.9)                   | 1.0 1                         |
| Intermittent doses | 5                                           | 18954 (10801)                               | 1 0                                         | 10420 (2906)                                | 0.5 5                                       | 5                                           | 48.7 (41.7)                                 | 1 0                           | 38.4 (8.78)                   | 0.7 9                         |
|                    | Dose-Normalised C min                       | Dose-Normalised C min                       | Dose-Normalised C min                       | Dose-Normalised C min                       | Dose-Normalised C min                       | Dose-Normalised Unbound C min               | Dose-Normalised Unbound C min               | Dose-Normalised Unbound C min | Dose-Normalised Unbound C min | Dose-Normalised Unbound C min |
| Regimen            | N                                           | Norma l                                     | N Mild + Moderate                           | N Mild + Moderate                           | Rat io                                      | N                                           | Normal Moderate                             | N                             | Mild +                        | Rat io                        |
| Daily doses        | 17                                          | 958 (680)                                   | 13                                          | 909 (524)                                   | 0.9 5                                       | 1 7                                         | 2.84 (1.10) (1.24)                          | 13                            | 2.49                          | 0.8 8                         |
| Intermittent doses | 8                                           | 339 (284)                                   | 14                                          | 213 (156)                                   | 0.6 3                                       | 8                                           | 0.941 (0.815) (0.574)                       | 14                            | 0.775                         | 0.8 2                         |

The plasma PK of total and free erdafitinib was examined in participants with normal hepatic function (N=8) and with preexisting mild (N=8, Grade A, Child-Pugh score of 5 or 6) or moderate (N=8, Grade B, Child-Pugh score of 7 to 9) hepatic impairment (see below).

## EDI1008 (hepatic impairment)

Hepatic impairment has been studied in an open-label, single-dose, non-randomised, Phase 1 PK study of erdafitinib in participants who either had hepatic impairment (mild and moderate) or participants with normal hepatic function who qualified for the healthy control group. Hepatic impairment was classified according to the Child-Pugh Classification of Severity of Liver Disease: mild (Grade A, ChildPugh score of 5 or 6) and moderate (Grade B, Child-Pugh score of 7 to 9).

Healthy men and women between 18 and 80 years of age (inclusive) who had a body mass index between 18 and 34.9 kg/m (inclusive) and a body weight of  50 kg were eligible.

## Severe hepatic impairment

The enrolment of the severe hepatic impairment cohort at 6 mg erdafitinib was to be initiated after review of safety and PK data from the mild and moderate hepatic impairment cohorts. PK and safety data were reported from only 2 patients enrolled in the severe hepatic impairment group.

<div style=\"page-break-after: always\"></div>

Moderate and mild hepatic impairment

Table 23: Summary of the Statistical Analysis of the Pharmacokinetic Parameters of Total and Free Erdafitinib after Administration of 6 mg of Erdafitinib in Subjects with Mild Hepatic Impairment and in Subjects with Normal Hepatic Function

|                         | Hepatic Function                               | Hepatic Function    | Geometric Means              |               |                       |
|-------------------------|------------------------------------------------|---------------------|------------------------------|---------------|-----------------------|
| PK Parameter            | Normal Hepatic function Impairment (Reference) | Mild Hepatic (Test) | Ratio of Geometric Means (%) | 90% CI (%)    | Total Variability (%) |
| C max (ng/mL)           | 157                                            | 130                 | 83.02                        | 59.91- 115.04 | 38.7                  |
| AUC last (h*ng/mL)      | 11152                                          | 9208                | 82.57                        | 55.27- 123.37 | 48.5                  |
| AUC  (h*ng/mL)         | 11393                                          | 9374                | 82.28                        | 54.98- 123.13 | 48.7                  |
| C max , free (ng/mL)    | 0.71                                           | 0.68                | 96.07                        | 83.43- 110.63 | 16.3                  |
| AUC last,free (h*ng/mL) | 50.4                                           | 48.2                | 95.56                        | 76.67- 119.09 | 25.6                  |
| AUC ,free (h*ng/mL)    | 51.5                                           | 49.1                | 95.22                        | 75.85- 119.54 | 26.5                  |

The ANOVA model included log transformed PK parameters as response variable, fixed effect term as level of hepatic function [normal and mild subjects] and age, body weight, and sex as covariate.

Note: Analysis done on log transformed data and the results were back-transformed using anti-logarithm.

Reference: Normal Hepatic Function (n=8)

Test: Mild Hepatic Function (n=8)

Total Variability (%)= 100*sqrt(exp(MSE)-1)

Table 24: Summary of the Statistical Analysis of the Pharmacokinetic Parameters of Total and Free Erdafitinib after Administration of 6 mg of Erdafitinib in Subjects with Moderate Hepatic Impairment and in Subjects with Normal Hepatic Function

|                        | Hepatic Function                               | Hepatic Function        | Geometric Means              |              |                       |
|------------------------|------------------------------------------------|-------------------------|------------------------------|--------------|-----------------------|
| PK Parameter           | Normal Hepatic function Impairment (Reference) | Moderate Hepatic (Test) | Ratio of Geometric Means (%) | 90%CI(%)     | Total Variability (%) |
| Cmax (ng/mL)           | 157                                            | 126                     | 80.30                        | 56.72-113.70 | 38.7                  |
| AUClast (h*ng/mL)      | 11152                                          | 9315                    | 83.53                        | 54.45-128.15 | 48.5                  |
| AUC  (h*ng/mL)        | 11393                                          | 9671                    | 84.89                        | 55.24-130.45 | 48.7                  |
| Cmax,free (ng/mL)      | 0.71                                           | 0.72                    | 100.97                       | 86.87-117.36 | 16.3                  |
| AUClast,free (h*ng/mL) | 50.4                                           | 53.0                    | 105.03                       | 83.06-132.81 | 25.6                  |
| AUC ,free             | 51.5                                           | 55.0                    | 106.73                       | 83.75-136.02 | 26.5                  |

The ANOVA model included log transformed PK parameters as response variable, fixed effect term as level of hepatic function [normal and moderate subjects] and age, body weight, and sex as covariate.

Note: Analysis done on log transformed data and the results were back-transformed using anti-logarithm.

Reference: Normal Hepatic Function (n=8)

Test: Moderate Hepatic Function (n=8)

Total Variability (%)= 100*sqrt(exp(MSE)-1)

## Gender

The popPK model predicted regarding exposition (AUCfree) for female patients a geometric mean ratio of 1.12 (90% PI 0.64 - 1.97) compared to 0.94 (90% PI 0.54 - 1.56). Female sex on bioavailability was included as covariate in the popPK model. In addition to that, the popPK-PD analysis revealed that the initial [PO4] baseline was 6.5% higher in women.

<div style=\"page-break-after: always\"></div>

## Race

GAC1001 study (Asian participants) This was a Phase 1, open-label, multicentre, 2-part, dose escalation (Part 1), and dose expansion (Part 2) study conducted in 19 participants with advanced or refractory solid tumors or lymphoma.

Erdafitinib PK parameters are summarised in the table below:

Table 25: Summary of Single and Multiple Dose Plasma PK Parameters of Erdafitinib for the Continuous and Intermittent Dose Cohorts

| Parameter (Unit)                                                             | Mean (SD)                                                                    | Mean (SD)                                                                    | Mean (SD)                                                                    | Mean (SD)                                                                    | Mean (SD)                                                                    |
|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
|                                                                              | ContinuousDoses                                                              | ContinuousDoses                                                              | ContinuousDoses                                                              | IntermittentDoses                                                            | IntermittentDoses                                                            |
|                                                                              | 2 mg (N=3)                                                                   | 4 mg (N=3)                                                                   | 6 mg (N=3)                                                                   | 10 mg (N=3)                                                                  | 12 mg (N=7)                                                                  |
| Cycle 1 Day 1                                                                |                                                                              |                                                                              |                                                                              |                                                                              |                                                                              |
| tmaxa (h)                                                                    | 3.00 (3.0-6.0)                                                               | 2.00 (1.0-4.0)                                                               | 2.92 (1.9-3.9)                                                               | 2.88 (2.0-3.9)                                                               | 2.82 (1.0-4.0)                                                               |
| Cmax (ng/mL)                                                                 | 98.0 (21.2)                                                                  | 162 (52.5)                                                                   | 398 (97.3)                                                                   | 521 (164)                                                                    | 701 (451)                                                                    |
| AUC (ng.h/mL)                                                                | 1770 (388)                                                                   | 2458 (563)                                                                   | 6989 (1812)                                                                  | 8935 (1935)                                                                  | 12698 (6698)                                                                 |
| Cycle 1 Day 8 (Continuous Dose Cohorts) or Day 7 (Intermittent Dose Cohorts) | Cycle 1 Day 8 (Continuous Dose Cohorts) or Day 7 (Intermittent Dose Cohorts) | Cycle 1 Day 8 (Continuous Dose Cohorts) or Day 7 (Intermittent Dose Cohorts) | Cycle 1 Day 8 (Continuous Dose Cohorts) or Day 7 (Intermittent Dose Cohorts) | Cycle 1 Day 8 (Continuous Dose Cohorts) or Day 7 (Intermittent Dose Cohorts) | Cycle 1 Day 8 (Continuous Dose Cohorts) or Day 7 (Intermittent Dose Cohorts) |
| tmaxa (h)                                                                    | 4.05 (4.0-5.9)                                                               | 2.98 (3.0-4.1)                                                               | 2.95 (2.8-3.9)                                                               | 2.95 (2.0-3.9)                                                               | 5.93 (2.0-23.9)                                                              |
| Cmax (ng/mL)                                                                 | 283 (37.4)                                                                   | 375 (114)                                                                    | 1146 (294)                                                                   | 1567 (506)                                                                   | 1947 (1106)                                                                  |
| AUC: (ng.h/mL)                                                               | 5941 (878)                                                                   | 7383 (2537)                                                                  | 22790 (6622)                                                                 | 31425 (10534)                                                                | 40280 (21049)                                                                |
| Cycle 2 Day 1                                                                |                                                                              |                                                                              |                                                                              |                                                                              |                                                                              |
| tmaxa (h)                                                                    | _b                                                                           | 5.93 (4.0-7.4)                                                               | q                                                                            | _b                                                                           | 6.01 (4.1-23.9)c                                                             |
| Cmax (ng/mL)                                                                 | 662 (-)b                                                                     | 524 (181)                                                                    | 1375 (-)b                                                                    | 492 (-)b                                                                     | 652 (277)c                                                                   |
| AUC, (ng.h/mL)                                                               | 11671 (-)b                                                                   | 11552 (4271)                                                                 | 26128 (-)b                                                                   | q 0666                                                                       | 13301 (6375)c                                                                |

a Median (range); b N=2; c N=4.

As tabulated above, Cmax and AUC increased with increasing dose on both Days 1 and 8 (Day 7 for the 10 and 12 mg intermittent dose cohorts). The median tmax ranged between 2 and 3 hours after the first dose on Day 1 and between 3 and 6 hours following multiple daily dose administration.

The maximum concentrations of plasma Fu of erdafitinib were seen 3 to 4 hours after the first dose.

## Study HCC1001 (Asian participants)

This was an open-label, multicentre, 2-part, Phase 1/2a study conducted at multiple sites in Asia, including South Korea, China Taiwan, and Mainland China. The study had 'Part 1 Dose Escalation' and 'Part 2 Dose Expansion'. A total of 53 (98.1%) participants were treated with erdafitinib, provided as tablets for oral administration in 2 dosing schemes:

- a) intermittent dosing (erdafitinib at 8, 10, or 12 mg administered on Days 1 to 7 and Days 15 to 21 of each 28-day cycle), and
- b) continuous dosing (erdafitinib at 8 mg administered once daily for 28 days on a 28-day cycle). The 8 mg continuous dose was selected as the final RP2D for further expansion in the HCC indication. Erdafitinib PK parameters are summarised in the table below:

<div style=\"page-break-after: always\"></div>

Table 26: Summary of Single and Multiple Dose Plasma Total PK Parameters of Erdafitinib for the Continuous and Intermittent Dose Cohorts (Study HCC1001)

| Parameter (Unit)                                                             | Mean (SD)                                                                    | Mean (SD)                                                                    | Mean (SD)                                                                    | Mean (SD)                                                                    |
|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------|
|                                                                              | ContinuousDoses                                                              | IntermittentDoses                                                            | IntermittentDoses                                                            | IntermittentDoses                                                            |
|                                                                              | 8 mg                                                                         | 8 mg                                                                         | 10 mg (N=8)                                                                  | 12 mg (N=4)                                                                  |
|                                                                              | (N=6)                                                                        | (N=3)                                                                        |                                                                              |                                                                              |
| Cycle 1 Day 1                                                                |                                                                              |                                                                              |                                                                              |                                                                              |
| tmaxa (h)                                                                    | 4.1 (2.2-6.0)                                                                | 3.0 (2.0-3.0)                                                                | 4.0 (1.0-5.9)                                                                | 2.3 (1.8-5.1)                                                                |
| Cmaxb (ng/mL)                                                                | 330.50 (26.3)                                                                | 577 (27.8)                                                                   | 467 (44.2)                                                                   | 662 (49.8)                                                                   |
| AUCo-24b (ng.h/mL)                                                           | 6091 (22.7)c                                                                 | 13981 (-)d                                                                   | 9161 (43.1)e                                                                 | 3281 (-)d                                                                    |
| Cycle 1 Day 8 (Continuous Dose Cohorts) or Day 7 (Internittent Dose Cohorts) | Cycle 1 Day 8 (Continuous Dose Cohorts) or Day 7 (Internittent Dose Cohorts) | Cycle 1 Day 8 (Continuous Dose Cohorts) or Day 7 (Internittent Dose Cohorts) | Cycle 1 Day 8 (Continuous Dose Cohorts) or Day 7 (Internittent Dose Cohorts) | Cycle 1 Day 8 (Continuous Dose Cohorts) or Day 7 (Internittent Dose Cohorts) |
| tmaxa (h)                                                                    | 3.5 (1.9-7.0)                                                                | 3.0 (2.0-4.0)                                                                | 3.05 (2.0-5.7)                                                               | 4.46 (3.1-5.9)                                                               |
| Cmaxb (ng/mL)                                                                | 749 (20.7)                                                                   | 1553 (30.3)                                                                  | 1329 (58.4)                                                                  | 1768 (52.1)                                                                  |
| AUCo-24b (ng.h/mL)                                                           | 15228 (21.1)                                                                 | 32198 (27.5)                                                                 | 26939 (59.3)                                                                 | 34703 (52.6)                                                                 |
| Cycle 1 Day 21 (Continuous DoseCohorts)                                      | Cycle 1 Day 21 (Continuous DoseCohorts)                                      | Cycle 1 Day 21 (Continuous DoseCohorts)                                      | Cycle 1 Day 21 (Continuous DoseCohorts)                                      | Cycle 1 Day 21 (Continuous DoseCohorts)                                      |
| tmaxa (h)                                                                    | 3.0 (2.9-6.0)c                                                               |                                                                              |                                                                              |                                                                              |
| C max b (ng/mL)                                                              | 787.00 (17.3)c                                                               |                                                                              |                                                                              |                                                                              |
| AUCo.24b (ng.h/mL)                                                           | 15576.18 (15.4)c                                                             |                                                                              |                                                                              |                                                                              |

a Median (range); b Cmax and AUC0-24 are reported as mean (CV%); c N=5; d N=1; e N=7

As tabulated above, systemic exposure of erdafitinib generally increased with increasing doses. However, no clear trend was observed based on the limited sample size.

Median tmax was observed at 2.30 to 4.10 hours post-dose after single dosing and 3.00 to 4.46 hours post-dose after repeated dosing. The accumulation ratios at steady state were 2.57 and 2.84 based on Cmax and AUC , respectively. Erdafitinib was characterised by a low total apparent plasma clearance (on average 0.436-0.562 L/h).

## Weight

In popPK modelling the relationships between weight and clearance and weight and volumes of distribution were described using allometric scaling. CLfree and the volumes of the central and peripheral compartments (V2, V3, V4) were found to increase with increasing weight, described by power functions with powers of 0.68 and 0.53, respectively.

## Elderly

In the PopPK analysis, oral CL decreased with increasing age (range, 12-92 years, or 21-92 years excluding 3 paediatric participants), by  15.2% in the 65 to 75 years old group (N=367) and  20.6% in the &gt;75 years old group (N=111) as compared with the &lt;65 years old group (N=664).

## Pharmacokinetic interaction studies

## In vitro

Potential for drug interactions: in vitro studies with metabolic enzymes

In vitro studies assessing possible relevance of CYP enzymes for drug interactions of erdafitinib are summarised in Table 27.

<div style=\"page-break-after: always\"></div>

Table 27: Overview of in vitro studies assessing relevance of metabolic enzymes for drug interactions of erdafitinib

| Study nr.   | Erdafitinib:                | Study system                                      | Enzymes / Receptors   | Results / unbound IC 50 or K i                                                                         | Implications                                                |
|-------------|-----------------------------|---------------------------------------------------|-----------------------|--------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|
| ADME_22183  | inhibitor                   | human liver microsomes                            | CYP1A2                | IC 50 > 15  M                                                                                         | no in vivo study needed *                                   |
| ADME_22183  | inhibitor                   | human liver microsomes                            | CYP2C8                | IC 50 > 15  M                                                                                         | no in vivo study needed *                                   |
| ADME_22183  | inhibitor                   | human liver microsomes                            | CYP2C9                | IC 50 > 15  M                                                                                         | no in vivo study needed *                                   |
| ADME_22183  | inhibitor                   | human liver microsomes                            | CYP2C19               | IC 50 > 15  M                                                                                         | no in vivo study needed *                                   |
| ADME_31191  | inhibitor                   | human liver microsomes                            | CYP2D6                | IC 50 > 15  M                                                                                         | no in vivo study needed *                                   |
| ADME_22183  | inhibitor                   | human liver microsomes                            | CYP3A4 (testosterone) | IC 50 > 15  M                                                                                         | no in vivo study needed *                                   |
| ADME_22183  | inhibitor                   | human liver microsomes                            | CYP3A4/5 (midazolam)  | IC 50 > 15  M                                                                                         | no in vivo study needed *                                   |
| FK10109     | inhibitor, mechanism- based | human liver microsomes                            | CYP1A2                | + NADPH: no  CYP activity                                                                             | no irreversible inhibition                                  |
| FK10109     | inhibitor, mechanism- based | human liver microsomes                            | CYP2C9 CYP2C19        | + NADPH: no  CYP activity + NADPH:                                                                    | no irreversible inhibition                                  |
| FK10109     | inhibitor, mechanism- based | human liver microsomes                            | CYP2D6                | + NADPH: no  CYP activity                                                                             | no irreversible inhibition                                  |
| FK10109     | inhibitor, mechanism- based | human liver microsomes                            | CYP3A4                | + NADPH: 43%  CYP activity                                                                            | irreversible inhibition                                     |
| FK11141     | inhibitor, mechanism- based | human liver microsomes                            | CYP3A4                | K I = 1.81  M k inact = 0.0209 1/min                                                                  | irreversible inhibition                                     |
| FK12003     | inducer #                   | human hepatocytes 0.4 - 15  M  10  M cytotoxic | CYP1A2 CYP2B6 CYP3A4  | FC > 2 in 2/3 donors not conc.-dependent FC > 2 in 3/3 donors not conc.-dependent FC > 2 in 1/3 donors | inconclusive, concentration range above 15C max,u (172 nM) |
| FK12003     | inducer #                   | human hepatocytes 0.4 - 15  M  10  M cytotoxic |                       | not conc.-dependent 200 nM: FC < 2                                                                     | inconclusive, concentration range above 15C max,u (172 nM) |
| FK12003     |                             |                                                   | CYP1A2                | in 3/3 donors                                                                                          |                                                             |

<div style=\"page-break-after: always\"></div>

| FK13265   | inducer #   | human hepatocytes   | CYP2B6   | 200 nM: FC > 2 in 2/3 donors                 | no inducer                           |
|-----------|-------------|---------------------|----------|----------------------------------------------|--------------------------------------|
|           |             | 5 - 3000 nM         |          | not conc.-dependent                          |                                      |
|           |             |                     | CYP3A4   | 200 nM: FC > 2 in 1/3 donors (20% pos. ctrl) | inconclusive (s. Assessor's comment) |
|           |             |                     |          | not conc.-dependent                          |                                      |

need for in vivo study as estimated by the assessor according to the EMA guideline on the investigation of drug interactions (CPMP/EWP/560/95/Rev. 1 Corr. 2**) and draft ICH M12 guideline on drug interactions: in vivo evaluation is warranted if

# at least in one donor a drug increases mRNA expression of a CYP enzyme in a concentration-dependent manner and the foldchange (FC) of CYP mRNA expression is  2 -fold at 15Cmax,u

*[I]/Ki  0.02 where [I] is the unbound mean C max obtained during treatment with the highest recommended dose ([I] = 11.5 nM), for intestinal enzymes [I]/Ki  10 where [I] is max. dose taken one occasion (9 mg)/ 250 ml

Potential for drug interactions: in vitro studies with transporters

In vitro studies assessing possible relevance of transport proteins for drug interactions of erdafitinib are summarised in Table 28.

Table 28: Overview of in vitro studies assessing relevance of transporters for drug interactions of erdafitinib

| Study nr.                   | Erdafitinib:   | Study system                             | Transporters      | Results / unbound IC 50 or K i                                      | Implications                   |
|-----------------------------|----------------|------------------------------------------|-------------------|---------------------------------------------------------------------|--------------------------------|
| FK11162                     | inhibitor      | inside-out vesicles expressing BCRP      | BCRP              | IC 50 = 14.9  M                                                    | no in vivo study needed *      |
| FK11162                     | substrate      | MDCKII/BCRP cells                        | BCRP              | no effect of BCRP inhibitor                                         | not a transporter substrate    |
| FK11164                     | inhibitor      | LLC-PK1/MDR1 cells                       | P-gp              | IC 50 = 0.666  M                                                   | in vivo study warranted *      |
| ADME14455 ADME24540 FK11164 | substrate      | LLC-PK1/MDR1 cells                       | P-gp              | P-gp inhibitor reduces transport P-gp transport saturated > 0.3  M | likely a transporter substrate |
| FK11163                     | inhibitor      | HEK293 cells overexpressing transporters | OATP1B1 OATP1B3   | IC 50 = 36.5  M IC 50 = 63.1  M                                   | no in vivo study needed *      |
| FK11163                     | substrate      | HEK293 cells overexpressing transporters | OATP1B1/3 OATP1B3 | uptake = wt cells no inhibitor effect                               | not a transporter substrate    |
| FK11158                     | inhibitor      | MDCKII cells overexpressing              | MATE1             | IC 50 = 2.26  M                                                    | no in vivo study needed *      |
| FK11158                     |                | transporters                             | MATE2-K           | IC 50 = 1.89  M                                                    |                                |

<div style=\"page-break-after: always\"></div>

| FK11157   | inhibitor   | CHO cells overexpressing transporters   | OAT1 OAT3   | no inhibition up to 20.7  M no inhibition up to 68.6  M   | no in vivo study needed *   |
|-----------|-------------|-----------------------------------------|-------------|-------------------------------------------------------------|-----------------------------|
| FK11156   | inhibitor   | CHO cells overexpressing transporters   | OCT1        | IC 50 = 0.73  M                                            | no in vivo study needed *   |
| FK11156   |             |                                         | OCT2        | IC 50 = 0.043  M                                           | in vivo study warranted *   |

** need for in vivo study as estimated by the assessor according to the ICH M12 draft guideline on drug interactions: in vivo evaluation is warranted if Ki or IC50 

- for BCRP and P-gp: 0.1-fold the maximum dose on one occasion (9 mg)/250 ml

-  for OATP1B1 and OATP1B3: 10-fold the unbound hepatic inlet concentration (13 nM)

-  for OCT2, OAT1 and OAT3: 10-fold unbound Cmax (11.5 nM)

-  for MATE1 and MATE2-K: 50-fold unbound Cmax (11.5 nM)

-for OCT1 according to the EMA guideline on the investigation of drug interactions (CPMP/EWP/560/95/Rev. 1 Corr. 2**): in vivo evaluation is warranted if Ki  25 -fold the unbound hepatic inlet concentration (13 nM)

## In vivo

## Erdafitinib Effect on Other Drugs (erdafitinib=perpetrator)

CYP induction/inhibition (erdafitinib=perpetrator)

BLC2001: Phase 2 - DDI Substudy

Drug-drug Interaction Substudy to Assess the Effect of Repeated Doses of Erdafitinib on the Singledose Pharmacokinetics of Midazolam and Metformin in Subjects with Advanced Solid Tumors that Harbor Target FGFR Mutations or FGFR Gene Fusions at Selected Sites.

<div style=\"page-break-after: always\"></div>

## Results

Figure 2: Mean (Standard Deviation) Plasma Concentration-time Profiles of Midazolam After Single Oral Administration of 2.5 mg of Midazolam Alone (Day -2) and in Combination With Erdafitinib at 8 mg Once Daily (Day 13) (Study 42756493BLC2001: Pharmacokinetic Data Analysis Set)

<!-- image -->

Table 29: Summary of the Statistical Analysis of the PK Parameters of Midazolam after Single Oral Administration of 2.5 mg Midazolam Alone (Day -2) and in Combination With Erdafitinib at 8 mg Once Daily (Day 13) (BLC2001 DDI Substudy: PK Data Analysis Set)

|                          | GeometricMean                      | GeometricMean                        |         |              |        |
|--------------------------|------------------------------------|--------------------------------------|---------|--------------|--------|
| PKParametersof Midazolam | Midazolam Alone Day -2 (Reference) | Midazolam+ Erdafitinib Day 13 (Test) | GMR (%) | I0 %06 (%)   | CV (%) |
| 11                       | 21a                                | 21a                                  |         |              |        |
| Cmax (ng/mL)             | 16.4                               | 14.2                                 | 86.29   | 73.52-101.28 | 30.8   |
| AUClast (ng.h/mL)        | 55.8                               | 49.4                                 | 88.46   | 76.55-102.22 | 27.7   |
| AUC (ng.h/mL)            | 55.0                               | 45.1                                 | 82.11   | 70.83-95.18  | 23.3   |

a n=17 for AUC

<div style=\"page-break-after: always\"></div>

Figure 3: Linear Mean (Standard Deviation) Plasma Concentration-time Profiles of Metformin after Single Oral Administration of 1000 mg of Metformin Alone (Day -1) and in Combination with Erdafitinib at 8 mg Once Daily (Day 14) (Study 42756493BLC2001: Pharmacokinetic Data Analysis Set)

<!-- image -->

Table 30: Summary of the Statistical Analysis of the PK Parameters of Metformin after Single Oral Administration of 1000 mg of Metformin Alone (Day -1) and in Combination with Erdafitinib at 8 mg Once Daily (Day 14) (BLC2001 DDI Substudy: PK Data Analysis Set)

|                          | Geometricean                      | Geometricean                         |         |              |        |
|--------------------------|-----------------------------------|--------------------------------------|---------|--------------|--------|
| PKParametersof Metfornin | MetforminAlone Day -1 (Reference) | Metformin+ Erdafitinib Day 14 (Test) | GMR (%) | I0 %06 (%)   | CV (%) |
| 11                       | 16a                               | 16a                                  |         |              |        |
| C max (ng/mL)            | 2376                              | 2582                                 | 108.66  | 90.31-130.75 | 30.5   |
| AUCiast (ng.h/mL)        | 20102                             | 23922                                | 119.01  | 98.85-143.27 | 30.6   |
| AUC (ng.h/mL)           | 22225                             | 25319                                | 113.92  | 93.22-139.23 | 30.7   |

a n=14 for AUC

## Potential for Interactions with Hormonal Contraceptives (erdafitinib=perpetrator)

Not explicitly investigate in clinical DDI studies.

## Transporter (erdafitinib=perpetrator)

The potential of erdafitinib to interact with transporters has only been investigated in one clinical study:

In the BLC2001 DDI Substudy discussed in detail above, mean ratios of Cmax and AUC for metformin (a sensitive OCT2 substrate) were 108.66% (90% CI: 90.31-130.75) and 113.92% (90% CI: 93.22-139.23), respectively, when co-administered with erdafitinib relative to metformin alone.

OATP1B3, OAT1, and OAT3

Erdafitinib is not considered an inhibitor of OATP1B3, OAT1, or OAT3.

<div style=\"page-break-after: always\"></div>

## BCRP and OATP1B

Mean (CV%) steady-state Cmax (Day 21) in participants with cancer at the highest clinical dose of 9 mg was 2018 ng/mL (36.9%), well below the IC50 values of BCRP and OATP1B. Therefore, erdafitinib is not expected to affect the PK of BCRP or OATP1B substrates.

P-gp

Erdafitinib is a Pgp inhibitor with an IC50 of 0.67 M (299 ng/mL) in LLC -PK1 cells and an unbound intracellular IC50 calculated at 0.026 M (11.6 ng/mL).

As a P-gp inhibitor, simulated luminal and enterocyte concentration after administration of 9 mg erdafitinib showed a potential risk of P-gp inhibition only in the first 5 hours after administration in the different parts of the intestinal tract.

## OCT1, OCT2, MATE-1, and MATE-2

Inhibitory effects were noted for OCT1, OCT2, MATE-1, and MATE-2 with IC50 values in the low micromolar range. Comprehensive analysis based on recommended static models (agency DDI guidelines) indicated that other than OCT2, there were no clinically relevant inhibition-based DDIs expected for OCT1, MATE-1, and MATE-2 by erdafitinib.

OCT2 showed the lowest IC50 of 0.0434 M (19.4 ng/mL), while mean steady -state unbound Cmax (Day 21) in participants with cancer at the highest clinical dose of 9 mg was 3-fold lower at 6.5 ng/mL (based on mean Cmax of 2018 ng/mL and mean Fu of 0.32%).

## Effect of Other Drugs on erdafitinib (erdafitinib=victim)

## CYP3A4 Inhibitors (erdafitinib=victim)

## EDI1007

A Randomized, Open-Label, Parallel-Group, Drug-Drug Interaction Study to Evaluate the Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adult Subjects.

Table 31: GMR and 90% CI for Comparison of Erdafitinib Administered Alone (Reference) Versus Administered with Fluconazole (Test) or with Itraconazole (Test) (Primary Analysis)

CoadninistrationWithFluconazole

| Parameter (Unit)   | GeometricMean                     | GeometricMean                       | GMR, % (90% CI)         |
|--------------------|-----------------------------------|-------------------------------------|-------------------------|
| Parameter (Unit)   | ErdafitinibAlone (Reference) N=17 | Erdafitinib+Fluconazole (Test) N=15 | GMR, % (90% CI)         |
| AUCo-168 (ng.h/mL) | 7490                              | 10306                               | 137.59 (113.56, 166.70) |
| AUClast (ng.h/mL)  | 8413                              | 12540                               | 149.05 (120.30, 184.67) |
| AUC (ng.h/mL)      | 8655                              | 12796                               | 147.85 (119.95, 182.24) |
| Cmax (ng/mL)       | 136                               | 164a                                | 121.10 (99.88, 146.84)  |

CoadministrationWithItraconazole

|                    | Geometric Mean                   | Geometric Mean                       | GMR, %                  |
|--------------------|----------------------------------|--------------------------------------|-------------------------|
|                    | ErdafitinibAlone (Reference)N=17 | Erdafitinib+Itraconazole (Test) N=17 | (90% CI)                |
| AUCo-168 (ng.h/mL) | 7490                             | 9000                                 | 120.15 (99.81, 144.62)  |
| AUClast (ng.h/mL)  | 8413                             | 11198                                | 133.10 (108.21, 163.72) |
| AUC (ng.h/mL)      | 8655                             | 11585a                               | 133.86 (109.05, 164.33) |
| Cmax (ng/mL)       | 136                              | 142                                  | 104.79 (86.66. 126.70)  |

Note: The analysis was performed based on a mixed effect model, including both genotype and treatment as fixed effects. The primary analysis included CYP2C9 genotype *1/*1 + *1/*2.

Reference: 4 mg erdafitinib tablet administered alone on Day 1.

Test: 4 mg erdafitinib tablet administered on Day 5 + 400 mg fluconazole administered once daily on Days 1 to 11 or 4 mg erdafitinib tablet administered on Day 5 + 200 mg itraconazole once daily on Days 1 to 11. a N=16.

<div style=\"page-break-after: always\"></div>

Figure 4: Mean (SD) Linear Plasma Concentration-time Curves of Erdafitinib after a Single Dose Administration of 4 mg Erdafitinib Alone (Treatment A) or in Combination with Daily Administration of 400 mg Fluconazole (Treatment B, Day 5), or 200 mg Itraconazole (Treatment C, Day 5), in Healthy Subjects with CYP2C9 Genotype *1/*1 or *1/*2

<!-- image -->

## CYP3A4/CYP2C9 Inducers (erdafitinib=victim)

## NAP1001

An Open-label, Single-sequence, Drug-drug Interaction Study to Evaluate the Effect of Steady-state Carbamazepine on the Single-dose Pharmacokinetics of Erdafitinib Tablets in Healthy Adult Subjects

Summary PK statistical results are presented in the tables below:

Table 32: Summary of the Statistical Analysis of the PK Parameters of Total Erdafitinib after Single Administration of Erdafitinib Alone at 12 mg and in Combination with Multiple Doses of Carbamazepine; PK Data Statistical Primary Analysis Set

|                                 |   GeometricMean | GeometricMean                       | GeometricMean                            | Testver'susReference   | Testver'susReference   | Source ofVariability   | Source ofVariability                  |
|---------------------------------|-----------------|-------------------------------------|------------------------------------------|------------------------|------------------------|------------------------|---------------------------------------|
| PKParameter (Total Erdafitinib) |              11 | Erdafitinib 12 mg Alone (Reference) | Erdafitinib 12 mg + Carbamazepine (Test) | GMR (%)                | I %06 (%)              | Intra- CV (%)          | Inter- participant participant CV (%) |
| Cmax (ng/mL)                    |              13 | 365                                 | 239                                      | 65.44                  | (60.77, 70.46)         | 10.6                   | 24.6                                  |
| AUC168h (ng.h/mL)               |              12 | 21,616                              | 9,407                                    | 43.52                  | (40.12, 47.21)         | 11.1                   | 25.8                                  |
| AUClast (ng.h/mL)               |              12 | 24,537                              | 9,714                                    | 39.59                  | (36.28, 43.20)         | 11.9                   | 26.4                                  |
| AUC (ng.h/mL)                  |              11 | 26,494                              | 9.993                                    | 37.72                  | (35.35, 40.25)         | 8.4                    | 24.7                                  |

n=number of paired observations.

Note: Log-transformed PK parameters were analysed by a linear model analysis of variance controlling for treatment as fixed effect and participant as a random effect and the results were back-transformed using antilogarithm.

<div style=\"page-break-after: always\"></div>

Table 33: Summary of the Statistical Analysis of the PK Parameters of Free Erdafitinib after Single Administration of Erdafitinib Alone at 12 mg and in Combination with Multiple Doses of Carbamazepine; PK Data Statistical Primary Analysis Set

|                                | GeometricMean   | GeometricMean                       | GeometricMean                            | Test versus Reference   | Test versus Reference   | SourceofVariability       | SourceofVariability       |
|--------------------------------|-----------------|-------------------------------------|------------------------------------------|-------------------------|-------------------------|---------------------------|---------------------------|
| PKParameter (Free Erdafitinib) | n1              | Erdafitinib 12 mg Alone (Reference) | Erdafitinib 12 mg + Carbamazepine (Test) | GMR (%)                 | ID %06 (%)              | Intra- participant CV (%) | Inter- participant CV (%) |
| Cmax (ng/mL)                   | 12              | 2.42                                | 1.88                                     | 77.76                   | (72.76, 83.12)          | 9.1                       | 11.5                      |
| AUC168h (ng.h/mL)              | 11              | 142                                 | 73.8                                     | 52.07                   | (46.14, 58.75)          | 15.7                      | 12.5                      |
| AUClast (ng.h/mL)              | 11              | 161                                 | 76.5                                     | 47.62                   | (41.91, 54.10)          | 16.6                      | 13.4                      |
| AUC (ng.h/mL)                  | 10              | 173                                 | 78.5                                     | 45.28                   | (39.74, 51.59)          | 16.0                      | 13.3                      |

n=number of paired observations.

Note: Log-transformed PK parameters were analysed by a linear model analysis of variance controlling for treatment as fixed effect and participant as a random effect and the results were back-transformed using antilogarithm

<div style=\"page-break-after: always\"></div>

## Figure PK 1

Figure 5: Mean Plasma Concentrations of Total Erdafitinib vs Time; PK Data Analysis Set

<!-- image -->

Erdafitinib alonc (rcfcrcncc):Erdafitinib (12mg as thrcc 4 mg tablctsat Day 1.

Linear-Linear scale, Reduced X-axis

Erdafitinib+carbamazepine(test):Erdafitinib(12mg as three4mg tablets at Day 28+carbamazepine(300mg q12h).

<!-- image -->

Linear-Lincar scalc

Erdafitinib + carbamazepine (test: Erdafitinib (12 mg as three 4mg tablets) at Day 28+ carbamazepine (300 mg ql2h).

Erdafitinib alone (reference):Erdafitinib (12 mg as three 4 mg tablets) at Day 1.

## Inhibitors of Transporters (erdafitinib=victim)

In vitro transporter studies indicated that erdafitinib is a substrate for P-gp but not for BCRP, OATP1B1, and OATP1B3. Based on the expected intestinal concentration in humans at the clinical dose (9 mg once daily), victim-based DDI with concomitant administration of P-gp inhibitors at the intestinal level was excluded, while renal CL was limited (13%) in the total CL of erdafitinib. This was consistent with near complete oral absorption of erdafitinib at the intestinal level and coadministration with itraconazole, an inhibitor of CYP3A4 and P-gp, did not lead to clinically meaningful changes in erdafitinib and metabolite urinary excretion.

## Acid Lowering Agents (erdafitinib=victim)

Erdafitinib is a weak base with pKa1 and pKa2 of 9.1 (secondary amine moiety) and 1.9 (quinoxaline moiety), respectively. Erdafitinib is a BCS Class I compound with adequate solubility across the pH range of 1 to 7.4. The solubility of erdafitinib is pH-dependent: solubility decreased from 10 mg/mL at pH 1 to 0.19 mg/mL at pH 7.4. Nevertheless, erdafitinib is still considered highly soluble at pH of 7.4 at the highest clinical dose per regulatory guidance based on dose number. The dose number was calculated as the number of times 250 mL of aqueous media was needed to dissolve the highest

<div style=\"page-break-after: always\"></div>

proposed clinical dose of 9 mg, using the lowest solubility (0.19 mg/mL) observed at the highest pH (7.4). When the dose number is 1 or less than 1, the compound is considered highly soluble, and absorption is unlikely to be affected by drugs that increase gastric pH. For erdafitinib, a dose number of 1 was reached at a clinical dose of 47 mg, which was &gt;5 times higher than the maximal dose proposed for clinical use (9 mg).

## Interaction of erdafitinib and sevelamer, a phosphate-binding drug (erdafitinib=victim or perpetrator)

Sevelamer, a phosphate-binding drug, is a concomitant medication used in clinical studies to manage hyperphosphataemia, the most common AE upon erdafitinib treatment.

In a cohort-by-cohort analysis of the first-in-human Study EDI1001, erdafitinib exposure was comparable with or without concomitant administration of sevelamer within the same dose regimen (table below).

Table 34: Arithmetic Mean  SD Plasma Erdafitinib Pharmacokinetic Parameters after 21 Days (C2D1) of Erdafitinib Administration in Subjects Assigned to the Continuous Daily Dosing Regimen (Part 1 and Part 2 of the Study) with or without Sevelamer Coadministration.

|                   | No Sevelamer            | No Sevelamer            | No Sevelamer            | No Sevelamer            | No Sevelamer            | With Sevelamer          | With Sevelamer          | With Sevelamer          | With Sevelamer          | With Sevelamer          |
|-------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                   | Continuous daily dosing | Continuous daily dosing | Continuous daily dosing | Continuous daily dosing | Continuous daily dosing | Continuous daily dosing | Continuous daily dosing | Continuous daily dosing | Continuous daily dosing | Continuous daily dosing |
|                   | Part 1                  | Part 1                  | Part 1                  | Part 2                  | Part 1                  | Part 1                  | Part 1                  | Part 1                  | Part 2                  | Part 1                  |
|                   | 4 mg                    | 6 mg                    | 9 mg                    | 9 mg                    | 12 mg                   | 4 mg                    | 6 mg                    | 9 mg                    | 9 mg                    | 12 mg                   |
| N                 | 2                       | 3                       | 0                       | 1                       | 1                       | 3                       | 5                       | 1                       | 5                       | 2                       |
| Cmax (ng/mL)      | 639  418               | 717  429               | NA                      | 1970                    | 4890                    | 699  229               | 879  335               | 494                     | 2028  831              | 2140  467              |
| T max (h)         | 3.15 (2.25- 4.05)       | 3.07 (2.08- 8.02)       | NA                      | 2.00                    | 8.25                    | 4.00 (2.73- 7.00)       | 2.10 (2.00- 3.00)       | 3.00                    | 3.12 (2.00- 23.75)      | 1.50 (1.00- 2.00)       |
| Cmin (ng/mL)      | 418  180               | 548  415               | NA                      | 831                     | 4020                    | 437  216               | 555  348               | 290                     | 1330  825              | 1465  559              |
| AUC  (ng.h/mL)   | 7421 a                  | 14974  10261           | NA                      | 2406 4                  | 11383 3                 | 19610 a                 | 12621  3892 b          | NA                      | 43468  17648 c         | 39211  8889            |
| ARCmax            | 3.01  0.151            | 4.41  1.33             | NA                      | 4.56                    | 4.14                    | 3.30  0.146            | 2.88  0.754            | 4.15                    | 3.42  0.786            | 3.83  1.54             |
| AR AUC           | 2.73 a                  | 5.32  1.67             | NA                      | 3.52                    | 5.42                    | 3.44 a                  | 3.00  1.36 b           | NA                      | 3.85 0.336 d           | 4.12  1.37             |
| CL/F (L/h)        | 0.539 a                 | 0.528  0.289           | NA                      | 0.374                   | 0.105                   | 0.204 a                 | 0.515  0.192 b         | NA                      | 0.237 0.0988 c         | 0.314  0.0712          |
| t 1/2eff (h)      | 36.5 a                  | 79.9 27.9              | NA                      | 49.7                    | 81.5                    | 48.3 a                  | 40.9  23.0 b           | NA                      | 55.3 5.64 d            | 59.8  22.9             |
| Cmaxu (ng/mL)     | 1.51  0.224            | 3.26  1.00             | NA                      | 9.26                    | 6.06                    | 2.67  0.842            | 2.73  1.09             | 4.0 1                   | 4.29 2.26              | 8.96  2.91             |
| AUC u (ng.h/mL ) | 36.1 a                  | 65.0  15.4             | NA                      | 113                     | 141                     | 39.4 a                  | 42.5  23.8 b           | NA                      | 95.1 41.1 c            | 164  54.8              |

Tmax is reported as median (min-max).The 0.5 and 2 mg doses in C2D1 of Part 1 Continuous Dosing did not have any Sevelamer so they are not shown in this table. MeanSD values and median for Tmax are not reported in cohorts with n=1, instead the individual value is presented.

NA: not assessable

a:n=1; b:n=3; c:n=4; d:n=2

In addition, a pooled analysis across all doses demonstrated comparable dose-normalised Cmax and AUC on Cycle 1 Day 1; Cmax values with (N=31) or without (N=45) sevelamer were 465 and 451

<div style=\"page-break-after: always\"></div>

ng/mL, respectively, and AUC0-24 values with (N=29) or without (N=43) sevelamer were 8073 and 7377 ng/h/mL, respectively. Similar results were observed with free parameters and on Cycle 1 Day 8 [data not shown].

## Population PK Modelling

Erdafitinib dosing is individualised based on serum PO4 concentrations, therefore popPK and popPK-PD models were developed for erdafitinib. The previously developed models for erdafitinib PK and erdafitinib effects on phosphate levels were further refined using additional clinical data.

The final PopPK dataset included data from 11 clinical studies: Studies EDI1001, EDI1002, EDI1003, EDI1005, GAC1001, BLC2002, CAN2002, HCC1001, LUC2001, updated data from Study BLC2001, and the primary study of focus, Study BLC3001. In the final popPK model 8,566 total and 839 free erdafitinib plasma concentrations from 1,145 subjects were included. The relationship between total and free erdafitinib concentrations appears to be linear, except at very low concentrations and the free fraction is strongly related to AGP concentrations.

The following changes to the previous model were tested and incorporated in the updated base model:

1. The relationship between the free fraction, Fu, and AGP was fitted to the data instead of calculated based on a fixed Kd. IIV on the Kd parameter was incorporated, to use both AGP measurements and measurements of free and total concentrations in the estimation of Fu. Kd was estimated at 30.3 ng/mL, with an IIV of 17%.

2. The volume of the central compartment, V2, and the relative bioavailability, F1, were found to increase with increasing Fu, described by power functions, with respective powers of 0.77 and 0.27, respectively.

3. CLfree and the volumes of the central and peripheral compartments (V2, V3, V4) were found to increase with increasing weight, described by power functions with powers of 0.68 and 0.53, respectively.

4. The Fu was found to be approximately 20% higher in spiked predose samples than for other samples.

5. F1 for the capsule formulation was found to be 6% higher than for the other formulations.

6. IIV was applied to CLtotal, F1, V3, Ka, and Kd.

Model parameters of the updated base model (run391) and the final model (run393) are presented in Table 35. The model resulting from the backward step was selected as the final model. CLfree was estimated at 107 L/h, corresponding to a CLtotal of 0.321 L/h at the median Fu, 0.30%. The volume of the central compartment, for total drug, was estimated at 25.9 L. Ka and lag times varied between formulations, with the solution having the shortest lag time and fastest Ka, as expected. The lag time for Study GAC1001 using capsule formulation was longer than for the other studies. IIV was modest for CLfree (32%), F1 (21%), and Kd (17%), but higher for V3 (78%) and Ka (178%).

<div style=\"page-break-after: always\"></div>

Table 35: Parameters of Base and Final PopPK Models

|                       |       |                                                                             | Base Model (run391)   | Base Model (run391)   | Base Model (run391)   | Final Model(run393)   | Final Model(run393)   | Final Model(run393)   |
|-----------------------|-------|-----------------------------------------------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Parameter             | Unit  | Description                                                                 | ParameterEstinate     | RSE (%)               | 95% CI                | Parameter Estimate    | RSE (%)               | 95% CI                |
| MVOF                  |       | Minimum value of objective function                                         |                       |                       |                       |                       |                       |                       |
| Clree/F               | L/h   | Clearance of free drug                                                      |                       | 1.72                  | (91.4 -97.8)          |                       | 2.01                  | (103-111)             |
| V2total/F             | L/h   | Volume of central compartment of total drug                                 |                       | 1.64                  | (23.7-25.3)           |                       | 1.77                  | (25.0-26.8)           |
| V3/F                  | L     | Volume of first peripheral compartment (only free drug distributes)         |                       | 7.71                  | (1740-2360)           |                       | 6.43                  | (1861-2399)           |
| Q3/F                  | L/h   | Inter-compartmental clearance offreedrugtofirstperipheral compartment       |                       | 8.47                  | (41.5 - 58.1)         |                       | 12.3                  | (40.5- 66.3)          |
| V4/F                  | L     | Volume of second peripheral compartment (only free drug distributes)        |                       | 12                    | (512 -826)            |                       | 7.24                  | (584-778)             |
| Q4/F                  | L/h   | Inter-compartmental clearance of free drug to second peripheral compartment |                       | 18.6                  | (1.04 -2.24)          |                       | 11.2                  | (1.29 -2.01)          |
| Kd                    | ng/mL | Dissociation constant toAGP used toestimateFu                               |                       | 1.66                  | (29.3 -31.3)          |                       | 1.63                  | (29.3 -31.3)          |
| Ka solution           | h-l   | Absorption rate constant for solution                                       |                       | 18.9                  | (2.98 -6.48)          |                       | 13.5                  | (3.38 - 5.82)         |
| Ka capsule            | h-l   | Absorption rate constant for capsules                                       |                       | 12.3                  | (0.888-1.45)          |                       | 10.9                  | (0.913-1.41)          |
| Ka tablet             | h-l   | Absorption rate constant for tablets                                        |                       | 14                    | (1.35 -2.37)          |                       | 10.2                  | (1.47-2.19)           |
| Lagtime solution      | h     | Lagtime for solution                                                        |                       | 5.85                  | (0.166 -0.21)         |                       | 5.33                  | (0.167-0.207)         |
| Lagtime capsule       | h     | Lagtime for capsules                                                        |                       | 0.29                  | (0.244-0.246)         |                       | 0.292                 | (0.244-0.246)         |
| Lagtime tablet        | h     | Lagtime for tablets                                                         |                       | 1.91                  | (0.22-0.238)          |                       | 1.93                  | (0.22-0.238)          |
| Lagtime Study GAC1001 | h     | Lagtime forStudy GAC1001                                                    |                       | 0.511                 | (0.411 -0.419)        |                       | 0.675                 | (0.41 - 0.42)         |
| F1 capsule            | %     | Bioavailability change for capsules                                         |                       | 42.9                  | (0.964% - 11.2%)      |                       | 52.7                  | (-0.158% - 9.88%)     |

|                       |      |                                                                   | Base Model (run391)   | Base Model (run391)   | Base Model (run391)   | Final Model (run393)   | Final Model (run393)   | Final Model (run393)   |
|-----------------------|------|-------------------------------------------------------------------|-----------------------|-----------------------|-----------------------|------------------------|------------------------|------------------------|
| Parameter             | Unit | Description                                                       | ParameterEstimate     | RSE (%)               | 95%CI                 | Parameter Estimate     | RSE (%)                | 95%CI                  |
| Fu on V2total         |      | PowerofeffectofFu on the volume of the central compartment        |                       | 4.29                  | (0.706-0.836)         |                        | 4.26                   | (0.732-0.866)          |
| Fu on F1              |      | Power of effect of Fu on bioavailability                          |                       | 9.70                  | (0.219 -0.323)        |                        | 9.67                   | (0.222 -0.326)         |
| Spiking on Fu         | %    | change in Fu in spiked samples                                    |                       | 12.8                  | (15.0% -25.0%)        |                        | 13.0                   | (14.7% -24.7%)         |
| WT on V2total, V3, V4 |      | Power of weight effect on volumes                                 |                       | 7.50                  | (0.577 -0.777)        |                        | 9.15                   | (0.483 -0.695)         |
| WT on Clhee           |      | Power of weight effect on clearance of free drug                  |                       | 10.0                  | (0.428-0.636)         |                        | 12.0                   | (0.342 -0.552)         |
| CLAGECAT1             | %    | Effect of age65-75y comparedto<65yonclearance of free drug        |                       |                       |                       |                        | 14.1                   | (-19.4% - 11.0%)       |
| CLAGECAT2             | %    | Effect of age >75y compared to<65yonclearance of free drug        |                       |                       |                       |                        | 15.5                   | (-26.9% - 14.3%)       |
| F1SEX1                | %    | Effect of female sex compared to male on bioavailability          |                       |                       |                       |                        | 17.2                   | (8.61% - 17.4%)        |
| F1HLTH1               | %    | Effect of healthy subjects compared topatients on bioavailability |                       |                       |                       |                        | 27.0                   | (8.60% -28.0%)         |
| IIV Clotal            |      | IIV on clearance of total drug                                    |                       | 5.00                  | (0.329 -0.35)         |                        | 5.07                   | (0.314-0.334)          |
| IIV F1                |      | IIV of bioavailability                                            |                       | 6.59                  | (0.209 -0.23)         |                        | 6.78                   | (0.198 -0.218)         |
| IIV V3                |      | IIV of the volume of the first peripheral compartment             |                       | 13.4                  | (0.686 -0.873)        |                        | 12.9                   | (0.695 -0.873)         |
| IIV Ka                |      | IIV of absorption rate (all formulations)                         |                       | 8.59                  | (1.72 -1.89)          |                        | 7.83                   | (1.71-1.86)            |
| IIV Ka                |      | IIV on the AGP dissociation constant                              |                       | 11.8                  | (0.149 -0.187)        |                        | 11.7                   | (0.15 -0.187)          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                    |      |                                                       | BaseModel(run391)   | BaseModel(run391)   | BaseModel(run391)   | FinalModel(run393)   | FinalModel(run393)   | FinalModel(run393)   |
|--------------------|------|-------------------------------------------------------|---------------------|---------------------|---------------------|----------------------|----------------------|----------------------|
| Parameter          | Unit | Description                                           | ParameterEstimate   | RSE (%)             | 95%CI               | Parameter Estimate   | RSE (%)              | 95%CI                |
| RUVtot             | %    | Residualunexplained variabilityoftotal concentrations |                     | 4.27                | (27.3%-28.6%)       |                      | 4.3                  | (27.3%-28.6%)        |
| RUVtee             | %    | Residualunexplained variabilityoffree concentrations  |                     | 6.72                | (25.1% -27.6%)      |                      | 7.82                 | (24.9% - 28.1%)      |
| Correlation CL.F1  | %    |                                                       |                     |                     |                     |                      |                      |                      |
| Correlation CL. V3 | %    |                                                       |                     |                     |                     |                      |                      |                      |
| CorrelationF1,V3   | %    |                                                       |                     |                     |                     |                      |                      |                      |

The following covariates were selected for evaluation: For CL: age category, weight category, sex, patient/healthy status, hepatic impairment, renal impairment, race, East Asian region, Chinese origin, Chinese or Taiwanese origin, Japanese origin, CYP2C9 polymorphism and for F1: weight category, sex, patient/healthy status, race, East Asian region, Chinese origin, Chinese or Taiwanese origin, Japanese origin. The covariate effects are shown in the forest plots presented in Figure 3 and Figure 4, where the summaries of individual predictions of the steady state AUCfree were plotted by covariate categories. Overall, the observed effects were modest, as expected from the covariate effect estimates in the final model and median predicted AUCfree across all covariate subgroups was within the 86% to 126% range of the population median.

<div style=\"page-break-after: always\"></div>

Figure 6: Summary of Individual Predicted Normalised Steady State AUCfree by Covariate Categories

<!-- image -->

ChangeofAuCfreerelativetoreference

Numbers indicate geometric mean ratio (5th to 95th percentile); PI=prediction interval. Steady state AUCfee normalized by overall median steady state AUCfee. Dots indicate the geometric mean ratio by category;: horizontal lines indicate 5th to 95th percentile range. Groups with fewer than 20 subjects excluded. Pediatric population (n=3) excluded.

Figure 7: Summary of Individual Predicted Normalised Steady State AUCfree by Race and Region Covariate Categories

<!-- image -->

Numbers indicate geometric mean ratio (5th to 95th percentile); PI=prediction interval.

Steady state AUCfee normalized by overall median steady state AUCfee. Dots indicate geometric mean ratio by category; horizontal lines indicate 5th to 95th percentile range. Groups with fewer than 20 subjects excluded. Pediatric population (n=3) excluded.

<div style=\"page-break-after: always\"></div>

Figure 8: GOF Plots, Final Model (run393) for Erdafitinib Total (Flag=0) and Free (Flag=1) Concentrations

<!-- image -->

Symbols represent observations/predictions(upperpanels),conditional weightedresiduals(lowerpanels)for erdafitinib total (flag=0, grey symbols) and free (flag=1, orange symbols) concentrations. Solid black lines represent the identity lines, solid red lines represent a smooth of the data. Blue dashed lines represent 95th percentile of residual probability. Red dashed lines represent 99t p percentile ofresidual probability.

<div style=\"page-break-after: always\"></div>

Figure 9: pcVPC of Total and Free Erdafitinib Concentrations Versus Time Since First Dose, Final Model (run393)

<!-- image -->

## Population PK-PD Modelling

The final PopPK-PD dataset was comprised of a subset of the PopPK dataset with patient data from subjects with cancer obtained from 8 studies: Studies EDI1001, GAC1001, BLC2002, CAN2002, HCC1001, LUC2001, and BLC3001. In the final popPK-PD model data from 1,132 subjects receiving continuous once daily doses (range, 0.5-12 mg) or intermittent once daily doses (range, 10-12 mg) of erdafitinib, contributing 15,494 serum [PO4], were included in the analysis.

An Emax model described the erdafitinib effect on PO4 driven by free concentrations in the effect compartment, with an attenuation of the erdafitinib effect on serum [PO4] with time, used to describe the relationship between erdafitinib free plasma concentrations and serum [PO4]. This model characterised serum [PO4] and their variability in subjects with cancer treated with different dosing regimens of erdafitinib. The initial [PO4] baseline was estimated to be 6.5% higher in women. Emax was 26.9% higher in subjects who received PO4-lowering drugs. Emax decreased with increasing age (decreasing by 8.1% when age went from 60 to 80 years) and was 12.6% lower in subjects of Japanese origin.

Time(weeks)

<div style=\"page-break-after: always\"></div>

Model parameters are presented in Table 36, goodness-of-fit plots and pcVPCs are depicted in Figure 10 and Figure 11, respectively.

Table 36: Parameters of Base and Final PopPK-PD Models

|                 |       |                                                                             | Base Model(run469)   | Base Model(run469)   | Base Model(run469)   | Final Model (run462)   | Final Model (run462)   | Final Model (run462)   |
|-----------------|-------|-----------------------------------------------------------------------------|----------------------|----------------------|----------------------|------------------------|------------------------|------------------------|
| Parameter       | Unit  | Description                                                                 | Parameter Estimate   | RSE (%)              | 95% CI               | Parameter Estimate     | RSE (%)                | 95% CI                 |
| MVOF            |       | Minimum value of objective function                                         |                      |                      |                      |                        |                        |                        |
| Baseline        | mg/dL | Initial [PO4] baseline                                                      |                      | 0.59                 | (3.25-3.33)          |                        | 1.87                   | (3.10- 3.34)           |
| Plateaubaseline | mg/dL | Post-treatment interruption[PO4] baseline plateau                           |                      | 0.993                | (2.65 - 2.75)        |                        | 1.83                   | (2.59 - 2.79)          |
| kbase           | h-1   | Rate constant for treatment interruption change of [PO4] baseline           |                      | 43                   | (0.00227 -0.0267)    |                        | 43.5                   | (0.00193 -0.0241)      |
| tlag            | h     | Post-treatment interruptionlagtime before [PO4] baseline decline            |                      | 26.8                 | (50.3 -162)          |                        | 24.2                   | (45.1-126)             |
| ke0             | h-l   | Effect compartment rate constant                                            |                      | 5.23                 | (0.0115-0.0141)      |                        | 35.9                   | (0.00389-0.0223)       |
| EC50            | ng/mL | Effect compartment free erdafitinib concentration giving halfmaximal effect |                      | 40.6                 | (0.923 - 8.10)       |                        | 22.2                   | (2.12 - 5.36)          |
| Emax            | mg/dL | Maximal erdafitinib effect on [PO4]                                         |                      | 29.6                 | (2.93 -11.0)         |                        | 13.6                   | (4.13 -7.13)           |
| Power           |       | Power in Hill equation                                                      |                      | 9.16                 | (1.07-1.55)          |                        | 11.2                   | (1.02 -1.60)           |
| kin             | h-    | Rate constant describing attenuation of drug effect over time               |                      | 3.20%*               | (8.32E-05-1.10E-04)  |                        | 3.45*                  | (8.12E-5 -1.12E-4)     |

|                        |      |                                                          | Base Model (run469)   | Base Model (run469)   | Base Model (run469)   | Final Model (run462)   | Final Model (run462)   | Final Model (run462)   |
|------------------------|------|----------------------------------------------------------|-----------------------|-----------------------|-----------------------|------------------------|------------------------|------------------------|
| Parameter              | Unit | Description                                              | Parameter Estimate    | RSE (%)               | 95%CI                 | Parameter Estimate     | RSE (%)                | 95%CI                  |
| Sex effect on baseline | %    | Effect of female sex on initial baseline                 |                       |                       |                       |                        | 39.4                   | (0.0148 -0.116)        |
| CORENA on Emax         | %    | Effect of coadministration of PO4-lowering drugs on Emax |                       |                       |                       |                        | 10.6                   | (0.213 -0.325)         |
| Age on Emax            |      | Effect of age on Emax, power                             |                       |                       |                       |                        | 42.2                   | (-0.537 --0.051)       |
| JPNS on Emax           |      | Effect of Japanese origin on Emax                        |                       |                       |                       |                        | 41.6                   | (-0.229 - -0.0233)     |
| IIV Baseline           |      | IIV, initial baseline                                    |                       | 4.37                  | (0.466 -0.488)        |                        | 4.27                   | (0.449 -0.471)         |
| IIV Emax               |      | IIV, Emax                                                |                       | 4.86                  | (0.331 -0.351)        |                        | 5.04                   | (0.282 -0.3)           |
| IIV ke0                |      | IIV, effect compartmentrate constant                     |                       | 6.99                  | (1.03 -1.12)          |                        | 15.1                   | (0.934 -1.22)          |
| IIV kin                |      | IIV, attenuation of drug effect over time                |                       | 7.21                  | (1.15 - 1.25)         |                        | 6.96                   | (1.15 - 1.25)          |
| IIV final baseline     |      | IIV, post-treatment interruptionbaseline                 |                       | 7.62                  | (0.495 -0.552)        |                        | 8.89                   | (0.488 -0.561)         |
| Correlation IIVkeO-kin |      | Correlation between individual ke0 and kin               |                       |                       |                       |                        |                        |                        |
| Residual error         |      | Additive residual error on log scale                     |                       | 2.9                   | (0.138 -0.142)        |                        | 3.05                   | (0.137-0.141)          |

*sd on log scale.

<div style=\"page-break-after: always\"></div>

Figure 10: GOF Plots, PK-PD Final Model

<!-- image -->

Figure 11: pcVPC of [PO4] Concentrations Versus Time Since First Dose, Final PK-PD Model

<!-- image -->

Mediansolidline),5thand95th(dashedlines)ofobserved data;Percentilesof the simulated datawith their95%CI (greyandblueshadedareas).

## PBPK Modelling

The DDI potential for erdafitinib was further investigated using PBPK modelling. The aim was to assess DDI potential of CYP3A4 inhibitors, CYP2C9 inhibitors, as well as CYP3A4/CYP2C9 inducers on the

<div style=\"page-break-after: always\"></div>

pharmacokinetics of erdafitinib in patients and in poor CYP2C9 metabolising populations. In addition, the DDI potential of erdafitinib as perpetrator for transporter inhibition (Pgp and OCT2/MATE2) and for mechanism based inhibition and/or induction of CYP3A was assessed.

## 2.8.2.2. Pharmacodynamics

## Mechanism of action

Erdafitinib is a highly selective and potent oral pan-FGFR tyrosine kinase inhibitor with high affinity and inhibitory activity at low nanomolar levels for all FGFR family members, FGFR 1, 2, 3 and 4. In FGFR pathway activated cancer cell lines, the concentration required for 50% tumour growth inhibition (IC50) is in the low nanomolar range 0.1 to 129.2 nM.

Erdafitinib demonstrated antitumour activity in FGFR-driven cell lines and xenograft models derived from multiple tumour types, including bladder cancer.

## Primary and Secondary pharmacology

FIH Study EDI1001 [study design is described in section 'Absorption' above]

Systemic PD, including serum phosphate concentrations, vitamin D, FGFR ligand FGF-23, calcium levels, and PTH secretion were characterised in the first-in-human Study EDI1001.

Figure 12: Mean Pharmacodynamic Markers in Blood - 1, 25-Dihydroxyvitamin D

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 13: Mean Pharmacodynamic Markers in Blood - Intact Fibroblast Growth Factor 23

<!-- image -->

Figure 14: Mean Percent Change of Pharmacodynamic Markers in Blood - Intact Fibroblast Growth Factor 23

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 15: Mean Pharmacodynamic Markers in Blood - Calcium

<!-- image -->

Figure 16: Mean Pharmacodynamic Markers in Blood - Intact Parathyroid Hormone

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 17: Phosphate Over Time (9 mg Once Daily) (Min, First Quartile, Median [Solid Line], Third Quartile, Max)

<!-- image -->

## Cardiac Electrophysiology

Exposure-response analyses were conducted based on data from Study EDI1001 over a dose range from 0.5 to 12 mg from 187 subjects, including ECG obtained during study, manually read ECG by a central reader [I], and ECG extracted from Holter monitor with matching baseline [II].

The exposure-response analyses consistently indicated no significant relationship between erdafitinib plasma concentration (total and free) and change in QTc. The 2 sided 90% upper CIs at Cmax from the highest clinical dose (9 mg) was  2.5 ms, lower than the accepted threshold of 20 ms for oncology compounds.

## Pharmacokinetic-Pharmacodynamic Relationship of Serum Phosphate

Serum phosphate concentration was identified as a relevant PD marker of target engagement with erdafitinib and selected as the metric of exposure for the E-R analysis, as it reflects both variability in the PK of free erdafitinib and individual responses to FGFR inhibition (Dosne 2022; E-R Report 2018). Serum phosphate was stated to directly reflect erdafitinib target engagement and to be closely related to erdafitinib PK-based exposure metrics: AUCfree, AUCtotal, Cmax, and Cmin.

## Exposure-response Analyses of Efficacy and Safety

Serum phosphate concentration was used as the primary measure of erdafitinib exposure in analyses to describe the erdafitinib effect on both efficacy and safety endpoints.

To account for dose titration and dose interruptions and reductions, daily serum phosphate concentrations were simulated based on the individual patient's observations and the final post hoc PKPD model parameters (Mod5.3.3.5/PopPK-PD Report 2023), and the associated exposure metrics were predicted for each participant to assess their relationship with efficacy or safety endpoints.

E-R Report 2023 quantifying the relationship between serum phosphate and OS, the primary efficacy endpoint of Study BLC3001, as well as for the secondary endpoints PFS and ORR.

The exposure-efficacy analysis was performed using Study BLC3001 Cohort 1 data collected in subjects following 1 or 2 prior line(s) of systemic therapy, with at least 1 line containing anti-PD-(L)1 treatment.

Individual average serum phosphate concentrations up to Week 6, as well as individual average serum phosphate concentrations up to an event, were evaluated and compared for the efficacy endpoints OS and PFS as exposure metrics for participants enrolled and treated in Cohort 1 (erdafitinib arm) of Study BLC3001. In addition, a time-dependent serum phosphate analysis, assuming a direct effect of

[GSFLAB01e.png]JNJ-42756493VEDI10011DBR\\_P1P2CSRIRE\\_P1P2CSRgsflab01e.sas]26JUN2017,18:34

<div style=\"page-break-after: always\"></div>

serum phosphate concentrations on the OS or PFS hazard, were performed to further investigate how variations of individual phosphate concentrations over time could affect the risk of disease progression and/or death. For participants randomly assigned to the chemotherapy-comparator arm, baseline serum phosphate levels were used as an exposure metric, given the limited fluctuation over time. A Kaplan-Meier analysis of OS, stratified by serum phosphate concentration into 4 groups ([1] chemotherapy with baseline serum phosphate concentration and [2] low, [3] medium, and [4] high average erdafitinib phosphate concentration up to Week 6 based on phosphate terciles). Univariate and multivariate Cox regression analysis models were also applied to assess the relationship with serum phosphate after adjusting by baseline prognostic factors: haemoglobin, ECOG performance status, and race. Similar analyses were conducted for PFS.

For the ORR endpoint, univariate and multivariate logistic regression models were applied to assess the relationship between serum phosphate and ORR accounting for potential baseline prognostic factors. ORR was defined as the proportion of participants achieving complete response or PR with response dichotomised as best confirmed and unconfirmed investigator-assessed response. For ORR, average serum phosphate up to Week 6 was evaluated as an exposure metric because erdafitinib is associated with an early clinical response (Dosne 2022) and because of the fluctuations in serum phosphate concentration over this period.

## Results

OS/PFS

The Cox proportional hazard analyses indicated that the weekly average of daily serum phosphate concentration ( PO4-Time dependent ) predicted OS and PFS better than PO4avg 6 weeks and PO4avg up to event (lowest AIC). Data not shown.

## ORR

The relationship between ORR and average serum phosphate concentrations up to Week 6 (planned time of first response assessment) is shown in the figure below:

Figure 18: Probability of ORR by Investigator as a Function of PO4ave, 6 weeks of data of Cohort 1 in Study BLC3001

<!-- image -->

AverageDailyPhosphate,mg/dL

The upper and lower open circles represent the presence or absence of response across the range of serum PO4 concentrations. The purple dots depict the observed incidence for the terciles of average daily serum PO4 up to Week 6 of subjects receiving erdafitinib and the corresponding vertical bars represent the 95% CI. The red dot depicts the observed incidence of median baseline serum PO4 of subjects receiving chemotherapy and the corresponding vertical bars represent the 95% CI. The full blue line and the associated

<div style=\"page-break-after: always\"></div>

shaded area represent the model-based exposure-efficacy relationship and its 95% CI. Unconfirmed partial responses were considered as partial responses for this analysis.

The ORR increased with higher serum phosphate concentrations and resulted in an OR of 1.84 (95% CI: 1.43-2.37; p&lt;0.001) per 1 mg/dL change in average serum phosphate concentration (see table above). The submitted report highlighted that the results obtained from Study BLC3001 Cohort 1 data are in line with the previous analysis of Study BLC2001 data, for which an OR of 1.38 was obtained (95% CI: 1.02-1.86; p=0.04).

E-R Report 2023 quantifying the relationship between serum phosphate and selected clinical safety endpoints: eye disorders (excluding CSR), CSR disorders, nail disorders, skin disorders, and GI disorders.

The exposure-safety analysis was performed using data obtained from 6 mg or 8 mg once daily erdafitinib monotherapy dosed patients harbouring susceptible FGFR aberrations, collected in a locally advanced or metastatic urothelial cancer population. In this context, pooled data from 814 participants in 3 studies were included. These data were from the 6 and 8 mg once daily regimens of Study BLC2001 (end of main study, 27 July 2021 clinical data cut), the erdafitinib monotherapy arm data of Study BLC2002 (30 September 2022 data cut), and data collected in Cohort 1 and Cohort 2 of Study BLC3001.

For the safety analysis, the relationships between erdafitinib serum phosphate and the incidence of the selected clinical safety endpoints were investigated using univariate logistic regression models. Participants were dichotomised into the presence or absence of the TEAEs that are at the first occurrence at such severity as to require a potential dose adaptation in the protocol: Grade  2 for eye disorders, Grade  1 for CSR disorders, Grade  2 for nail disorders, Grade  2 for skin disorders, and Grade  2 for GI disorders. Average serum phosphate concentration up to an event (PO4avg, event) was selected as the exposure metric for the safety analysis.

## Results

The incidence of eye disorders (other than CSR), nail disorders, skin disorders, GI disorders at Grade  2 of severity, and CSR disorders at Grade  1 of severity, with a potential to require dose interruption, show a statistically significant relationship with the serum phosphate level associated with erdafitinib treatment. The incidence of eye disorders, nail disorders, and skin disorders had a positive and statistically significant relationship with average serum phosphate concentrations up to the day the disorder appeared, see figure below:

<div style=\"page-break-after: always\"></div>

Figure 19: Probability of Experiencing Eye (Upper Left), Nail (Upper Right), and Skin (Bottom) Disorders as a Function of PO4avg, event

<!-- image -->

Average DailyPhosphate,mg/dL

<!-- image -->

Average DailyPhosphate,mg/dL

Upper  and  lower  open  circles  represent  the  presence  or  absence  of  disorder  across  the  range  of  serum  PO4 concentrations. The purple dots depict the observed incidence for the terciles of average serum PO4 up to event of subjects receiving erdafitinib and the corresponding vertical bars represent the 95% CI. The red dot depicts the observed incidence of median baseline serum PO4 of subjects receiving chemotherapy and the corresponding vertical bars represent the 95% CI. The full blue and red line and the associated shaded area represent the model based exposure-efficacy relationship and its 95% CI.

Within the range of average serum phosphate concentrations observed in erdafitinib-treated participants (0.93 mg/dL to 10.5 mg/dL) in the analysis dataset, the magnitude of the association varied across the different disorders and was strongest for nail disorders, with an OR of 2.39 for a 1 mg/dL increase in serum phosphate concentrations up to the day of event, with a slightly lower OR for eye disorders (1.90) and skin disorders (1.85).

The incidence of Grade  1 CSR and Grade  2 GI disorders showed a statistically significant effect of erdafitinib treatment (p&lt;0.001), but no effect of phosphate, see figure below:

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 20: Probability of Experiencing CSR (left) and GI (right) Disorders as a Function of PO4avg, event

<!-- image -->

Upper  and  lower  open  circles  represent  the  presence  or  absence  of  disorder  across  the  range  of  serum  PO4 concentrations. The purple dots depict the observed incidence for the terciles of average serum PO4 up to event of subjects receiving erdafitinib and the corresponding vertical bars represent the 95% CI. The red dot depicts the observed incidence of median baseline serum PO4 of subjects receiving chemotherapy and the corresponding vertical bars represent the 95% CI. The full blue and red line and the associated shaded area represent the model based exposure-efficacy relationship and its 95% CI.

The relationship of serum phosphate with CSR, significant for Study BLC2001 with OR of 1.97, was not statistically significant for the current analysis.

The probability of CSR disorders (a known class effect of FGFR inhibitors) in the erdafitinib arm was 19% compared with pembrolizumab or chemotherapy, where there was no observed incidence of CSR disorders. The OR of GI disorders comparing erdafitinib to treatment with pembrolizumab or chemotherapy was 9.1.

## Exposure-response Analyses of Safety E-R relationship between the change from baseline in QTc intervals (QTcF and QTcB) and total and unbound plasma concentration of erdafitinib [ Analysis I ]

A pharmacokinetic-pharmacodynamic (PK-PD) analysis was performed using all subjects who had timematched ECG and plasma concentrations for JNJ-42756493 [ erdafitinib ]. The primary analysis was performed using ECGs (mean of triplicates or whatever number of ECGs are available at a timepoint) and PK assessments which were collected within a +/- 15 minute window. A secondary analysis was performed using a wider +/- 60 minute window. The primary analyses were performed using the total plasma concentration of JNJ-42756493, and the secondary analyses were performed using the unbound plasma concentration of JNJ-42756493.

The PK-PD analysis was a concentration response analysis of a baselineadjusted QTc (QTc) (QTcF and QTcB) against the independent variables of plasma concentration of JNJ-42756493, and time (i.e., the nominal time post dose categorically). The primary endpoint for this trial was the change from baseline in QTcF. A negative result (i.e., no evidence of a QTc prolongation) was defined as a model based upper bound of the twosided 90% CI of the predicted mean QTcF less than 20 ms at the observed mean Cmax for the therapeutic dose of JNJ-42756493. If modelling was completed with plasma concentration on the log scale, the geometric mean Cmax was used for this calculation.

<div style=\"page-break-after: always\"></div>

A linear mixed effects modelling approach was used to examine the E-R relationship between the change from baseline in QTc intervals (QTcF and QTcB) and total and unbound plasma concentration of erdafitinib. The model included plasma concentration, time (categorical), and treatment with random subject effects on plasma concentration and the intercept included in the model. This model was used to estimate the population slope and the standard error of the slope of the relationship between change from baseline in QTc intervals and other ECG continuous parameters (QTcF and QTcB) and plasma concentration of erdafitinib.

The results of this PK-PD model showed that the slope for QTcF for erdafitinib was negative, see figure below:

Figure 21: Relationship between Total Plasma Concentration of Erdafitinib and QTcF (ECG and PK collections within +/- 15 minute window) by Pooled Treatment

QTcF Change fromBaselineVersus JNJ-42756493 Plasma Concentration(ng/mL) PK-ECG matches within 15minutes-Total Concentration (bound plus unbound) Estimatesfrom theMixedEffectsRegressionModel

<!-- image -->

PredictionLinesarebasedonmodelestimatesusing Concentration,Treatment Dose and LSMean estimates of the Time (i.e.,Visit and Time-Point) Values.

The overall predicted baseline-corrected QTcF value at the geometric mean Cmax (1263 ng/mL) was 4.0 ms with an upper bound of the 2-sided 90% CI of -1.2 ms, see details in the table below:

<div style=\"page-break-after: always\"></div>

Table 37: Treatment-Specific Change from Baseline versus the Total Plasma Concentration of erdafitinib - Predicted from Mean Cmax QTc Fridericia (msec). PharmacokineticPharmacodynamic Population; +/- 15 Minute Window for ECGs and PK

| Treatment Dose                  |   GeometricMean Cmax (arithmetic scale) (ng/mL) |   Mean Cmax. (log scale I1 |   Predicted Mean Effect at Mean Cmar (ms) [3] |   Lower CI (ms 21 |   Upper CI (ms) (2) |
|---------------------------------|-------------------------------------------------|----------------------------|-----------------------------------------------|-------------------|---------------------|
| 0.50 mg Liquid                  |                                           63.52 |                      1.803 |                                         6.378 |            -7.214 |              19.481 |
| 2.00 mg Liquid                  |                                          370.34 |                      2.569 |                                        -7.758 |           -14.12  |              -1.997 |
| 4.00 mg Liquid                  |                                          569.82 |                      2.756 |                                        -0.72  |            -3.504 |               1.973 |
| 6.00 mg Liq/Cap                 |                                          852.29 |                      2.931 |                                        -8.438 |           -11.49  |              -5.544 |
| 9.00 mg Capsule                 |                                         1453.46 |                      3.162 |                                        -0.849 |            -2.831 |               0.99  |
| 10.00 mg Capsule (7d on/7d off) |                                         1499.03 |                      3.176 |                                        -2.136 |            -4.192 |              -0.096 |
| 12.00 mg Capsule                |                                         2206.04 |                      3.344 |                                        -3.047 |            -5.749 |              -0.366 |
| 12.00 mg Capsule (7d on/7d off) |                                         2060.57 |                      3.314 |                                        -0.71  |            -3.356 |               1.878 |
| Pooled Treatments               |                                         1262.56 |                      3.101 |                                        -4.031 |            -6.992 |              -1.205 |

[1] Geometric Mean Cmax and Mean Cmax (log scale) were estimated as the geometric mean of Cmax values and arithmetic mean of the logtransformed

Cmax values, respectively, of the absolute maximum concentration observed in each individual (i.e., in any PK occasion).

[2] Lower/Upper Confidence = upper one-sided 95% linear mixed model based confidence limit, based on bootstrap methods using percentile confidence intervals with 1000 replicates.

[3] Estimates include the mean values for time included in the model. This varies from the Garnett et al. 2016 model specifications

For the highest dose group, 12 mg daily, the overall predicted baseline-corrected QTcF value at the geometric mean Cmax (2206 ng/mL) was -3.0 ms with an upper bound of the 2-sided 90% CI of -0.4 ms. Similar results were obtained using free concentrations.

Exposure-response analysis to describe the exposure-response (ER) relationships between total and free erdafitinib plasma concentration and QT/QTc interval changes extracted from Holter monitors from Part 1 of the Phase 1 Study EDI1001 [ Analysis II ]

Holter recordings were obtained from Part 1 of Study EDI1001 at screening, on Cycle 1 Day 1, and at steady state on Cycle 2 Day1, and Cycle 3 Day 1. ECG measurements were obtained at the same time as total and free erdafitinib plasma concentrations, resulting in paired PK-ECG measurements. The timematched QT measurements at screening were used as baseline. QTcI was selected as the dependent variable since Fridericia's correction was not sufficient to correct for heart rate. After confirming the lack of hysteresis and the linearity of the drug effect, the linear mixed effect model including QTcI as the dependent variable, the erdafitinib plasma concentration (total or free), Cp, as a continuous covariate and each nominal post-dose timepoint (timei) as categorical factors was used to analyse the data.

The outcome of this analysis was compared with the results obtained when QTcF was used.

The final dataset included 62 subjects with 704 paired PK and Holter ECG data for the analysis based on total concentrations. A total of 1142 Holter ECG measurements were used with 438 ECGs included as baseline time-matched (Screening), and 375, 324, and 5 ECGs obtained on Cycle 1, Cycle 2, and

<div style=\"page-break-after: always\"></div>

Cycle 3, respectively. For the analysis based on free concentrations, a total of 685 free erdafitinib concentrations from 60 subjects were available. The number of Holter ECG measurements at baseline, Cycle 1, Cycle 2, and Cycle 3 were 424, 362, 318, and 5, respectively.

A linear mixedeffect model was fitted to the data with QTcI as dependent variable, erdafitinib plasma concentrations as continuous independent variable, and each timei 1  as categorical covariate. While the inclusion of a random intercept term improved model fit both for total and free concentration models, the addition of a random slope of the erdafitinib plasma concentration effect did not improve model fit. This finding was consistent for the models where total and free erdafitinib plasma concentrations were used as independent variables.

The estimated parameters of the final model for total and free erdafitinib plasma concentrations and QTcI are shown in the tables below:

Table 38: Final Parameter Estimates for the Exposure-Response Model with Erdafitinib Total Plasma Concentrations and QTcI

|                     |   Estimate |   Lower Limit 95% CI a |   Upper Limit 95% CI a |   Pr(>|t|) b |
|---------------------|------------|------------------------|------------------------|--------------|
| Intercept (ms)      |    2.783   |               -2.413   |               7.975    |       0.297  |
| Slope (ms/(ng/mL))  |   -0.00269 |               -0.00498 |              -0.000387 |       0.0229 |
| Timepoint 1 h (ms)  |   -0.469   |               -6.223   |               5.308    |       0.874  |
| Timepoint 2 h (ms)  |    1.171   |               -4.625   |               6.995    |       0.694  |
| Timepoint 3 h (ms)  |    0.469   |               -5.291   |               6.262    |       0.874  |
| Timepoint 4 h (ms)  |   -4.196   |               -9.885   |               1.521    |       0.151  |
| Timepoint 6 h (ms)  |   -3.529   |               -9.173   |               2.143    |       0.224  |
| Timepoint 8 h (ms)  |   -2.396   |               -8.028   |               3.264    |       0.408  |
| Timepoint 24 h (ms) |   -2.81    |               -9.971   |               4.373    |       0.445  |

Pr(&gt;|t|): p-value

a Model parameters were reported with a 95% CI for significance in the model.

b Calculated with Kenward-Roger approximations to degrees of freedom.

Table 39: Final Parameter Estimates for the Exposure-Response Model with Erdafitinib Free Plasma Concentrations and QTcI

|                         |   Estimate |   Lower Limit 95% CI a |   Upper Limit 95% CI a |   Pr(>|t|) b |
|-------------------------|------------|------------------------|------------------------|--------------|
| Intercept (ms)          |      3.355 |                 -1.941 |                  8.646 |      0.217   |
| Slope free (ms/(ng/mL)) |     -1.138 |                 -1.968 |                 -0.308 |      0.00813 |
| Timepoint 1 h (ms)      |     -0.473 |                 -6.295 |                  5.365 |      0.874   |
| Timepoint 2 h (ms)      |      0.796 |                 -5.08  |                  6.688 |      0.792   |
| Timepoint 3 h (ms)      |      0.72  |                 -5.119 |                  6.582 |      0.81    |
| Timepoint 4 h (ms)      |     -4.405 |                -10.165 |                  1.375 |      0.137   |
| Timepoint 6 h (ms)      |     -3.165 |                 -8.879 |                  2.568 |      0.281   |
| Timepoint 8 h (ms)      |     -2.645 |                 -8.344 |                  3.073 |      0.366   |
| Timepoint 24 h (ms)     |     -3.056 |                -10.234 |                  4.135 |      0.408   |

Pr(&gt;|t|): p-value

a Model parameters were reported with a 95% CI for significance in the model.

b Calculated with Kenward-Roger approximations to degrees of freedom.

Model parameters were reported with 95% CI to evaluate the significance in the model. The slopes for total and free erdafitinib plasma concentrations were the only significant parameters and were

1  timei: nominal post-dose timepoint

<div style=\"page-break-after: always\"></div>

estimated at -0.00269 ms/(ng/mL) and -1.138 ms/(ng/mL), respectively, indicating that increases in erdafitinib plasma concentrations resulted in decreased QTcI. The ratio of the slopes for total and free erdafitinib plasma concentrations, 0.00236, was consistent with the free fraction estimated for erdafitinib. The results obtained with the final model when using QTcF as the dependent variable were comparable.

The modelpredicted mean QTcI at the observed geometric mean of the Cmax for total (1911 ng/mL) and free (4.51 ng/mL) plasma concentration at steady state following a 9-mg dose of erdafitinib was 5.1 ms (90% CI: -8.8, -1.5 ms) and -5.1 ms (90% CI: -8.3, -2.0 ms), respectively.

See figures below:

Figure 22: QTcI versus Erdafitinib Total Concentrations

<!-- image -->

Solid green line (+shaded area): model-predicted mean QTcI (+90% CI). Blue boxes (+vertical bars): observed arithmetic  means  (+90% CI)  for  the QTcI within  each  plasma  concentration decile. Red  star  represents QTcI predicted for the geometric Cmax at steady state of a 9-mg dose (1911 ng/mL). Observed QTcI were corrected by the estimated individual intercept and the effect of each timepoints, which were not considered to be related to the plasma concentration effect of erdafitinib.

<div style=\"page-break-after: always\"></div>

Figure 23: QTcI versus Erdafitinib Free Concentrations

<!-- image -->

Solid green line (+shaded area): model-predicted mean QTcI (+90% CI). Blue boxes (+vertical bars): observed arithmetic  means  (+90% CI)  for  the QTcI within  each  plasma  concentration decile. Red  star  represents QTcI predicted for the geometric Cmax at steady state of a 9-mg dose (4.51 ng/mL). Observed QTcI were corrected by the estimated individual intercept and the effect of each timepoints, which were not considered to be related to the plasma concentration effect of erdafitinib.

The upper limit of the 2-sided 90% CI of the modelpredicted mean QTcI was below 20 ms at the observed geometric mean of the total and free Cmax at steady state following a 9-mg dose of erdafitinib.

Consistent with the results on QTcI, the model -predicted mean QTcF at the observed geometric mean of the Cmax for total (1911 ng/mL) and free (4.51 ng/mL) plasma concentration at steady state following a 9-mg dose of erdafitinib was -4.4 ms (90% CI: -8.0, -0.8 ms) and -4.5 ms (90% CI: -7.5, 1.4 ms), respectively. Since the upper limit of the 2-sided 90% CI of the modelpredicted mean QTcF was below 20 ms at the observed geometric mean of the total and free Cmax at steady state following a 9-mg dose of erdafitinib, the provided CSR concluded that erdafitinib does not prolong the QTcF.

## 2.8.3. Discussion on clinical pharmacology

## Pharmacokinetics

Pharmacokinetic data from study EDI1005 (ADME) in healthy volunteers showed that erdafitinib is readily absorbed after administration as oral solution, with Tmax values around 2.5 hours. The tmax value in the SmPC including range is taken from EDI1006 which was adequately justified.

In subjects with advanced or refractory solid tumours or lymphoma in study EDI1001 (FTIH), after a single dose (Cycle 1 Day 1) in the 76 participants with serial PK sampling, tmax values ranged between 1.00- and 3.44-hours post-dose across the different cohorts and was independent of dose.

After multiple doses at steady state in the continuous dose cohorts, mean accumulation ratios based on Cmax ranged between 2.74 and 3.94 and based on AUC  between 3.08 and 4.96.

For SD and MD, Cmax and AUCs increased with increasing dose without consistent or significant deviations from the dose-proportionality across the range of dose levels and results are reported in section 5.2 of the SmPC.

The SmPCs information ' Following administration of 8 mg once daily, the proposed starting dose, mean (coefficient of variation [CV%]) erdafitinib steady-state Cmax, AUC, and minimum observed

<div style=\"page-break-after: always\"></div>

plasma concentration (Cmin) were 1399 ng/mL (50.8%), 29268 ng.h/mL (59.9%), and 936 ng/mL (64.9%). Daily fluctuations in erdafitinib plasma concentrations were low, with a mean (CV%) peak-totrough ratio of 1.47 (23%) at steady state upon daily dosing .' are based on additional pharmacokinetic analyses of individual dose normalised PK parameters pooled over dose levels based on results of Clinical Study EDI1001.

Based on non-clinical data, erdafitinib was 99.7% bound to human plasma proteins. The plasma to blood ratio was 0.60, with no concentration dependency. The mean apparent volume of distribution of erdafitinib in patients with cancer was 0.411 L/kg (see SmPC 5.2).

The results of mass balance study EDI1005 indicate that faecal excretion is the major route of elimination, while urinary excretion is the minor elimination pathway: Excretion of radioactivity was primarily via faeces (68.7%), with unchanged drug representing 14.1% to 20.8% of the total dose. Radioactivity was also excreted in the urine (18.7%), with unchanged drug being the major entity (11.3%). Statements in the SmPC in section 5.2 on excretion are adequately justified.

Results from in vitro studies suggest that mainly CYP2C9 and CYP3A4 are responsible for erdafitinib biotransformation in human (refer to Non-Clinical Part of the dossier): Erdafitinib metabolism in human liver microsomes was low. Therefore, human hepatocytes were considered a more suitable system to investigate the involvement of CYP enzymes. The formation of M6 was inhibited by ketoconazole by 22% and by sulphaphenazole by 90.6% indicating that CYP2C9 is mainly involved in M6 metabolic pathway with a minor contribution of CYP3A4. The formation of M8 is largely mediated by CYP3A4 as it was inhibited by ketoconazole by 73%. These results were further confirmed by metabolic profile in CYP-specific supersomes.

Possible influence of CYP2C9 polymorphism on erdafitinib exposure was investigated as part of Clinical DDI study EDI1007 and via PBPK and PopPK analysis. Results from Clinical Study EDI1007 do not indicate clinically significant effects on PK in patients with CYP2C9*1/*2, and CYP2C9*1/*3 genotype compared to wild type CYP2C9*1/*1. The popPK analysis supports that there is no significant effect of CYP2C9 status on clearance. However, these results are based on n=75 for intermediate and n=11 for poor metabolisers. Based on the aforementioned results, it is agreed that no need for an individualised dose adjustment based on CYP2C9 polymorphism is indicated. As outlined above, predictions from PBPK modelling should not be used in the SmPC.

## Food effect

Food effects were investigated in crossover study EDI1006. Cmax, AUClast, and AUC were comparable under fasted and fed conditions. The 90% CIs of the GMRs of Cmax, AUClast, and AUC were within the standard bioequivalence range of 80% to 125%. Based on the provided study results from study EDI1006 investigating the phase III formulation it is agreed that no clinically relevant effect of food on erdafitinib PK would be expected. According to the Clinical Study Protocol in the pivotal Phase III study, subjects were to avoid consuming grapefruit or Seville oranges due to CYP450 3A4/5 inhibition and this information is also stated in section 4.5 of the SmPC.

The SmPC does not include information for patient who cannot take the whole tablets. According to the applicant nothing is known about reported 'swallowability issues' from any of the studies in the adult clinical development programme, including the mUC population. The combination of the small size of the tablets and the film coating would improve swallowability in the elderly subject population. The reason for not breaking or crushing the tablet seems to be due to avoiding unnecessary inhalation of the tablet particles during the process. In conclusion, section 4.2 of the SmPC clarifies that the tablets should be swallowed whole. For the future the applicant is to consider the Reflection paper on 'Pharmaceutical-development of medicines-for use-in the older-population'.

<div style=\"page-break-after: always\"></div>

## Special Populations

Clinical pharmacology studies were conducted to evaluate the effect of race and hepatic impairment but not the role of impaired renal function, age and gender.

## Hepatic impairment

A formal dedicated Study EDI1008 investigating the effect of mild and moderate hepatic impairment (HI) on the PK of erdafitinib has been performed. With regard to hepatic status, subjects were graded according to the Child-Pugh Classification. This is acceptable as the recommended metric for hepatic function classification was used. As per the provided results, compared to normal hepatic function group, Cmax and AUCs of total erdafitinib decreased by 17.0% and 17.7% respectively for mild HI, and by 26.4% to 38.6% respectively for the moderate HI group. However, Cmax and AUCs of free erdafitinib were comparable in both mild and moderate HI groups, compared to those observed in the normal hepatic group with a maximum decrease of 12.6%. As reflected in 5.2 of the SmPC, no clinically meaningful differences were observed. For the severe HI group, PK of erdafitinib was not characterised as only very limited numbers of subjects (n=2) were available; therefore no formal conclusion could be drawn for this subgroup of patients (see section 4.2 of the SmPC).

Impact of HI on erdafitinib PK was also investigated as part of the Pop-PK analysis using ALT and AST values as a marker of hepatic function. As per the provided classification, the majority of subjects, 914 (80%) and 220 (19.3%) were graded as normal hepatic function and mild HI respectively. The number of patients with moderate and severe hepatic impairment was too limited (n=3, n=1, respectively) to allow meaningful conclusions. The analysis indicated that there was no clinically meaningful effect of mild HI on the systemic exposure of erdafitinib. However, such results should be regarded with caution as the recommended Child-Pugh metric for hepatic function was not used.

Overall, based firstly on results from the formal study, no dose adjustment is required for patients with mild or moderate hepatic impairment (see SmPC 4.2). Alternative treatment should be considered in patients with severe hepatic impairment.

## Renal impairment

No dedicated study was performed in subjects with renal impairment, and this appears acceptable given the low renal excretion of erdafitinib observed in the mass balance study EDI1005 (approximately 13.3% of the total administered dose) and since a major impact of renal impairment on erdafitinib PK does not seem likely.

Impact of renal impairment on erdafitinib PK was investigated as part of the Pop PK analysis using both creatinine clearance (CLCR expressed in mL/min) and estimated glomerular filtration rate (eGFR expressed in mL/min/1.73m2). CLCR was tested in the model and was not found to be statistically significant at the predetermined significance level (p&gt;0.001). The Pop-PK dataset included n=412 (36.1%), n=421 (36.9%), n=301 (26.4%) and n=8 (0.7%) subjects with normal renal function, mild, moderate and severe renal impairment, respectively. It is noted that the numbers of patients included in the severe category is too low and not considered sufficient to detect a potential clinically relevant change in clearance. Therefore, no formal conclusion could be drawn for this subgroup of patients. Overall, no dose adjustment is needed in patients with mild and moderate RI, as reflected in SmPC 4.2.

Information regarding renal impairment is presented in section 5.2 of the SmPC.

With regard to renal impairment, pcVPCs stratified by renal impairment were also submitted and further supported that no dose adjustment is required for patients with mild or moderate renal impairment (data not shown).

<div style=\"page-break-after: always\"></div>

## Race

Results from studies in Asian patients (GAC1001 and HCC1001) were generally in line with results from non-Asian participants.

Even though race/ethnicity did not have a significant effect on erdafitinib PK in the population PK analysis, it should be noted that races other than Asian and Caucasian were minimally represented in the dataset.

## Body weight

The mean (range) body weight (BW) was 72.0 kg (36-166 kg, excluding 3 paediatric participants). In the Pop-PK analysis, BW was identified as a statistically significant covariate on the clearance CLfree and the central and peripheral compartments (V2, V3, V4) for erdafitinib with exponent effects (allometric scaling) of 0.589 and 0.447, respectively (both lower than the classical values of 0.75 and 1). Therefore, CLfree and the volumes parameters of erdafitinib were found to increase with increasing BW; range of78.3-157 L/h for CL and 17-43 L for volume among the range of bodyweight observed in the pooled population dataset.

To investigate the effect of BW categories on erdafitinib steady state AUCfree BW was categorised in 3 different categories: &lt;60 kg, 60 to 80 kg (reference), and &gt;80 kg. Based on provided Pop-PK model simulations, predicted mean ratio [CI: 5th-95th] of normalised steady state AUCfree was 1.16 [0.712.09] for BW &lt;60 kg and 0.86 [0.49-1.40] for BW &gt;80 kg relative to the reference group of weight [60-80 kg]. Thus, patients with lower body weight will have relatively higher exposure and in the contrary patients with higher body weights will have lower exposure relative to the reference BW. A significant increase on the systemic exposure to free erdafitinib, up to 209% (doubling), is expected in patients with extreme lower BW and a significant decrease, up to reduction by half, is expected in patients with extreme higher BW relative to the reference BW. Simulations of AUCfree for the extreme low [30-40 kg], [40-50 kg] and high [120-130 kg], [130-140 kg] and [&gt;140 kg] body weight ranges in comparison to the reference systemic exposure were presented. Based on the results, there is no need for dose adjustment in obese and underweighted patients.

## Age

No or very limited PK / clinical data are provided in the paediatric population &lt;18 years. Erdafitinib is not indicated for the treatment of locally advanced unresectable or metastatic urothelial cancer. Only adult population is claimed. This is clearly stated in section 4.2 of the SmPC and is agreed.

The mean (range) age was 60.9 years (21-92 years, by excluding 3 paediatric participants.

In the Pop-PK analysis, age was identified as a statistically significant covariate on the oral clearance CL. Age was categorised in 3 different subgroups: &lt;65 years old (reference, n=664), 65 to 75 years old (n=367) and &gt;75 years old (N=111). In elderly, oral CL is expected to decrease with age by 15.2% in the [65-75 years] group and by 20.6% in the &gt;75 years group in comparison to patients &lt;65 years old. Overall, the applicant's conclusion that no dose adjustment is needed in elderly could be agreed.

## DDIs

Erdafitinib is a substrate for P-gp. P-gp inhibitors are not expected to affect the PK of erdafitinib in a clinically relevant manner. Erdafitinib has adequate solubility across the pH range of 1 to 7.4. Acid lowering agents (e.g., antacids, H2-antagonists, or proton pump inhibitors) are not expected to affect the bioavailability of erdafitinib. No clinically meaningful differences in the pharmacokinetics of erdafitinib were observed in patients taking sevelamer.

<div style=\"page-break-after: always\"></div>

Drug-drug interactions have been discussed based on the provided results of in vitro studies using human biomaterial, clinical DDI studies in healthy volunteers and patients ( in vivo ) as well as PBPK modelling ( in silico ). Overall, potential DDIs with erdafitinib as a victim or perpetrator have been adequately investigated and relevant information are included in sections, 4.4 and  4.5 of the SmPC.

## Pharmacodynamics

## Mechanism of action

Activating mutations and translocations in FGFR genes have been associated with neoplastic progression and tumour vascularisation in multiple cancer types including, most commonly, UC (Dienstmann 2014; Parker 2014). Several lines of evidence point to deregulation of FGFR signalling (e.g., via FGFR mutation and gene fusion) being involved in bladder cancer pathogenesis (Babina 2017; Dienstman 2014; Touat 2015). Recurrent FGFR mutations and gene fusions are observed in urothelial cancer (Robertson 2017).

Preclinical models have shown that expression of FGFR mutations and gene fusions leads to increased cellular proliferation, and FGFR altered bladder cancer cell lines have shown sensitivity to FGFR inhibition in vitro and in vivo ( Dienstmann 2014;Touat 2015).

Targeting FGFRs is aiming on simultaneously inhibiting tumour cell growth, survival, and migration, as well as tumour angiogenesis (Beenken 2009; Turner 2010; Wesche 2011).

Erdafitinib is a highly selective and potent oral pan-FGFR tyrosine kinase inhibitor with high affinity and inhibitory activity at low nanomolar levels for all FGFR family members, FGFR 1, 2, 3 and 4.

## Primary pharmacology

Systemic PD, including serum phosphate concentrations, vitamin D, FGFR ligand FGF-23, calcium levels, and PTH secretion were characterised in the first-in-human Study EDI1001.

Pharmacodynamic biomarkers measured in the blood showed that:

- -Vitamin D3 levels started to increase by 24 hours after the first dose, peaked in average with a change of approximately 100% across doses and then began to decline with average levels returning to near baseline levels around cycle 4.
- -FGF23 overall increased mildly compared to baseline.
- -Calcium levels remained overall stable.
- -PTH levels, after a very modest initial peak, mildly decreased compared to baseline.
- -Dose dependent increases in phosphate levels were observed at the first assessed time points. Phosphate levels peaked between Cycles 1 and 2 of treatment. Phosphate level changes from baseline declined over time beginning at approximately Cycle 3 of treatment.

Population PK-PD modelling used an Emax model to describe the erdafitinib effect on PO4 driven by free concentrations in the effect compartment, with an attenuation of the erdafitinib effect on serum [PO4] with time, used to describe the relationship between erdafitinib free plasma concentrations and serum [PO4]. This model characterised serum [PO4] and their variability in subjects with cancer treated with different dosing regimens of erdafitinib. Diagnostic plots showed an underprediction for the first 6 months of the study as well as an underprediction of the variability but overall described the effect of erdafitinib on [PO4] reasonably well.

<div style=\"page-break-after: always\"></div>

## Secondary Pharmacology / Exposure-response Analyses of Safety E-R relationship between the change from baseline in QTc intervals (QTcF and QTcB) and total and unbound plasma concentration of erdafitinib

Exposure-response analyses were conducted based on data from Study EDI1001 over a dose range from 0.5 to 12 mg from 187 subjects, including ECG obtained during study, manually read ECG by a central reader [I], and ECG extracted from Holter monitor with matching baseline [II].

The submitted analysis [I and II] are based on data for exposures after doses of up to 12 mg erdafitinib per day in clinical study EDI1001. Analysis I is based on preliminary data (Jan 26, 2015 data cut-off, see eRT report). For Analysis II, mean  QTcI was always calculated for the observed mean of the Cmax for total (1911 ng/mL) and free (4.51 ng/mL) plasma concentration at steady state following a 9-mg dose of erdafitinib. The submitted exposure-response analysis based on time-matched QTc Holter data do not indicate a critical effect of erdafitinib on cardiac repolarisation.

Nevertheless caution is advised when administering Balversa with medicinal products known to prolong the QT interval or medicinal products with a potential to induce torsades de pointes, such as class IA (e.g., quinidine, disopyramide) or class III (e.g., amiodarone, sotalol, ibutilide) antiarrhythmic medicinal products, macrolide antibiotics, SSRIs (e.g., citalopram, escitalopram), methadone, moxifloxacin, and antipsychotics (e.g., haloperidol and thioridazine) (SmPC section 4.4).

## Pharmacodynamic interactions

During the procedure, a discussion on whether concomitant use of medicinal products that can alter serum phosphate levels might be problematic in the initial dose increase period based on serum phosphate levels have been submitted (Data not shown). Based on the data presented it is reasonable to advise against the use of concomitant medications with the potential to alter serum phosphate levels during the period up to the up-titration decision and proposed to add respective information in section 4.5 of the SmPC.

## Exposure-response analyses of efficacy following treatment with erdafitinib

This exposure-response analysis quantifies the relationship between serum phosphate and OS, the primary efficacy endpoint of Study BLC3001, as well as for the secondary endpoints PFS, ORR, and DOR. The exposure-efficacy analysis was performed using Study BLC3001 Cohort 1 data.

The Cox proportional hazard analyses indicated that the weekly average of daily serum phosphate concentration (PO4-Time dependent) predicted OS and PFS better than PO4avg 6 weeks and PO4avg up to event (lowest AIC).

For ORR, an increase in average serum PO4 concentrations up to 6 weeks was found to significantly increase ORR as assessed by the investigator.

As reflected in SmPC 4.2, daily doses can be up-titrated to 9 mg once daily if the serum phosphate level is &lt;9.0 mg/dL (serum phosphate level should be assessed between 14 and 21 days after initiating treatment) and there is no drug-related toxicity. However, patients should not be actively further up-titrated based on phosphate levels. Therefore, the relevance of information about phosphate as an indicator of PD activity (reflects target engagement) for the prescriber could be regarded minor.

## Exposure-response analysis of safety following treatment with erdafitinib

This exposure-response analysis quantifies the relationship between serum phosphate and selected clinical safety endpoints: eye disorders (excluding CSR), CSR disorders, nail disorders, skin disorders, and GI disorders.

<div style=\"page-break-after: always\"></div>

The exposure-safety analysis was performed using data obtained from 6 mg or 8 mg once daily erdafitinib monotherapy dosed patients harboring susceptible FGFR aberrations, collected in a locally advanced or metastatic urothelial cancer population. In this context, pooled data from 814 participants in 3 studies were included. These data were from the 6 and 8 mg once daily regimens of Study BLC2001 (end of main study, 27 July 2021 clinical data cut), the erdafitinib monotherapy arm data of Study BLC2002 (30 September 2022 data cut), and data collected in Cohort 1 and Cohort 2 of Study BLC3001.

For the safety analysis, the relationships between erdafitinib serum phosphate and the incidence of the selected clinical safety endpoints were investigated using univariate logistic regression models.

The incidence of eye disorders (other than CSR), nail disorders, skin disorders, GI disorders at Grade  2 of severity, and CSR disorders at Grade  1 of severity, with a potential to require dose interruption, show a statistically significant relationship with the serum phosphate level associated with erdafitinib treatment.

The incidence of Grade  1 central serous retinopathy and Grade  2 gastrointestinal disorders had no such associations.

## 2.8.4. Conclusions on clinical pharmacology

Pharmacokinetic and pharmacodynamic properties of erdafitinib have been overall adequately described and support the use in the intended indication.

## 2.8.5. Clinical efficacy

## 2.8.5.1. Dose response study(ies)

The recommended starting dose of erdafitinib is 8 mg daily, with individualised up-titration to 9 mg once daily based on serum phosphate levels and drug-related toxicity, and a stepwise dose reduction to 6, 5, or 4 mg and/or interruption for tolerability.

The 8 mg once daily dose was evaluated in Study BLC2001 as Regimen 3 in participants with urothelial carcinoma. Study BLC2001 was started with 2 treatment regimens, to which participants were randomly assigned: Regimen 1 (intermittent dosing 10 mg daily with pharmacodynamically guided uptitration to 12 mg daily 7 days on/7 days off) and Regimen 2 (continuous dosing 6 mg daily with pharmacodynamically guided up-titration to 8 mg daily). At Interim Analysis 1, intermittent dosing was discontinued due to a low response rate (21.2%, 95% CI: 7.3-35.2). Based on further analysis of safety and efficacy data for the continuous daily dosing regimen and PK-PD modelling, a starting dose of 8 mg daily with pharmacodynamically guided up-titration to 9 mg (Regimen 3) was predicted to be superior to Regimen 2, which was also discontinued and, following implementation of Amendment 3, all subsequently enrolled participants received Regimen 3.

Based on the final analysis, the 8 mg daily regimen demonstrated higher investigator-assessed ORR than the 6 mg once daily regimen (40.2% versus 34.6%). PFS and OS data also showed a consistent trend of superior efficacy for the 8 mg once daily regimen.

In Study BLC2001, a serum phosphate concentration threshold of 5.5 mg/dL was used for up-titration of erdafitinib. Safety data from that study demonstrated no increased risk of AEs considered potential sequelae of prolonged hyperphosphataemia (more than 1 month) in participants with phosphate levels &gt;5.5 mg/dL. Furthermore, increased serum phosphate levels correlated with improved clinical efficacy

<div style=\"page-break-after: always\"></div>

with a requirement for concomitant increased dose interruptions or reductions. Consequently, in Study BLC3001, the threshold for individualised up-titration serum phosphate concentration was increased to 9 mg/dL. In Study BLC3001, all participants in the erdafitinib treatment group started erdafitinib 8 mg once daily from Day 1 to Day 14 of Cycle 1, and serum phosphate concentrations were measured on Day 14 of Cycle 1. Participants with serum phosphate concentrations &lt;9.0 mg/dL with no significant toxicity could increase the erdafitinib dose to 9 mg daily. Dose interruption and dose reduction guidelines were also provided based on tolerability and AEs in Study BLC3001.

In Study BLC3001 Cohort 1 (N=266; erdafitinib n=136, chemotherapy n=130), erdafitinib significantly prolonged OS (primary endpoint) compared with chemotherapy (median OS of 12.1 months versus 7.8 months; HR=0.64, p=0.0050). The results of the primary endpoint are reinforced by superiority of erdafitinib versus chemotherapy for the key secondary endpoints of PFS and ORR. The exposureefficacy analysis demonstrated that treatment with erdafitinib resulted in increased serum phosphate concentrations, which were associated with statistically significant improvements in OS, PFS, and ORR, thereby supporting the individualised dose titration used in Study BLC3001 Cohort 1.

## 2.8.5.2. Main study

## Study BLC3001 (cohort 1): A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Study BLC3001 was a randomised (1:1) controlled open-label phase 3 study with two independent cohorts.

- -Cohort 1 (object of this application) evaluated erdafitinib monotherapy versus investigator's choice of chemotherapy (docetaxel or vinflunine) in patients with advanced urothelial cancer and susceptible FGFR alterations, who had progressed on or after 1 or 2 prior line(s) of therapy, with at least 1 line including anti-PD-(L)1 as monotherapy or as combination therapy; and no more than 2 prior lines of systemic treatment. The choice of the type of chemotherapy (i.e. docetaxel or vinflunine) was made at the site level by the investigator prior to enrolment of subjects.
- -Cohort 2 evaluated erdafitinib monotherapy versus pembrolizumab in patients with advanced urothelial cancer and susceptible FGFR alterations, who had progressed on or after 1 prior line of systemic treatment and who had no prior treatment with an anti-PD-(L) 1 agent.

<div style=\"page-break-after: always\"></div>

Figure 24: schematic study design of study BLC3001

<!-- image -->

Chemo=Chemotherapy; FU=follow-up; lab=laboratory; PD (L)1= programmed death-ligand 1; Pembro=Pembrolizumab

Note: Treatment until disease progression, intolerable toxicity, withdrawal of consent, or decision by investigator. An IDMC was commissioned for this study. A review of one predefined interim analysis for each cohort was performed by the IDMC on both safety and efficacy data.

Source: figure 1, CSR BLC3001 cohort 1

## Methods

##  Study Participants

## Key inclusion criteria for cohort 1

- 1)  18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place)
- 2) Histologic demonstration of transitional cell carcinoma of the urothelium. Minor components (&lt;50% overall) of variant histology such as glandular or squamous differentiation, or evolution to more aggressive phenotypes such as sarcomatoid or micropapillary change are acceptable.
- 3) Metastatic or surgically unresectable urothelial cancer
- 4) Documented progression of disease, defined as any progression that requires a change in treatment, prior to randomisation
- 5) Prior treatment with an anti-PD-(L)1 agent as monotherapy or as combination therapy; no more than 2 prior lines of systemic treatment. Prior treatment with an anti-PD-(L)1 agent could have been given as neo-adjuvant, adjuvant, or in metastatic line of treatment as frontline or maintenance therapy, as follows:
6. -Together with chemotherapy or as maintenance therapy
7. -Together with chemotherapy in metastatic setting

<div style=\"page-break-after: always\"></div>

- -For superficial cancer (early disease/non-muscle invasive bladder cancer), OR in neo-adjuvant OR adjuvant setting. If these subjects did not relapse within a year of their last dose of antiPD-(L)1, this will not be counted as a prior line of systemic treatment. These subjects will however still be eligible only for Cohort 1.

Note: Subjects who received neoadjuvant or adjuvant chemotherapy or immunotherapy and showed disease progression within 12 months of the last dose are considered to have received systemic therapy in the metastatic setting.

- 6) Subjects must meet appropriate molecular eligibility criteria, as determined by central laboratory screening or by local historical test results (from tissue or blood) performed at a Clinical Laboratory Improvement Amendments (CLIA)-certified or regional equivalent laboratory using the following methods: local next-generation sequencing (NGS), direct digital counting methods, or the Qiagen therascreen FGFR Rotor-Gene Q (RGQ) reverse transcription polymerase chain reaction (RT-PCR) test; see Section 9.1.2 for details.

Tumours must have at least 1 of the following translocations: FGFR2-BICC1, FGFR2-CASP7, FGFR3TACC3, FGFR3-BAIAP2L1; or 1 of the following FGFR3 gene mutations: R248C, S249C, G370C, Y373C.

## Key exclusion criteria for cohort 1

1. Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 30 days prior to randomisation
2. Active malignancies (that is, requiring treatment change in the last 24 months). The only allowed exceptions are: urothelial cancer, skin cancer treated within the last 24 months that is considered completely cured, localised prostate cancer with a Gleason score of 6 (treated within the last 24 months or untreated and under surveillance) and localised prostate cancer with a Gleason score of 3+4 that has been treated more than 6 months prior to full study screening and considered to have a very low risk of recurrence.
3. Symptomatic central nervous system metastases
4. Received prior fibroblast growth factor receptor (FGFR) inhibitor treatment
5. Known allergies, hypersensitivity, or intolerance to erdafitinib or its excipients
6. Current central serous retinopathy (CSR) or retinal pigment epithelial detachment of any grade.
7. History of uncontrolled cardiovascular disease
8. Impaired wound healing capacity defined as skin/decubitus ulcers, chronic leg ulcers, known gastric ulcers, or unhealed incisions

##  Treatments

Patients randomised to the experimental arm received erdafitinib orally with or without food at a starting dose of 8 mg once daily for 21 days in a 21-day cycle. Erdafitinib dose should be up-titrated to 9 mg once daily if the serum phosphate level on Cycle 1 Day 14 is &lt;9.0 mg/dL, and there was no drug-related toxicity. For eye, skin/nail, dry mouth/mucositis, and phosphate toxicity, specific recommendations for dose modifications or dose delays were provided in the study protocol.

Patients randomised to the control arm received either vinflunine or docetaxel by investigator's choice (choice was made at the site level by the investigator prior to enrolment of subjects). Vinflunine was administered at a dose of 320 mg/m as a 20-minute intravenous infusion once every 3 weeks.

Docetaxel was administered at a dose of 75 mg/m as a 1-hour intravenous infusion every 3 weeks. All

<div style=\"page-break-after: always\"></div>

patients should continue treatment with the study drug until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment.

##  Objectives

The primary objective was to show superiority on the effect of erdafitinib monotherapy vs investigator's choice chemotherapy (i.e. vinflunine or docetaxel) by assessment of OS.

##  Outcomes/endpoints

## Primary endpoint

- Overall survival (OS) as measured from the date of randomisation to the date of the subject's death. If the subject is alive or the vital status is unknown, the subject will be censored at the date the subject was last known to be alive.

Key secondary endpoints (hierarchically tested if superiority of erdafitinib to chemotherapy is established for the primary endpoint; testing order as listed)

- Progression free survival (PFS) as duration in days from the date of randomisation to the date of disease progression (or relapse from CR) assessed per RECIST v1.1 by the investigator or death, whichever is reported first.
- Objective response rate (ORR)  the proportion of subjects who achieve CR or PR, as assessed per RECIST v1.1 by the investigator.
- Time to urinary bladder cancer symptom deterioration (TUSD-3) (subset of 3 FACT-Bl items)  urinary bladder cancer Symptoms (US) score from 3 items from the FACT-Bl (BL1: urinary incontinence, BL2: urinary frequency, BL3: urinary pain) and is defined as the first time to increase in US score from the day of randomisation beyond a meaningful change threshold compared to baseline.

Tumour assessments were performed every 6 weeks for the first 6 months and then every 12 weeks for the next 6 months (7-day window) using date of randomisation as reference. After the first year, assessments were to be performed as clinically indicated. Assessment of responses for solid tumours were to be performed according to RECIST (Version 1.1) by investigators. More frequent radiological assessments were allowed, if clinically indicated/desirable. Identical methodology (CT scan or MRI) was to be used for disease assessment at baseline, and throughout the course of the study, to characterise each identified and reported lesion to document disease status. If symptomatic deterioration (on the basis of global deterioration of health status) occurred without documentation of radiographic progression, the clinical findings used to make this determination must be specified in the eCRF and documented in the source documents. For subjects who discontinued study therapy without documented disease progression, monitoring of their disease status by tumour imaging according to the imaging schedule were to be continued, until the start of new anti-cancer treatment, disease progression, withdrawal of consent, death, or the end of the study, whichever occurs first.

##  Sample size

Approximately 280 subjects (approximately 140 subjects to each arm) were planned to be enrolled in cohort 1 of study BLC3001. The data cut-off date for the final analysis was planned when approximately 208 death events had occurred. Assuming a 53% improvement in median OS of the erdafitinib arm over the chemotherapy arm (a hazard ratio [HR] of 0.65 for the erdafitinib group relative to chemotherapy group, under the exponential distribution assumption), the study had at least 85% power to detect a HR of 0.65 at a statistical significance level of 5% (2-sided) with one interim analysis for efficacy at an approximately 65% information fraction (approximately 136 deaths) and a final analysis.

<div style=\"page-break-after: always\"></div>

##  Randomisation and Blinding (masking)

Eligible patients were randomised in a 1:1 ratio to each arm.  The randomisation was stratified by

- -Region (North America vs EU vs rest of world)
- -Eastern Cooperative Oncology Group (ECOG) performance status (0 or 1 vs. 2)
- -Disease distribution (presence vs. absence of visceral metastases) (yes, no).

Study BLC3001 was an open-label study.

##  Statistical methods

## Estimand (Target of estimation)

Study intervention:

- Erdafitinib
- Chemotherapy (Cohort 1)

Population: Subjects with advanced urothelial cancer harboring selected FGFR aberrations who have progressed on or after 1 or 2 prior treatments, at least 1 of which includes an anti-PD-(L)1 agent (Cohort 1)

Variable: Overall survival (OS)

Summary measure (Population-level summary): HR of erdafitinib vs. chemotherapy

Intercurrent events: The intercurrent events of treatment discontinuation and subsequent anti-cancer therapy were accounted for by a treatment policy strategy.

The planned analyses and determination of sample size are described in the final version of the SAP. Cohort 1 and Cohort 2 were assessed independently, i.e., as if there were 2 separate studies.

The Intent-to-Treat (ITT) population was defined as all randomised subjects.

Subjects lacking data beyond randomisation have their OS censored at the date of randomisation.

The primary efficacy analysis was based on the ITT analysis set. The distribution  of OS for each treatment group, including estimated median (in months) and 95% CI, was estimated  using the Kaplan-Meier method. The log-rank test was used to compare the treatment groups (within each cohort) at an overall alpha level of 0.05 for the primary analyses. Additionally, the HR for erdafitinib relative to the control and its associated 95% CI was calculated based on a Cox proportional hazards model.

The three stratification factors separated the total subjects into 24 subgroups when treatment arm is taken into consideration. Due to a limited number of events by treatment group per strata (ie, &lt;10 events) for OS and PFS per treatment group, a pre-specified pooling algorithm was applied resulting in unstratified analysis for OS and PFS.

The ITT analysis set was used for the analyses of all secondary endpoints. PFS and time to urinary bladder symptom deterioration were analysed using the same methods as the primary endpoint.

Inference for ORR was accomplished using the stratified Cochran-Mantel-Haenszel test.

The Type 1 error rate was controlled at 5% (2-sided) for the primary and key secondary endpoints. All tests were conducted at a 2-sided alpha level of 0.05, and 95% CIs were provided, unless stated otherwise. The familywise Type 1 error rate was strongly controlled at 5% (2-sided) for the secondary endpoints. A hierarchical testing approach was utilised for testing the secondary endpoints. At both interim and final analyses, the secondary endpoints were to be tested at the same significance levels as specified for testing the primary endpoint (OS) based on the O'Brien-Fleming alpha-spending

<div style=\"page-break-after: always\"></div>

function to control the overall Type 1 error rate. The testing order of these endpoints was as follows: PFS; ORR; Time to urinary bladder cancer symptom deterioration.

The interim analysis for Cohort 1 was planned after an approximately 65% information fraction. Both superiority and futility were assessed at the interim analysis. The classical O'Brien-Fleming boundaries were used for these assessments. The stopping boundaries were implemented by Lan-DeMets spending function to control the Type 1 error rate at the 0.05 significance level overall. The Cohort 1 interim analysis occurred after 155 death events had been observed (at approximately 75% information fraction), and the significance level was determined using the O'Brien-Fleming alpha-spending function to control the Type 1 error rate at the 0.05 significance level (2-sided). The efficacy boundary p-value was predetermined to be 0.019 (2-sided). The IDMC recommended that Cohort 1 be stopped due to superiority of erdafitinib over chemotherapy and that subjects be allowed to crossover to erdafitinib treatment. As Cohort 1 was stopped, the interim analysis of Cohort 1 is considered the final analysis.

To evaluate the impact of the asymmetry in the number of patients randomized to chemotherapy vs erdafitinib who did not receive treatment, sensitivity analyses, including a tipping point analysis, were conducted.  This included an analysis where OS for the 10 censored subjects due to dropout in the chemotherapy arm were imputed using multiple imputation with two approaches: a) by applying the top 20% OS values observed across both erdafitinib and chemotherapy arms and b) by applying the top 20% OS values observed in the chemotherapy arm alone. In the tipping point analysis, the OS hazard rate for the 10 censored subjects on the chemotherapy arm was incrementally improved until a null result was achieved, ie, the hazard ratio was no longer statistically significant at the 0.05 (2-sided) level.

## Results

##  Participant flow

## Figure 25: disposition of subjects cohort 1 study BLC3001

A total of 824 patients entered full study screening for the study BLC3001 (Cohorts 1 and 2), 619 (75.1%) passed and 207 (24,9%) failed full study screening.

Although cohort 1 and cohort 2 were performed and assessed independently, patient screening for both cohorts was combined and it is not possible to provide an analysis of screening failures for the pivotal 'study BLC3001 cohort 1' specifically.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Threesubjectshad prior anti-PDL1 therapybut were incorrectlyrandomized to Cohort 1.

- 10subjectswerewithdrawnfrom thestudy:2subjectsdiscontinued treatment
- Including those still on treatment and thosewho discontinued treatment without discontinuing the study at time ofclinical cutoff
- bSubjects experienced at least 1adverseevent afterbeing randomized
- dIncluding10subjectswhowererandomizedbutdidnotreceivetreatment

##  Recruitment

Initiation date: 6 August 2018 (first patient signed informed consent)

Primary completion date:

15 January 2023 (stopped for superiority in OS in interim analysis;

clinical cut-off date)

Study completion date:

N/A (study ongoing)

Data lock:

2 March 2023

Release date of CSR:

7 August 2023

Patients were recruited in 121 study sites in 23 countries (Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, Russia, South Korea, Spain, Taiwan, Turkey, UK, USA).

##  Conduct of the study

## Protocol amendments

The original study protocol (Version 1.0, dated 29 September 2017) was amended 6 times:

##  Amendment 1 (26 October 2017) (before study start of cohort 1)

The overall reason for the amendment was to clarify collection time-points for biomarker samples and correct numbering of exclusion criteria.

<div style=\"page-break-after: always\"></div>

##  Amendment 2 (1 May 2018) (before study start of cohort 1)

The overall reason for the amendment was to address feedback from health authorities.

##  Amendment 3 (18 January 2019)

The overall reason for the amendment was to expand the subject population eligible for cohort 1 and to align with current standard of care following FDA and EMA label restrictions of the patient population eligible for treatment with anti-PD-(L)1 at frontline to those with high PD-L1 status and common practice to administer a platinum-based treatment as standard of care as a second-line treatment in this patient population.

##  Amendment 4 (29 Mar 2020)

The overall reason for the amendment was to allow subjects to meet appropriate molecular eligibility for the study by local historical test results for selected FGFR aberrations; ie, subjects can meet molecular eligibility criteria as determined by central laboratory screening as previously specified, or by local historical test results. However, if a subject is enrolled based on local historical testing, a tissue sample must still be submitted at the time of enrolment for retrospective confirmation of FGFR status, diagnostic development, and biomarker research.

##  Amendment 5 (25 March 2021)

The overall reason for this amendment was to revise the timing of the interim analysis to occur at a higher percentage of total events (65% information fraction), ie, allow for more mature data. Also, the possible sample size re-estimation was removed and guidance on the futility boundary was provided.

##  Amendment 6 (20 January 2023) (after clinical cut-off for IA cohort 1)

The overall reason for the amendment was to add the Long-term Extension (LTE) Phase. The addition of the LTE Phase modifies the overall end of study definition. Study completion is distinct from end of study. Study completion is defined as the end-of-data-collection time-point for both cohorts, which is defined as when the clinical cut-off at for the final analysis has been achieved. End of study is defined as when the last subject receives the last dose of study drug on the study.

Protocol deviations / protocol compliance

Table 40: Summary of Subjects with Major Protocol Deviations

|                                            | Erdafitinib   | Chemotherapy   | Total     |
|--------------------------------------------|---------------|----------------|-----------|
| Analysis set: ITT                          | 136           | 130            | 266       |
| Subjects with major protocol deviations    | 8(5.9%)       | 3(2.3%)        | 11 (4.1%) |
| Entered but did not satisfy criteria       | 4 (2.9%)      | 2 (1.5%)       | 6 (2.3%)  |
| Received wrong treatment or incorrect dose | 2 (1.5%)      | 0              | 2 (0.8%)  |
| Other                                      | 2 (1.5%)      | 1 (0.8%)       | 3(1.1%)   |

Note: Subjects may appear in more than one category.

Source: Table 7, CSR BLC3001 cohort 1

## GCP inspection findings

To date one GCP inspection of a site in Korea was conducted by the Korean health authority with no observations. In the context of this inspection, the clinical site and the sponsor site were inspected. In addition, US FDA conducted 3 post-submission investigator site inspections in Spain, Italy and US with no observations noted.

<div style=\"page-break-after: always\"></div>

##  Baseline data

Table 41: Summary of demographic characteristics at baseline (ITT)

|                   | Erdafitinib    | Chemotherapy   | Total          |
|-------------------|----------------|----------------|----------------|
| Analysis set: ITT | 136            | 130            | 266            |
| Age , years       |                |                |                |
| N                 | 136            | 130            | 266            |
| Mean (SD)         | 64.8 (10.40)   | 67.9 (9.07)    | 66.3 (9.87)    |
| Range             | (32; 85)       | (35; 86)       | (32; 86)       |
| < 65 years        | 59 (43.4%)     | 45 (34.6%)     | 104 (39.1%)    |
| 65 - 69 years     | 30 (22.1%)     | 23 (17.7%)     | 53 (19.9%)     |
| 70 - 74 years     | 21 (15.4%)     | 32 (24.6%)     | 53 (19.9%)     |
| 75 years         | 26 (19.1%)     | 30 (23.1%)     | 56 (21.1%)     |
| Sex               |                |                |                |
| N                 | 136            | 130            | 266            |
| Female            | 40 (29.4%)     | 36 (27.7%)     | 76 (28.6%)     |
| Male              | 96 (70.6%)     | 94 (72.3%)     | 190 (71.4%)    |
| Geographic region |                |                |                |
| N                 | 136            | 130            | 266            |
| North America     | 8 (5.9%)       | 5 (3.8%)       | 13 (4.9%)      |
| Europe            | 82 (60.3%)     | 80 (61.5%)     | 162 (60.9%)    |
| Rest of the World | 46 (33.8%)     | 45 (34.6%)     | 91 (34.2%)     |
| Weigh t, kg       |                |                |                |
| N                 | 136            | 130            | 266            |
| Mean (SD)         | 73.24 (17.867) | 72.51 (15.261) | 72.88 (16.617) |
| Range             | (41.0; 166.0)  | (44.0; 113.0)  | (41.0; 166.0)  |
| Height , cm       |                |                |                |
| N                 | 135            | 130            | 265            |
| Mean (SD)         | 168.77 (9.281) | 168.10 (9.711) | 168.45 (9.483) |
| Range             | (145.5; 192.0) | (144.0; 190.0) | (144.0; 192.0) |

Note: N for each parameter reflects non-missing values.

Source: Table 3, 'summary of clinical efficacy'

Table 42: Summary of disease characteristics at baseline (ITT)

|                                                                                                | Erdafitinib    | Chemotherapy   | Total          |
|------------------------------------------------------------------------------------------------|----------------|----------------|----------------|
| Analysis set: ITT                                                                              | 136            | 130            | 266            |
| Time from progression/relapse on the last line of prior therapy to randomisation (months)      |                |                |                |
| N                                                                                              | 128            | 124            | 252            |
| Mean (SD)                                                                                      | 2.72 (4.715)   | 1.82 (1.993)   | 2.28 (3.660)   |
| Range                                                                                          | (0.2; 41.1)    | (0.2; 19.7)    | (0.2; 41.1)    |
| Time from diagnosis of surgically unresectable or metastatic disease to randomisation (months) |                |                |                |
| N                                                                                              | 135            | 130            | 265            |
| Mean (SD)                                                                                      | 17.53 (13.158) | 14.15 (10.415) | 15.87 (11.989) |
| Range                                                                                          | (0.6; 74.6)    | (1.8; 63.5)    | (0.6; 74.6)    |
| Primary tumour location                                                                        |                |                |                |
| N                                                                                              | 136            | 130            | 266            |
| Lower tract                                                                                    | 95 (69.9%)     | 82 (63.1%)     | 177 (66.5%)    |
| Bladder                                                                                        | 90 (66.2%)     | 74 (56.9%)     | 164 (61.7%)    |
| Urethra                                                                                        | 5 (3.7%)       | 8 (6.2%)       | 13 (4.9%)      |
| Upper tract                                                                                    | 41 (30.1%)     | 48 (36.9%)     | 89 (33.5%)     |
| Renal Pelvis                                                                                   | 19 (14.0%)     | 20 (15.4%)     | 39 (14.7%)     |
| Ureter                                                                                         | 22 (16.2%)     | 28 (21.5%)     | 50 (18.8%)     |
| Type of histology                                                                              |                |                |                |
| N                                                                                              | 136            | 130            | 266            |
| Transitional Cell Carcinoma                                                                    | 128 (94.1%)    | 124 (95.4%)    | 252 (94.7%)    |

<div style=\"page-break-after: always\"></div>

|                                                                                       | Erdafitinib   | Chemotherapy   | Total       |
|---------------------------------------------------------------------------------------|---------------|----------------|-------------|
| Transitional Cell Carcinoma with minor components (<50% overall) of variant histology | 8 (5.9%)      | 6 (4.6%)       | 14 (5.3%)   |
| Bladder Cancer Stage at initial diagnosis                                             |               |                |             |
| N                                                                                     | 102           | 102            | 204         |
| 0a                                                                                    | 7 (6.9%)      | 8 (7.8%)       | 15 (7.4%)   |
| 0is                                                                                   | 2 (2.0%)      | 2 (2.0%)       | 4 (2.0%)    |
| I                                                                                     | 14 (13.7%)    | 16 (15.7%)     | 30 (14.7%)  |
| II                                                                                    | 19 (18.6%)    | 8 (7.8%)       | 27 (13.2%)  |
| III                                                                                   | 32 (31.4%)    | 35 (34.3%)     | 67 (32.8%)  |
| IV                                                                                    | 28 (27.5%)    | 33 (32.4%)     | 61 (29.9%)  |
| Baseline ECOG                                                                         |               |                |             |
| N                                                                                     | 136           | 130            | 266         |
| 0                                                                                     | 63 (46.3%)    | 51 (39.2%)     | 114 (42.9%) |
| 1                                                                                     | 61 (44.9%)    | 66 (50.8%)     | 127 (47.7%) |
| 2                                                                                     | 12 (8.8%)     | 13 (10.0%)     | 25 (9.4%)   |
| Disease distribution at study entry                                                   |               |                |             |
| N                                                                                     | 136           | 130            | 266         |
| Presence of visceral metastases a                                                     | 101 (74.3%)   | 97 (74.6%)     | 198 (74.4%) |
| Lung                                                                                  | 71 (52.2%)    | 67 (51.5%)     | 138 (51.9%) |
| Liver                                                                                 | 31 (22.8%)    | 38 (29.2%)     | 69 (25.9%)  |
| Bone                                                                                  | 36 (26.5%)    | 39 (30.0%)     | 75 (28.2%)  |
| Absence of visceral metastases(lung,                                                  |               |                |             |
| liver, or bone)                                                                       | 35 (25.7%)    | 33 (25.4%)     | 68 (25.6%)  |
| PD-(L)1 Status                                                                        |               |                |             |
| N                                                                                     | 96            | 79             | 175         |
| CPS >= 1                                                                              | 38 (39.6%)    | 38 (48.1%)     | 76 (43.4%)  |
| CPS < 1                                                                               | 58 (60.4%)    | 41 (51.9%)     | 99 (56.6%)  |
| PD-(L)1 Status                                                                        |               |                |             |
| N                                                                                     | 96            | 79             | 175         |
| CPS >= 10                                                                             | 7 (7.3%)      | 11 (13.9%)     | 18 (10.3%)  |
| CPS < 10                                                                              | 89 (92.7%)    | 68 (86.1%)     | 157 (89.7%) |
| Number of prior systemic therapy lines                                                |               |                |             |
| 1                                                                                     | 45 (33.1%)    | 33 (25.4%)     | 78 (29.3%)  |
| 2                                                                                     | 90 (66.2%)    | 97 (74.6%)     | 187 (70.3%) |
| 3                                                                                     | 1 (0.7%)      | 0              | 1 (0.4%)    |
| Creatinine Clearance                                                                  |               |                |             |
| N                                                                                     | 136           | 130            | 266         |
| < 30 mL/min                                                                           | 2 (1.5%)      | 1 (0.8%)       | 3 (1.1%)    |
| 30 - <60 mL/min                                                                       | 57 (41.9%)    | 73 (56.2%)     | 130 (48.9%) |
| >= 60 mL/min                                                                          | 77 (56.6%)    | 56 (43.1%)     | 133 (50.0%) |
| Haemoglobin                                                                           |               |                |             |
| N                                                                                     | 136           | 130            | 266         |
| < 10 g/dL                                                                             | 24 (17.6%)    | 20 (15.4%)     | 44 (16.5%)  |
| >= 10 g/dL                                                                            | 112 (82.4%)   | 110 (84.6%)    | 222 (83.5%) |

ECOG = Eastern Cooperative Oncology Group.

Percentages are based on the number of subjects in a specified group with non-missing values for the relevant parameter.

Time from date of initial diagnosis to randomisation (months)=(randomisation date - date of initial diagnosis)/30.4375.

Time from progression/relapse on the last line of prior therapy to randomisation (months)=(randomisation date - date of progression/relapse on the last line of prior therapy)/30.4375.

a Number and percentages for lung, liver, and bone are based on subjects marked with 'Yes' in the eCRF question 'Are there currently any metastatic disease sites involving liver, lung, and/or bone?'

<div style=\"page-break-after: always\"></div>

Table 43: Summary of prior anti-cancer therapy by line of therapy (ITT)

|                                                                            | Erdafitinib   | Chemotherapy   | Total       |
|----------------------------------------------------------------------------|---------------|----------------|-------------|
| Analysis Set: ITT                                                          | 136           | 130            | 266         |
| One line of prior systemic therapy                                         | 45 (33.1%)    | 33 (25.4%)     | 78 (29.3%)  |
| Chemotherapy+Anti-PDL1                                                     | 32 (23.5%)    | 14 (10.8%)     | 46 (17.3%)  |
| Anti-PDL1                                                                  | 9 (6.6%)      | 13 (10.0%)     | 22 (8.3%)   |
| Anti-PDL1+Other                                                            | 2 (1.5%)      | 3 (2.3%)       | 5 (1.9%)    |
| Chemotherapy                                                               | 1 (0.7%)      | 2 (1.5%)       | 3 (1.1%)    |
| Chemotherapy+Anti-PDL1+Other                                               | 1 (0.7%)      | 1 (0.8%)       | 2 (0.8%)    |
| Two lines of prior systemic therapy                                        | 90 (66.2%)    | 97 (74.6%)     | 187 (70.3%) |
| Chemotherapy; Anti-PDL1                                                    | 75 (55.1%)    | 74 (56.9%)     | 149 (56.0%) |
| Chemotherapy+Anti-PDL1;                                                    |               |                |             |
| Chemotherapy                                                               | 5 (3.7%)      | 6 (4.6%)       | 11 (4.1%)   |
| Anti-PDL1; Chemotherapy                                                    | 4 (2.9%)      | 5 (3.8%)       | 9 (3.4%)    |
| Anti-PDL1+Other; Chemotherapy                                              | 1 (0.7%)      | 3 (2.3%)       | 4 (1.5%)    |
| Chemotherapy; Chemotherapy+Anti- PDL1                                      | 2 (1.5%)      | 1 (0.8%)       | 3 (1.1%)    |
| Chemotherapy+Anti-PDL1; ADC                                                | 0             | 2 (1.5%)       | 2 (0.8%)    |
| Anti-PDL1; Other                                                           | 2 (1.5%)      | 0              | 2 (0.8%)    |
| Other; Anti-PDL1                                                           | 0             | 2 (1.5%)       | 2 (0.8%)    |
| Chemotherapy+Anti-PDL1;                                                    |               |                |             |
| Chemotherapy+Anti-PDL1                                                     | 0             | 1 (0.8%)       | 1 (0.4%)    |
| Chemotherapy+Anti-PDL1;                                                    |               |                |             |
| Chemotherapy+Other                                                         | 0             | 1 (0.8%)       | 1 (0.4%)    |
| Chemotherapy+Anti-PDL1; Anti-PDL1                                          | 1 (0.7%)      | 0              | 1 (0.4%)    |
| Chemotherapy; Anti-PDL1+Other                                              | 0             | 1 (0.8%)       | 1 (0.4%)    |
| Anti-PDL1; Chemotherapy+Anti- PDL1+Other                                   | 0             | 1 (0.8%)       | 1 (0.4%)    |
| Two lines of prior systemic therapy (categorised by first and second line) |               |                |             |
| First line of therapy                                                      |               |                |             |
| Chemotherapy                                                               | 77 (56.6%)    | 76 (58.5%)     | 153 (57.5%) |
| Chemotherapy+Anti-PDL1                                                     | 6 (4.4%)      | 10 (7.7%)      | 16 (6.0%)   |
| Anti-PDL1                                                                  | 6 (4.4%)      | 6 (4.6%)       | 12 (4.5%)   |
| Anti-PDL1+Other                                                            | 1 (0.7%)      | 3 (2.3%)       | 4 (1.5%)    |
| Other                                                                      | 0             | 2 (1.5%)       | 2 (0.8%)    |
| Second line of therapy                                                     |               |                |             |
| Anti-PDL1                                                                  | 76 (55.9%)    | 76 (58.5%)     | 152 (57.1%) |
| Chemotherapy                                                               | 10 (7.4%)     | 14 (10.8%)     | 24 (9.0%)   |
| Chemotherapy+Anti-PDL1                                                     | 2 (1.5%)      | 2 (1.5%)       | 4 (1.5%)    |
| ADC                                                                        | 0             | 2 (1.5%)       | 2 (0.8%)    |
| Other                                                                      | 2 (1.5%)      | 0              | 2 (0.8%)    |
| Chemotherapy+Anti-PDL1+Other                                               | 0             | 1 (0.8%)       | 1 (0.4%)    |
| Chemotherapy+Other                                                         | 0             | 1 (0.8%)       | 1 (0.4%)    |
| Anti-PDL1+Other                                                            | 0             | 1 (0.8%)       | 1 (0.4%)    |

Percentages are based on the number of subjects in analysis set of the corresponding treatment group.

<div style=\"page-break-after: always\"></div>

Table 44: Summary of prior anti-cancer therapy

|                                   | Erdafitinib   | Chemotherapy   | Total       |
|-----------------------------------|---------------|----------------|-------------|
| Analysis Set: ITT                 | 136           | 130            | 266         |
| Radiation therapy                 | 39 (28.7%)    | 44 (33.8%)     | 83 (31.2%)  |
| Prior urinary surgery             | 122 (89.7%)   | 116 (89.2%)    | 238 (89.5%) |
| Chemotherapy                      | 123 (90.4%)   | 114 (87.7%)    | 237 (89.1%) |
| Any Platinum-based therapy        | 122 (89.7%)   | 111 (85.4%)    | 233 (87.6%) |
| Cisplatin                         | 76 (55.9%)    | 59 (45.4%)     | 135 (50.8%) |
| Gem-cisplatin                     | 69 (50.7%)    | 55 (42.3%)     | 124 (46.6%) |
| Carboplatin                       | 37 (27.2%)    | 41 (31.5%)     | 78 (29.3%)  |
| Gem-carboplatin                   | 36 (26.5%)    | 40 (30.8%)     | 76 (28.6%)  |
| Multiple platinum-based therapy   | 8 (5.9%)      | 10 (7.7%)      | 18 (6.8%)   |
| No platinum based therapy         | 1 (0.7%)      | 3 (2.3%)       | 4 (1.5%)    |
| Antibody drug conjugate           | 0             | 2 (1.5%)       | 2 (0.8%)    |
| Enfortumab Vedotin                | 0 (0.0%)      | 2 (1.5%)       | 2 (0.8%)    |
| Anti-PD-(L)1 therapy              | 135 (99.3%)   | 128 (98.5%)    | 263 (98.9%) |
| Prior systemic therapy indication |               |                |             |
| Metastatic Urothelial Cancer      | 128 (94.1%)   | 122 (93.8%)    | 250 (94.0%) |
| Adjuvant                          | 17 (12.5%)    | 15 (11.5%)     | 32 (12.0%)  |
| Neoadjuvant                       | 11 (8.1%)     | 14 (10.8%)     | 25 (9.4%)   |

Percentages are based on the number of subjects in analysis set of the corresponding treatment group.

Table 45: Summary of subsequent anti-cancer therapy

|                                                | Erdafitinib   | Chemotherapy   | Total      |
|------------------------------------------------|---------------|----------------|------------|
| Analysis Set: ITT                              | 136           | 130            | 266        |
| Number of subjects with any subsequent therapy | 44 (32.4%)    | 48 (36.9%)     | 92 (34.6%) |
| Number of subsequent systemic therapy lines    |               |                |            |
| 1                                              | 33 (24.3%)    | 40 (30.8%)     | 73 (27.4%) |
| 2                                              | 9 (6.6%)      | 8 (6.2%)       | 17 (6.4%)  |
| 3                                              | 0             | 0              | 0          |
| >3                                             | 2 (1.5%)      | 0              | 2 (0.8%)   |
| Chemotherapy                                   | 21 (15.4%)    | 21 (16.2%)     | 42 (15.8%) |
| Immunotherapy                                  | 9 (6.6%)      | 9 (6.9%)       | 18 (6.8%)  |
| FGFR inhibitors                                | 3 (2.2%)      | 10 (7.7%)      | 13 (4.9%)  |
| Antibody drug conjugate                        | 22 (16.2%)    | 14 (10.8%)     | 36 (13.5%) |
| Other systemic therapy                         | 2 (1.5%)      | 1 (0.8%)       | 3 (1.1%)   |
| Investigational systemic therapy               | 0             | 3 (2.3%)       | 3 (1.1%)   |

Modified from Source: Table 7, 'summary of clinical efficacy'

<div style=\"page-break-after: always\"></div>

Table 46: Summary of FGFR genetic alterations

|                                    | Erdafitinib   | Chemotherapy   | Total       |
|------------------------------------|---------------|----------------|-------------|
| Analysis Set: ITT                  | 136           | 130            | 266         |
| Subjects with any FGFR alterations | 135 (99.3%)   | 129 (99.2%)    | 264 (99.2%) |
| Mutations (excluding fusions)      | 108 (79.4%)   | 107 (82.3%)    | 215 (80.8%) |
| Fusions (excluding mutations)      | 25 (18.4%)    | 19 (14.6%)     | 44 (16.5%)  |
| Mutations and fusions              | 2 (1.5%)      | 3 (2.3%)       | 5 (1.9%)    |

Percentages are based on the number of subjects in analysis set of the corresponding treatment group.

FGFR genetic alterations from local laboratory are used if no central laboratory data available.

| Gene (Exon) CDS point mutation Amino acid variant                                                                                    | pathophysiological impact of alteration                                                                                              | number of subjects BLC3001 (n = 266)*                                                                                                |
|--------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| FGFR3 (7) c.746C>G p. S249C                                                                                                          | Ligand - independent constitutive phosphorylation and proliferation                                                                  | 124 (46.6%)                                                                                                                          |
| FGFR3 (7) c.1118A>G p. Y373C                                                                                                         | Ligand- independent dimerisation and proliferation                                                                                   | 45 (16.9%)                                                                                                                           |
| FGFR3 (10) c.742C>T p. R248C                                                                                                         | Ligand- independent proliferation                                                                                                    | 25 (9.4%)                                                                                                                            |
| FGFR3 (10) c.1108G>T p. G370C                                                                                                        | Constitutive activation of FGFR3                                                                                                     | 13 (4.9%)                                                                                                                            |
| Fusion - ID (Exons) Genomic breakpoints                                                                                              | Fusion - ID (Exons) Genomic breakpoints                                                                                              | Fusion - ID (Exons) Genomic breakpoints                                                                                              |
| FGFR3-TACC3v1 (17,11) chr4: 1:1808661 C; G chr4: 1741428                                                                             | Promotes dimerisation, anchorage - independent proliferation                                                                         | 26 (9.8%)                                                                                                                            |
| FGFR3-TACC3                                                                                                                          |                                                                                                                                      | 11 (4.1%)                                                                                                                            |
| FGFR3-TACC3v3 (17, 10) chr4: 1:1808661 C, G chr4: 1739324                                                                            | Promotes dimerisation, anchorage - independent proliferation                                                                         | 4 (1.5%)                                                                                                                             |
| FGFR3-BAIAP2L1 + (17, 2) chr4: 1:1808661 C A chr7: 97991744                                                                          | Ligand - independent receptor activation                                                                                             | 1 (0.4%)                                                                                                                             |
| FGFR2-BICC1 + chr10: 123243211 G; A chr10: 60461834                                                                                  | Anchorage - independent cell - growth                                                                                                | -                                                                                                                                    |
| FGFR2-CASP7 + chr10:123243211G A chr10:115457252                                                                                     | Anchorage - independent cell - growth                                                                                                | -                                                                                                                                    |
| + therascreen FGFR Kit is clinically not validated to detect these fusions * subjects with more than one alteration not shown (n=17) | + therascreen FGFR Kit is clinically not validated to detect these fusions * subjects with more than one alteration not shown (n=17) | + therascreen FGFR Kit is clinically not validated to detect these fusions * subjects with more than one alteration not shown (n=17) |

For further details on biomarker and companion diagnostics (CDx) please refer to section 3.6 'In vitro biomarker test for patient selection for efficacy'.

<div style=\"page-break-after: always\"></div>

##  Numbers analysed

Table 47: Number of subjects in each analysis set

|                                                                                             |   Erdafitinib |   Chemotherapy |   Total |
|---------------------------------------------------------------------------------------------|---------------|----------------|---------|
| Intention-to-treat population (ITT) (i.e. all randomised subjects)                          |           136 |            130 |     266 |
| Safety population (i.e. all randomised subjects who received at least 1 dose of study drug) |           135 |            112 |     247 |

Source: Table 8, CSR BLC3001 cohort 1

##  Outcomes and estimation

## Primary endpoint (OS)

Table 48: Summary of Overall Survival - unstratified analysis (ITT)

|                                   | Erdafitinib              | Chemotherapy         |
|-----------------------------------|--------------------------|----------------------|
| Analysis set: ITT                 | 136                      | 130                  |
| Overall survival a                |                          |                      |
| Number of events (%)              | 77 (56.6%)               | 78 (60.0%)           |
| Number censored (%)               | 59 (43.4%)               | 52 (40.0%)           |
| Kaplan-Meier estimates (months)   |                          |                      |
| 25% Percentile (95% CI)           | 8.02 (6.14, 9.40)        | 3.25 (2.30, 5.22)    |
| Median (95% CI)                   | 12.06 (10.28, 16.36)     | 7.79 (6.54, 11.07)   |
| 75% Percentile (95% CI)           | 24.48 (18.23, NE)        | 19.61 (13.17, 26.51) |
| Min, Max                          | (0.2+, 49.7+)            | (0.0+, 38.7+)        |
| 6-month Survival rate (95% CI)    | 0.85 (0.77, 0.90)        | 0.66 (0.56, 0.74)    |
| 9-month Survival rate (95% CI)    | 0.68 (0.59, 0.76)        | 0.47 (0.37, 0.56)    |
| 12-month Survival rate (95% CI)   | 0.51 (0.41, 0.60)        | 0.38 (0.28, 0.47)    |
| 24-month Survival rate (95% CI)   | 0.26 (0.17, 0.36)        | 0.20 (0.11, 0.31)    |
| Hazard ratio (95% CI)  P-value  | 0.64 (0.47, 0.88) 0.0050 |                      |

Key: CI = confidence interval; NE = not estimable.

a Overall survival (OS) in months is calculated as (date of death - date of randomisation+1)/30.4375. If  the  subject is alive or the vital status is unknown (for example, lost to follow-up or withdrew consent etc.), OS is censored at the date the subject was last known to be alive. Subjects lacking data beyond randomisation have their OS censored at the date of randomisation.

b Hazard ratio and 95% CI are estimated using a Cox proportional hazards regression model with treatment as the only explanatory variable. A hazard ratio less than 1 indicates longer survival time in the erdafitinib arm as compared to the chemotherapy (vinflunine or docetaxel) arm.

c P-value is 2-sided and is based on a log-rank test.

+   indicates censored observation.

<div style=\"page-break-after: always\"></div>

Figure 26: Kaplan-Meier Plot of Overall Survival - unstratified analysis (ITT)

<!-- image -->

Source: Figure 3, CSR BLC3001 cohort 1

## Key secondary endpoints (PFS, ORR, TUSD-3)

## Progression Free Survival (PFS)

Table 49: Summary of Progression Free Survival - unstratified analysis (ITT)

| Analysis set: ITT                         | Erdafitinib 136     | Chemotherapy 130   |
|-------------------------------------------|---------------------|--------------------|
| Progression-free survival a               |                     |                    |
| Number of events (%)                      | 101 (74.3%)         | 90 (69.2%)         |
| Number censored (%)                       | 35 (25.7%)          | 40 (30.8%)         |
| Withdrawal by subject                     | 1 (0.7%)            | 11 (8.5%)          |
| Start Subsequent Anti-cancer              | 2 (1.5%)            | 14 (10.8%)         |
| Therapy No progression until data cut-off | 32 (23.5%)          | 15 (11.5%)         |
| Kaplan-Meier estimates (months)           |                     |                    |
| 25% Percentile (95% CI)                   | 3.09 (2.69, 4.14)   | 1.35 (1.25, 1.51)  |
| Median (95% CI)                           | 5.55 (4.40, 5.65)   | 2.73(1.81, 3.68)   |
| 75% Percentile (95% CI)                   | 10.71 (7.03, 11.30) | 6.74 (4.50, 8.11)  |
| Min, Max                                  | (0.0+, 35.4)        | (0.0+, 26.3+)      |
| 6-month Survival rate (95% CI)            | 0.37 (0.28, 0.46)   | 0.27 (0.19, 0.37)  |
| 9-month Survival rate (95% CI)            | 0.25 (0.18, 0.34)   | 0.12 (0.06, 0.20)  |
| 12-month Survival rate (95% CI)           | 0.17 (0.10, 0.25)   | 0.08(0.03, 0.15)   |
| 24-month Survival rate (95% CI)           | 0.05 (0.01, 0.12)   | 0.04 (0.00, 0.13)  |

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure 27: Kaplan-Meier Plot Progression Free Survival (ITT)

<!-- image -->

To evaluate the impact of the asymmetry in the number of subjects randomised to chemotherapy vs erdafitinib who did not receive treatment, a post-hoc sensitivity analysis using the safety population was performed showing consistent results (PFS: HR=0.60; 95% CI: 0.45, 0.81).

<div style=\"page-break-after: always\"></div>

## Objective response rate (ORR)

Table 50: Summary of best objective response - stratified analysis (IWRS defined stratification factors) (ITT)

|                                   | Erdafitinib       | Chemotherapy   |
|-----------------------------------|-------------------|----------------|
| Analysis set: ITT                 | 136               | 130            |
| Best overall response             |                   |                |
| Complete response (CR)            | 9 (6.6%)          | 1 (0.8%)       |
| Partial response (PR)             | 53(39.0%)         | 14 (10.8%)     |
| Stable disease (SD) a             | 50 (36.8%)        | 41 (31.5%)     |
| Progressive disease (PD)          | 14 (10.3%)        | 31 (23.8%)     |
| Not evaluable (NE)                | 10 (7.4%)         | 43(33.1%)      |
| Objective response rate (CR + PR) | 62 (45.6%)        | 15 (11.5%)     |
| Relative risk (95% CI) b          | 3.94 (2.37, 6.57) |                |
| P-value b                         | <.001             |                |

Key: CI = confidence interval; NE = not estimable.

a Minimum duration requirement for SD is 6 weeks from the date of randomisation. Stable disease includes subjects with no measurable disease at baseline and their best response was Non-CR/Non-PD.

b Relative risk, 95% CI and p-value are estimated using Cochran-Mantel-Haenszel (CMH) test with ECOG performance status (0 or 1 vs 2) as a stratification factor.

All p-values are 2-sided.

ORR: Relative risk greater than 1 indicates that the probability of achieving an objective response (PR or CR) is higher on the Erdafitinib arm compared to the chemotherapy arm.

As of the clinical cut-off, of 9 subjects in the erdafitinib group with a best overall response of CR, 7 subjects were ongoing in study follow-up (4 of these subjects discontinued study treatment due to progression of disease), and 2 subjects died. One subject in the chemotherapy group with a best overall response of CR was ongoing in the study.

The confirmed ORR by investigator assessment was 35.3% for the erdafitinib treatment group and 8.5% for the chemotherapy treatment group (observed relative risk of 4.16 [95% CI: 2.27, 7.64]).

The median duration of response (DoR) determined by the investigator was 4.86 (95% CI: 3.84, 7.46) months for the erdafitinib treatment group and 5.55 (95% CI: 2.14, 6.01) months for the chemotherapy treatment group. Consistently, the median duration of confirmed response determined by the investigator was 5.55 (95% CI: 4.17, 8.31) months for the erdafitinib treatment group and 5.75 (95% CI: 4.86, 7.16) months for the chemotherapy treatment group.

## Ancillary analyses

## Sensitivity analyses (OS)

To evaluate the impact of the asymmetry in the number of subjects randomised to chemotherapy vs erdafitinib who did not receive treatment, a post-hoc sensitivity analysis using the safety population was performed showing results consistent with the ITT analysis (OS: HR=0.68; 95% CI: 0.49, 0.94).

Results of the OS analyses in which the best 20% OS distribution was used to impute the survival times  of the 10 subjects censored due to dropout in the chemotherapy arm are provided below:

<div style=\"page-break-after: always\"></div>

Table 51: Analysis of Multiple Imputation for 10 Droopouts from Best 20% of OS

| ImputationPool                        | #ofDropouts Imputed                   | %of Best OS                           | HR (95% CI)                           | 2-sidedP-value                        |
|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
| Acrossarms                            | 10                                    | 20%                                   | 0.712 (0.519,0.977)                   | 0.0355                                |
| Chemo arm                             | 10                                    | 20%                                   | 0.706(0.514,0.969)                    | 0.0310                                |
| KMinimputation andCoxmodelin analysis | KMinimputation andCoxmodelin analysis | KMinimputation andCoxmodelin analysis | KMinimputation andCoxmodelin analysis | KMinimputation andCoxmodelin analysis |

In the OS tipping point analysis for these 10 censored patients, with the observed OS hazard rate in the erdafitinib arm fixed, at least 95% reduction in the hazard rate for the 10 subjects, randomised but not treated, in the chemotherapy arm was needed to obtain a null result i.e., the corresponding 2sided p-value from less than 0.05 to 0.05 or above.

<div style=\"page-break-after: always\"></div>

## Subgroup analyses (OS)

Figure 28: Forest Plot of Overall Survival - Subgroup Analysis (ITT)

|                                | HazardRatioand95%Cl                 | Erdafitinib EVT/NMedian   | Erdafitinib EVT/NMedian   | Chemotherapy EVT/N Median   | Chemotherapy EVT/N Median   | Hazard Ratio (95% CI)   |
|--------------------------------|-------------------------------------|---------------------------|---------------------------|-----------------------------|-----------------------------|-------------------------|
| Overall                        |                                    | 77/136                    | 12.1                      | 78/130                      | 7.8                         | 0.64 (0.47,0.88)        |
| Lines of prior therapy         |                                     |                           |                           |                             |                             |                         |
| One line                       |                                     | 27/45                     | 14.0                      | 21/33                       | 7.8                         | 0.61 (0.35,1.09)        |
| Two lines                      | T                                   | 49/90                     | 11.6                      | 57/97                       | 7.7                         | 0.67 (0.45, 0.98)       |
| Prior anti-cancer therapy      |                                     |                           |                           |                             |                             |                         |
| Platinum-based chemotherapy*   |                                     | 70/122                    | 11.6                      | 64/111                      | 7.7                         | 0.67 (0.48, 0.94)       |
| Cisplatin-based chemotherapy   | T                                   | 44/76                     | 10.8                      | 33/59                       | 8.8                         | 0.74 (0.47, 1.16)       |
| Carboplatin-based chemotherapy |                                     | 20/37                     | 14.7                      | 24/41                       | 7.5                         | 0.64 (0.35, 1.16)       |
| No platinum-based chemotherapy |                                     | 7/14                      | 20.5                      | 14/19                       | 8.7                         | 0.43 (0.17, 1.06)       |
| Anti-PD-L1 Therapy             |                                     |                           |                           |                             |                             |                         |
| First line                     |                                     | 35/57                     | 14.3                      | 29/50                       | 8.7                         | 0.61 (0.37,1.01)        |
| Second line                    | H                                   | 42/78                     | 10.8                      | 49/80                       | 7.7                         | 0.71 (0.47, 1.07)       |
| Treatment                      |                                     |                           |                           |                             |                             |                         |
| ErdafitinibvsDocetaxel         |                                     | 77/136                    | 12.1                      | 44/82                       | 8.7                         | 0.72 (0.49,1.04)        |
| ErdafitinibvsVinflunine        | T                                  | 77/136                    | 12.1                      | 34/48                       | 7.6                         | 0.54 (0.36, 0.81)       |
| Age group                      |                                     |                           |                           |                             |                             |                         |
| <65 years                      |                                     | 36/59                     | 14.0                      | 25/45                       | 8.7                         | 0.46 (0.27, 0.79)       |
| >=65years                      | T                                   | 41/77                     | 10.9                      | 53/85                       | 7.6                         | 0.71 (0.47, 1.07)       |
| Gender                         |                                     |                           |                           |                             |                             |                         |
| Female                         |                                     | 24/40                     | 10.6                      | 24/36                       | 7.3                         | 0.71 (0.40, 1.26)       |
| Male                           |                                     | 53/96                     | 14.0                      | 54/94                       | 8.7                         | 0.61 (0.41,0.89)        |
| Race                           |                                     |                           |                           |                             |                             |                         |
| Asian                          |                                     | 15/37                     | 23.3                      | 18/40                       | 11.3                        | 0.53 (0.27,1.06)        |
| White                          | TH                                  | 55/81                     | 10.3                      | 42/63                       | 7.6                         | 0.83 (0.55,1.24)        |
| Other                          |                                     | 7/18                      | 29.1                      | 18/27                       | 7.5                         | 0.29 (0.11, 0.73)       |
| Ethnicity                      |                                     |                           |                           |                             |                             |                         |
| Hispanic or Latino             | 0.01 0.1 1 10 FavorErda Favor Chemo | 1/2                       | NE                        | 2/4                         | 12.8                        | 1.22 (0.08,19.86)       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                | Hazard Ratio and 95% Cl   | Erdafitinib EVT/N Median   | Erdafitinib EVT/N Median   | Chemotherapy EVT/NMedian   | Chemotherapy EVT/NMedian   | Hazard Ratio (95% CI)   |
|--------------------------------|---------------------------|----------------------------|----------------------------|----------------------------|----------------------------|-------------------------|
| Not Hispanic or Latino         |                           | 68/114                     | 11.6                       | 58/96                      | 7.6                        | 0.70 (0.49,0.99)        |
| Not Reported                   |                           | 8/20                       | 29.1                       | 18/30                      | 7.7                        | 0.32 (0.13, 0.78)       |
| FGFR alteration type           |                           |                            |                            |                            |                            |                         |
| Translocation                  |                           | 13/25                      | 16.4                       | 15/19                      | 8.0                        | 0.49 (0.23,1.03)        |
| Mutation                       |                           | 63/108                     | 10.9                       | 60/107                     | 7.7                        | 0.67 (0.47,0.95)        |
| PD-L1 status                   |                           |                            |                            |                            |                            |                         |
| CPS >= 1                       |                           | 22/38                      | 10.9                       | 25/38                      | 10.3                       | 0.78 (0.44,1.38)        |
| CPS<1                          |                           | 36/58                      | 14.0                       | 23/41                      | 9.6                        | 0.63 (0.37,1.08)        |
| PD-L1 status                   |                           |                            |                            |                            |                            |                         |
| CPS >=10                       |                           | 5/7                        | 10.2                       | 8/11                       | 19.6                       | 1.98 (0.57,6.91)        |
| CPS<10                         |                           | 53/89                      | 12.1                       | 40/68                      | 8.8                        | 0.58 (0.38, 0.89)       |
| Region                         |                           |                            |                            |                            |                            |                         |
| North America                  |                           | 5/8                        | 10.3                       | 4/5                        | 7.1                        | 1.00 (0.23,4.36)        |
| Europe                         |                           | 50/82                      | 10.9                       | 51/80                      | 7.6                        | 0.70 (0.47,1.04)        |
| Rest of the World              |                           | 22/46                      | 19.4                       | 23/45                      | 11.3                       | 0.48 (0.26, 0.88)       |
| Baseline ECOG performance stat |                           |                            |                            |                            |                            |                         |
| 0-1                            |                           | 70/125                     | 12.2                       | 71/119                     | 8.7                        | 0.65 (0.46, 0.90)       |
| 2                              |                           | 7/11                       | 6.1                        | 7/11                       | 2.8                        | 0.47 (0.16,1.35)        |
| BaselineHemoglobinLevel        |                           |                            |                            |                            |                            |                         |
| <10 g/dL                       |                           | 17/24                      | 8.3                        | 17/20                      | 4.4                        | 0.54 (0.28, 1.07)       |
| >=10 g/dL                      |                           | 60/112                     | 14.6                       | 61/110                     | 10.3                       | 0.66 (0.46, 0.94)       |
| Baseline Creatinine Clearance  |                           |                            |                            |                            |                            |                         |
| 30 -<60 mL/min                 |                           | 30/57                      | 11.6                       | 47/73                      | 7.3                        | 0.55 (0.34,0.87)        |
| >=60 mL/min                    |                           | 46/77                      | 13.2                       | 31/56                      | 9.6                        | 0.73 (0.46,1.15)        |
| Visceral metastases            |                           |                            |                            |                            |                            |                         |
| Presence                       |                           | 59/103                     | 12.2                       | 57/101                     | 7.7                        | 0.65 (0.45,0.93)        |
| Absence                        |                           | 18/33                      | 10.6                       | 21/29                      | 8.8                        | 0.61 (0.32,1.14)        |
| Bone Metastasis                |                           |                            |                            |                            |                            |                         |
| Yes                            |                           | 25/36                      | 10.3                       | 28/39                      | 6.3                        | 0.57 (0.33,0.99)        |
| No                             |                           | 52/100                     | 14.7                       | 50/91                      | 10.3                       | 0.68 (0.46,1.00)        |
| Liver Metastasis               |                           |                            |                            |                            |                            |                         |
| Yes                            |                           | 24/31                      | 8.5                        | 26/38                      | 6.5                        | 0.76 (0.43,1.32)        |
| No                             |                           | 53/105                     | 15.7                       | 52/92                      | 10.6                       | 0.60 (0.41,0.89)        |
| Lung Metastasis                |                           |                            |                            |                            |                            |                         |
| Yes                            |                           | 38/71                      | 14.7                       | 39/67                      | 7.5                        | 0.59 (0.37,0.92)        |
| No                             |                           | 39/65                      | 10.6                       | 39/63                      | 9.6                        | 0.73 (0.47, 1.13)       |
| PrimaryTumorLocation           |                           |                            |                            |                            |                            |                         |
| Upper tract                    |                           | 16/41                      | 23.3                       | 27/48                      | 7.2                        | 0.34 (0.18, 0.64)       |
| Lower tract                    |                           | 61/95                      | 10.5                       | 51/82                      | 9.6                        | 0.82 (0.56, 1.18)       |
|                                | Favor Erda Favor Chemo    |                            |                            |                            |                            |                         |

* Include cisplatin, carboplatin, and multiple platinum-based chemotherapy.

## Summary of main efficacy results

The following table summarises the efficacy results from the main study supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

Table 52: Summary of efficacy for the single pivotal study BLC3001 (Cohort 1)

| Title: A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (Cohort 1).   | Title: A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (Cohort 1).                                                                                                                                    | Title: A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (Cohort 1).                                                                                                                                    | Title: A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (Cohort 1).                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                          | Study Number: 42756493BLC3001 EudraCT Number: 2017-002932-18 ClinicalTrials.gov Identifier: NCT03390504                                                                                                                                                                                                                    | Study Number: 42756493BLC3001 EudraCT Number: 2017-002932-18 ClinicalTrials.gov Identifier: NCT03390504                                                                                                                                                                                                                    | Study Number: 42756493BLC3001 EudraCT Number: 2017-002932-18 ClinicalTrials.gov Identifier: NCT03390504                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Design                                                                                                                                                                                    | A randomised, controlled, open-label Phase 3 study.                                                                                                                                                                                                                                                                        | A randomised, controlled, open-label Phase 3 study.                                                                                                                                                                                                                                                                        | A randomised, controlled, open-label Phase 3 study.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                                                                                                                                                                                           | Duration of main phase:                                                                                                                                                                                                                                                                                                    | Duration of main phase:                                                                                                                                                                                                                                                                                                    | 6 August 2018 (first subject in Cohort 1 signed informed consent) to 15 January 2023 (clinical cut-off for analysis of Cohort 1). The Treatment Phase extended from administration of first dose until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment or study completion (ie, end of data collection time-point).                                                                                                                                                                                                                    |
|                                                                                                                                                                                           | Duration of Run-in phase:                                                                                                                                                                                                                                                                                                  | Duration of Run-in phase:                                                                                                                                                                                                                                                                                                  | n/a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                                                                                                                                                                                           | Duration of Extension phase:                                                                                                                                                                                                                                                                                               | Duration of Extension phase:                                                                                                                                                                                                                                                                                               | The post-treatment follow-up Phase extended from the End-of-Treatment Visit until the subject died, withdrew consent, was lost to follow-up, or the end of study data collection time-point, whichever came first. Extension phase is still ongoing.                                                                                                                                                                                                                                                                                                                                                             |
| Hypothesis                                                                                                                                                                                | Erdafitinib treatment prolongs overall survival (OS) in subjects with advanced urothelial cancer harbouring selected FGFR aberrations following 1 or 2 prior line(s) of systemic therapy, with at least 1 line containing anti-PD-(L)1, compared with the OS of those treated with chemotherapy (docetaxel or vinflunine). | Erdafitinib treatment prolongs overall survival (OS) in subjects with advanced urothelial cancer harbouring selected FGFR aberrations following 1 or 2 prior line(s) of systemic therapy, with at least 1 line containing anti-PD-(L)1, compared with the OS of those treated with chemotherapy (docetaxel or vinflunine). | Erdafitinib treatment prolongs overall survival (OS) in subjects with advanced urothelial cancer harbouring selected FGFR aberrations following 1 or 2 prior line(s) of systemic therapy, with at least 1 line containing anti-PD-(L)1, compared with the OS of those treated with chemotherapy (docetaxel or vinflunine).                                                                                                                                                                                                                                                                                       |
| Treatment groups                                                                                                                                                                          | Erdafitinib                                                                                                                                                                                                                                                                                                                | Erdafitinib                                                                                                                                                                                                                                                                                                                | Erdafitinib was administered orally in a tablet form once daily for 21 days in 21-day cycles. All subjects randomised to erdafitinib received a starting dose of erdafitinib 8 mg once daily from Day 1 to Day 14 of Cycle 1. Subjects with Cycle 1, Day 14, serum phosphate levels less than or equal to 8.99 mg/dL (  2.90 mmol/L) had the option to increase the dose to 9 mg once daily. Subjects with toxicity or consistent hyperphosphataemia had specific dose modification rules where lower doses of erdafitinib were to be considered (ie, 6 mg, 5 mg, or 4 mg once daily). 136 patients randomised. |
|                                                                                                                                                                                           | Chemotherapy                                                                                                                                                                                                                                                                                                               | Chemotherapy                                                                                                                                                                                                                                                                                                               | Vinflunine was administered at a dose of 320 mg/m 2 as a 20-minute intravenous infusion once every 3 weeks. Docetaxel was administered at a dose of 75 mg/m 2 as a 1-hour intravenous infusion every 3 weeks. 130 patients randomised.                                                                                                                                                                                                                                                                                                                                                                           |
| Endpoints and definitions                                                                                                                                                                 | Primary endpoint                                                                                                                                                                                                                                                                                                           | Overall Survival (OS)                                                                                                                                                                                                                                                                                                      | OS was measured from the date of randomisation to the date of the subject's death.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                                                 | Key secondary endpoints                                                                                                                                                                                                           | Progression- Free Survival (PFS)                                                                                                                                                                                                  | PFS was measured as duration in days from the date of randomisation to the date of disease progression (or relapse from complete response [CR]) assessed per RECIST v1.1 by the investigator or death, whichever is reported first.   | PFS was measured as duration in days from the date of randomisation to the date of disease progression (or relapse from complete response [CR]) assessed per RECIST v1.1 by the investigator or death, whichever is reported first.   |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | Key secondary endpoints                                                                                                                                                                                                           | Objective Response Rate (ORR)                                                                                                                                                                                                     | ORR was measured as the proportion of subjects who achieve complete response or partial response, as assessed per RECIST v1.1 by the investigator.                                                                                    | ORR was measured as the proportion of subjects who achieve complete response or partial response, as assessed per RECIST v1.1 by the investigator.                                                                                    |
| Database lock                                   | 2 March 2023                                                                                                                                                                                                                      | 2 March 2023                                                                                                                                                                                                                      | 2 March 2023                                                                                                                                                                                                                          | 2 March 2023                                                                                                                                                                                                                          |
| Results and Analysis                            | Results and Analysis                                                                                                                                                                                                              | Results and Analysis                                                                                                                                                                                                              | Results and Analysis                                                                                                                                                                                                                  | Results and Analysis                                                                                                                                                                                                                  |
| Analysis description                            | Primary endpoint                                                                                                                                                                                                                  | Primary endpoint                                                                                                                                                                                                                  | Primary endpoint                                                                                                                                                                                                                      | Primary endpoint                                                                                                                                                                                                                      |
| Analysis population and time point description  | BLC3001 Cohort 1 ITT Analysis Set (Unstratified Analysis)                                                                                                                                                                         | BLC3001 Cohort 1 ITT Analysis Set (Unstratified Analysis)                                                                                                                                                                         | BLC3001 Cohort 1 ITT Analysis Set (Unstratified Analysis)                                                                                                                                                                             | BLC3001 Cohort 1 ITT Analysis Set (Unstratified Analysis)                                                                                                                                                                             |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                   | Treatment group                                                                                                                                                                                                                   | Erdafitinib                                                                                                                                                                                                                           | Chemotherapy                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                | Number of subjects                                                                                                                                                                                                                | 136                                                                                                                                                                                                                                   | 130                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability | Median OS, months (95% CI)                                                                                                                                                                                                        | Median OS, months (95% CI)                                                                                                                                                                                                        | 12.06 (10.28, 16.36)                                                                                                                                                                                                                  | 7.79 (6.54, 11.07)                                                                                                                                                                                                                    |
| per comparison                                  | Effect estimate                                                                                                                                                                                                                   | Effect estimate                                                                                                                                                                                                                   | Comparison groups                                                                                                                                                                                                                     | Erdafitinib vs Chemotherapy                                                                                                                                                                                                           |
| per comparison                                  |                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                   | Hazard ratio                                                                                                                                                                                                                          | 0.64                                                                                                                                                                                                                                  |
| per comparison                                  |                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                   | 95% CI                                                                                                                                                                                                                                | 0.47, 0.88                                                                                                                                                                                                                            |
| per comparison                                  |                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                               | 0.0050                                                                                                                                                                                                                                |
| Analysis description                            | Key Secondary endpoints                                                                                                                                                                                                           | Key Secondary endpoints                                                                                                                                                                                                           | Key Secondary endpoints                                                                                                                                                                                                               | Key Secondary endpoints                                                                                                                                                                                                               |
| Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                   | Treatment group                                                                                                                                                                                                                   | Erdafitinib                                                                                                                                                                                                                           | Chemotherapy                                                                                                                                                                                                                          |
| Descriptive statistics and estimate variability | Number of subjects                                                                                                                                                                                                                | Number of subjects                                                                                                                                                                                                                | 136                                                                                                                                                                                                                                   | 130                                                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability | Median PFS, months (95% CI)                                                                                                                                                                                                       | Median PFS, months (95% CI)                                                                                                                                                                                                       | 5.55 (4.40, 5.65)                                                                                                                                                                                                                     | 2.73 (1.81, 3.68)                                                                                                                                                                                                                     |
| Effect estimate per comparison                  | PFS                                                                                                                                                                                                                               | PFS                                                                                                                                                                                                                               | Comparison groups                                                                                                                                                                                                                     | Erdafitinib vs Chemotherapy                                                                                                                                                                                                           |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                   | Hazard ratio                                                                                                                                                                                                                          | 0.58                                                                                                                                                                                                                                  |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                   | 95% CI                                                                                                                                                                                                                                | 0.44, 0.78                                                                                                                                                                                                                            |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                               | 0.0002                                                                                                                                                                                                                                |
| Effect estimate per comparison                  | Confirmed ORR                                                                                                                                                                                                                     | Confirmed ORR                                                                                                                                                                                                                     | Relative risk                                                                                                                                                                                                                         | 4.16                                                                                                                                                                                                                                  |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                   | 95% CI                                                                                                                                                                                                                                | 2.27, 7.64                                                                                                                                                                                                                            |
| Effect estimate per comparison                  |                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                   | P-value                                                                                                                                                                                                                               | < 0.001                                                                                                                                                                                                                               |
| Effect estimate per comparison                  | Confirmed ORR (%) 48                                                                                                                                                                                                              | Confirmed ORR (%) 48                                                                                                                                                                                                              | (35.3%)                                                                                                                                                                                                                               | 11 (8.5%)                                                                                                                                                                                                                             |
| Notes                                           | CI = confidence interval; NE = not estimable. OS in months is calculated as (date of death - date of randomisation+1)/30.4375. If the subject is alive or the vital status is unknown (for example, lost to follow-up or withdrew | CI = confidence interval; NE = not estimable. OS in months is calculated as (date of death - date of randomisation+1)/30.4375. If the subject is alive or the vital status is unknown (for example, lost to follow-up or withdrew | CI = confidence interval; NE = not estimable. OS in months is calculated as (date of death - date of randomisation+1)/30.4375. If the subject is alive or the vital status is unknown (for example, lost to follow-up or withdrew     | CI = confidence interval; NE = not estimable. OS in months is calculated as (date of death - date of randomisation+1)/30.4375. If the subject is alive or the vital status is unknown (for example, lost to follow-up or withdrew     |

<div style=\"page-break-after: always\"></div>

## 2.8.5.3. Clinical studies in special populations

Table 53: Summary of efficacy for the single pivotal study BLC3001b (Cohort 1 and 2)

|                       | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   | Age 85+ (Older subjects number /total number)   |
|-----------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| Controlled Trials     | 249/617 (40.4%)                                   | 119/617 (19.3%)                                   | 8/617 (1.3%)                                    |
| Non Controlled trials | 70/172 (40.7%)                                    | 30/172 (17.4%)                                    | 7/172 (4.1%)                                    |

## 2.8.5.4. In vitro biomarker test for patient selection for efficacy

## Scientific rationale for testing of the FGFR alteration status

## Mechanism of action:

Erdafitinib is an orally bioavailable pan-FGFR tyrosine kinase inhibitor.

FGFR genetic alterations, particularly mutations and fusions activate the FGFR receptor-signalling pathway by promoting receptor hyperactivation leading to cell proliferation and metastasis. These genetic alterations activate FGFR signalling through a variety of mechanisms including kinase activation, reduced degradation, and aberrant ligand-independent receptor dimerisation.

## Biomarker definition / definition of biomarker positivity ('FGFR-positive'):

Tumours must have at least one of the following:

- FGFR fusions / translocations: FGFR2-BICC1, FGFR2-CASP7, FGFR3-TACC3, FGFR3-BAIAP2L1 or
- FGFR3 gene mutations: R248C, S249C, G370C, Y373C

## detected by

- central laboratory screening from tissue with 'Qiagen t herascreen FGFR Rotor-Gene Q reverse transcription polymerase chain reaction' ('Qiagen therascreen FGFR RGQ RT-PCR') test, or
- local (historical) test results from tissue or blood in a CLIA-certified or regional equivalent laboratory using 'next-generation sequencing' (NGS), direct digital counting methods, or 'Qiagen therascreen FGFR RGQ RT-PCR'.

## Justification / validation of biomarker definition

As to the information applied, the justification for the definition of biomarker-positivity (i.e. 'FGFRpositive' as specified above) is following a scientific rationale being based on preclinical data and uncontrolled clinical response data. Regarding clinical validation see below.

## Tests used

'Qiagen therascreen FGFR RGQ RT-PCR' was used as central confirmation test from tissue samples.

In addition, diverse local tests from tissue or blood using different analytical methods were used for the inclusion of patients.

For further details, please refer to 'definition of biomarker positivity' above and the discussion of clinical validation below.

## Analytical method including assay platform, specimen, pre-analytical processing requirements and read-out method (central confirmation test)

The therascreen FGFR RGQ RT-PCR Kit is a real time, reverse transcription PCR test for the qualitative detection of 2 point mutations in exon 7 [p.R248C (c.742C&gt;T) and p.S249C (c.746C&gt;G)], 2 point

<div style=\"page-break-after: always\"></div>

mutations in exon 10 [p.G370C (c.1108G&gt;T) and p.Y373C (c.1118A&gt;G)] and 2 fusions [FGFR3TACC3v1 and FGFR3-TACC3v3] in the FGFR3 gene in RNA samples derived from formalin-fixed paraffin embedded (FFPE) urothelial tumour tissue.

Specimens are processed using the RNeasy DSP FFPE Kit for manual sample preparation followed by reverse transcription and then automated amplification and detection on the Rotor Gene Q MDx 5plex high resolution melt analyser (HRM) instrument.

The therascreen FGFR RGQ RT-PCR Kit is also designed to identify FGFR3 fusion, FGFR3-BAIAP2L1 and FGFR2 fusions, FGFR2-BICC1 and FGFR2-CASP7, however, the test is not clinically validated to detect these three fusions due to lack of required clinical samples as the prevalence of these alterations in UC is low.

Allele-specific technology allows accurate and highly reproducible detection of target FGFR alterations, based on the use of specific forward and reverse primer and probe sets; only a perfect match between the primers and probes with the target circular deoxyribonucleic acid (cDNA) allows extension and amplification in the PCR reaction. Result reporting is fully automated. If both the run controls and the sample results are valid and sufficient assay target amplification occurs below the pre-determined cycle number cut-off threshold, the report will display the FGFR alteration(s) detected in each sample.

Pre-clinical tests have been completed by QIAGEN and include limit of blank (LoB), Cut-off setting, limit of detection (LoD) determination, and House Keeping Gene Specifications.

## Analytical validation strategy (central confirmation test)

The therascreen FGFR RGQ RT-PCR kit is CE Marked under the IVD Directive 98/79/EC, for use with the QIAGEN Rotor Gene Q MDx 5plex HRM Instrument (RGQ) for the identification of certain FGFR genetic alterations in patients with UC.

The cycle threshold (CT) is inversely proportional to the amount of target present at the beginning of the reaction, allowing a sensitivity limit to be set for the test. CT values above cut-off can be, when the sample either contain less than the copy number able to be detected by the FGFR Kit (beyond the limit of detection of the Kit), or the sample is negative for an FGFR alteration, both of which are reported as 'No Alteration Detected'. The false-negative and false-positive rates for each assay were used to determine a cut-off value for each FGFR alteration-specific assay, such that a result equal to or less than the cut-off will result in an FGFR Alteration Detected classification.

The RNA quality is checked through the internal control (IC) CT values, which should be within the working range defined in the sample acceptance criteria.

The cut-off for each assay within the therascreen FGFR RGQ RT-PCR Kit is shown in the table below:

Table 54: Summary of assay cut-off results

| FGFR Assay          |   Assay cut-off(CTvalue) |
|---------------------|--------------------------|
| p.R248C (c.742C>T)  |                    36    |
| p.S249C (c.746C>G)  |                    39.09 |
| p.G370C (c.1108G>T) |                    41    |
| p.Y373C (c.1118A>G) |                    43    |
| FGFR3-TACC3v1       |                    43    |
| FGFR3-TACC3v3       |                    43    |
| FGFR3-BAIAP2L1*     |                    43    |
| FGFR2-BICC1*        |                    43    |
| FGFR2-CASP7*        |                    42    |

* FGFR3 fusion FGFR3-BAIAP2L1 and FGFR2 fusions FGFR2-BICC1 and FGFR2-CASP7 have not been validated with the therascreen?FGFR RGQ RT-PCR Kit and clinical specimens.

<div style=\"page-break-after: always\"></div>

Limit of blank (LoB) is defined in Clinical and Laboratories Standard's Institute (CLSI) guideline as 'the highest result that can reasonably be expected from a blank sample (i.e., a sample with concentration at or near 0) for a given error probability '. For the therascreen FGFR RGQ RTPCR Kit, this is the data point that corresponds to the upper 95th percentile in FGFR alteration negative samples. The LoB was determined by measuring the levels of breakthrough for each of the 9 FGFR alteration assays of the therascreen FGFR RGQ RT-PCR Kit, where breakthrough is defined as the nonspecific, low-level amplification of an FGFR alteration-negative RNA sample.

High FGFR alteration level samples were tested with the therascreen FGFR RGQ RT-PCR Kit and no offtarget amplification below the cut-off was observed in any of the assays. Therefore, no crossreactivity was observed between the assays for susceptible FGFR alterations that comprise the therascreen FGFR RGQ RT-PCR Kit.

The limit of detection ( LoD , lowest number of FGFR alteration copies/l that is possible to be detected in 95% of repetitions) was determined by spiking in-vitro transcripts, one for each alteration, into a pool of normalised RNA extracted from wild-type clinical specimens and serially diluted. Sixty replicates of each dilution were tested using three therascreen FGFR RGQ RT-PCR Kit lots. The result was reported as the highest RNA copy number/ l (i.e. worst case) LoD detected across the three kit lots used.

Table 55: Summary of LoD results

| FGFR Assay          |   LoD (copies/l) |
|---------------------|-------------------|
| p.R248C (c.742C>T)  |             75.8  |
| p.S249C (c.746C>G)  |            289.82 |
| p.G370C (c.1108G>T) |            141.57 |
| p.Y373C (c.1118A>G) |            274.71 |
| FGFR3-TACC3v1       |             25.26 |
| FGFR3-TACC3v3       |             45.75 |
| FGFR3-BAIAP2L1*     |              9.07 |
| FGFR2-BICC1*        |             14.34 |
| FGFR2-CASP7*        |             27.18 |

* FGFR3 fusion FGFR3-BAIAP2L1 and FGFR2 fusions FGFR2-BICC1 and FGFR2-CASP7 have not been analytically validated with the therascreen? FGFR RGQ RT-PCR Kit and clinical specimens.

The LoDs of the p.R248C (c.742C&gt;T), p.S249C (c.746C&gt;G), p.G370C (c.1108G&gt;T), p.Y373C (c.1118A&gt;G), FGFR3-TACC3v1, and FGFR3-TACC3v3 assays were verified using FGFR alterationpositive clinical UC samples.

The repeatability (within laboratory) of the therascreen FGFR RGQ RT-PCR Kit was assessed by testing contrived samples at 3x LoD, representing the nine alterations detected by the therascreen FGFR RGQ RT-PCR Kit and an FGFR alteration-negative sample. Repeatability was assessed by testing these samples at one site across multiple days, Rotor Gene Q instruments, and operators to generate a total of 60 replicates per sample.

Assay reproducibility was measured by testing contrived samples at 3x LoD level, clinical samples close to LoD and wild-type samples across the 3 different sites. The contrived samples for all susceptible FGFR alterations at 3 LoD and wild-type samples were tested by 3 operators (per site) over 5 days using three Rotor Gene Q MDx instruments at each external site. In addition, RNA extracted from FFPE UC clinical samples was used to test the device reproducibility.

<div style=\"page-break-after: always\"></div>

Table 56: Assay reproducibility: Number of correct callas and two sided 95% confident limits for each FGFR alteration at 3xLoD and wild-type samples tested across one site.

| Mutation            | Target level   | Specimen type      | No. correct calls result   | Percent correct calls   | Lower two- sided 95% confidence limit   | Upper two-sided 95% confidence limit   |
|---------------------|----------------|--------------------|----------------------------|-------------------------|-----------------------------------------|----------------------------------------|
| p.R248C (c.742C>T)  | 3xLoD 1xLoD    | Contrived Clinical | 120/120 72/72              | 100% 100%               | 96.97% 95.01%                           | 100% 100%                              |
| p.S249C (c.746C>G)  | 3xLoD 1xLoD    | Contrived Clinical | 120/120 72/72              | 100% 100%               | 96.97% 95.01%                           | 100% 100%                              |
| p.G370C (c.1108G>T) | 3xLoD 1xLoD    | Contrived Clinical | 120/120 71/72              | 100% 98.61%             | 96.97% 92.50%                           | 100% 99.96%                            |
| p.Y373C (c.1118A>G) | 3xLoD 1xLoD    | Contrived Clinical | 120/120 71/72              | 100% 98.61%             | 96.97% 92.50%                           | 100% 99.96%                            |
| FGFR3-TACC3v1*      | 1xLoD 1/3LoD  | Contrived Clinical | 119/120 63/72              | 99.17% 87.50%           | 95.44% 77.59%                           | 99.98% 94.12%                          |
| FGFR3-TACC3v3       | 3xLoD 1xLoD    | Contrived Clinical | 119/120 71/72              | 99.17% 87.50%           | 95.44% 92.50                            | 99.98% 99.96%                          |
| FGFR3- BAIAP2L1     | 3xLoD 1xLoD    | Contrived Clinical | 120/120 NA                 | 96.97% NA               | 96.97% NA                               | 100.00% NA                             |
| FGFR2-BICC1         | 3xLoD 1xLoD    | Contrived Clinical | 120/120 NA                 | 96.97% NA               | 96.97% NA                               | 100.00% NA                             |
| FGFR2-CASP7         | 3xLoD 1xLoD    | Contrived Clinical | 120/120 NA                 | 96.97% NA               | 96.97% NA                               | 100.00% NA                             |
| WT (Mut-1)          | NA             | Clinical           | 120/120                    | 100.00%                 | 96.97%                                  | 100%                                   |
| WT (Mut-2)          | NA             | Clinical           | 120/120                    | 100.00%                 | 96.97%                                  | 100%                                   |
| WT (Fus-1)          | NA             | Clinical           | 120/120                    | 100.00%                 | 96.97%                                  | 100%                                   |
| WT (Fus-2)          | NA             | Clinical           | 116/120                    | 96.67%                  | 91.69%                                  | 99.08%                                 |

The false-negative and false-positive rates for each assay were used to determine a cut-off value for each FGFR alteration-specific assay. Performance Characteristics for the therascreen FGFR RGQ RTPCR Kit have been established, including analytical sensitivity, specificity, repeatability, and reproducibility.

## Clinical validation strategy (central confirmation test)

Erdafitinib clinical efficacy against tumours harbouring these susceptible FGFR alterations was evaluated in multiple studies including EDI1001 and BLC2001 prior to BLC3001. Results from BLC3001 study shows erdafitinib activity in most of the alterations enrolled.

A summary of susceptible FGFR alterations with efficacy outcomes for chemo-relapsed/refractory subjects who received the erdafitinib 8 mg daily starting dose in Study BLC2001 is provided in the table below.

Table 57: Susceptible FGFR alteration and efficacy outcomes, chemo-relapsed/refractory subjects (8mg QD), INV assessment (study BLC2001

|                      |            | Overall Response Rate   | Disease Control   |
|----------------------|------------|-------------------------|-------------------|
| Rate                 |            |                         |                   |
| Any FGFR alterations | 87         |                         |                   |
| Mutations            | 64 (73.6%) |                         |                   |
| FGFR3-S249C          | 40 (46.0%) | 18 (45.0%)              | 36 (90.0%)        |
| FGFR3-Y373C          | 11 (12.6%) | 6 (54.5%)               | 8 (72.7%)         |
| FGFR3-R248C          | 9 (10.3%)  | 5 (55.6%)               | 7 (77.8%)         |
| FGFR3-G370C          | 4 (4.6%)   | 2 (50.0%)               | 3 (75.0%)         |

<div style=\"page-break-after: always\"></div>

| Fusions                    | 23 (26.4%)   | 4 (17.4%)   | 15 (65.2%)   |
|----------------------------|--------------|-------------|--------------|
| FGFR3-TACC3_V1             | 10 (11.5%)   | 4 (40.0%)   | 7 (70.0%)    |
| FGFR3-TACC3_V3             | 6 (6.9%)     | 0           | 4 (66.7%)    |
| FGFR2-CASP7                | 3 (3.4%)     | 0           | 2 (66.7%)    |
| FGFR2-BICC1                | 2 (2.3%)     | 0           | 2 (100.0%)   |
| FGFR2-CASP7/FGFR3-TACC3_V3 | 1 (1.1%)     | 0           | 0            |
| FGFR3-BAIAP2L1             | 1 (1.1%)     | 0           | 0            |
| FGFR2-CASP7/FGFR3-BAIAP2L1 | 0            | 0           | 0            |

CR=complete response; PR=partial response, SD=stable disease.

For the pivotal study BLC3001, subjects randomised based on central testing results were molecularly screened using QIAGEN therascreen FGFR RGQ RT-PCR diagnostic assay, except for 4 randomised subjects, who were screened using the FGFR test by Almac labs. Local testing was permitted since protocol Amendment 4 dated 29 March 2020. Sixty-seven (25.4%) of 264 subjects randomised were enrolled based on local results. Tissue samples were collected from subjects enrolled by local tests for central test confirmation.

A summary of FGFR genetic alterations by treatment group for Study BLC3001 is provided in the table below.

Table 58: Summary of FGFR Genetic alterations in the pivotal study BLC3001

| Gene (Exon) CDS point mutation Amino acid variant                                                                                      | pathophysiological impact of alteration                                                                                                | number of subjects BLC3001 (n = 266)*                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| FGFR3 (7) c.746C>G p. S249C                                                                                                            | Ligand - independent constitutive phosphorylation and proliferation                                                                    | 124 (46.6%)                                                                                                                            |
| FGFR3 (7) c.1118A>G p. Y373C                                                                                                           | Ligand- independent dimerisation and proliferation                                                                                     | 45 (16.9%)                                                                                                                             |
| FGFR3 (10) c.742C>T p. R248C                                                                                                           | Ligand- independent proliferation                                                                                                      | 25 (9.4%)                                                                                                                              |
| FGFR3 (10) c.1108G>T p. G370C                                                                                                          | Constitutive activation of FGFR3                                                                                                       | 13 (4.9%)                                                                                                                              |
| Fusion - ID (Exons) Genomic breakpoints                                                                                                | Fusion - ID (Exons) Genomic breakpoints                                                                                                | Fusion - ID (Exons) Genomic breakpoints                                                                                                |
| FGFR3-TACC3v1 (17,11) chr4: 1:1808661 C; G chr4: 1741428                                                                               | Promotes dimerisation, anchorage - independent proliferation                                                                           | 26 (9.8%)                                                                                                                              |
| FGFR3-TACC3                                                                                                                            |                                                                                                                                        | 11 (4.1%)                                                                                                                              |
| FGFR3-TACC3v3 (17, 10) chr4: 1:1808661 C, G chr4: 1739324                                                                              | Promotes dimerisation, anchorage - independent proliferation                                                                           | 4 (1.5%)                                                                                                                               |
| FGFR3-BAIAP2L1 + (17, 2) chr4: 1:1808661 C A chr7: 97991744                                                                            | Ligand - independent receptor activation                                                                                               | 1 (0.4%)                                                                                                                               |
| FGFR2-BICC1 + chr10: 123243211 G; A chr10: 60461834                                                                                    | Anchorage - independent cell - growth                                                                                                  | -                                                                                                                                      |
| FGFR2-CASP7 + chr10:123243211G A chr10:115457252                                                                                       | Anchorage - independent cell - growth                                                                                                  | -                                                                                                                                      |
| + therascreen  FGFR Kit is clinically not validated to detect these fusions * subjects with more than one alteration not shown (n=17) | + therascreen  FGFR Kit is clinically not validated to detect these fusions * subjects with more than one alteration not shown (n=17) | + therascreen  FGFR Kit is clinically not validated to detect these fusions * subjects with more than one alteration not shown (n=17) |

Source:  adapted from appendix 2, table 3, 'biomarker report'

<div style=\"page-break-after: always\"></div>

Among the 67 subjects who were randomised based on local tests, 45 of them had tumour samples available for central test confirmation, while 22 subjects could not be retested centrally due to a lack of available tissue. Of the 45 tumours retested, 34 (75.6%) subjects were retrospectively confirmed by the central test, while only 11 (24.4%) subjects were not confirmed by the central test and were reported as negative.

Table 59: Efficacy of Erdafitinib vs. chemotherapy as assessed by OS and PFS in subjects enrolled by central and local tests

|                          |             | Hazard Ratio (95% CI)   | Hazard Ratio (95% CI)   |
|--------------------------|-------------|-------------------------|-------------------------|
|                          | N           | OS                      | PFS                     |
| Analysis set: ITT        | 266         | 0.64 (0.47-0.88)        | 0.58 (0.44-0.78)        |
| Subgroup                 |             |                         |                         |
| By Central Test          |             |                         |                         |
| Central FGFR + *         | 231 (86.8%) | 0.64 (0.46-0.89)        | 0.59 (0.44-0.81)        |
| Central FGFR Unknown **  | 24 (9.0%)   | 0.49 (0.12-1.99)        | 0.31 (0.10-0.90)        |
| Central FGFR -           | 11 (4.1%)   | 0.63 (0.14-2.87)        | 1.34 (0.42-5.66)        |
| By Enrolment             |             |                         |                         |
| Centrally Enrolled ***   | 199 (74.8%) | 0.69 (0.48-0.98)        | 0.64 (0.46-0.89)        |
| Locally Enrolled         | 67 (25.2%)  | 0.47 (0.24-0.94)        | 0.37 (0.20-0.68)        |
| Centrally Confirmed **** | 34 (50.7%)  | 0.41 (0.16-1.07)        | 0.18 (0.06-0.61)        |

* Include 197 randomised subjects and 34 subjects enrolled by local and confirmed by central testing ** Include 22 enrolled by local with unknown central test result and 2 false positives enrolled by cent al test ***   Include 2 false positives enrolled by central test

**** Percentage is within local enrolled, i.e., 34/67=50.7%

Source: adapted from Table 12, 'biomarker report'

Observed clinical response to erdafitinib in FGFR-selected BLC3001 shows the clinical utility and predictive value of the QIAGEN therascreen FGFR RGQ RT-PCR Kit and suggests the selected biomarker panel identifies a subset of UC tumours that are truly FGFR driven and erdafitinib is a potential treatment option for mUC patients harbouring these FGFR alterations who progressed on at least one prior line of anti-PD-(L1) treatment.

## Cut-point selection (central confirmation test)

'Qiagen therascreen FGFR RGQ RT-PCR' is a qualitative biomarker test delivering a binary result, i.e. 'FGFR alteration detected' or 'FGFR alteration not detected'. The selected cut-off values (PCR - cycle threshold, CT) are analytically driven cut-offs and are intended to optimise the sensitivity of the FGFR assay without compromising the false-positive rate. However, no clinical thresholding was performed.

Table 60: Summary of assay cut-off results within the 'Qiagen therascreen FGFR RGQ RTPCR' (equal or lower numbers indicate a positive result, i.e. 'alteration detected')

| FGFR Assay                                                                                                                                                   | Assay cut-off (CT value)                                                                                                                                     |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| p.R248C (c.742C>T)                                                                                                                                           | 36.00                                                                                                                                                        |
| p.S249C (c.746C>G)                                                                                                                                           | 39.09                                                                                                                                                        |
| p.G370C (c.1108G>T)                                                                                                                                          | 41.00                                                                                                                                                        |
| p.Y373C (c.1118A>G)                                                                                                                                          | 43.00                                                                                                                                                        |
| FGFR3-TACC3v1                                                                                                                                                | 43.00                                                                                                                                                        |
| FGFR3-TACC3v3                                                                                                                                                | 43.00                                                                                                                                                        |
| FGFR3-BAIAP2L1*                                                                                                                                              | 43.00                                                                                                                                                        |
| FGFR2-BICC1*                                                                                                                                                 | 43.00                                                                                                                                                        |
| FGFR2-CASP7*                                                                                                                                                 | 42.00                                                                                                                                                        |
| * subjects FGFR3 fusion FGFR3-BAIAP2L1 and FGFR2 fusions FGFR2-BICC1 and FGFR2-CASP7 have not been validated with the therascreen Kit and clinical specimens | * subjects FGFR3 fusion FGFR3-BAIAP2L1 and FGFR2 fusions FGFR2-BICC1 and FGFR2-CASP7 have not been validated with the therascreen Kit and clinical specimens |

Source: adapted from table 3, 'biomarker report'

<div style=\"page-break-after: always\"></div>

## 2.8.5.5. Analysis performed across trials (pooled analyses and meta-analysis)

## Prior  platinum  chemotherapy  versus  No  prior  platinum  chemotherapy  (post-hoc  defined analysis)

Prior platinum-based chemotherapy was not an eligibility requirement for the pivotal RCT 'BLC3001 Cohort 1' (details see above in section 'main study') and the supportive SAT BLC2001 (further details see below in section 'supportive studies'). Subjects were required to be cisplatin-ineligible and without prior systemic therapy for mUC to be eligible for supportive SAT BLC2002 (further details see below in section 'supportive studies').

For BLC3001 Cohort 1, notable differences in demographics and baseline characteristics between subjects with prior platinum-based chemotherapy vs no prior platinum-based chemotherapy are as follows: 1 prior systemic therapy line 21.9% vs 81.8%, presence of visceral metastases at baseline 76% vs 63.6%, baseline ECOG 28.2% vs 18.2%, creatinine clearance 30 &lt;60 mL/min 47.6% vs 57.6%, male 70% vs 81.8%. Neither the information on why the 33 (12.4%) subjects were not previously treated with platinum-based chemotherapy, nor the reason for discontinuation of prior therapies, and whether the full planned dose of any component of prior lines of therapy was applied, was collected at screening.

For BLC2001, notable differences in demographics and baseline characteristics between subjects with prior platinum-based chemotherapy vs no prior platinum-based chemotherapy include the following: median age 67 vs 74 years; male 80.2% vs 53.3%; no prior systemic therapy 0% vs 66.7%; median time from initial diagnosis to first dose 27.63 vs 21.91 months; creatinine clearance 30 to &lt;60 mL/min 46.5% vs 80%; and baseline haemoglobin &lt;10 g/dL 16.3% vs 6.7%.

Table 61: Comparison of efficacy by prior anti-cancer therapy (platinum-based or no platinum-based prior therapy) from Studies BLC3001 Cohort 1, BLC2001 and BLC2002

|                      | BLC3001 Cohort 1     | BLC3001 Cohort 1   | BLC2001                   | BLC2002                     |
|----------------------|----------------------|--------------------|---------------------------|-----------------------------|
|                      | Erdafitinib          | Chemotherapy       | Erdafitinib (8 mg QD All) | Erdafitinib (8 mg with Upt) |
| n                    |                      |                    |                           |                             |
| Platinum             | 122                  | 111                | 86                        | na                          |
| No platinum          | 14                   | 19                 | 15                        | 43*                         |
| mOS (95% CI)         |                      |                    |                           |                             |
| Platinum             | 11.56 (10.18, 15.74) | 7.72 (6.31, 11.30) | 11.17 (9.03, 14.85)       | na                          |
| No platinum          | 20.53 (6.11, NE)     | 8.74 (2.37, 19.98) | 16.18 (6.08, 42.09)       | 16.23 (7.36, NE)            |
| mPFS (95% CI)        |                      |                    |                           |                             |
| Platinum             | 5.52 (4.37, 5.62)    | 2.73 (1.54, 3.58)  | 5.52 (4.04, 5.68)         | na                          |
| No platinum          | 5.88 (2.79, 8.31)    | 2.53 (1.28, 8.41)  | 9.82 (2.76, 15.90)        | 5.59 (4.34, 7.36)           |
| ORR (n, confirmed %) |                      |                    |                           |                             |
| Platinum             | 44 (36.1%)           | 9 (8.1%)           | 35 (40.7%)                | na                          |
| No platinum          | 4 (28.6%)            | 2 (10.5%)          | 5 (33.3%)                 | 19 (44.2%)                  |

Key:   Chemo=Chemotherapy (docetaxel or vinflunine), mOS=median overall survival, mPFS=median progression-free survival, na=not applicable, NE=not evaluable, ORR=objective response rate, Pembro=pembrolizumab, Upt=uptitration

* cisplatin ineligible study population

<div style=\"page-break-after: always\"></div>

## 2.8.5.6. Supportive studies

## Study BLC3001 - Cohort 2

Cohort 2 of Study BLC3001 is an ongoing randomised, controlled, open- label phase III study comparing erdafitinib 8 mg qd monotherapy to pembrolizumab 200 mg q3w in 351 platinum - based pre-treated subjects with FGFR-positive metastatic urothelial cancer. Primary endpoint was overall survival. For further study design details please see above.

The primary endpoint was failed with a median OS of 10.91 months in the erdafitinib treatment-group and 11.07 in the pembrolizumab group (hazard ratio of 1.18, 95% CI 0.92, 1.51, p-value 0.1819).

## Study BLC2001

Study BLC2001 was an uncontrolled open-label phase 2 study to evaluate the efficacy and safety of multiple regimens of single-agent erdafitinib in subjects with advanced metastatic or surgically unresectable UC that harbour specific FGFR genomic alterations and had progressed on or after at least 1 prior chemotherapy; or progressed/relapsed within 12 months of last dose of neoadjuvant or adjuvant chemotherapy; or were treatment nave but determined to be ineligible for cisplatin based upon impaired renal function. Definition of biomarker positivity ('FGFR-positive') was identical to the pivotal study BLC3001.

A subpopulation of 99 patients was treated in the 8 mg daily regimen (with individualised up-titration to 9 mg daily). Results of this subpopulation are presented here.

The median age was 68 years, 96% had metastatic disease, with visceral metastasis reported for 79% of subjects. Mutations in FGFR3 (G370C, R248C, S249C, Y373C) were observed for 75% of subjects, fusions in FGFR2 and FGFR3 were observed for 25% of subjects. No subject had both mutations and fusions. The majority of subjects had chemotherapy relapsed/refractory disease (88%). Of 87 subjects with prior chemotherapy, 84 had received prior platinum-based chemotherapy. Confirmed ORR based on investigator assessment was 40.4% (95% CI: 30.7%, 50.1%).

## Study BLC2002

Study BLC2002 was an non-comparative open-label phase 2 study to evaluate the safety and efficacy of erdafitinib monotherapy and erdafitinib in combination with cetrelimab (an anti-PD-1 agent) +/platinum (cisplatin or carboplatin) chemotherapy in patients with metastatic or locally advanced urothelial carcinoma. The study included 2 parts: Phase 1b (Dose Escalation) followed by Phase 2 (Dose Expansion).

The study included one erdafitinib monotherapy arm in the phase 2 part of the study, including 43 patients who received at least 1 dose of erdafitinib 8-9 mg within study BLC2002. The safety and efficacy of erdafitinib monotherapy was evaluated in subjects with metastatic or locally advanced UC tumours expressing select FGFR gene alterations, who were ineligible for cisplatin-based therapy and had not received prior systemic therapy for metastatic disease. Definition of biomarker positivity ('FGFR-positive') was identical to the pivotal study BLC3001. Results of this subpopulation are presented here.

The median age was 72 years, visceral metastases were present for over half of the patients. Subjects had baseline ECOG Performance Status of 0 (16.3%), or 1 (55.8%), or 2 (27.9%). Per protocol, subjects enrolled in Study BLC2002 were not allowed to have received any prior systemic therapy for metastatic disease. Confirmed ORR based on investigator assessment was 44.2% (95% CI: 29.1%, 60.1%).

<div style=\"page-break-after: always\"></div>

## 2.8.6. Discussion on clinical efficacy

## Dose finding and dose recommendation

The recommended starting dose is 8 mg taken orally once daily. This dose should be maintained and serum phosphate level should be assessed between 14 and 21 days after initiating treatment. The dose can then be uptitrated to 9 mg once daily if the serum phosphate level is &lt;9.0 mg/dL and there is no drug-related toxicity. To manage adverse drug reactions, the SmPC recommends stepwise dose reductions to 6, 5, or 4 mg and/or treatment interruptions.

The 8 mg once daily dose was already evaluated in Study BLC2001 as Regimen 3 in participants with urothelial carcinoma. In this study, a serum phosphate concentration threshold of 5.5 mg/dL was used for up-titration of erdafitinib. In the pivotal Phase III Study BLC3001, the threshold for individualised up-titration - based on serum phosphate concentrations measured on Day 14 of Cycle 1 - was increased to 9 mg/dL. Dose interruption and dose reduction guidelines were also provided based on tolerability and AEs. The results of the E/R Analysis indicating correlations of ORR with serum PO4 concentrations up to 6 weeks are acknowledged.

Results of subjects on each dose level at later months for BLC3001 showed that erdafitinib doses are overall fairly distributed between the different daily doses between 4 mg and 9 mg.

In study BLC3001 the subgroup efficacy analyses by number of dose reductions (0, 1 and 2 or more) show higher outcomes in subjects experiencing more dose reductions, i.e. mOS of 9.95 (95% CI: 8.11, 10.94), 10.25 (95% CI: 8.51, 16.76) and 23.33 (95% CI: 18.23, NE) months; mPFS of 4.24 (95% CI: 2.79, 5.39), 5.55 (95% CI: 4.01, 5.88) and 10.84 (95% CI: 5.82, 13.67), confirmed ORR of 19.7%, 48.5% and 52.8% in subjects with no erdafitinib dose reduction, with 1 dose reduction and with 2 or more dose reductions, respectively. However, it remains challenging interpreting those outcomes due to the limited size of subgroup and the likely differences in median duration of treatment across subgroups. At this stage, it is acknowledged that these subgroup data do not suggest reduced efficacy with dose reductions.

Also in study BLC3001, the baseline characteristics for the subgroups by up-titration to 9mg (yes/no) show a higher rate of ECOG PS 2, high PD-L1 expression (CPS  10), creatinine clearance &lt;60 mL/min and haemoglobin &lt;10 g/dL in subjects with no up-titration compared to subjects with up-titration. In addition, median age was higher in the subgroup with no up-titration than the subgroup with uptitration (70 vs 65 yrs), however, the percentage of visceral metastases was lower (58.1% vs 78.8%). The subgroup efficacy analyses show numerically higher OS outcomes in subjects with up-titration compared to those without up-titration with higher 95% CI lower bound, i.e. mOS (95%CI) of 12.22 (10.28, 16.76) and 11.56 (6.90, NE) months, respectively, and similar PFS and ORR outcomes for both groups, i.e., mPFS (95%CI) of 5.52 [4.40, 5.65] and 5.62 [3.09, 10.84] months and ORR (confirmed) of 36.5% and 32.3% in subjects with and without up-titration, respectively. It is however pointed out that the small number of subjects with no up-titration (n=31), the post-hoc setting of the subgroup analyses and the unbalanced baseline characteristics across subgroups should lead to caution of interpretation.

Based on the submitted clinical data package, the dosing regimen and its individual titrations as proposed in the SmPC are acceptable.

## Design and conduct of clinical studies

This application is based on the result from a single pivotal study, namely study BLC3001 Cohort 1 . Study 'BLC3001 Cohort 1' is a randomised (1:1) controlled open-label phase 3 study. Eligibility criteria

<div style=\"page-break-after: always\"></div>

adequately describe a patient population of 'adult patients with advanced urothelial cancer and defined FGFR alterations, who had progressed on or after 1 or 2 prior line(s) of therapy, with at least 1 line including anti-PD-(L)1 as monotherapy or as combination therapy; and no more than 2 prior lines of systemic treatment (ECOG 0-2)'.

According to current scientific guidelines, treatment of patients with metastatic urothelial cancer (mUC), for patients who are ineligible for or have progressed on or after (cis)platin-based chemotherapy and progress on immunotherapy, include enfortumab vedotin or single-agent chemotherapy (including vinflunine and docetaxel) not previously received. However, enfortumab vedotin is approved in the EU since April 2022 only and was therefore not available at study start. Furthermore, the marketing authorisation for enfortumab vedotin is a relevant precedent, as in that procedure in the pivotal study investigator's choice (vinflunine, docetaxel or paclitaxel) was accepted as comparator.

## Of note, the applicant received CHMP scientific advice in November 2017

(EMA/CHMP/SAWP/718304/2017) accepting investigator's choice of chemotherapy consisting of vinflunine or docetaxel as comparator arm.

Dosing regimen for vinflunine and docetaxel applied in study BLC3001 follows common standard.

The comparator used in study BLC3001 (i.e. INV choice: vinflunine or docetaxel) is considered acceptable for the 2L+ population studied.

In the intended patient population, OS is the appropriate time-to-event endpoint for evaluation of the direct treatment effect.

The key secondary endpoints PFS and ORR are relevant secondary endpoints and are standard in a situation where OS is the primary endpoint. The hierarchical testing approach with having PFS before ORR in the testing order is agreed.

Patients health-related quality of life was captured using 3 PRO measures: the FACT-Bl, PGIS, and the EQ-5D-5L. These are standardised measures appropriate for the target population.

## Randomisation / Blinding

Prognosis in metastatic urothelial cancer is impacted by the presence of visceral metastases and the ECOG performance status. Furthermore, treatment guidelines and use of anticancer treatment may differ across different geographical regions. Therefore, stratification with the chosen stratification factors is endorsed.

Open-label design of the pivotal study is agreed due to investigator's choice in the control arm and due to the different routes of administration of erdafitinib (orally once daily), vinflunine (20-minute intravenous infusion once every 3 weeks) and docetaxel (1-hour intravenous infusion every 3 weeks).

## Statistical methods / sample size

An estimand was specified in the SAP. To support HR, standard summary measure of the treatment effect for time to event data, the Restricted Mean Survival Time (differences) (+ 95% CIs) were provided after 6,12, and 24 months.

The treatment policy strategy for treatment discontinuation and subsequent anti-cancer therapy is in line with regulatory standards in oncology and acceptable for the primary estimand. Following all patients and using their data irrespective of intercurrent events was appropriately aligned with the targeted estimand.

According to the description of Protocol Amendment 5, the interim analysis was originally planned at an earlier time and included the possibility for sample size re-estimation, which was modified to a group sequential design with the possibility for an early efficacy stop. To provide reassurance that the

<div style=\"page-break-after: always\"></div>

study integrity was preserved, the applicant provided details on the firewalls to prevent bias. The measures taken to prevent knowledge of unblinded by-arm data of all study team involved in the study conduct, the data management and data analysis were sufficient to guarantee the trial integrity.

A Cox regression model was pre-specified for estimating the HR, however, details including whether a stratified model was to be used or the covariates to be included were not pre-specified.

Due to the 3 stratification factors resulting in 24 strata, it was planned to pool strata in case of &lt; 10 events per stratum by a pre-specified algorithm. Finally, an unstratified analysis was performed per the pooling algorithm. As sensitivity analyses, an analysis (1) stratified for all 3 factors, and (2) for ECOG status were provided on request. In addition, a Cox regression including the stratification factors as covariates was performed.

The study had two cohorts that were independently analysed. In both cohorts, a 0.05 significance level was used. Although the study-wise type 1 error is not controlled at the 0.05 level, this is acceptable as the two underlying populations were not overlapping.

The study had a group sequential design such that stopping efficacy boundaries corresponding to significance levels &lt;0.05 were defined for interim and final analysis. However, as confidence intervals, still the nominal 95% CI was provided. To ensure consistency of testing and confidence intervals and appropriately reflect the uncertainty, the repeated confidence interval consistent with the testing procedure was requested and is included the SmPC.

The same significance levels as specified for testing the primary endpoint (OS) based on the O'BrienFleming alpha-spending function was used for secondary endpoints. This is not appropriate, as these should depend on the information fraction that is not necessarily the same for primary and secondary endpoints. However, considering the size of the p-values for secondary analyses, conclusions would have been the same.

For OS, a treatment policy strategy was to be applied, i.e. patients were to be followed and their data included in the analysis irrespectively of intercurrent events such as refusal or discontinuation of treatment. Still, patients discontinued the study and informative censoring is possible for these patients.  The applicant provided several sensitivity analyses (including multiple imputation analyses, tipping point analyses) that are considered sufficient to assess in how far deviations from the noninformative censoring assumption could influence the results.

Censoring rules for PFS were not in line with the recommendations from EMA GL, as patients were censored after new anti-cancer therapy. However, as PFS is only a supportive endpoint this is acceptable.

## Study conduct

Most of the study protocol amendments that occurred after the enrolment of the first study patient are not likely to have a major impact on the efficacy outcomes. For the potential impact of the change in timing of the interim analysis in this open-label study see above (section 'statistical methods').

## Participant flow

A greater number of subjects who were randomised to the chemotherapy group did not receive study treatment (n=18) compared with the erdafitinib group (n=1), the main reason was 'refused treatment' (n=12; all from control group). This number shows a relevant imbalance; however, demographic and disease characteristics at baseline were sufficiently comparable between those patients 'randomised and treated' and those 'randomised and not treated'. There are no reasonable concerns of informative censoring. Furthermore, the applicant was able to obtain the death date for 8 of the 18 subjects randomised to chemotherapy as well as the subject randomised to erdafitinib.

<div style=\"page-break-after: always\"></div>

## Baseline data

The demographic characteristics at baseline were sufficiently balanced between the treatment groups.

The disease characteristics at baseline were sufficiently balanced between the treatment groups.

Prior anti-cancer therapy received by subject was generally balanced across treatment groups.

Subjects had at least 1 FGFR3 alteration; no subjects had FGFR2 alterations. FGFR3-S249C was the most prevalent alteration (46.6%) followed by FGFR3-Y373C (16.9%), and FGFR3-TACC3 fusion (9.8%).

## Efficacy data and additional analyses

## Primary endpoint (OS)

The primary efficacy endpoint of OS showed a statistically and clinically significant improvement in OS for subjects treated with erdafitinib vs chemotherapy (HR=0.64; 95% CI: 0.47, 0.88; pvalue=0.0050). The median OS was 12.1 months (95% CI: 10.3, 16.4) in the erdafitinib group versus 7.8 months (95% CI: 6.5, 11.1) in the chemotherapy group, each with approximately 40% of subjects censored. The median survival follow-up was 15.90 months (95% CI: 13.57, 19.22).

Sensitivity and subgroup analyses did not challenge the OS benefit of the primary analysis. Regarding the discussion on the small subpopulation of patients not having received prior platinum-based chemotherapy, please refer to discussion below.

## Key secondary endpoints (PFS, ORR, TUSD-3)+

Analysis of key secondary endpoint PFS showed a statistically significant improvement in PFS for subjects treated with erdafitinib vs chemotherapy (HR=0.58; 95% CI: 0.44, 0.78; p value=0.0002).

Best ORR by investigator assessment and per RECIST 1.1 was 45.6% for the erdafitinib treatment group and 11.5% for the chemotherapy treatment group. The difference was statistically significant. 'Confirmed ORR analysis' was consistent with 'best ORR analysis'.

TUSD-3 is not established as a validated PRO endpoint; its clinical relevance is unclear. Furthermore, due to the open-label design of the study and the relevantly imbalanced censoring, no reasonable conclusions can be drawn from the PRO score TUSD-3. Its validation status is not evaluated in this MAA, as no robust benefit claims can be based on this PRO.

## Other secondary endpoints

No results were provided for PGIS and only very high-level information was provided for EQ-5D-5L and

FACT-Bl ('no meaningful differences') in the clinical study report and its 'supplemental PRO report'. However, due to the open-label design of the pivotal study - no robust benefit claims can be based on PRO data in this MAA.

## Companion diagnostic (CDx) / Biomarker 'FGFR positive'

## CDx used for central confirmation

'Qiagen therascreen FGFR RGQ RT-PCR' from tissue was used as central confirmation test. However, 12.5% of patients (33/264) were included into study BLC3001 based on local testing only (tissue or blood) without having a (positive) central confirmation test (for 22 patients no tissue for central confirmation was available, for 11 patients central confirmation test was negative).

<div style=\"page-break-after: always\"></div>

## Definition of biomarker positivity ('FGFR-positive') and its justification

Regarding definition to declare a patient as 'FGFR-positive' in the pivotal study BLC3001 please refer to 'eligibility criteria' above. Despite limitations to the biomarker validation (preclinical data and uncontrolled clinical response data), the definition of biomarker positivity is accepted.

## Analytical method (of central confirmation test)

FGFR RGQ-RT-PCR Kit (Qiagen) was chosen as IVD to determine presence of FGFR point mutations. The kit is CE certified according to IVD Directive 98/79/EC, for use with the Qiagen Rotor Gene Q MDx 5plex HRM instrument.

An appropriately detailed description of sample preparation is presented. Run and sample validity is determined based on a no template control (NTC) and a positive control (PC) being within defined specifications. Results are only reported if these criteria are met. The reporting of the results above the established cut-points is fully automated.

## Analytical validation strategy (of central confirmation test)

The assay based on therascreen FGFR RGQ RT-PCR Kit was validated with respect to mutation specific cut-off values, LoB, cross-reactivity, LoD, repeatability, and reproducibility. The relevant parameters were addressed. The assay is qualitative in nature, hence, it is not possible to draw conclusions on the ratio of mutated vs WT RNA in the samples.

## Clinical validation strategy (of central confirmation test)

Patients in BLC3001 were randomised based on central test using therascreen FGFR RGQ RT-PCR diagnostic assay (74.6%), or local test (25.4%). Where tumour samples were available, patients with local test were centrally retested. The applicant showed that the treatment effects in patients with central positive test at enrolment, and in patients with central positive test either at enrolment or retesting were consistent with the treatment effect in the ITT population. The applicant claims that the observed clinical response to erdafitinib in FGFR-selected BLC3001 shows the clinical utility and predictive value of the QIAGEN therascreen .

While it is agreed that clinical benefit has been demonstrated for the population selected based on the therascreen FGFR RGQ RT-PCR, this does not imply clinical validity of the test or its predictive value. A test being clinically valid usually means that it is predictive for an effect on clinical outcomes, i.e., the treatment effect in test positive patients is larger than in negative patients (or can even be observed only in test positive patients). Therefore, while an effect on clinical outcomes such as OS in the central test positive patients is necessary, this is not sufficient for concluding that the test is predictive, as this would require clinical data in test-negative patients. The justification of clinical validity needs to be based on the clinical rationale in this case.

The number of patients enrolled based on a local test with tumour samples available for central test confirmation was limited (n=45), however, 24.4% (n=11) of these were centrally not confirmed (i.e. biomarker-negative in central confirmation test). While this number is too small for any conclusions on clinical effects in these patients, this shows that not all patients who might benefit from erdafitinib may be identified by ' therascreen FGFR RGQ RT-PCR'.

Initially, only an analysis of activity (objective response rates, ORRs) by genetic alteration was available for study BLC2001. Upon request, an exploratory analysis of clinical benefit (overall survival, OS, and progression-free survival, PFS) supported by ORR was provided for study BLC3001, focusing on genetic alterations. Due to small sample sizes in different subgroups, no definitive conclusions can be drawn. However, trends favouring erdafitinib over chemotherapy were observed across all investigated alterations. Pooled analyses of patients with mutations and fusions also consistently favoured erdafitinib.

<div style=\"page-break-after: always\"></div>

## Cut-point selection (of central confirmation test)

Cut-points used for the respective genetic alteration defining 'FGFR-positivity' were provided for the central confirmation test 'Qiagen therascreen FGFR RGQ RT-PCR'. However, no clinical thresholding was performed. Therefore, it remains unclear whether the thresholds / cut-off values applied in study BLC3001 were optimal or whether a lower or higher threshold defining patients as 'FGFR alteration positive' would lead to a better benefit-risk ratio.

## Additional analysis - Prior platinum chemotherapy versus No prior platinum chemotherapy (post-hoc defined)

The applicant claims an indication in a second- and later-line setting (2 nd +-setting) for a patient population that has received prior treatment with a PD-(L)1 inhibitor. Prior treatment with platinumbased chemotherapy was not required.

However, in-line with the scientific treatment guidelines, the majority of patients included in pivotal study BLC3001 had received prior platinum-containing chemotherapy and only a minority of patients was platinum-nave. For this ITT study population a statistically and clinically relevant effect on overall survival was shown.

In the platinum-nave subpopulation the applicant performed a post-hoc defined cross-trial comparison for RCT BLC3001 cohort 1, SAT BLC2001 and SAT BLC2002 showing consistent promising objective responses for the study subpopulations without prior platinum. Results for ORR, OS and PFS are overall comparable to results from the pivotal RCT BLC3001 for the ITT-population. However, the absolute number of patients showing responses is limited (especially in the pivotal RCT) and analyses performed are post-hoc defined, making it difficult to draw robust conclusions from this data.

## Patient and healthcare provider engagement

A methodology of engaging with patient organisations at the start of evaluation of new MAAs has been agreed by CHMP (for more details see the dedicated process and FAQs document:

https://www.ema.europa.eu/en/documents/other/chmp-early-contact-patient-and-healthcareprofessional-organisations-process-and-faqs\\_en.pdf). In this context the CHMP invited a healthcare professional society to share their perspectives regarding the assessment of erdafitinib for the applied indications on behalf of its members. The response from one Healthcare Professional Society confirmed the view that there is a substantial need for better treatment options, in particular to meaningfully improve survival and quality of life in patients with advanced bladder cancer following chemotherapy.

## 2.8.7. Conclusions on the clinical efficacy

Efficacy claims are based on the single pivotal phase 3 study BLC3001 (cohort 1) performed in line with the CHMP scientific advice provided in 2017 (before study start). The RCT met its primary endpoint of OS, showing a statistically and clinically significant improvement in OS in favour of erdafitinib monotherapy. This outcome is supported by analysis of the key secondary endpoints of PFS and ORR showing statistically significant improvement in favour of erdafitinib monotherapy.

The efficacy of erdafitinib has been demonstrated in the second- and later-line setting (2 nd +-setting) in patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alteration who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor regardless of prior treatment with platinum-based chemotherapy.

## 2.8.8. Clinical safety

Clinical Studies providing safety and tolerability data are summarised in Table 62 .

<div style=\"page-break-after: always\"></div>

Key safety data come from BLC3001 Cohort 1 for erdafitinib compared with chemotherapy in the locally advanced or metastatic UC population.

In addition, the following 2 pooled datasets are provided to characterise the overall safety profile of erdafitinib:

 The BLC3001 erdafitinib pool (n=308), comprised of safety data from erdafitinib treated subjects in the two cohorts from the BLC3001 study . The control arms from Study BLC3001 (chemotherapy group [Cohort 1] and pembrolizumab Group [Cohort 2]) provide context of the safety profile for erdafitinib in the mUC patient population.

 The mUC Pool (n=479) integrates data across studies that included subjects with locally advanced or metastatic UC treated with erdafitinib monotherapy 8 mg daily with individualised up-titration to 9 mg daily (8/9 mg daily dose regimen; n=467) or erdafitinib monotherapy 9 mg daily (n=9). Studies included in the pool were: BLC3001 (308/479) BLC2001 (main study plus mUC subjects in the ongoing DDI sub study), BLC2002 (erdafitinib monotherapy arm), and EDI1001 .

Table 62: Overview of Clinical Studies Providing Safety and Tolerability Data

| Study                                     | Phase                                        | Study drugs                                                                                                                                                                                                                                                                                                                      | Number of erdafitinib - treated subjects in participating in the mUC Pool (erdafitinib 8-9 mg qd)   |
|-------------------------------------------|----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| 42756493BLC3001 Further termed as BLC3001 | Phase III open label, randomised, controlled | Cohort 1: Arm 1A: erdafitinib 8mg qd Arm 1B: docetaxel 75mg/m 2 q3w or vinflunine 320 mg/m q3w, investigators choice) Anti - PDL1 - agent +/- chemotherapy pretreated FGFR+ mUC patients Cohort 2: Arm 2A: erdafitinib 8mg Arm 2B: pembrolizumab 200 mg q3w after 1-2L chemotherapy Both cohorts: Up-titration to 9 mg based on | Cohort 1 N=135 Cohort 2 N=173                                                                       |
| 42756493 BLC2001 (main study)             | Phase II two arms, open label, uncontrolled  | Different dosing regiments of erdafitinib tablet Regimen 1: 10 mg qd intermittent (7d on / 7d off) Regimen 2: 6 mg qd Regiment 3: 8 mg qd, up-titration to 9 mg (included in mUC pool)                                                                                                                                           | 101                                                                                                 |
| 42756493 BLC2001 (DDI substudy)           | Phase II open label, single sequence         | erdafitinib tablet 8 mg qd, up- titration to 9 mg DDI with Metformin and Midazolam                                                                                                                                                                                                                                               | 15                                                                                                  |

<div style=\"page-break-after: always\"></div>

| 42756493 BLC2002   | Phase Ib/II open label, dose escalation/ dose expansion   | Erdafitinib tablet 8 mg qd, up- titration to 9 mg erdafitinib + cetrelimab erdafitinib + cetrelimab + chemotherapy   | 43    |
|--------------------|-----------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|-------|
| 42756493 EDI1001   | Phase I 1st in human, open-label, 4 - part                | erdafitinib solution or capsule up to 12 mg continuous or daily                                                      | 12    |
|                    |                                                           |                                                                                                                      |  479 |

## 2.8.8.1. Patient exposure

Table 63 provides an overview of the subjects' disposition, whereas  Table 64summarises the extent of exposure.

Table 63: Subject Disposition and Treatment Withdrawal Information; mUC Safety Analysis Set (JNJ-42756493 (Erdafitinib))

|                                                    | BLC3001                                | BLC3001        | BLC3001         | mUC Pool          |
|----------------------------------------------------|----------------------------------------|----------------|-----------------|-------------------|
|                                                    | ERDA Cohort 1 and Cohort 2 8or 9 mg QD | CHEMO Cohort 1 | PEMBRO Cohort 2 | ERDA 8 or 9 mg QD |
| Total mumber of subjects                           | 308                                    | 112            | 173             | 479               |
| Study treatment ongoing                            | 38 (12.3%)                             | 10 (8.9%)      | 13 (7.5%)       | 57 (11.9%)        |
| Discontimued study treatment                       | 270 (87.7%)                            | 102 (91.1%)    | 160 (92.5%)     | 422 (88.1%)       |
| Reason for discontinuation Adverse event           | 52 (16.9%)                             | 19 (17.0%)     | 18 (10.4%)      | 80 (16.7%)        |
| Death                                              | 2 (0.6%)                               | 1 (0.9%)       | 4 (2.3%)        | 5 (1.0%)          |
| Non-Compliance with study dnug*                    | 7 (2.3%)                               | 9 (8.0%)       | 3 (1.7%)        | 10 (2.1%)         |
| Progressive disease                                | 206 (66.9%)                            | 62 (55.4%)     | 130 (75.1%)     | 322 (67.2%)       |
| Physician decision                                 | 2 (0.6%)                               | 6 (5.4%)       | 3 (1.7%)        | 3 (0.6%)          |
| Other                                              | 1 (0.3%)                               | 5 (4.5%)       | 2 (1.2%)        | 2 (0.4%)          |
| Completed study c                                  | 210 (68.2%)                            | 70 (62.5%)     | 120 (69.4%)     | 319 (66.6%)       |
| Ongoing in study                                   | 88 (28.6%)                             | 37 (33.0%)     | 51 (29.5%)      | 118 (24.6%)       |
| Discontimued study                                 | 10 (3.2%)                              | 5 (4.5%)       | 2 (1.2%)        | 42 (8.8%)         |
| Reason for discontimuation Withdrawal by subject b | 7 (2.3%)                               | 3 (2.7%)       | 2 (1.2%)        | 13 (2.7%)         |
| Lost to follow-up                                  | 0                                      | 2 (1.8%)       | 0               | 1 (0.2%)          |
| Other                                              | 3 (1.0%)                               | 0              | 0               | 28 (5.8%)         |

<div style=\"page-break-after: always\"></div>

Table 64: Extent of Exposure; mUC Safety Analysis Set (JNJ-42756493 (Erdafitinib))

|                                                                  |                                         | BLC3001        |               | mUC Pool                  |
|------------------------------------------------------------------|-----------------------------------------|----------------|---------------|---------------------------|
|                                                                  | ERDA Cohort 1 and Cohort 2 8 or 9 mg QD | CHEMO Cohort 1 |               | PEMBROCohort2ERDA8or9mgQD |
| Total mumber of subjects                                         | 308                                     | 112            | 173           | 479                       |
| Total treatment duration (months)                                |                                         |                |               |                           |
| N                                                                | 308                                     | 112            | 173           | 479                       |
| 0to3                                                             | 107 (34.7%)                             | 75 (67.0%)     | 84 (48.6%)    | 159 (33.2%)               |
| 3 to 6                                                          | 91 (29.5%)                              | 23 (20.5%)     | 32 (18.5%)    | 140 (29.2%)               |
| 6to-9                                                            | 45 (14.6%)                              | 7 (6.3%)       | 15 (8.7%)     | 70 (14.6%)                |
| 9to <12                                                          | 22 (7.1%)                               | 4 (3.6%)       | 8 (4.6%)      | 37 (7.7%)                 |
| 212                                                              | 43 (14.0%)                              | 3 (2.7%)       | 34 (19.7%)    | 73 (15.2%)                |
| Mean (SD)                                                        | 6.74 (7.081)                            | 2.79 (3.861)   | 7.10 (9.454)  | 7.08 (7.340)              |
| Median                                                           | 4.60                                    | 1.40           | 3.50          | 4.80                      |
| Range                                                            | (0.1; 43.4)                             | (0.0; 26.9)    | (0.0; 50.5)   | (0.1; 43.4)               |
| Total duation of exposuure - excluding dose intemuption (months) |                                         |                |               |                           |
| N                                                                | 308                                     | 112            | 173           | 479                       |
| Mean (SD)                                                        | 6.7 (7.08)                              | 2.8 (3.86)     | 7.1 (9.45)    | 6.7 (6.93)                |
| Median                                                           | 4.6                                     | 1.4            | 3.5           | 4.5                       |
| Range                                                            | (0; 43)                                 | (0; 27)        | (0; 51)       | (0; 43)                   |
| Relative dose intensity ( %)*                                    |                                         |                |               |                           |
| N                                                                | 308                                     | 112            | 173           | 479                       |
| =70%                                                             | 161 (52.3%)                             | 2 (1.8%)       | 1 (0.6%)      | 204 (42.6%)               |
| 70% to <90%                                                      | 91 (29.5%)                              | 1 (0.9%)       | 0             | 140 (29.2%)               |
| 90%                                                             | 56 (18.2%)                              | 109 (97.3%)    | 172 (99.4%)   | 135 (28.2%)               |
| Mean (SD)                                                        | 69.35 (19.339)                          | 98.76 (10.447) | 99.81 (2.534) | 74.25 (19.870)            |
| Median                                                           | 68.24                                   | 100.00         | 100.00        | 75.13                     |
| Range                                                            | (12.5;100.0)                            | (4.0;116.7)    | (66.7; 100.1) | (12.5; 100.0)             |

## 2.8.8.2. Adverse events

The definition of ADRs from the ICH guideline entitled E6 was used as guidance for the ADR medical assessment.

Table 65 provides an overall summary of adverse events reported in study BLC3001, in the complete mUC pool and in the supportive study BLC2001.

Table 65: Overall Summary of Treatment-emergent Adverse Events; mUC Safety Analysis Set (JNJ-42756493 (Erdafitinib))

|                            | BLC3001                                 | BLC3001        | BLC3001         | mUC Pool          | BLC2001   |
|----------------------------|-----------------------------------------|----------------|-----------------|-------------------|-----------|
|                            | ERDA Cohort 1 and Cohort 2 8 or 9 mg QD | CHEMO Cohort 1 | PEMBRO Cohort 2 | ERDA 8 or 9 mg QD |           |
| Total number of subjects   | 308                                     | 112            | 173             | 479               | 99        |
| Any TEAEs                  | 306 (99.4%)                             | 109 (97.3%)    | 167 (96.5%)     | 477 (99.6%)       | 99 (100%) |
| Study treatment related    | 300 (97.4%)                             | 97 (86.6%)     | 105 (60.7%)     | 464 (96.9%)       | 96 (97%)  |
| Grade 3 or 4 TEAEs         | 197 (64.0%)                             | 72 (64.3%)     | 88 (50.9%)      | 321 (67.0%)       | 66 (67%)  |
| Study treatment related    | 137 (44.5%)                             | 52 (46.4%)     | 21 (12.1%)      | 220 (45.9%)       | 45 (46%)  |
| Serious TEAEs              | 125 (40.6%)                             | 47 (42.0%)     | 80 (46.2%)      | 204 (42.6%)       | 39 (39%)  |
| Study treatment related    | 41 (13.3%)                              | 27 (24.1%)     | 18 (10.4%)      | 62 (12.9%)        | 9 (9.1%)  |
| Grade 3 or 4 serious TEAEs | 108 (35.1%)                             | 41 (36.6%)     | 68 (39.3%)      | 177 (37.0%)       | 33 (33%)  |
| Study treatment related    | 35 (11.4%)                              | 23 (20.5%)     | 11 (6.4%)       | 51 (10.6%)        | N/A       |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                                                                                                                                                                                                                                                               | BLC3001                                                                                                                                                                                                                                                                                                                                                                                                                                       | BLC3001                                                                                                                                                                                                                                                                                                                                                                                                                                       | BLC3001                                                                                                                                                                                                                                                                                                                                                                                                                                       | mUC Pool                                                                                                                                                                                                                                                                                                                                                                                                                                      | BLC2001    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                               | ERDA Cohort 1 and Cohort 2 8 or 9 mg QD                                                                                                                                                                                                                                                                                                                                                                                                       | CHEMO Cohort 1                                                                                                                                                                                                                                                                                                                                                                                                                                | PEMBRO Cohort 2                                                                                                                                                                                                                                                                                                                                                                                                                               | ERDA 8 or 9 mg QD                                                                                                                                                                                                                                                                                                                                                                                                                             |            |
| TEAE leading to dose reduction                                                                                                                                                                                                                                                                                                                                                                                                                | 91 (62%)                                                                                                                                                                                                                                                                                                                                                                                                                                      | 27 (24.1%)                                                                                                                                                                                                                                                                                                                                                                                                                                    | 0                                                                                                                                                                                                                                                                                                                                                                                                                                             | 286 (59.7%)                                                                                                                                                                                                                                                                                                                                                                                                                                   | 55 (55.6%) |
| Study treatment related                                                                                                                                                                                                                                                                                                                                                                                                                       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                           | 55 (55.6%) |
| TEAE leading to dose interruption                                                                                                                                                                                                                                                                                                                                                                                                             | 222 (72.1%)                                                                                                                                                                                                                                                                                                                                                                                                                                   | 35 (31.3%)                                                                                                                                                                                                                                                                                                                                                                                                                                    | 57 (32.9.0%)                                                                                                                                                                                                                                                                                                                                                                                                                                  | 345 (72.0%)                                                                                                                                                                                                                                                                                                                                                                                                                                   | 70 (70.7%) |
| Study treatment related                                                                                                                                                                                                                                                                                                                                                                                                                       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                           | 61 (61.6%) |
| TEAE leading to study treatment discontinuation                                                                                                                                                                                                                                                                                                                                                                                               | 52 (16.9%)                                                                                                                                                                                                                                                                                                                                                                                                                                    | 20 (17.9%)                                                                                                                                                                                                                                                                                                                                                                                                                                    | 19 (11.0%)                                                                                                                                                                                                                                                                                                                                                                                                                                    | 93 (19.4%)                                                                                                                                                                                                                                                                                                                                                                                                                                    | 21 (21.2%) |
| Study treatment related                                                                                                                                                                                                                                                                                                                                                                                                                       | 37 (12.0%)                                                                                                                                                                                                                                                                                                                                                                                                                                    | 15 (13.4%)                                                                                                                                                                                                                                                                                                                                                                                                                                    | 8 (4.6%)                                                                                                                                                                                                                                                                                                                                                                                                                                      | 61 (12.7%)                                                                                                                                                                                                                                                                                                                                                                                                                                    | 12 (12.1%) |
| TEAEs leading to death                                                                                                                                                                                                                                                                                                                                                                                                                        | 11 (3.6%)                                                                                                                                                                                                                                                                                                                                                                                                                                     | 7 (6.3%)                                                                                                                                                                                                                                                                                                                                                                                                                                      | 12 (6.9%)                                                                                                                                                                                                                                                                                                                                                                                                                                     | 29 (6.1%)                                                                                                                                                                                                                                                                                                                                                                                                                                     | 7 (7.1%)   |
| Study treatment related                                                                                                                                                                                                                                                                                                                                                                                                                       | 1 (0.3%)                                                                                                                                                                                                                                                                                                                                                                                                                                      | 6 (5.4%)                                                                                                                                                                                                                                                                                                                                                                                                                                      | 3 (1.7%)                                                                                                                                                                                                                                                                                                                                                                                                                                      | 1 (0.2%)                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0          |
| Key: QD = once daily, TEAE = treatment-emergent adverse event. BLC3001 CHEMO Cohort 1: vinflunine 320 mg/m 2 as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m 2 as a 1-hour intravenous infusion every 3 weeks. BLC3001 PEMBRO Cohort 2: pembrolizumab 200 mg as a 30 - minute intravenous infusion once every 3 weeks. TEAE leading to death: TEAE with outcome death on the AE CRF page or with toxicity grade 5 | Key: QD = once daily, TEAE = treatment-emergent adverse event. BLC3001 CHEMO Cohort 1: vinflunine 320 mg/m 2 as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m 2 as a 1-hour intravenous infusion every 3 weeks. BLC3001 PEMBRO Cohort 2: pembrolizumab 200 mg as a 30 - minute intravenous infusion once every 3 weeks. TEAE leading to death: TEAE with outcome death on the AE CRF page or with toxicity grade 5 | Key: QD = once daily, TEAE = treatment-emergent adverse event. BLC3001 CHEMO Cohort 1: vinflunine 320 mg/m 2 as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m 2 as a 1-hour intravenous infusion every 3 weeks. BLC3001 PEMBRO Cohort 2: pembrolizumab 200 mg as a 30 - minute intravenous infusion once every 3 weeks. TEAE leading to death: TEAE with outcome death on the AE CRF page or with toxicity grade 5 | Key: QD = once daily, TEAE = treatment-emergent adverse event. BLC3001 CHEMO Cohort 1: vinflunine 320 mg/m 2 as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m 2 as a 1-hour intravenous infusion every 3 weeks. BLC3001 PEMBRO Cohort 2: pembrolizumab 200 mg as a 30 - minute intravenous infusion once every 3 weeks. TEAE leading to death: TEAE with outcome death on the AE CRF page or with toxicity grade 5 | Key: QD = once daily, TEAE = treatment-emergent adverse event. BLC3001 CHEMO Cohort 1: vinflunine 320 mg/m 2 as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m 2 as a 1-hour intravenous infusion every 3 weeks. BLC3001 PEMBRO Cohort 2: pembrolizumab 200 mg as a 30 - minute intravenous infusion once every 3 weeks. TEAE leading to death: TEAE with outcome death on the AE CRF page or with toxicity grade 5 |            |

## Treatment-emergent Adverse Events Related to Study Treatment

Table 66 summarises the incidence of Treatment-emergent Adverse Events Related to Study Treatment by System Organ Class and Preferred Term Occurring in &gt;2%.

Of note, related TEAEs with a worst severity of Grade 3 or 4 were reported for 220 (45.9%) subjects, with stomatitis (49 [10.2%] subjects), PPES (38 [7.9%] subjects) and oncholysis (23 [4.8%] subjects) being the most commonly reported.

<div style=\"page-break-after: always\"></div>

Table 66: Incidence of Treatment-emergent Adverse Events Related to Study Treatment by System Organ Class and Preferred Term Occurring in &gt;2% in any Group; mUC Safety Analysis Set (JNJ-42756493 (Erdafitinib))

|                                             |                                           | BLC3001            |                    | mUC Pool                       |
|---------------------------------------------|-------------------------------------------|--------------------|--------------------|--------------------------------|
| Total number of subjects                    | ERDA Cohont 1 and Cohort 2 8 or 9 EQD 308 | CHEMO Cohort 1 112 | PEMBRO Cohort2 173 | ERDA 8 or9 mg QD 479           |
| Subjects with TEAEs                         | 300 (97.4%)                               | 97 (86.6%)         | 105 (60.7%)        | 464 (96.9%)                    |
| System organ class Preferred tem            |                                           |                    |                    |                                |
| Gastrointestinal disorders                  | 263 (85.4%)                               | 61 (54.5%)         | 34 (19.7%)         | 408 (85.2%6)                   |
| Stomatilis                                  | 140 (45.5%)                               | 13 (11.6%)         | 5 (2.9%%)          | 242 (50.5%%)                   |
| Dianhoea                                    | 151 (49.0%)                               | 12 (10.7%)         | 10 (5.8%%)         | 222 (46.3%)                    |
| Dry mouth                                   | 113 (36.7%)                               | 3 (2.7%)           | 5 (2.9%)           | 186 (38.8%)                    |
| Nausea                                      | 35 (11.4%)                                | 22 (19.6%)         | 8 (4.6%)           | 57 (11.9%)                     |
| Constipation                                | 29 (9.4%)                                 | 21 (18.8%)         | 7 (4.0%)           | 50 (10.4%)                     |
| Vomiting                                    | 24 (7.8%)                                 | 15 (13.4%)         | 3 (1.7%)           | 40 (8.4%6)                     |
| Dyspepsia                                   | 13 (4.2%)                                 | 2 (1.8%)           | 0                  | 24 (5.0%)                      |
| Abdominal pain                              | 16 (5.2%%)                                | 5 (4.5%)           | 1 (0.6%)           | 21 (4.4%)                      |
| Abdominal pain upper                        | 8 (2.6%)                                  | 1 (0.9%)           | 1 (0.6%)           | 18 (3.8%)                      |
| Gastrooesophngeal reflux disense            | 7 (2.3%)                                  | 3 (2.7%4)          | 0                  | 14 (2.9%)                      |
| Mouth ulceration                            | 11 (3.6%)                                 | 2 (1.8%6)          | 0                  | 12(2.5%)                       |
| Aphthous ulcer                              | 5 (1.6%)                                  | 1 (0.9%)           | 0                  | 10 (2.1%)                      |
| Dysphagia                                   | 5 (1.6%)                                  | 1 (0.9%%)          | 2 (1.2%)           | 10 (2.1%)                      |
| Metabolism and nutrition disorders          | 248 (80.5%6)                              | 24 (21.4%)         | 11 (6.4%)          | 392 (81.8%%)                   |
| Hyperphosphataemia                          | 232 (75.3%)                               | 0                  | 0                  | 361 (75.4%)                    |
| Decreased appetite                          | 67 (21.8%%)                               | 20 (17.9%%)        | 5 (2.9%)           | 108 (22.5%%)                   |
| Hyponataemia                                | 21 (6.8%)                                 | 3 (2.7%)           | 1 (0.6%)           | 28 (5.89%)                     |
| Hypomagnesaemia                             | 6 (1.9%)                                  | 0                  | 0                  | 15 (3.1%)                      |
| Cell death                                  | 7 (2.39)                                  | 0                  | 1 (0.6%)           | 7 (1.5%:)                      |
| Skin and subcutaneous tissue                |                                           |                    |                    |                                |
| disorders                                   | 223 (72.4%)                               | 34 (30.4%)         | 35 (20.2%%)        | 345 (72.0%%)                   |
| Dry skin                                    | 73 (23.7%6)                               | 4 (3.6%6)          | 6 (3.5%)           | 132 (27.6%)                    |
| Palmar-plantar erythrodysaesthesia syndrome | 79 (25.6%%)                               | 1 (0.9%)           | 0                  | 120 (25.1%) 101 (21.1%)        |
| Onycholysis                                 | 72 (23.4%) 58 (18.8%)                     | 1(0.9%) 24 (21.4%) | 0 1 (0.6%)         | 100 (20.9%)                    |
| Alopecia                                    |                                           |                    |                    |                                |
| Nai discolouration                          | 51 (16.6%)                                | 2 (1.8%%)          | 0                  | 73 (15.2%%)                    |
| Nail dystrophy                              | 30 (9.7%)                                 |                    | 0                  | 56 (11.7%)                     |
| Onychomadesis                               | 42 (13.6%)                                | 2 (1.8%)           | 0                  | 54 (11.3%)                     |
| Nail disorder                               | 29 (9.4%6)                                | 2 (1.8%)           | 2 (1.2%)           | 47 (9.8%%)                     |
| Onychalgia                                  | 9 (2.9%)                                  | 0                  | 0                  | 18 (3.8%)                      |
| Pninitus                                    | 9 (2.9%)                                  | 2 (1.8%6)          | 21 (12.1%)         | 18 (3.8%6)                     |
| Rash                                        | 11 (3.6%)                                 | 4 (3.6%)           | 10 (5.8%)          | 17 (3.5%)                      |
| Skin fisswres                               | 8 (2.6%)                                  | 1 (0.9%)           | 0                  | 17 (3.5%)                      |
| Hyperkeratosis                              | 10 (3.2%)                                 | 0                  | 0                  | 16 (3.3%)                      |
| Erythema                                    | 7 (2.3%)                                  | 1 (0.9%)           | 2 (1.2%)           | 14 (2.9%)                      |
| Nail tosicity                               | 13 (4.2%)                                 | 0                  | 0                  | 14 (2.9%)                      |
| Nail nidging                                | 7 (2.3%)                                  | 1 (0.9%)           | 0                  | 12 (2.5%)                      |
| Skin exfoliation                            | 7 (2.3%)                                  | 0                  | 0                  | 12 (2.5%)                      |
| Xerodemma                                   | 12 (3.9%%)                                | 0                  | 0                  | 12 (2.5%.)                     |
| Eye disorders                               |                                           | 7 (6.3%6)          | 3 (1.7%)           |                                |
|                                             | 143 (46.4%)                               |                    |                    | 234 (48.9%)                    |
| Dry eye                                     | 42 (13.6%) 21 (6.8%%)                     | 2 (1.8%4) 0        | 2(1.2%)            | 75 (15.7%4)                    |
| Vision blured Lacrimafion increased         | 24 (7.8%)                                 | 1 (0.9%)           | 0 0                | 42 (8.8%%) 38 (7.9%%)          |
| Chorioretinopathy                           |                                           |                    |                    |                                |
| Detachment of retinal pigment               | 20 (6.5%)                                 | 0                  | 0                  | 30 (6.39%) 22 (4.69%)          |
| epithelium                                  | 16 (5.2%) 11 (3.6%)                       | 0 1 (0.9%)         | 0 0                | 21 (4.4%) 21 (4.4%) 19 (4.0%%) |
| Visual impainment Xerophthalmia Keratitis   | 16 (5.2%%) 10 (3.2%)                      | 1 (0.9%) 0         | 1 (0.6%) 0         |                                |
|                                             | 11 (3.6%)                                 | 0                  | 0                  | 17 (3.5%)                      |
| Visual acuity reduced                       |                                           |                    |                    | 14 (2.9%)                      |
| Blepharitis                                 | 8 (2.6%)                                  | 0                  | 0                  | 11 (2.3%)                      |
| Retinal detachment                          | 4 (1.3%)                                  | 0                  | 0                  | 10 (2.1%)                      |
| Retinopathy                                 | 6 (1.9%)                                  | 0                  | 0                  |                                |
| Subretinal fluid                            | 7 (2.3%)                                  | 0                  | 0                  | 8 (1.7%,)                      |

<div style=\"page-break-after: always\"></div>

Table 67: Incidence of Treatment-emergent Adverse Events Related to Study Treatment by System Organ Class and Preferred Term Occurring in &gt;2% in any Group; mUC Safety Analysis Set (JNJ-42756493 (Erdafitinib))

|                                                                 | ERDA Cohort 1          | BLC3001             |                               | mUC Pool               |
|-----------------------------------------------------------------|------------------------|---------------------|-------------------------------|------------------------|
| General disorders and administration                            | mgQD                   |                     | CHEMO Cohort 1PEMBRO Cohort 2 | QD                     |
| site conditions                                                 | 104 (33.8%%)           | 52 (46.486)         | 42 (24.374)                   | 171 (35.7%)            |
| Asthenia                                                        | 46 (14.9%)             | 21 (18.8%)          | 18 (10.4%)                    | 76 (15.9%6)            |
| Fatigue                                                         | 36 (11.7%6)            | 17 (15.2%)          | 17 (9.8%%)                    | 69 (14.4%6)            |
| Xerosis                                                         | 11 (3.6%)              | 0                   | 1 (0.6%)                      | 16 (3.3%%)             |
| Mucosal inflammation                                            | 10 (3.2%)              | 2 (1.8%)            | 0                             | 10 (2.1%)              |
| Pyrexia                                                         | 4 (1.3%)               | 7 (6.3%)            | 6 (3.5%%)                     | 4 (0.8%6)              |
| Oedema peripheral                                               | 3 (1.0%.)              | 7 (6.3%)            | 0                             | 3 (0.6%6)              |
| Malaise                                                         | 1(0.3%)                | 3 (2.7%)            | 2 (1.2%)                      | 2 (0.4%)               |
| Nervous system disorders                                        | 98 (31.8%)             | 32 (28.6%)          | 7 (4.0%)                      | 165 (34.47)            |
| Dysgeusia                                                       | 75 (24.4%)             | 7 (6.3%)            | 1 (0.6%)                      | 119 (24.8%)            |
| Taste disorder                                                  | 10 (3.2%)              | 2 (1.8%:)           | 1 (0.6%)                      | 20 (4.2%)              |
| Peripheral sensory neuropathy                                   | 8 (2.6%)               | 6 (5.4%)            | 0                             | 13 (2.7%.)             |
| Ageusia                                                         | 6 (1.9%)               | 0                   | 0                             | 10 (2.1%)              |
| Dizziness                                                       | 3 (1.0%)               | 6 (5.4%)            | 2 (1.2%)                      | 5 (1.0%)               |
| Headache                                                        | 2 (0.6%)               | 4 (3.6%)            | 0                             | 4 (0.8%6)              |
|                                                                 | 0                      | 4 (3.6%)            | 0                             | 2 (0.4%6)              |
| Newopathy peripheral Investigations                             |                        |                     | 22 (12.7%)                    | 148 (30.9%)            |
|                                                                 | 97 (31.596) 52 (16.9%) | 11 (9.8%) 3 (2.7%%) | 7 (4.0%)                      | 79 (16.5%)             |
| Alanine aminotransferase increased Aspatate aminotransfernse    | 44 (14.3%)             | 1 (0.9%)            | 8(4.6%%)                      | 63 (13.2%)             |
| increased Weight decreased                                      | 32 (10.4%)             | 3 (2.7%)            | 0                             | 51 (10.6%)             |
| Blood alkaline phosphatase increased                            | 18 (5.8%%)             | 1 (0.9%)            | 3 (1.7%%) 5 (2.9%)            | 20 (4.2%%) 19 (4.0%)   |
| Blood creatinine increased Gawma-glutamyltransferase incrensed  | 14 (4.5%) 7 (2.3%%)    | 4 (3.6%) 2 (1.8%)   | 0                             | 9 (1.9%6)              |
| Infections and infestations                                     | 74 (24.0%)             | 12 (10.7%)          | 12 (6.9%)                     | 125 (26.1%)            |
| Paronychia                                                      | 27 (8.8%)              |                     | 1(0.6%)                       | 55 (11.5%)             |
| Conjmctivitis                                                   | 23 (7.5%%)             | 0                   | 2 (1.2%)                      | 35 (7.376)             |
| Nail infection                                                  | 9 (2.9%)               |                     | 0                             | 14 (2.9%)              |
|                                                                 |                        | 0                   |                               |                        |
| Respiratory, thoracic and mediastinal                           | (%861) 19              | 16 (14.3%)          | 15 (8.7%)                     | 103 (21.5%) 35 (7.3%%) |
| disorders Epistaxis                                             | 25 (8.1%)              | 2 (1.8%) 0          | 0 0                           | 25 (5.2%)              |
| Nasal drymess Oropharyngeal pain                                | 14 (4.5%) 4 (1.3%)     | 0                   | 1 (0.6%)                      | 13 (2.7%)              |
| Dyspnoea                                                        | 4 (1.3%)               |                     | 3 (1.7%)                      | 6 (1.3%6)              |
| Cough                                                           |                        | 4 (3.6%)            | 3 (1.7%)                      | 3 (0.6%)               |
|                                                                 | 1 (0.3%)               |                     |                               |                        |
| Pneumonitis                                                     |                        | 4 (3.6%)            | 5 (2.9%)                      | 0                      |
| Musculoskeletal and connective tissue                           | 0                      | 2 (1.8%)            |                               |                        |
| disorders                                                       | 48 (15.6%)             | 18 (16.1%)          | 12 (6.9%) 1 (0.6%)            | 75 (15.7%) 27 (5.6%)   |
| Pain in exremity Arthralgia                                     | 15 (4.9%) 11 (3.6%)    | 3 (2.7%) 4 (3.6%)   | 3 (1.7%%)                     | 20 (4.2%)              |
| Muscle spasms                                                   | 10 (3.2%)              | 1(0.9%)             | 0                             | 18 (3.8%%)             |
| Myalgia                                                         | 5 (1.6%)               | 8 (7.1%)            | 1 (0.6%)                      | 12 (2.5%) 69 (14.4%)   |
| Blood and lymphatic system disorders Anaemia                    | 55 (17.9%6) 38 (12.3%) | 53 (47.3%%)         | 15 (8.7%%) 8 (4.6%)           | 48 (10.0%)             |
|                                                                 |                        | 31 (27.7%6)         |                               | 16 (3.3%6)             |
| Thrombocytopenia                                                | 14 (4.5%)              | 6 (5.4%)            | 5 (2.9%)                      |                        |
| Lymphopenia                                                     | 7 (2.3)                | 3 (2.7%)            | 2 (1.2%) 0                    | 8 (1.726) 6 (1.3%)     |
| Neutropenia Leukopenia                                          | 2 (0.6%)               | 21 (18.8%)          |                               |                        |
|                                                                 | 3 (1.0%)               | 13 (11.6%)          | 0                             | 3 (0.6%6)              |
| Febrile bone marrow aplasia Febrile neutropenia                 | 0 0                    | 3 (2.7%) 9 (8.0%)   | 0 0                           | 0 0                    |
|                                                                 | 23 (7.5%)              | 4 (3.6%)            |                               |                        |
| Renal and wrinary disorders                                     | 20 (6.5%)              | 1 (0.9%)            | 8 (4.6%6)                     | 32 (6.7%6) 24 (5.0%%)  |
| Hepatobiliary disorders Hepatic function abnormal               |                        | 0                   | 4(2.3%) 1 (0.6%)              | 7(1.5%)                |
|                                                                 | 7 (2.3%)               |                     | 5 (2.9%)                      |                        |
| Vascular disorders                                              | 7 (2.396)              | 4 (3.6%)            |                               | 18 (3.8%%)             |
| Endocrine disorders Hyperparathyroidism                         | 13 (4.2%) 8 (2.6%)     | 0 0                 | 26 (15.0%) 0                  | 17 (3.5%) 11 (2.3%)    |
| Hypothyroidism                                                  | 1 (0.3%%)              | 0                   | 18 (10.4%%)                   | 2 (0.4%)               |
| Hyperthyroidism                                                 | 0                      | 0                   | 7 (4.0%)                      | 0                      |
| Reproductive system and breast                                  |                        |                     | 5 (2.9%)                      |                        |
| disorders Ear and labyrinth disorders                           | 12 (3.9%) 6 (1.9%)     | 0 1 (0.9%)          | 2 (1.2%)                      | 17 (3.5%) 10 (2.1%)    |
| Psychiatric disorders                                           | 3 (1.0%)               | 2 (1.8%%)           | 2 (1.2%)                      | 10 (2.1%)              |
|                                                                 | 5 (1.6%)               |                     | 0                             | 7 (1.5%)               |
| Injuy., poisoning and procedual complications Cardiac disorders |                        | 1 (0.9%)            | 1 (0.6%)                      | 4 (0.8%6)              |
| Neoplasms benign, malignant and                                 | 4 (1.3%)               | 2 (1.8%)            |                               | 3 (0.6%)               |
| specified (incl cysts and polyps)                               | 3 (1.0%)               | 2 (1.8%)            | 1 (0.6%)                      |                        |
| Congenital, familial and genetic                                | 0                      |                     | 0                             | 0                      |
| disorders                                                       |                        | 1 (0.9%)            |                               |                        |
|                                                                 |                        | 1(0.9%)             | 0                             | 0                      |
| Immune system disorders                                         | 0                      |                     |                               |                        |

<div style=\"page-break-after: always\"></div>

## Adverse Events of Special Interest (AESI) and of clinical importance

Central serous retinopathy (CSR) has been identified as an AESI for erdafitinib and is a known class effect of FGFR inhibitors. Central serous retinopathy (specifically RPED) is characterised by the separation of the RPE from Bruch's membrane due to the presence of sub-RPE fluid, blood, fibrovascular membrane, or drusenoid material and is attributed to the disruption of the ionic pump of the RPE cells or hyperpermeability of the choroidal vasculature (McCannel 2014).

An overview of Central Serous Retinopathy by worst severity, seriousness, action taken, time to onset and resolution (mUC pool and BLC3001 erdafitinib pool, BLC2001) is provided in Table 68 . No events of CSR were reported for the chemotherapy and the pembrolizumab arm of study BLC3001.

Table 68: Central Serous Retinopathy by Worst Severity, Seriousness, Action Taken, Time to Onset, and Resolution: mUC Pool and BLC3001 Erdafitinib Pool, BLC2001

|                                             | BLC3001 Erdafitinib Pool (n=308)   | mUC Pool (n=479)   | BLC2001 (n=99)   |
|---------------------------------------------|------------------------------------|--------------------|------------------|
| Overall Incidence                           | 62 (20.1%)                         | 103 (21.5%)        | 23 (23.2%)       |
| Maximum Severity                            |                                    |                    |                  |
| Grade 3 or 4:                               | 5 (1.6%)                           | 11 (2.3%)          | 3 (3.0%)         |
| Grade 4:                                    | 0                                  | 0                  | 0                |
| Serious Events                              | 5 (1.6%)                           | 12 (2.5%)          | 3 (3%)           |
| Dose Modification                           |                                    |                    |                  |
| Reduction                                   | 40 (13.0%)                         | 58 (12.1%)         | 13 (13%)         |
| Interruption                                | 25 (8.1%)                          | 41 (8.6%)          | 8 (8%)           |
| Discontinuation                             | 8 (2.6%)                           | 14 (2.9%)          | 3 (3%)           |
| Median Time to First                        |                                    |                    |                  |
| Onset (days [range])                        |                                    |                    |                  |
| Any grade                                   | 44 (5; 274)                        | 45 (5; 554)        | 53               |
| Grade 3:                                   | 52 (24; 111)                       | 83 (24; 207)       | 87               |
| Time to First Onset by Treatment Interval a |                                    |                    |                  |
| 1 month                                    | 21 (6.8%)                          | 34 (7.1%)          | 6 (6.1%)         |
| >1-2 months                                 | 16 (5.3%)                          | 27 (5.7%)          | 8 (8.5%)         |
| >2-3 months                                 | 13 (4.6%)                          | 20 (4.5%)          | 4 (5%)           |
| >3 months                                   | 12 (4.9%)                          | 22 (5.7%)          | 5 (7.6%)         |
| Resolution at Data Cutoff b                 |                                    |                    |                  |
| Resolved:                                   | 40 (64.5%)                         | 65 (63.1%)         |                  |
| Unresolved                                  | 22 (7.1%)                          | 38 (7.9%)          |                  |
| Grade 1                                     | 14 (4.5%)                          | 23 (4.8%)          |                  |
| Grade 2                                     | 6 (1.9%)                           | 12 (2.5%)          |                  |
| Grade 3                                     | 2 (0.6%)                           | 3 (0.6%)           |                  |
| Grade 4                                     | 0                                  | 0                  |                  |

a For each interval, only subjects who were treated in corresponding intervals and only AE which occurred in corresponding intervals are counted. AEs beyond last doses are assigned to last intervals in which subjects were treated.

b For 'Resolved' percentage calculations are based on the 'Overall Incidence' as the denominator. For 'Unresolved' percentage calculations are based on the total number of subjects as the denominator.

Source: SCS page 52ff

Adverse events of clinical importance include events that are class effects of FGFR inhibitors ( hyperphosphataemia, eye disorders [other than central serous retinopathy], nail and skin disorders ), as well as those identified based on clinical findings (e.g., gastrointestinal disorders ).

<div style=\"page-break-after: always\"></div>

Adverse events of clinical importance were observed at a similar frequency across the mUC pool and the BLC3001 erdafitinib pool, and were observed less frequently in the chemotherapy and pembrolizumab groups.

Hyperphosphataemia is an expected and transient laboratory abnormality of FGFR inhibitors due to their mechanism of action (IB Erdafitinib 2023). Hyperphosphataemia was classified as an adverse event of clinical relevance and detailed recommendations for management of elevated phosphate levels in the further course of treatment were provided in the BLC3001, BLC2001, BLC2002, and EDI1001 protocols. The same recommendations are given in SmPC.

An overview of hyperphosphataemia by worst severity, seriousness, action taken, time to onset and resolution (mUC pool and BLC3001 erdafitinib pool, BLC2001) is provided in Table 69.

Table 69: Hyperphosphataemia by Worst Severity, Seriousness, Action Taken, Time to Onset, and Resolution: mUC Pool and BLC3001 Erdafitinib Pools

|                             | BLC3001 Erdafitinib Pool (n=308)   | mUC Pool (n=479)   | BLC2001 (n=99)   |
|-----------------------------|------------------------------------|--------------------|------------------|
| Overall Incidence           | 242 (78.6%)                        | 376 (78.5%)        | 76 (76.8%)       |
| Maximum Severity            |                                    |                    |                  |
| Grade 3 or 4:               | 8 (2.6%)                           | 14 (2.9%)          | 2 (2%)           |
| Grade 4:                    | 1 (0.3%)                           | 1 (0.2%)           | 0                |
| Serious Events              | 0                                  | 0                  | 0                |
| Dose Modification           |                                    |                    |                  |
| Reduction                   | 11 (3.6%)                          | 25 (5.2%)          | 9 (9%)           |
| Interruption                | 14 (4.5%)                          | 48 (10.0%)         | 23 (23%)         |
| Discontinuation             | 0                                  | 1 (0.2%)           | 1 (1%)           |
| Median Time to First        |                                    |                    |                  |
| Onset (days [range])        |                                    |                    |                  |
| Any grade                   | 15.5 (8; 337)                      | 16 (6; 449)        | 20               |
| Grade 3:                   | 35.5 (22; 190)                     | 35.5 (14; 190)     | 18               |
| Time to First Onset by      |                                    |                    |                  |
| Treatment Interval a        |                                    |                    |                  |
| 1 month                    | 183 (59.4%)                        | 289 (60.3%)        | 60 (60.9%)       |
| >1-2 months                 | 42 (13.8%)                         | 56 (11.8%)         | 8 (8.5%)         |
| >2-3 months                 | 6 (2.1%)                           | 14 (3.2%)          | 5 (6.3%)         |
| >3 months                   | 11 (4.5%)                          | 17 (4.4%)          | 3 (4.5%)         |
| Resolution at Data Cutoff b |                                    |                    |                  |
| Resolved:                   | 200 (82.6%)                        | 315 (83.8%)        |                  |
| Unresolved                  | 42 (13.6%)                         | 60 (12.5%)         |                  |
| Grade 1                     | 32 (10.4%)                         | 48 (10.0%)         |                  |
| Grade 2                     | 10 (3.2%)                          | 12 (2.5%)          |                  |
| Grade 3                     | 0                                  | 0                  |                  |
| Grade 4                     | 0                                  | 0                  |                  |

a For each interval, only subjects who were treated in corresponding intervals and only AE which occurred in corresponding intervals are counted. AEs beyond last doses are assigned to last intervals in which subjects were treated.

b For 'Resolved' percentage calculations are based on the 'Overall Incidence' as the denominator. For 'Unresolved' percentage calculations are based on the total number of subjects as the denominator.

Overall, there was a low incidence of prolonged hyperphosphataemia in both the mUC pool and the BLC3001 erdafitinib pool. The most frequently reported TEAE considered a potential sequela of prolonged hyperphosphataemia (i.e.,  7 mg/dL for &gt;1 month) was hypercalcemia.

<div style=\"page-break-after: always\"></div>

Table 70: Treatment-emergent Adverse Events (TEAEs) Considered Potential Sequalae of Prolonged Hyperphosphataemia by Serum Phosphate; mUC Safety Analysis Set (JNJ42756493 (Erdafitinib))

|                                                                                         | BLC3001                                 | BLC3001        | BLC3001         | mUC Pool          |
|-----------------------------------------------------------------------------------------|-----------------------------------------|----------------|-----------------|-------------------|
|                                                                                         | ERDA Cohort 1 and Cohort 2 8 or 9 mg QD | CHEMO Cohort 1 | PEMBRO Cohort 2 | ERDA 8 or 9 mg QD |
| Overall                                                                                 |                                         |                |                 |                   |
| Total number of subjects                                                                | 308                                     | 112            | 173             | 479               |
| Subjects with any TEAEs considered potential sequalae of prolonged hyperphosphataemia   | 30 (9.7%)                               | 1 (0.9%)       | 12 (6.9%)       | 49 (10.2%)        |
| Hypercalcaemia                                                                          | 16 (5.2%)                               | 1 (0.9%)       | 9 (5.2%)        | 29 (6.1%)         |
| Hyperparathyroidism                                                                     | 11 (3.6%)                               | 0              | 0               | 14 (2.9%)         |
| Hypocalcaemia                                                                           | 5 (1.6%)                                | 0              | 4 (2.3%)        | 11 (2.3%)         |
| Hyperparathyroidism secondary                                                           | 1 (0.3%)                                | 0              | 0               | 2 (0.4%)          |
| With phosphate>=7 mg/dl for >1 month                                                    |                                         |                |                 |                   |
| Total number of subjects                                                                | 13                                      | -              | -               | 16                |
| Subjects with any TEAEs considered potential sequalae of prolonged hyperphosphataemia # | 1 (7.7%)                                | -              | -               | 2 (12.5%)         |
| Hypercalcaemia                                                                          | 0                                       | -              | -               | 1 (6.3%)          |
| Hyperparathyroidism                                                                     | 1 (7.7%)                                | -              | -               | 1 (6.3%)          |

Key: QD = once daily.

TEAEs considered potential sequalae of prolonged hyperphosphataemia include Calcium metabolism disorder, Chondrocalcinosis pyrophosphate, Chvostek  s sign, Hypercalcaemia, Hypercalcaemic nephropathy,

Hypercalcitoninaemia, Hyperparathyroidism, Hyperparathyroidism primary, Hyperparathyroidism secondary, Hyperreflexia, Hypocalcaemia, Hypocalcaemic seizure, Osteomalacia, Tetany, Trousseau  s sign.

#  Only include adverse events which occurred after first assessment of phosphate&gt;=7.0 mg/dL which met the duration criteria of &gt;1 months.

BLC3001 CHEMO Cohort 1: vinflunine 320 mg/m  2  as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m  2  as a 1-hour intravenous infusion every 3 weeks.

BLC3001 PEMBRO Cohort 2: pembrolizumab 200 mg as a 30 -minute intravenous infusion once every 3 weeks.

Table 71 to 74 present the overviews of eye toxicities , n ail and skin disorders as well as gastrointestinal disorders by worst severity, seriousness, action taken, time to onset and resolution (mUC pool and BLC3001 erdafitinib pool, BLC2001).

Table 71: Other Eye Disorders by Worst Severity, Seriousness, Action Taken, Time to Onset, and Resolution: (mUC Pool and BLC3001 Erdafitinib Pool, BLC2001)

|                                           | BLC3001 Erdafitinib Pool (n=308)   | mUC Pool (n=479)   | BLC2001 (N=99)   |
|-------------------------------------------|------------------------------------|--------------------|------------------|
| Overall Incidence                         | 123 (39.9%)                        | 207 (43.2%)        | 62 (62.6%)       |
| Maximum Severity                          |                                    |                    |                  |
| Grade 3 or 4:                             | 6 (1.9%)                           | 14 (2.9%)          | 9 (9%)           |
| Grade 4:                                  | 0                                  | 1 (0.2%)           | 1 (1%)           |
| Serious Events                            | 3 (1.0%)                           | 9 (1.9%)           | 9 (9%)           |
| Dose Modification                         |                                    |                    |                  |
| Reduction                                 | 17 (5.5%)                          | 36 (7.5%)          | 23 (23%)         |
| Interruption                              | 23 (7.5%)                          | 44 (9.2%)          | 16 (16%)         |
| Discontinuation                           | 6 (1.9%)                           | 10 (2.1%)          | 6 (6%)           |
| Median Time to First Onset (days [range]) |                                    |                    |                  |
| Any grade                                 | 46 (1; 444)                        | 49 (1; 828)        |                  |
| Grade 3:                                 | 263.5 (71; 640)                    | 212.5 (60; 640)    |                  |

<div style=\"page-break-after: always\"></div>

## Time to First Onset by Treatment Interval a

| 1 month                    | 33 (10.7%)   | 60 (12.5%)   |
|-----------------------------|--------------|--------------|
| >1-2 months                 | 43 (14.1%)   | 69 (14.6%)   |
| >2-3 months                 | 24 (8.5%)    | 38 (8.6%)    |
| >3 months                   | 23 (9.4%)    | 40 (10.4%)   |
| Resolution at Data Cutoff b |              |              |
| Resolved:                   | 53 (43.1%)   | 102 (49.3%)  |
| Unresolved                  | 70 (22.7%)   | 105 (21.9%)  |
| Grade 1                     | 53 (17.2%)   | 76 (15.9%)   |
| Grade 2                     | 15 (4.9%)    | 26 (5.4%)    |
| Grade 3                     | 2 (0.6%)     | 2 (0.4%)     |
| Grade 4                     | 0            | 1 (0.2%)     |

- a For each interval, only subjects who were treated in corresponding intervals and only AE which occurred in corresponding intervals are counted. AEs beyond last doses are assigned to last intervals in which subjects were treated.

b For 'Resolved' percentage calculations are based on the 'Overall Incidence' as the denominator. For 'Unresolved' percentage calculations are based on the total number of subjects as the denominator.

Source: SCS, page58

Table 72: Nail Disorders by Worst Severity, Seriousness, Action Taken, Time to Onset, and Resolution (mUC Pool and BLC3001 Erdafitinib Pools, BLC2001)

|                                             | BLC3001 Erdafitinib Pool (n=308)   | mUC Pool (n=479)   | BLC2001 (n=99)   |
|---------------------------------------------|------------------------------------|--------------------|------------------|
| Overall Incidence                           | 192 (62.3%)                        | 300 (62.6%)        | 56 (56.6%)       |
| Maximum Severity                            |                                    |                    |                  |
| Grade 3:                                    | 39 (12.7%)                         | 60 (12.5%)         | 14 (14%)         |
| No CTCAE Grade 4                            |                                    |                    | none             |
| Serious Events                              | 2 (0.6%)                           | 2 (0.4%)           | none             |
| Dose Modification                           |                                    |                    |                  |
| Reduction                                   | 70 (22.7%)                         | 105 (21.9%)        | 20 (20%)         |
| Interruption                                | 66 (21.4%)                         | 98 (20.5%)         | 17 (17%)         |
| Discontinuation                             | 8 (2.6%)                           | 10 (2.1%)          | 1 (1%)           |
| Median Time to First Onset (days [range])   |                                    |                    |                  |
| Any grade                                   | 59 (2; 617)                        | 63 (2; 617)        | 68               |
| Grade 3:                                   | 104 (50; 357)                      | 106 (50; 390)      | 112              |
| Time to First Onset by Treatment Interval a |                                    |                    |                  |
| 1 month                                    | 23 (7.5%)                          | 30 (6.3%)          | 4 (4%)           |
| >1-2 months                                 | 77 (25.3%)                         | 116 (24.5%)        | 20 (21.3%)       |
| >2-3 months                                 | 46 (16.3%)                         | 84 (19.0%)         | 21 (26.3%)       |
| >3 months                                   | 46 (18.9%)                         | 70 (18.3%)         | 11 (16.7%)       |
| Resolution at Data Cutoff b                 |                                    |                    |                  |
| Resolved:                                   | 44 (22.9%)                         | 83 (27.7%)         |                  |
| Unresolved                                  | 148 (48.1%)                        | 217 (45.3%)        |                  |
| Grade 1                                     | 66 (21.4%)                         | 112 (23.4%)        |                  |
| Grade 2                                     | 67 (21.8%)                         | 87 (18.2%)         |                  |
| Grade 3                                     | 15 (4.9%)                          | 18 (3.8%)          |                  |
| Grade 4                                     | 0                                  | 0                  |                  |

<div style=\"page-break-after: always\"></div>

| BLC3001 Erdafitinib Pool (n=308)   | mUC Pool (n=479)   | BLC2001 (n=99)   |
|------------------------------------|--------------------|------------------|

a    For each interval, only subjects who were treated in corresponding intervals and only AE which occurred in corresponding intervals are counted. AEs beyond last doses are assigned to last intervals in which subjects were treated.

b For 'Resolved' percentage calculations are based on the 'Overall Incidence' as the denominator. For 'Unresolved' percentage calculations are based on the total number of subjects as the denominator.

Source: SCS page 61

Table 73: Skin Disorders by Worst Severity, Seriousness, Action Taken, Time to Onset, and Resolution (mUC Pool and BLC3001 Erdafitinib Pool, BLC2001)

|                                             | BLC3001 Erdafitinib Pool (n=308)   | mUC Pool (n=479)   | BLC2001 (n=99)   |
|---------------------------------------------|------------------------------------|--------------------|------------------|
| Overall Incidence                           | 168 (54.5%)                        | 261 (54.5%)        | 50 (50%)I        |
| Maximum Severity                            |                                    |                    |                  |
| Grade 3 or 4:                               | 36 (11.7%)                         | 48 (10.0%)         | 7 (7%)           |
| Grade 4:                                    | 0                                  | 0                  | 0                |
| Serious Events                              | 2 (0.6%)                           | 3 (0.6%)           | 1 (1%)           |
| Dose Modification                           |                                    |                    |                  |
| Reduction                                   | 42 (13.6%)                         | 58 (12.1%)         | 9 (9%)           |
| Interruption                                | 51 (16.6%)                         | 72 (15.0%)         | 10 (10%)         |
| Discontinuation                             | 4 (1.3%)                           | 8 (1.7%)           | 3 (3%)           |
| Median Time to First Onset (days)           |                                    |                    |                  |
| Any grade                                   | 43.5 (2; 463)                      | 47 (1; 463)        | 40               |
| Grade 3:                                   | 135 (27; 463)                      | 116 (27; 463)      | 94               |
| Time to First Onset by Treatment Interval a |                                    |                    |                  |
| 1 month                                    | 49 (15.9%)                         | 75 (15.7%)         | 22 (22.2%)       |
| >1-2 months                                 | 57 (18.8%)                         | 91 (19.2%)         | 13 (13.8%)       |
| >2-3 months                                 | 27 (9.5%)                          | 44 (10.0%)         | 9 (11.3%)        |
| >3 months                                   | 35 (14.3%)                         | 51 (13.3%)         | 6 (9.1%)         |
| Resolution at Data Cutoff b                 |                                    |                    |                  |
| Resolved:                                   | 70 (41.7%)                         | 109 (41.8%)        |                  |
| Unresolved                                  | 97 (31.5%)                         | 151 (31.5%)        |                  |
| Grade 1                                     | 58 (18.8%)                         | 91 (19.0%)         |                  |
| Grade 2                                     | 30 (9.7%)                          | 50 (10.4%)         |                  |
| Grade 3                                     | 9 (2.9%)                           | 10 (2.1%)          |                  |
| Grade 4                                     | 0                                  | 0                  |                  |

a    For each interval, only subjects who were treated in corresponding intervals and only AE which occurred in corresponding intervals are counted. AEs beyond last doses are assigned to last intervals in which subjects were treated.

b    For 'Resolved' percentage calculations are based on the 'Overall Incidence' as the denominator. For 'Unresolved' percentage calculations are based on the total number of subjects as the denominator.

<div style=\"page-break-after: always\"></div>

Table 74: Gastrointestinal Events by Worst Severity, Seriousness, Action Taken, Time to Onset, and Resolution (mUC Pool and BLC3001 Erdafitinib Pool, BLC2001)

|                             | BLC3001 Erdafitinib Pool (n=308)   | mUC Pool (n=479)   | BLC2001 (n=99)   |
|-----------------------------|------------------------------------|--------------------|------------------|
| Overall Incidence           | 255 (82.8%)                        | 402 (83.9%)        | 91 (91.9%)       |
| Diarrhea                    | 176 (57.1)                         | 266 (55.5%)        | 50 (50.5%)       |
| Stomatitis                  | 147 (57.1)                         | 253 (52.8%)        | 57 (57.6%)       |
| Dry mouth                   | 116 (47.7)                         | 191 (39.9%)        | 45 (45.5%)       |
| Maximum Severity            |                                    |                    |                  |
| Grade 3 or 4:               | 38 (12.3%)                         | 68 (14.2%)         |                  |
| Grade 4:                    | 1 (0.3%)                           | 1 (0.2%)           |                  |
| Diarrhea                    | 12 (3.9%)                          | 19 (4%)            | 10 (10.1%)       |
| Stomatitis                  | 4 (1.3%)                           | 5 (1%)             | 4 (4.0%)         |
| Dry mouth                   |                                    |                    |                  |
| Serious Events              | 6 (1.9%)                           | 7 (1.5%)           |                  |
| Dose Modification           |                                    |                    |                  |
| Reduction                   | 61 (19.8%)                         | 99 (20.7%)         |                  |
| Interruption                | 65 (21.1%)                         | 118 (24.6%)        |                  |
| Discontinuation             | 6 (1.9%)                           | 13 (2.7%)          |                  |
| Median Time to First        |                                    |                    |                  |
| Any grade                   | 15 (1; 343)                        | 15 (1; 445)        |                  |
| Grade 3:                   | 50.5 (2; 287)                      | 54.5 (2; 585)      |                  |
| Time to First Onset by      |                                    |                    |                  |
| 1 month                    | 187 (60.7%)                        | 298 (62.2%)        |                  |
| >1-2 months                 | 44 (14.5%)                         | 55 (11.6%)         |                  |
| >2-3 months                 | 12 (4.2%)                          | 24 (5.4%)          |                  |
| >3 months                   | 12 (4.9%)                          | 25 (6.5%)          |                  |
| Resolution at Data Cutoff b |                                    |                    |                  |
| Resolved:                   | 110 (43.1%)                        | 186 (46.3%)        |                  |
| Unresolved                  | 144 (46.8%)                        | 215 (44.9%)        |                  |
| Grade 1                     | 99 (32.1%)                         | 148 (30.9%)        |                  |
| Grade 2                     | 37 (12.0%)                         | 57 (11.9%)         |                  |
| Grade 3                     | 7 (2.3%)                           | 9 (1.9%)           |                  |
| Grade 4                     | 1 (0.3%)                           | 1 (0.2%)           |                  |

a    For each interval, only subjects who were treated in corresponding intervals and only AE which occurred in corresponding intervals are counted. AEs beyond last doses are assigned to last intervals in which subjects were treated.

b    For 'Resolved' percentage calculations are based on the 'Overall Incidence' as the denominator. For 'Unresolved' percentage calculations are based on the total number of subjects as the denominator.

In view of the already approved FGFR inhibitors (pemigatinib and futibatinib), attention should also be paid to potential renal and hepatic toxicities .

<div style=\"page-break-after: always\"></div>

In the erdafitinib pool, increase of blood creatinine was reported as a treatment emergent AE in 14.9% (46 subjects) of subjects, consisting of 8.1% (25 subjects) Grade 1 and 6.8% (21 subjects) Grade 2 elevations (in contrast to 6.3% in the chemotherapy arm and 7.5% in the pembrolizumab arm). Furthermore, acute kidney injury was seen in 5.5% (17 subjects), renal impairment in 3.6% (11 subjects) and renal failure in 3.2% (10 subjects). For 9 subjects (2.9%) a SAE of acute kidney injury was reported, 2 out of 52 patients discontinued the treatment due to acute kidney injury resp. renal failure.

In the erdafitinib pool increase of transaminases was reported as a treatment emergent AE in 21.1% (ALT) respectively 18.5% (AST) (in contrast to 3.6% (ALT) resp. 2.7% (AST) in the chemotherapy arm and 7.5% (ALT) resp. 8.1% (AST) in the pembrolizumab arm). In addition, hepatobiliary disorders were reported in 10.4%. Dose modifications due to increased transaminases were reported for 3.9%.

## 2.8.8.3. Serious adverse event/deaths/other significant events

Serious adverse events were reported in 42.6% of patients in the mUC pool. SAEs were considered treatment-related in 12.9% of patients (n=62).

SAEs occurred at a similar frequency in the BLC3001 erdafitinib pool (125 [40.6%] of 308 subjects), the chemotherapy group (47 [42.0%] of 112 subjects), and the pembrolizumab group (80 [46.2%] of 173 subjects). Of note, in the supportive study BLC2001 in the 8-mg daily regimen, serious TEAEs occurred in 39 subjects (39%).

Overall, 66.2% of 479 subjects on the mUC pool died. The majority of deaths (270 of 317) were due to progressive disease, 4.8% were due to adverse events. 12.3% of the 479 subjects died within 30 days of the last dose: 41 of 59 (8.6%) deaths were due to progressive disease and 18 of 59 (3.8%) deaths were due to an AE. Of note, in the BLC3001 erdafitinib pool 12 of 40 (3.9%) deaths were due to an AE.

Grade 5 TEAEs considered by the investigator to be related to treatment were reported by 1 subject in the BLC3001 erdafitinib pool (sudden death), 6 subjects in the chemotherapy group (febrile bone marrow aplasia [n=2], septic shock [n=2], atypical pneumonia, and febrile neutropenia), and 3 subjects in the pembrolizumab group (pulmonary embolism, respiratory failure, and urinary tract infection).

For subjects in the 8-mg daily regimen of the phase 2 study BLC2001, as of the clinical cut-off, 40 subjects (40%) had died. The primary reason for death (39 subjects; 39%) was progression of disease. One subject died due to an adverse event (acute myocardial infarction, considered not related to erdafitinib). Eight subjects (8.1%) died within 30 days of last dose including the 1 subject who died due to the adverse event.

Of note, in the BLC3001 erdafitinib pool 1 patient died due to an adverse event of renal failure within the 30-day safety follow-up period. However, this death was not considered treatment-related.

## 2.8.8.4. Laboratory findings and vital signs

Table 75 describes haematological laboratory abnormalities observed in  10%, or in  5% at Grade 3 or 4, of subjects in the BCL3001 erdafitinib pool.

<div style=\"page-break-after: always\"></div>

Table 75: Laboratory Abnormalities Reported in  10% (All Grade) or  5% (Grade 3-4); Erdafitinib Safety Analysis Set (Study 42756493-BLC3001)

|                                | Erdafitinib(N=308)   | Erdafitinib(N=308)   |
|--------------------------------|----------------------|----------------------|
|                                | All Grades (%)       | Grade 3-4 (%)        |
| HematologyLaboratoryAbnomslity |                      |                      |
| Anemia                         | 47.1                 | 9.1                  |
| WhiteBloodCellDecreased        | 26.9                 | 0.6                  |
| PlateletCountDecreased         | 15.9                 | 1.0                  |
| NeulrophilCouwtDecreased       | 15.6                 | 0.6                  |

Table 76 describes chemistry laboratory abnormalities observed in  10%, or in  5% at Grade 3 or 4, in subjects in the BCL3001 erdafitinib pool. Of note, hyperphosphataemia, hyponatremia, and blood creatinine increased have been identified as ADRs.

Table 76: Laboratory Abnormalities Reported in  10% (All Grade) or  5% (Grade 3-4); Erdafitinib Safety Analysis Set (Study 42756493-BLC3001)

|                                      | Erdafilimib (N=308)   | Erdafilimib (N=308)   |
|--------------------------------------|-----------------------|-----------------------|
|                                      | All Grades (%)        | Grade 3-4 (%6)        |
| ChemistryLaboratoryAbnonmality       |                       |                       |
| Hyperphosphatemia                    | 68.8                  | 2.6                   |
| Alkaline PhosphataseIncreased        | 49.7                  | 4.2                   |
| Creatinine Increased                 | 49.7                  | 2.3                   |
| AlamineAminotransferaseIncreased     | 46.1                  | 3.2                   |
| Aspariate Aminotransferase Increased | 43.5                  | 2.3                   |
| Hyponatremia                         | 40.9                  | 15.3                  |
| Hypophosphatemia                     | 33.1                  | 8                     |
| Hypomaguesemia                       | 24.0                  | E'0                   |
| Hyperkalemia                         | 21.8                  | 2.3                   |
| Hypoalbuminemia                      | 15.6                  | 0                     |
| Blood BilinubinIncreased             | 11.7                  | 1.9                   |
| Hypokalemia                          | 10.7                  | 1.6                   |

Electrocardiograms were collected throughout the study EDI1001. No subjects had an average change from baseline in QTcF or QTcB that exceeded 60 msec. 10% had maximum average change in QTcB between 30 and 60 msec. Furthermore, average QTc values exceeded 500 msec post-baseline for 2 subjects, 1 subject with average QTcF and QTcB over 500 msec and 1 subject with average QTcB over 500 msec. 5 subjects had individual recordings that exceeded 500 msec. 10% and 0.5% of subjects had maximum post baseline QTcF values of 450 - 480 msec, and 480 - 500 msec, respectively.

Four subjects (2%) had electrocardiogram QT prolonged reported as an AE. For 2 subjects, electrocardiogram QT prolonged was considered related to study drug. One subject discontinued treatment due to electrocardiogram QT prolonged of grade3 and considered related to erdafitinib.

In study BLC3001 cohort 1, 12-lead ECGs were performed at screening, cycle 2 day 1, and cycle 4 day 1. 3 (2.5%) subjects in the erdafitinib group had  60 msec change in QTcF interval during treatment. 7 (5.8%) subjects in the erdafitinib group had  30-60 msec change in QTcF interval during treatment. At cycle 2 day 1, 1 (0.9%) subject in the erdafitinib group had a QTcF value above 500 msec (and 60 msec change in QTcF interval). The subject was hospitalised and the investigator considered these events not related to erdafitinib. The subject subsequently died suddenly; no signs or symptoms were reported prior to death. 5 subjects (4.4%) had a QTcF value &gt;450(M) or &gt;470(F). At cycle 4 day 1, 3 (3.4%) subjects in the erdafitinib group had a QTcF value 450(M) or &gt;470(F).

In study BLC3001 cohort 2, at cycle 2 day 1, 9 (6%) subjects in the erdafitinib group had a QTcF value &gt;450(M) or &gt;470(F). At cycle 4 day 1, 4 (3.8%) subjects had a QTcF value &gt;450(M) or &gt;470(F) and 1 subject (1%) had a QTcF value above 500 msec. Three (2.0%) subjects in the erdafitinib group had  60 msec change in QTcF interval during treatment, and 8 subjects (5.3%) had  30-60 msec change in QTcF interval during treatment.

<div style=\"page-break-after: always\"></div>

## 2.8.8.5. Safety in special populations

Analyses of TEAEs were performed to evaluate potential differences in the safety of erdafitinib in subgroups of subjects defined by age, sex, geographic region, tumour histology, and creatinine clearance. An overview of these results for the mUC pool is presented in Table 77 .

Table 77: Overall Summary of Treatment-emergent Adverse Events by Demographic Subgroups; mUC Safety Analysis Set (JNJ-42756493 (Erdafitinib))

|                                         |                   | Na   | TEAE         | Serious TEAE   | Grade 3 or Higher   | Grade 3     | Grade 4    | TEAE Leading to Study Treatment Discontinuationb   | TEAE Leading to Deathc   |
|-----------------------------------------|-------------------|------|--------------|----------------|---------------------|-------------|------------|----------------------------------------------------|--------------------------|
| mUCPool ERDA8or 9 mgQD                  |                   |      |              |                |                     |             |            |                                                    |                          |
| Total number of subjects                |                   | 479  | 477 (99.6%)  | 204 (42.6%)    | 322 (67.2%)         | 317 (66.2%) | 42 (8.8%)  | 93 (19.4%)                                         | 29 (6.1%)                |
| Age (years):                            | <65 years         | 191  | 190 (99.5%)  | 73 (38.2%)     | 126 (66.0%)         | 123 (64.4%) | 13 (6.8%)  | 20 (10.5%)                                         | 7 (3.7%)                 |
|                                         | >=65 years        | 288  | 287 (99.7%)  | 131 (45.5%)    | 196 (68.1%)         | 194 (67.4%) | 29 (10.1%) | 73 (25.3%)                                         | 22 (7.6%)                |
| Sex:                                    | Male              | 365  | 363 (99.5%)  | 154 (42.2%)    | 237 (64.9%)         | 232 (63.6%) | 32 (8.8%)  | 70 (19.2%)                                         | 21 (5.8%)                |
|                                         | Female            | 114  | 114 (100.0%) | 50 (43.9%)     | 85 (74.6%)          | 85 (74.6%)  | 10 (8.8%)  | 23 (20.2%)                                         | 8 (7.0%)                 |
| Geographic region:                      | North             |      |              |                |                     |             |            |                                                    |                          |
|                                         | America           | 44   | 44 (100.0%)  | 22 (50.0%)     | 32 (72.7%)          | 32 (72.7%)  | 5 (11.4%)  | 9 (20.5%)                                          | 2 (4.5%)                 |
|                                         | Europe            | 328  | 326 (99.4%)  | 134 (40.9%)    | 220 (67.1%)         | 216 (65.9%) | 29 (8.8%)  | 75 (22.9%)                                         | 21 (6.4%)                |
|                                         | Rest of the World | 107  | 107 (100.0%) | 48 (44.9%)     | 70 (65.4%)          | 69 (64.5%)  | 8 (7.5%)   | 9 (8.4%)                                           | 6 (5.6%)                 |
| Baseline creatinine clearance (mL/min): | 30                | 5    | 5 (100.0%)   | 4 (80.0%)      | 4 (80.0%)           | 4 (80.0%)   | 1 (20.0%)  | 2 (40.0%)                                          | 0                        |
|                                         | >=30 to <60       | 217  | 216 (99.5%)  | 99 (45.6%)     | 151 (69.6%)         | 149 (68.7%) | 21 (9.7%)  | 51 (23.5%)                                         | 17 (7.8%)                |
|                                         | >=60              | 257  | 256 (99.6%)  | 101 (39.3%)    | 167 (65.0%)         | 164 (63.8%) | 20 (7.8%)  | 40 (15.6%)                                         | 12 (4.7%)                |

Key:QD=once daily,TEAE=treatment-emergent adverse event,CRF=case report form.

b Treatment discontinuation due to adverse event on the end of treatment CRF page.

Percentages are calculated with the number of subjects in each subgroup as denominator.

c TEAE with outcome death on the AE CRF page or with toxicity grade 5.

BLC3001 inclusion criterion on renal function: Creatinine clearance (CrCl) &gt;30 mL/min either directly measured via 24-hour urine collection or calculated using the Cockcroft-Gault formula.In this table,Cockcroft-GaultFormulais usedfor calculating estimated baseline creatinine clearance.That is thereason why there arepatientswithbaseline creatinine clearance &lt;30 (mL/min) in the table.

BLC3001 CHEMO Cohort 1: vinflunine 320 mg/m as a 20-minute intravenous infusion once every 3weeks or docetaxel 75 mg/mas a1-hour intravenous infusion every 3weeks. BLC3001PEMBRO Cohort 2: pembrolizumab 200mg as a 30-minute intravenous infusion once every 3 weeks.

<div style=\"page-break-after: always\"></div>

Table 78: Treatment Emergency Adverse Events by Age group; mUC Safety Analysis

|                                                                                       | mUC Pool ERDA 8 or 9 mg QD   | mUC Pool ERDA 8 or 9 mg QD   | mUC Pool ERDA 8 or 9 mg QD   | mUC Pool ERDA 8 or 9 mg QD   |
|---------------------------------------------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                                                                       | Age <65                      | Age 65-74                    | Age 75-84                    | Age 85+                      |
| Total number of subjects                                                              | 191                          | 191                          | 85                           | 12                           |
| Subjects with 1 or more:                                                              |                              |                              |                              |                              |
| AEs                                                                                   | 190 (99.5%)                  | 191 (100.0%)                 | 84 (98.8%)                   | 12 (100.0%)                  |
| Related AEs                                                                           | 187 (97.9%)                  | 185 (96.9%)                  | 80 (94.1%)                   | 12 (100.0%)                  |
| AEs leading to discontinuation of study agent                                         | 20 (10.5%)                   | 39 (20.4%)                   | 29 (34.1%)                   | 5 (41.7%)                    |
| Serious AEs                                                                           | 73 (38.4%)                   | 92 (48.2%)                   | 35 (41.7%)                   | 4 (33.3%)                    |
| Fatal                                                                                 | 7 (3.7%)                     | 14 (7.3%)                    | 6 (7.1%)                     | 2 (16.7%)                    |
| Hospitalization/prolong existing hospitalization                                      | 66 (82.5%)                   | 78 (81.3%)                   | 31 (70.5%)                   | 4 (80.0%)                    |
| Life-threatening                                                                      | 5 (2.6%)                     | 10 (5.2%)                    | 5 (5.9%)                     | 0                            |
| Disability/incapacity                                                                 | 5 (2.6%)                     | 7 (3.7%)                     | 1 (1.2%)                     | 0                            |
| Other (medically significant)                                                         | 7 (3.7%)                     | 13 (6.8%)                    | 5 (5.9%)                     | 0                            |
| Infectionsandinfestations                                                             | 93 (48.7%)                   | 109 (57.1%)                  | 46 (54.1%)                   | 6 (50.0%)                    |
| Related AEs                                                                           | 43 (22.5%)                   | 54 (28.3%)                   | 25 (29.4%)                   | 3 (25.0%)                    |
| Serious AEs                                                                           | 17 (8.9%)                    | 31 (16.2%)                   | 12 (14.1%)                   | 1 (8.3%)                     |
| Nervous system disorders                                                              | 84 (44.0%)                   | 87 (45.5%)                   | 37 (43.5%)                   | 8 (66.7%)                    |
| Related AEs                                                                           | 64 (33.5%)                   | 67 (35.1%)                   | 28 (32.9%)                   | 6 (50.0%)                    |
| Serious AEs                                                                           | 2 (1.0%)                     | 3 (1.6%)                     | 1 (1.2%)                     | 0                            |
| Central serous retinopathy                                                            | 30 (15.7%)                   | 50 (26.2%)                   | 21 (24.7%)                   | 2 (16.7%)                    |
| Related AEs                                                                           | 28 (14.7%)                   | 47 (24.6%)                   | 20 (23.5%)                   | 2 (16.7%)                    |
| Serious AEs                                                                           | 3 (1.6%)                     | 7 (3.7%)                     | 2 (2.4%)                     | 0                            |
| Accidents and injuries                                                                | 26 (13.6%)                   | 26 (13.6%)                   | 16 (18.8%)                   | 3 (25.0%)                    |
| Related AEs                                                                           | 10 (5.2%)                    | 15 (7.9%)                    | 11 (12.9%)                   | 0                            |
| Serious AEs                                                                           | 4 (2.1%)                     | 1 (0.5%)                     | 1 (1.2%)                     | 1 (8.3%)                     |
| Vascular disorders                                                                    | 24 (12.6%)                   | 25 (13.1%)                   | 12 (14.1%)                   | 0                            |
| Related AEs                                                                           | 7 (3.7%)                     | 6 (3.1%)                     | 5 (5.9%)                     | 0                            |
| Serious AEs                                                                           | 1 (0.5%)                     | 4 (2.1%)                     | 2 (2.4%)                     | 0                            |
| Psychiatric disorders                                                                 | 21 (11.0%)                   | 14 (7.3%)                    | 9 (10.6%)                    | 2 (16.7%)                    |
| Related AEs                                                                           | 6 (3.1%)                     | 2 (1.0%)                     | 1 (1.2%)                     | 1 (8.3%)                     |
| Serious AEs                                                                           | 1 (0.5%)                     | 0                            | 1 (1.2%)                     | 0                            |
| Cardiac disorders                                                                     | 8 (4.2%)                     | 12 (6.3%)                    | 6 (7.1%)                     | 0                            |
| Related AEs                                                                           | 0                            | 4 (2.1%)                     | 0                            | 0                            |
| Serious AEs                                                                           | 1 (0.5%)                     | 3 (1.6%)                     | 4 (4.7%)                     | 0                            |
| Sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia, fractures | 6 (3.1%)                     | 6 (3.1%)                     | 7 (8.2%)                     | 2 (16.7%)                    |
| Related AEs                                                                           | 2 (1.0%)                     | 2 (1.0%)                     | 3 (3.5%)                     | 0                            |

|                              | mUCPoolERDA8or 9 mgQD   | mUCPoolERDA8or 9 mgQD   | mUCPoolERDA8or 9 mgQD   | mUCPoolERDA8or 9 mgQD   |
|------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
|                              | Age <65                 | Age 65-74               | Age 75-84               | Age 85+                 |
| SeriousAEs                   | 0                       | 0                       | 0                       | 0                       |
| Cerebrovascular disorders    | 1 (0.5%)                | 2 (1.0%)                | 1 (1.2%)                | 1 (8.3%)                |
| Related AEs                  | 0                       | 1 (0.5%)                | 0                       | 0                       |
| Serious AEs                  | 1 (0.5%)                | 0                       | 1 (1.2%)                | 0                       |
| Anticholinergic syndrome     | 127 (66.5%)             | 110 (57.6%)             | 52 (61.2%)              | 9 (75.0%)               |
| Related AEs                  | 110 (57.6%)             | 94 (49.2%)              | 45 (52.9%)              | 7 (58.3%)               |
| Serious AEs                  | 5 (2.6%)                | 4 (2.1%)                | 4 (4.7%)                | 3 (25.0%)               |
| AEsof clinicalimportance     |                         |                         |                         |                         |
| Gastrointestinaltoxicity     | 161 (84.3%)             | 156 (81.7%)             | 74 (87.1%)              | 11 (91.7%)              |
| Related AEs                  | 152 (79.6%)             | 145 (75.9%)             | 73 (85.9%)              | 11 (91.7%)              |
| Serious AEs                  | 1 (0.5%)                | 5 (2.6%)                | 1 (1.2%)                | 0                       |
| Hyperphosphatemia            | 155 (81.2%)             | 147 (77.0%)             | 63 (74.1%)              | 11 (91.7%)              |
| Related AEs                  | 151 (79.1%)             | 139 (72.8%)             | 60 (70.6%)              | 11 (91.7%)              |
| Serious AEs                  | 0                       | 0                       | 0                       | 0                       |
| Nail toxicity                | 121 (63.4%)             | 115 (60.2%)             | 54 (63.5%)              | 10 (83.3%)              |
| Related AEs                  | 120 (62.8%)             | 111 (58.1%)             | 51 (60.0%)              | 9 (75.0%)               |
| Serious AEs                  | 1 (0.5%)                | 1 (0.5%)                | 0                       | 0                       |
| Skin toxicity                | 111 (58.1%)             | 98 (51.3%)              | 45 (52.9%)              | 7 (58.3%)               |
| Related AEs                  | 108 (56.5%)             | 91 (47.6%)              | 44 (51.8%)              | 6 (50.0%)               |
| Serious AEs                  | 2 (1.0%)                | 0                       | 0                       | 1 (8.3%)                |
| Eye toxicity (excluding CSR) | 90 (47.1%)              | 72 (37.7%)              | 40 (47.1%)              | 5 (41.7%)               |
| Related AEs                  | 85 (44.5%)              | 63 (33.0%)              | 32 (37.6%)              | 3 (25.0%)               |
| Serious AEs                  | 4 (2.1%)                | 3 (1.6%)                | 2 (2.4%)                | 0                       |

Key:QD=once daily,TEAE =treatment-emergent adverse event

Accidents and injuries are based on the Standardized MedDRA Query (SMQ) per MedDRA Version 24.1.

## 2.8.8.6. Immunological events

N/A

<div style=\"page-break-after: always\"></div>

## 2.8.8.7. Safety related to drug-drug interactions and other interactions

Refer to section 2.6.1.

## 2.8.8.8. Discontinuation due to adverse events

Incidence  of  treatment-emergent  adverse  events  leading  to  dose  modification  by  preferred  term  is summarised in Table 79.

Table 79: Incidence of Treatment-emergent Adverse Events Leading to Dose Modification (which include dose interruption, dose reduction, or both) by Preferred Term; mUC Safety Analysis Set (JNJ-42756493 (Erdafitinib))

|                                             | BLC3001                                   | BLC3001            | BLC3001     | mUC Pool                   |
|---------------------------------------------|-------------------------------------------|--------------------|-------------|----------------------------|
| Total number of subjects                    | ERDA Cohort l and Cohort 2 8or 9mg QD 308 | CHEMO Cohort 1 112 | 173         | PEMBRO Cohont2ERDA8or9mgQD |
| Subjects with TEAEs                         | 259 (84.1%%)                              | 52 (46.4%)         | 57 (32.9%%) | 394 (82.3%6)               |
| Preferred tem                               |                                           |                    |             |                            |
| Stomatitis                                  | 65 (21.1%)                                | 2(1.8%)            | 0           | 121 (25.3%)                |
| Palmar-plantar erythrodysaesthesia syndrome | 49 (15.9%)                                | 1(0.9%)            | 0           | 71 (14.8%)                 |
| Hyperphosphataemia                          | 23 (7.5%0)                                | 0                  | 0           | 61 (12.7%0)                |
| Onycholysis                                 | 43 (14.0%)                                | 0                  | 0           | 58 (12.1%))                |
| Dianhoea                                    | 37 (12.0%)                                | 4 (3.6%%)          | 0           | 48 (10.0%)                 |
| Nail dystrophy                              | 13 (4.2%)                                 | 0                  | 0           | 28 (5.8%)                  |
| Onychomndesis                               | 21 (6.8%%)                                | 0                  | 0           | 28 (5.8%%)                 |
| Chorioretinopathy                           | 17 (5.5%)                                 | 0                  | 0           | 26 (5.4%)                  |
| Paronychia                                  | 9(2.9%6)                                  | 0                  | 0           | 24 (5.0%%)                 |
| Asthenia                                    | 11 (3.6%)                                 | 7 (6.39%)          | 1 (0.6%)    | 22 (4.6%%)                 |
| Decrensed appetite                          | 15 (4.9%)                                 | 2 (1.8%6)          | 1 (0.6%%)   | 22 (4.6%%)                 |
| Fatigue                                     | 7(2.3%4)                                  | 2(1.)              | 4(2.3%)     | 22 (4.6%)                  |
| Nail discolowation                          | 17 (5.5%)                                 | 0                  | 0           | 20 (4.2%:)                 |
| Alanine aminotransferase incrensed          | 12 (3.9%)                                 | 0                  | 3 (1.7%%)   | 18 (3.8%%)                 |
| Hyponatraemia                               | 12 (3.9%)                                 | 0                  | 0           | 18 (3.8%)                  |
| Vision blured                               | 7 (2.3%)                                  | 0                  | 0           | 18 (3.8%)                  |
| Detachment of retinal pigment epithelium    | 12 (3.9%%)                                | 0                  | 0           | 17 (3.5%)                  |
| Dry mouth                                   | 11 (3.6%)                                 | 0                  | 0           | 17 (3.5%)                  |
| Aspartate aminotransferase incrensed        | 12 (3.996)                                | 0                  | 3 (1.7%)    | 16 (3.3%)                  |
| Kernatitis                                  | 8 (2.6%)                                  | 0                  | 0           | 16 (3.3%)                  |
| Vomiting                                    | 9(2.9%)                                   | 0                  | 1 (0.6%)    | 16 (3.3%)                  |
|                                             | 12 (3.9%)                                 | 0                  |             | 15 (3.1%)                  |
| Dysgeusia                                   | 7 (2.3%)                                  | 0                  | 0           | 14 (2.9%)                  |
| Nail disorder                               | 8 (2.6%.)                                 | 0                  | D           | 14 (2.9%)                  |
| Nausea                                      | 8 (2.6%)                                  | 2(1.8%)            | 1 (0.6%)    | 13 (2.7%)                  |
| Pain in exiremity                           | 8 (2.6%)                                  | 1(0.9%%)           | 0           | 11 (2.3%)                  |
| Pyrexia                                     | 4 (1.3%)                                  | 2(1.8%.)           | 4(2.3%)     | 11 (23%)                   |
| Retinopathy                                 | 7(2.3%)                                   | 0                  | 0           | 11(2.3%)                   |
| Urinary tact infection                      | 7 (2.3%)                                  | 2 (1.8%)           | 5 (2.9%)    | 11(2.3%)                   |
| Weisht decrensed                            | 6(1.996)                                  | 0                  | 0           | 10 (2.1%)                  |

For the mUC pool, 93 (19.4%) of 479 subjects reported at least one TEAE leading to discontinuation of study treatment. There were 61 (12.7%) subjects who experienced TEAEs leading to discontinuation of study treatment that were considered by the investigator to be related to erdafitinib. Detachment of retinal pigment epithelium (8 [1.7%] subjects) was the most common TEAE considered by the investigator to be related to erdafitinib leading to discontinuation of study treatment.

Results were similar for the mUC pool and the BLC3001 erdafitinib pool.

<div style=\"page-break-after: always\"></div>

Adverse events leading to discontinuation of study treatment occurred at a similar frequency in the BLC3001 erdafitinib pool (52 [16.9%] of 308 subjects) and the chemotherapy group (20 [17.9%] of 112 subjects) and at a lower rate in the pembrolizumab group (19 [11.0%] subjects).

## 2.8.8.9. Post marketing experience

Erdafitinib was approved in the United States under the trade name of BALVERSA in April 2019. In addition, as of 11 April 2023, erdafitinib was approved in additional countries/territories (Argentina, Canada, Chile, Egypt, Hong Kong, Israel, Jordan, Mexico, Peru, Philippines, Saudi Arabia, Singapore, South Korea, Taiwan, Thailand, and Turkey) under the trade name of BALVERSA and in Brazil under the name of ERFANDEL for the treatment of adult patients with locally advanced or mUC. The applicant stated that the surveillance of spontaneous cases of AEs reported with the use of erdafitinib indicates that the safety profile of the drug in the post marketing setting is consistent with what is known about the drug's overall established safety profile from clinical studies.

## 2.8.9. Discussion on clinical safety

## Patient Exposure

In total, 479 subjects were included in the mUC pool. At the time of clinical cutoff, 57 (11.9%) subjects in the mUC pool were still receiving erdafitinib and 422 (88.1%) subjects had discontinued study treatment. The most common reason for study treatment discontinuation was progressive disease (322 [67.2%] subjects). Eighty (16.7%) subjects discontinued study treatment due to an AE. Death was listed as the reason for discontinuation of study treatment for 5 (1.0%) subjects.

For the mUC pool, the median (range) treatment duration was 4.8 months (0.1 to 43.4). 15% in the mUC pool received erdafitinib &gt;12 months. The median relative dose intensity was 75.1%. The median (range) treatment duration for the BLC3001 erdafitinib pool (4.6 [0.1 to 43.4] months) was longer than for the chemotherapy group (1.4 [0.0 to 26.9] months) and for the pembrolizumab group (3.5 [0.0 to 50.5] months).

## Adverse events (general)

TEAEs were reported by almost all subjects in the mUC pool and the BLC3001 erdafitinib pool, as well as in the chemotherapy and pembrolizumab groups. TEAEs considered by the investigator to be related to treatment occurred more frequently in BLC3001 erdafitinib pool (300 [97.4%] of 308 subjects) compared with the chemotherapy group (97 [86.6%] of 112 subjects) and the pembrolizumab group (105 [60.7%] of 173 subjects).

Grade 3 or Grade 4 TEAEs considered by the investigator to be related to erdafitinib were reported for 45.9% of subjects in the mUC pool. and at a similar frequently in the BLC3001 erdafitinib pool (44.5%) and the chemotherapy group (46.4%) while at a lower frequency in the pembrolizumab group (12.1%).

Serious TEAEs considered by the investigator to be related to erdafitinib were reported in 12.9% of subjects in the mUC pool. Serious TEAEs considered by the investigator to be related to study treatment occurred at a similar frequency in the BLC3001 erdafitinib pool (13.3%) and the pembrolizumab group (10.4%) and at a higher frequency in the chemotherapy group (24.1%).

TEAEs leading to discontinuation of study drug considered by the investigator to be related to erdafitinib were reported in 12.7% of subjects in the mUC pool. TEAEs leading to discontinuation of

<div style=\"page-break-after: always\"></div>

study drug considered by the investigator to be related to study treatment were reported more frequently in the BLC3001 erdafitinib pool (12.0%) and the chemotherapy group (13.4%) compared with the pembrolizumab group (4.6%).

There was 1 death (sudden death) considered by the investigator to be related to erdafitinib in BLC3001 Cohort 1. Six subjects in the chemotherapy group and 3 subjects in the pembrolizumab group experienced a TEAE with an outcome of death considered treatment related.

Overall, the frequencies of TEAEs, Grade 3 or 4 TEAEs, serious TEAEs, dose modifications respectively discontinuations due to TEAEs were similar across the mUC pool and the BLC3001 erdafitinib pool. In addition, the safety profile of study BLC3001 (Erdafitinib pool) was similar to the one of supportive phase 2 study (BLC2001).

Patients treated in the chemotherapy arm (Cohort 1) of study BLC3001 received either vinflunine or docetaxel (investigators choice). A subgroup analyses (comparison vinflunine vs erdafitinib respectively docetaxel vs erdafitinib) showed that more subjects in the erdafitinib group (41.5%) experienced SAEs compared with the docetaxel subgroup (31.9%), but a lower proportion compared with the vinflunine subgroup (58.1%). A similar pattern was noted for TEAEs leading to death (4.4%, 2.9%, and 11.6%, respectively) and Grade 3-4 AEs (63.0%, 55.1%, 79.1%, respectively). Whereas, the proportion of subjects with serious related TEAEs was lower in the erdafitinib group (13.3%) compared with the docetaxel group (18.8%), but notably lower than in the vinflunine group (32.6%); a similar pattern was noted for TEAEs leading to discontinuation of study drug (14.1%, 15.9%, and 20.9%, respectively). In summary, the comparisons of erdafitinib with type of investigator's choice chemotherapy (docetaxel or vinflunine) does not change the safety conclusions for erdafitinib. However, these data should be interpreted with caution, as there was no randomisation between docetaxel and vinflunine.

For the mUC pool, TEAEs considered by the investigator to be related to erdafitinib occurred in 464 (96.9%) of 479 subjects. Hyperphosphataemia was the most frequently reported drug-related TEAE (361 [75.4%] subjects). Other common TEAEs in the mUC pool that occurred with a frequency &gt;40% and were considered by the investigator to be related to erdafitinib were stomatitis (50.5%) and diarrhoea (46.3%).

Related TEAEs with a worst severity of Grade 3 were reported for 45.9% subjects with stomatitis being the most commonly reported (49 [10.2%] subjects). Related TEAEs with a worst severity of Grade 4 were reported for 5 (1.0%) subjects and included events of blood alkaline phosphatase increased (1 [0.2%] subject), duodenal ulcer haemorrhage (1 [0.2%] subject), gastrointestinal haemorrhage (1 [0.2%] subject), hyperphosphataemia (1 [0.2%] subject), and hyponatremia (1 [0.2%] subject).

## Adverse events of special interest (AESI) and clinical importance

Central serous retinopathy (CSR) has been identified as an AESI for erdafitinib and is a known class effect of FGFR inhibitors. Chronic CSR can lead to a decline in visual acuity and a lower vision-related quality of life.

Most events of central serous retinopathy in subjects in the mUC pool were Grade 1 or 2, with 2.3% of subjects experiencing Grade 3 events and no subjects experiencing Grade 4 events. The majority of central serous retinopathy events occurred within the first 90 days of treatment. The median time to first onset for any Grade event was 45 days. CSR had resolved for 2/3 of patients, whereas 1/3 had unresolved events. Of note, 8.6% of patients had dose interruptions, 12.1% had dose reductions and 2.9% discontinued Erdafitinib due to an event of CSR. Of the 41 subjects with CSR leading to dose interruption, 16 had recurrence and/or worsening of events after restarting: 15 (3.1) subjects had

<div style=\"page-break-after: always\"></div>

recurrent central serious retinopathy events without worsening and 1 subject had recurrent and worsening central serous retinopathy. No central serous retinopathy events of worsening alone were reported. Of the 58 subjects who had CSR events leading to dose reduction, 23 had recurrent CSR without worsening, 7 had recurrent and worsening central serous retinopathy, and 3 had worsening central serous retinopathy alone.

There were no reported events of blindness in clinical studies.

Overall, recurrent events in the same or contralateral eye upon resumption of erdafitinib at the same or lower dose are relatively frequent, while recurrent and worsening events are less common. However, close ophthalmologic surveillance is critically important in subjects who restart erdafitinib after an ocular event.

Central serous retinopathy is included in the SmPC (Section 4.2, 4.4 and 4.8) as well as an important identified risk in the in the list of safety concerns in the RMP.

In the mUC pool, the overall incidence of central serous retinopathy was higher in subjects  65 years of age (33.3%) compared with subjects &lt;65 years of age (28.87%). Events of RPED were reported more frequently in subjects  65 years of age (6.3%) compared with subjects &lt;65 years of age (2.1%). This was also the trend for grade 3 and higher CSR events, serious CSR events, dose reductions, dose modification and treatment discontinuation. Similarly, in the BLC3001 erdafitinib pool, the overall incidence of central serous retinopathy and RPED was higher in subjects  65 years of age compared with subjects &lt;65 years of age. This information about elderly is included in the SmPC.

The frequency of adverse reactions of CSR in the BLC3001 erdafitinib pool was similar to the mUC pool and to the phase 2 study BLC2001 whereas no events of CSR were reported for the chemotherapy and the pembrolizumab arm of study BLC3001.

Adverse events of clinical importance include events that are class effects of FGFR inhibitors (hyperphosphataemia, eye disorders [other than central serous retinopathy], nail and skin disorders), as well as those identified based on clinical findings (gastrointestinal disorders). Adverse events of clinical importance were observed at a similar frequency across the mUC pool and the BLC3001 erdafitinib pool and were observed less frequently in the chemotherapy and pembrolizumab groups.

Hyperphosphataemia is an expected and transient laboratory abnormality of FGFR inhibitors due to their mechanism of action (IB Erdafitinib 2023). This can serve as a pharmacodynamic marker of target engagement in early cycles.

Detailed up-titration guidelines as well as dose modification guidelines are given in SmPC. In the study BLC3001 the majority of patients increased erdafitinib dose to 9 mg (cohort 1 77.0%, cohort 2 82.1%) whereas in the phase 2 study only 41/99 patients (8mg regimen) were up titrated.

In the mUC pool adverse reactions of hyperphosphataemia were reported in 78.5% of patients (Grade 3/4 2.9%). The median time to first onset for any Grade event was 15 days. At data cut-off hyperphosphataemia had resolved for approx. most of the patients (83.8%). 10% of patients had dose interruptions, 5.2% had dose reductions and 0.2% discontinued Erdafitinib due to an event of hyperphosphataemia. Similar incidences were reported for the erdafitinib pool and the supportive phase 2 study BLC2001.

Overall, the safety profiles appeared similar between the phase 2 study (BLC2001, up-titration when serum phosphate was less than 5.5 mg/dL) and the phase 3 Study (BLC3001, up-titration when serum phosphate was less than 9 mg/dL) and between patients who were up-titrated vs. those who were not up-titrated in the phase 3 study. Up-titration criteria implemented in study BLC3001 demonstrated a favourable benefit-risk in this subject population when compared with chemotherapy.

<div style=\"page-break-after: always\"></div>

There was a low incidence of prolonged hyperphosphataemia in the BLC3001 erdafitinib pool. The most frequently reported TEAE considered a potential sequela of prolonged hyperphosphataemia was hypercalcemia, the interpretation of which is difficult as it a very common laboratory abnormality in patients with advanced malignancies (Stewart 2005). TEAEs considered potential sequelae of prolonged hyperphosphataemia were reported in 30 (9.7%) of 308 subjects in the BLC3001 erdafitinib pool and in 1 (7.7%) of 13 subjects in the BLC3001 erdafitinib pool with a phosphate value 7 mg/dL for &gt;1 month.

As discussed by the applicant hyperphosphataemia is most commonly seen in the setting of chronic kidney disease. Decreased renal function interferes with the kidneys' ability to maintain fluid and electrolyte homeostasis, which results in decreased ability to excrete excess phosphate, acid, and potassium. Prolonged hyperphosphataemia can lead to sequelae including anaemia, hypotension, hypercalcemia, worsening renal impairment, hypocalcaemia, hyperparathyroidism, and worsening renal failure. Comparison of the incidence of these events between all subjects in the study and those with prolonged hyperphosphataemia showed a lower incidence for subjects with prolonged hyperphosphataemia (25%) versus all subjects (34%). However, there was a slightly higher incidence of anaemia for subjects with prolonged hyperphosphataemia than in all subjects (25% vs 20%), and for renal impairment (10% vs 7.1%).

AEs considered potential sequelae of prolonged hyperphosphataemia and related to erdafitinib (vascular calcification, hypercalcaemia and hyperparathyroidism) are included in the list of ADR of the SmPC In addition, hypocalcaemia, muscle cramps, seizure activity, QT interval prolongation, and arrhythmias  were added to the warning of hyperphosphataemia in section 4.4 of the SmPC as potential risks of prolonged hyperphosphataemia.

Thirteen subjects (4.2%) treated with erdafitinib in BLC3001 (Cohorts 1 and 2) experienced hypophosphatemia versus 0% in chemotherapy arm. The majority (84.6%) of subjects with events of hypophosphatemia had experienced a prior event of hyperphosphataemia; most events were of low grade, and all but one resolved with a median duration of 21 days. In summary, reasons for hypophosphataemia in subjects treated with erdafitinib remain unclear. A warning about the risk of potential hypophosphataemia and the need to discontinue phosphate binders and dietary restrictions once a sufficient decline in serum phosphate is attained is included in section 4.4 of the SmPC.

In the mUC pool adverse reactions of eye disorders were reported in 43.2% of patients (Grade 3/4 2.9%). The median time to first onset for any Grade event was 50 days. Eye disorders had resolved for 49% of patients, whereas 51% had unresolved events of which the majority were Grade 1. Of note, 9.2% of patients had dose interruptions, 7.5 % had dose reductions and 2.1% discontinued Erdafitinib due to an event of eye disorders. Similar incidences were reported for the erdafitinib pool whereas the frequency of adverse reactions of eye disorders was remarkably lower in the chemotherapy and the pembrolizumab arm. SOC eye disorders is included in section 4.8 of the SmPC.

In the mUC pool adverse reactions of nail disorders were reported in 62.6% of patients (Grade 3 12.5%). The median time to first onset for any Grade event was 60 days. Nail disorders had resolved for 1/3 of patients, whereas 2/3 had unresolved events. Of note, 20.5% of patients had dose interruptions, 21.9% had dose reductions and 2.1% discontinued Erdafitinib due to an event of nail disorders. In the mUC pool adverse reactions of skin disorders were reported in 54.5% of patients (Grade 3/4 10.0%). No severe cutaneous adverse reactions (ie, Stevens-Johnson syndrome/toxic epidermal necrolysis [TENS], drug reaction with eosinophilia and systemic symptoms [DRESS], acute generalised exanthematous pustulosis [AGEP], and generalised bullous fixed drug eruptions [GBFDE]) were observed with erdafitinib. The median time to first onset for any Grade event was 47 days. Skin disorders had resolved for approx. half of patients, whereas 1/2 had unresolved events. Of note, 15% of patients had dose interruptions, 12.1% had dose reductions and 1.7% discontinued Erdafitinib due

<div style=\"page-break-after: always\"></div>

to an event of nail disorders. Similar incidences were reported for the erdafitinib pool and the phase 2 study BLC2001 whereas the frequency of adverse reactions of nail and skin disorders was remarkably lower in the chemotherapy and the pembrolizumab arm.

Recommendations for prophylaxis and symptom managements for nail toxicity, skin disorders, dry mouth and mucositis were applied during treatment with erdafitinib and are included in section 4.4 of the SmPC. Appropriate recommendations and warnings concerning a potential phototoxicity of erdafitinib were added in the relevant sections of the SmPC. In addition, phototoxicity will be subject to routine periodic safety reporting.

In the mUC pool adverse reactions of gastrointestinal disorders were reported in 83.9% of patients (Grade 3/4 14.2%). The median time to first onset for any Grade event was 15 days. Gastrointestinal disorders had resolved for approx. half of patients, whereas 1/2 had unresolved events. Of note, 24.6% of patients had dose interruptions, 20.7% had dose reductions and 2.7% discontinued erdafitinib due to an event of gastrointestinal disorders. Similar incidences were reported for the erdafitinib pool and the phase 2 study BLC2001 whereas the frequency of adverse reactions gastrointestinal disorders was slightly lower in the chemotherapy and the pembrolizumab arm.

SOC gastrointestinal disorders is included in 4.8 of the SmPC.

In view of the already approved FGFR inhibitors (Pemigatinib and futibatinib), attention should also be paid to potential renal and hepatic toxicities .

In the erdafitinib pool increase of blood creatinine was reported as a treatment emergent AE in 14.9% (46 subjects), consisting of 8.1% (25 subjects) Grade 1 and 6.8% (21 subjects) Grade 2 elevation (no &gt;Grade 2 event was observed) in contrast to 6.3% in the chemotherapy arm and 7.5% in the pembrolizumab arm. Furthermore, in the BLC3001 erdafitinib pool, acute kidney injury was seen in 5.5% (17 subjects), renal impairment in 3.6% (11 subjects) and renal failure in 3.2% (10 subjects). Of note for 9 subjects (2.9%) a SAE of acute kidney injury was reported and 2 out of 52 patients discontinued the treatment due to acute kidney injury resp. renal failure.

The potential nephrotoxic effect of erdafitinib, along with further analysis regarding the effect of erdafitinib (exposure and serum phosphate levels) on renal safety was further discussed. In summary, observed incidence of acute renal failure (ARF) events was similar in younger and older subjects, and higher in subjects with history of diabetes, hypertension or kidney impairment at baseline. Of note, neither the exposure to erdafitinib nor the serum phosphate levels were associated with higher incidence of Grade  2 serum creatinine increase. Creatinine elevations and renal toxicity are reflected in the SmPC.

It is agreed, that - based on the preclinical and clinical data - OCT2 inhibition is not considered to have contributed significantly to observed increases in serum creatinine among patients receiving erdafitinib.

Increase of transaminases : based on data presented erdafitinib might not have a potential for clinically significant hepatotoxicity. However, transaminase elevations and the potential hepatotoxicit y are reflected in the SmPC.

## Dose modification and discontinuation due to adverse events

Dose interruptions and reductions due to treatment-related adverse events were necessary for 82.3% in the mUC pool, indicating the non-negligible safety profile of erdafitinib. Similar incidences were reported for the erdafitinib pool whereas the frequency of dose modifications was remarkably lower in the chemotherapy (46.4%) and the pembrolizumab arm (33%).

<div style=\"page-break-after: always\"></div>

In the mUC pool, ~ 17% patients discontinued treatment due to adverse events and 61 (12.7%) experienced TEAEs leading to discontinuation of study treatment that were considered to be related to erdafitinib. Detachment of retinal pigment epithelium (8 [1.7%] subjects) was the most common TEAE leading to discontinuation of study treatment. Results were similar for the mUC pool and the BLC3001 erdafitinib pool.

The most common TEAEs leading to dose modification of erdafitinib were stomatitis (25.3%), PPES (14.8%), hyperphosphataemia (12.7%), onycholysis (12%), diarrhoea (10%), nail dystrophy (5.8%), onychomadesis (5.8%), chorioretinopathy (5.4%), paronychia, asthenia (4.6%), decreased appetite (4.6%) and fatigue (4.6%), increased ALT (3.8%), and increased AST (3.3%). Similar results were reported, for the BLC3001 erdafitinib pool.

Guidelines on dose modifications for management of specific toxicities (i.e. hyperphosphataemia, nail, skin, eye toxicities and mucosal changes) as well as for other toxicities are included in the SmPC.

## Laboratory findings and electrocardiogram QT prolongation

Haematology abnormalities were reported as treatment emergent treatment related adverse events. Particular anaemia occurred frequently with erdafitinib (27%). The incidence of events considered related to erdafitinib was 10%.

Incidence of treatment related anaemia was lower in the erdafitinib arm in comparison to the chemotherapy arm (Cohort 1 of study BLC3001). However, the incidence of treatment related anaemia was remarkably higher in the erdafitinib arm than in the pembrolizumab arm (Cohort 2 of study BLC3001). Haematology abnormalities are reported in the SmPC.

Correlation between anaemia and hyperphosphataemia under the treatment with erdafitinib is described in the literature (Kovesdy et al. 2011, Tran et al. 2015 , Wojcicki et al. 2013, Silver et al. 2010) cannot be excluded although rather unlikely.

As already stated above hyperphosphataemia is an expected and transient laboratory abnormality of FGFR inhibitors due to their mechanism of action. This can serve as a pharmacodynamic marker of target engagement in early cycles. Mean phosphate values increased immediately after start of dosing, with the observed peak on Cycle 2 Day 1 and Cycle 3 Day 1. Mean values generally decreased from that point forward. However, during treatment most patients had shifts to increased phosphate levels and it is fully supported that hyperphosphataemia is reported as a TEAE and has been identified as an ADR. Mild increases in creatinine laboratory values and mild increases in laboratory values of ALT and AST were observed in the erdafitinib group consistent with the reported TEAEs of ALT increased and AST increased (Cohort 1 and Cohort 2 of BLC3001) and are included as ADR in the SmPC.

In both Cohort 1 and Cohort 2 of BLC3001, moderate to severe hyponatremia was identified by clinical laboratory values in the erdafitinib group. The applicant outlined a pathophysiological mechanism for hyponatremia due to FGF23-inhibition by erdafitinib. Risk of hyponatremia was threefold higher in patients with concomitant use of diuretics. These laboratory findings were consistent with hyponatremia reported as a TEA and included in the SmPC.

QT prolongation events of all grades were reported in study BLC3001.

As the potential for hyperphosphataemia leading to QT prolongation cannot be excluded, QT prolongation will be added as an Important Potential Risk in the EU RMP for erdafitinib.

<div style=\"page-break-after: always\"></div>

## Safety in special populations

More subjects  65 years of age experienced serious TEAEs, Grade 4 TEAEs, TEAEs leading to study treatment discontinuation and TEAEs leading to death. As already discussed above, particular central serous retinopathy was reported more frequently in subjects  65 years of age.

There was a lower incidence of Grade 3 or 4 events reported for males (236 [64.7%] subjects) compared with females (85 [74.6%] subjects). In all other categories (SAE, death) women experience slightly higher percentages than men. Further monitoring will be done with routinely collected data.

A small trend to the detriment of patients with poorer creatinine clearance were seen, a possible higher toxicity for subjects with renal impairment will be further monitored with routinely collected data.

No clinically meaningful differences in the pharmacokinetics of erdafitinib were observed between subjects with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment and subjects with normal hepatic function.

## Post marketing experience

erdafitinib was approved for the first time in the United States in April 2019. Since then, it has been approved in several other countries. The applicant stated that the surveillance of spontaneous cases of AEs reported with the use of erdafitinib indicates that the safety profile of the drug in the post marketing setting is consistent with what is known about the medicine's overall established safety profile from clinical studies.

## 2.8.10. Conclusions on the clinical safety

The safety profile of erdafitinib as characterised with the current median of exposure in the applied target population is in accordance with what can be expected from the non-clinical studies and known class effects for FGFR inhibition.

Erdafitinib showed high incidence and high level of seriousness of the events reported. The currently identified main safety risks of erdafitinib are hyperphosphataemia, central serous retinopathy, further eye disorders, nail and skin disorders, gastrointestinal disorders and embryofoetal toxicity.

In summary, risks from erdafitinib toxicities in the applied population are clinically relevant, but manageable with treatment interruption and dose modifications, which occurred frequently (82%). Incidence of treatment discontinuation due to AEs were however, lower compared to the chemotherapy group.

## 2.9. Risk Management Plan

## 2.9.1. Safety concerns

The applicant proposed the following summary of safety concerns in the RMP version 1.4.

<div style=\"page-break-after: always\"></div>

Table 80: Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                              |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   |  Central serous retinopathy  Hyperphosphataemia                                                                                       |
| Important potential risks    |  Reproductive and developmental toxicity  Potential drug toxicity due to accumulation of P- glycoprotein substrates  QT prolongation |
| Missing information          |  None                                                                                                                                  |

## 2.9.2. Pharmacovigilance plan

## 2.9.2.1. Routine pharmacovigilance activities

No activity beyond routine pharmacovigilance activities is proposed by the MAH.

## 2.9.3. Risk minimisation measures

## Table 81: Summary table of pharmacovigilance activities and risk minimisation activities by safety concern

| Safety Concern             | Risk Minimisation Measures                                                                                                                                                       | Pharmacovigilance Activities                                                                                                                         |
|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risk  | Important Identified Risk                                                                                                                                                        | Important Identified Risk                                                                                                                            |
| Central serous retinopathy | Routine risk minimisation measures:  SmPC Section 4.2, 4.4, 4.7 and 4.8  PL Section 2 and 4  Legal status: medical prescription Additional risk minimisation measures:  None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:  None Additional pharmacovigilance activities:  None |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                            | Risk Minimisation Measures                                                                                                                                                               | Pharmacovigilance Activities                                                                                                                         |
|---------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hyperphosphataemia                                                        | Routine risk minimisation measures:  SmPC Section 4.2, 4.4, 4.8, 5.1 and 5.3  PL Section 2, 3 and 4  Legal status: medical prescription Additional risk minimisation measures:  None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:  None Additional pharmacovigilance activities:  None |
| Important Potential Risks                                                 | Important Potential Risks                                                                                                                                                                | Important Potential Risks                                                                                                                            |
| Reproductive and developmental toxicity                                   | Routine risk minimisation measures:  SmPC Section 4.4, 4.5, 4.6, 5.3  PL Section 2  Legal status: medical prescription Additional risk minimisation measures:                         | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:  None Additional pharmacovigilance activities:  None |
| Potential drug toxicity due to accumulation of P- glycoprotein substrates | Routine risk minimisation measures:  SmPC Section 4.5 and 5.2  Legal status: medical prescription Additional risk minimisation measures:  None                                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:  None Additional pharmacovigilance activities:  None |
| QT prolongation                                                           | Routine risk minimisation measures:  SmPC Section 4.4 and 5.3  Legal status: medical prescription Additional risk minimisation measures:  None                                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection:  None Additional pharmacovigilance activities:  None |

## 2.9.4. Conclusion

The CHMP and PRAC considers that the risk management plan version 1.4 is acceptable.

## 2.10. Pharmacovigilance

## 2.10.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the

<div style=\"page-break-after: always\"></div>

requirements of Article 8(3) of Directive 2001/83/EC.

## 2.10.2. Periodic Safety Update Reports submission requirements

The active substance is not included in the EURD list and a new entry will be required. The new EURD list entry uses the IBD to determine the forthcoming Data Lock Points. The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request alignment of the PSUR cycle with the international birth date (IBD). The IBD is 12 April 2019. The new EURD list entry will therefore use the 12 April 2019 to determine the forthcoming Data Lock Points.

## 2.11. Product information

## 2.11.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.11.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Balversa (erdafitinib) is included in the additional monitoring list as it contains a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the EU.

Therefore, the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The indication endorsed by CHMP is: Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PDL1 inhibitor in the unresectable or metastatic treatment setting (see section 5.1).

## 3.1.2. Available therapies and unmet medical need

Available systemic therapies in the EU can be broadly categorised as platinum-based chemotherapy regimens, other chemotherapy regimens, antibodies targeting programmed death receptor-1 or programmed death-ligand 1 (anti-PD-(L)1), and antibody-drug conjugates (ADCs). Due to the

<div style=\"page-break-after: always\"></div>

significant toxicities and morbidities, in particular kidney dysfunction and peripheral neuropathy, a relevant proportion of patients do not receive any systemic chemotherapy and the number of patients who are eligible for subsequent therapies decreases with every line of treatment. (ESMO; Powles 2022).

No therapies for a biomarker-selected population are approved so far.

There is substantial need for more effective therapies for patients with advanced urothelial cancer having received one or two line(s) of treatment.

## 3.1.3. Main clinical studies

Efficacy claims of erdafitinib in the proposed indication are based on a single pivotal study, namely study 'BLC3001 Cohort 1'. This is a randomised (1:1) controlled open-label phase 3 study comparing erdafitinib monotherapy versus investigator-choice chemotherapy (docetaxel or vinflunine) in patients with advanced urothelial cancer and susceptible FGFR3 alterations, who had progressed on or after 1 or 2 prior line(s) of therapy, with at least 1 line including anti-PD-(L)1 as monotherapy or as combination therapy; and no more than 2 prior lines of systemic treatment.

## 3.2. Favourable effects

At the interim analysis data cut-off 15 January 2023 Study 'BLC3001 Cohort 1' was stopped for superiority of erdafitinib (n=136 patients) over chemotherapy (n=130 patients). Patients were allowed to cross-over to erdafitinib treatment. The primary efficacy endpoint of OS showed a statistically and clinically significant improvement in OS for subjects treated with erdafitinib vs chemotherapy (HR=0.64; 95% CI: 0.47, 0.88; p-value=0.0050). The median OS was 12.06 months (95% CI: 10.28, 16.36) in the erdafitinib group versus 7.79 months (95% CI: 6.54, 11.07) in the chemotherapy group, each with approximately 40% of subjects censored.  Overall, the results of the sensitivity analyses do not challenge the results of the primary analysis. The OS benefit in favour of erdafitinib observed for the primary analysis was consistently reflected in the results of the subgroup analyses. The median survival follow-up was 15.90 months (95% CI: 13.57, 19.22) for the erdafitinib treatment group.

Analysis of key secondary endpoint PFS showed a statistically significant improvement for subjects treated with erdafitinib vs chemotherapy (HR=0.58; 95% CI: 0.44, 0.78; p value=0.0002). The median PFS was 5.55 (95% CI: 4.40, 5.65) months in the erdafitinib treatment group and 2.73 (95% CI: 1.81, 3.68) months in the chemotherapy treatment group.

Best ORR by investigator assessment and per RECIST 1.1 was 45.6% for the erdafitinib treatment group and 11.5% for the chemotherapy treatment group. The difference was statistically significant. Nine patients in the erdafitinib arm reached CR, while one patient in the chemotherapy arm reached CR. 'Confirmed ORR analysis' was consistent with 'best ORR analysis'.

## 3.3. Uncertainties and limitations about favourable effects

A greater number of subjects who were randomised to the chemotherapy group did not receive study treatment (n=18) compared with the erdafitinib group (n=1), the main reason was 'refused treatment' (n=12; all from control group). This number shows a relevant imbalance; however, demographic and disease characteristics at baseline were sufficiently comparable between those patients 'randomised and treated' and those 'randomised and not treated'. There are no reasonable concerns of informative censoring. Furthermore, the applicant was able to obtain the death date for 8 of the 18 subjects randomised to chemotherapy as well as the subject randomised to erdafitinib.

<div style=\"page-break-after: always\"></div>

A change to the confirmatory testing procedure was introduced in protocol amendment 5 but the applicant provided information that was reassuring regarding the sufficiency of the firewalls to preserve study integrity.

Companion diagnostic (CDx) 'Qiagen therascreen FGFR RGQ RT-PCR' / biomarker 'FGFR positive':

- -'Qiagen therascreen FGFR RGQ RT-PCR' from tissue was used as central confirmation test. However, 12.5% of patients (33/264) were included into study BLC3001 based on local testing only (tissue or blood) without having a (positive) central confirmation test (for 22 patients no tissue for central confirmation was available, for 11 patients central confirmation test was negative).
- -While a clear definition to declare a patient as 'FGFR-positive' in the pivotal study BLC3001 is provided (see eligibility criteria above) and justification of this definition can be followed, validation of the biomarker definition remains scientifically weak (being based on preclinical data and uncontrolled clinical response data).
- -A clinical validation demonstrating the test to be predictive is not possible in the presented trial setting without clinical data in test negative patients. It is acknowledged that including biomarkernegative patients in this study was not ethical/possible but this means that the justification of clinical validity needs to be based on the clinical rationale in this case.
- -An exploratory analysis of clinical benefit across the different FGFR alterations included in the biomarker panel was provided. Considering the small sample sizes of subgroups, the analysis is explorative and no definite conclusions are possible but trends in favour of erdafitinib vs chemotherapy were observed for all subgroups.
- -Cut-points used for the respective genetic alteration defining 'FGFR-positivity' were provided for the central confirmation test 'Qiagen therascreen FGFR RGQ RT-PCR'. However, no clinical thresholding was performed. Therefore, it remains unclear whether the thresholds / cut-off values applied in study BLC3001 were optimal or whether a lower or higher threshold defining patients as 'FGFR alteration positive' would lead to a better benefit-risk ratio.

Although the uncertainties, it is agreed that clinical benefit has been demonstrated for the population selected with the test.

## 3.4. Unfavourable effects

The data presented in this section mainly refers to the mUC pool (n=479) which integrates data across studies that included subjects with locally advanced or metastatic UC treated with erdafitinib monotherapy 8 mg daily with individualised up-titration to 9 mg daily (8/9 mg daily dose regimen; n=467) or erdafitinib monotherapy 9 mg daily (n=9).

The most frequently reported TRAEs included hyperphosphataemia (78.5.%), stomatitis (52.8.%) diarrhoea (55.5%), dry skin (28%), palmar-plantar erythrodysesthesia syndrome (25.5%), dysgeusia (26.3%), decreased appetite (31.7%), onycholysis (21.7%) The most common reported AEs are compatible with the safety profile as is known from other FGFR-inhibitors and the patient population with advanced cancer.

SAEs were reported in 42.6% of patients and were considered treatment-related in 12.9% of patients (n=62). Treatmentrelated SAEs reported in 5 patients included detachment of retinal pigment epithelium (n=5) and stomatitis (n=5).

<div style=\"page-break-after: always\"></div>

Overall, 66.2% of 479 subjects died. The majority of deaths (270 of 317) were due to progressive disease, 4.8% were due to adverse events. Grade 5 TEAEs considered by the investigator to be related to treatment were reported by 1 subject (sudden death).

Central serous retinopathy (CSR) has been identified as adverse event of special interest (AESI). Adverse reactions of CSR in any grade were reported in 31.5% of patients (Grade 3/4 2.7%). The most commonly reported events were chorioretinopathy, detachment of RPE, retinal detachment, retinopathy, and subretinal fluid.

Hyperphosphataemia, eye disorders [other than central serous retinopathy], nail and skin disorders, as and gastrointestinal disorders have been classified as adverse events of clinical importance and reported in section 4.4 of the SmPC.

Adverse drug reactions of hyperphosphataemia were reported in 78.5% of patients (Grade 3/4 2.9%).

There was a low incidence of prolonged hyperphosphataemia in the BLC3001 erdafitinib pool. The most frequently reported TEAE considered a potential sequela of prolonged hyperphosphataemia was hypercalcemia, the interpretation of which is difficult as it a very common laboratory abnormality in patients with advanced malignancies (Stewart 2005).

Adverse reactions of eye disorders (other than CSR) were reported in 36.3% of patients (Grade 3/4 2.9%).

Adverse reactions of nail disorders were reported in 62.6% of patients (Grade 3 12.5%).

Adverse reactions of gastrointestinal disorders were reported in 83.9% of patients (Grade 3/4 14.2%).

In the BLC3001 erdafitinib pool, increase of blood creatinine which was reported as a treatment emergent AE in 14.9% (46 subjects). Furthermore, acute kidney injury was seen in 5.5% (17 subjects), renal impairment in 3.6% (11 subjects) and renal failure in 3.2% (10 subjects).

In addition, increase of transaminases was reported as a treatment emergent AE in 21.7% (ALT) respectively 18.0% (AST) of subjects in the erdafitinib pool. Furthermore, hepatobiliary disorders were reported in 10.4%. Of note, dose modifications due to increased transaminases were reported for 3.9%.

In study BLC3001, drug related AEs of hypernatremia in the treatment group were reported for 6.8% of patients.

More subjects  65 years of age experienced serious TEAEs, Grade 4 TEAEs, TEAEs leading to study treatment discontinuation and TEAEs leading to death. Central serous retinopathy was reported more frequently in subjects  65 years of age.

Dose interruptions and reductions due to treatment-related adverse events were necessary for 82.3% in the mUC pool. In addition, 61 (12.7%) subjects experienced TEAEs leading to discontinuation of study treatment that were considered to be related to erdafitinib. Of note, detachment of retinal pigment epithelium (8 [1.7%] subjects) was the most common TEAE leading to discontinuation of study treatment.

<div style=\"page-break-after: always\"></div>

Central serous retinopathy, hyperphosphataemia, potential drug toxicity due to accumulation of P-glycoprotein substrates and QT prolongation are part of the Identified and Potential Risk included in the RMP and will be monitored with routine Pharmacovigilance activities.

## 3.5. Uncertainties and limitations about unfavourable effects

A relatively large proportion of patients experienced a rise in transaminases, there is a relatively high level of uncertainty as to whether erdafitinib can induce liver damage in certain patient populations. Thus, hepatotoxicity should be monitored in upcoming PSURs.

## 3.6. Effects Table

Table 82: Effects Table for erdafitinib in the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma, harbouring susceptible FGFR3 genetic alterations with disease progression during or following at least one line of therapy containing a PD-(L)1 inhibitor in the locally advanced unresectable or metastatic treatment setting (data cut-off: 15 January 2023).

| Effect                                                                                                         | Short Description                                                                                              | Unit                                                                                                           | Erdafitinib                                                                                                    | Control                                                                                                        | Uncertainties/ Strength of evidence                                                                            | References                                                                                                     |
|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|
| Favourable Effects (single pivotal study BLC3001 Cohort 1; erdafitinib arm 136 patients, CTx arm 130 patients) | Favourable Effects (single pivotal study BLC3001 Cohort 1; erdafitinib arm 136 patients, CTx arm 130 patients) | Favourable Effects (single pivotal study BLC3001 Cohort 1; erdafitinib arm 136 patients, CTx arm 130 patients) | Favourable Effects (single pivotal study BLC3001 Cohort 1; erdafitinib arm 136 patients, CTx arm 130 patients) | Favourable Effects (single pivotal study BLC3001 Cohort 1; erdafitinib arm 136 patients, CTx arm 130 patients) | Favourable Effects (single pivotal study BLC3001 Cohort 1; erdafitinib arm 136 patients, CTx arm 130 patients) | Favourable Effects (single pivotal study BLC3001 Cohort 1; erdafitinib arm 136 patients, CTx arm 130 patients) |
| OS primary endpoint                                                                                            | Overall Survival                                                                                               | Median in months (95%CI)                                                                                       | 12.06 (10.28, 16.36)                                                                                           | 7.79 (6.54, 11.07)                                                                                             | RCT data (HR=0.64; 95%CI: 0.47, 0.88; p=0.005)                                                                 | CSR study BLC3001 Cohort 1                                                                                     |
| PFS secondary endpoint                                                                                         | Progression Free Survival                                                                                      | Median in months (95%CI)                                                                                       | 5.55 (4.40, 5.65)                                                                                              | 2.73 (1.81, 3.68)                                                                                              | RCT data HR=0.58; 95%CI: 0.44, 0.78; p=0.0002                                                                  | CSR study BLC3001 Cohort 1                                                                                     |
| ORR secondary endpoint                                                                                         | Objective Response Rate, unconfirmed                                                                           | %                                                                                                              | 45.6%                                                                                                          | 11.5%                                                                                                          | RCT data                                                                                                       | CSR study BLC3001 Cohort 1                                                                                     |
| Unfavourable Effects based on BLC3001 erdafitinib pool data.                                                   | Unfavourable Effects based on BLC3001 erdafitinib pool data.                                                   | Unfavourable Effects based on BLC3001 erdafitinib pool data.                                                   | Unfavourable Effects based on BLC3001 erdafitinib pool data.                                                   | Unfavourable Effects based on BLC3001 erdafitinib pool data.                                                   | Unfavourable Effects based on BLC3001 erdafitinib pool data.                                                   | Unfavourable Effects based on BLC3001 erdafitinib pool data.                                                   |
| TEAEs Grade 3 or 4                                                                                             | regardless causality                                                                                           | %                                                                                                              | 64%                                                                                                            |                                                                                                                |                                                                                                                | Erdafitinib pool of study BLC3001:                                                                             |
| Serious AEs                                                                                                    | regardless causality                                                                                           | %                                                                                                              | 40.6                                                                                                           |                                                                                                                |                                                                                                                | CSR                                                                                                            |
| TEAEs leading to discontinuation                                                                               | regardless causality                                                                                           | %                                                                                                              | 16.9                                                                                                           |                                                                                                                |                                                                                                                | of Cohort 1 of study BLC3001                                                                                   |
| TEAEs leading to death                                                                                         | regardless causality                                                                                           | %                                                                                                              | 3.6                                                                                                            |                                                                                                                |                                                                                                                | CSR of Cohort 2 of study BLC3001                                                                               |
| Central serous retinopathy                                                                                     | Adverse event of special interest                                                                              | %                                                                                                              | 20.1                                                                                                           |                                                                                                                |                                                                                                                |                                                                                                                |
| Hyper- phosphataemia                                                                                           | Adverse event of clinical importance                                                                           | %                                                                                                              | 78.6                                                                                                           |                                                                                                                |                                                                                                                | Erdafitinib pool of study BLC3001:                                                                             |
| Eye disorders (other than Central serous retinopathy)                                                          | Adverse event of clinical importance                                                                           | %                                                                                                              | 39.9                                                                                                           |                                                                                                                |                                                                                                                | CSR                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Effect                     | Short Description                    | Unit   |   Erdafitinib | Control   | Uncertainties/ Strength of evidence   | References                   |
|----------------------------|--------------------------------------|--------|---------------|-----------|---------------------------------------|------------------------------|
| Nail disorders             | Adverse event of clinical importance | %      |          62.3 |           |                                       | of Cohort 1 of study BLC3001 |
| skin disorders             | Adverse event of clinical importance | %      |          54.5 |           |                                       | CSR of Cohort 2 of study     |
| gastrointestinal disorders | Adverse event of clinical importance | %      |          82.8 |           |                                       | BLC3001                      |

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Efficacy claims are based on the single pivotal phase 3 study 'BLC3001 cohort 1' being performed in line with CHMP scientific advice from 2017 (before study start).

The study treatment is intended for patients harbouring FGFR3 alterations.

A statistically significant and clinically relevant survival advantage in the experimental arm over the chemotherapy arm has been demonstrated. The RCT met its primary endpoint of OS, showing statistical and clinically significant improvement in favour of erdafitinib monotherapy over single agent chemotherapy (docetaxel or vinflunine). This outcome is supported by analysis of the key secondary endpoints of PFS and ORR.

Clinical benefit in the all-comer population of study BLC3001 (cohort 1) is robustly shown. The vast majority of the patients received prior platinum-based chemotherapy and efficacy data in platinumnave patients is limited. However, platinum-nave subpopulation efficacy data were analysed in a posthoc defined across trial comparison for RCT BLC3001 cohort 1, SAT BLC2001 and SAT BLC2002 and showed consistent objective responses with the population with prior platinum. Results for ORR, OS and PFS in the post-hoc analysis were overall comparable to the results from the pivotal RCT BLC3001 for the ITT-population.

Due to the open-label design of the study and the imbalanced censoring, no benefit claims can be supported by available PRO data reported in study BLC3001. This includes the key secondary endpoint of TUSD-3, which is not established as a validated PRO measure and its clinical relevance remains unclear.

Erdafitinib showed high incidence and high level of seriousness of the safety events reported. The main safety risks of erdafitinib are hyperphosphataemia, central serous retinopathy, eye disorders (other than CSR), nail and skin disorders, gastrointestinal disorders and embryofoetal toxicity.

Risks from erdafitinib treatment in the intended patient population are clinically relevant, but manageable with treatment interruption and dose modifications, which occurred frequently (82%). Incidence of treatment discontinuation due to AEs were lower compared to the chemotherapy group.

## 3.7.2. Balance of benefits and risks

Considering the benefit observed with erdafitinib on overall survival compared to single-agent chemotherapy (docetaxel or vinflunine) and the manageable safety profile, it can be concluded that the benefits of treatment with erdafitinib outweigh its risks.

<div style=\"page-break-after: always\"></div>

## 3.7.3. Additional considerations on the benefit-risk balance

N/A

## 3.8. Conclusions

The overall benefit/risk balance of Balversa (erdafitinib) is positive subject to the conditions stated in section 'Recommendations'.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Balversa is favourable in the following indication:

Balversa as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting (see section 5.1) .

## Other conditions and requirements of the marketing authorisation

- Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

- Risk Management Plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

## New Active Substance Status

Based on the CHMP review of the available data, the CHMP considers that erdafitinib is to be qualified as a new active substance in itself as it is not a constituent of a medicinal product previously authorised within the European Union.